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Abstract 
Trypanosoma brucei is the protozoan parasite causing African trypanosomiasis, a 
neurological disease that affects humans and farm-stock in the impoverished 
sub-Saharan areas where tsetse fly transmission vector is endemic. Although it 
has great impact on public health and local economies, it has been neglected in 
drug discovery for almost a century. Current treatments are either toxic or of 
difficult administration, besides having serious risks of inducing resistance.  
Protein kinases are the primary set of signaling proteins in eukaryotes, including 
Trypanosoma brucei. Their druggability has been widely exploited in cancer 
research, and has been established in the parasite too. A recent kinome-wide 
RNAi screen with 176 individual cell lines of mammalian infective bloodstream 
forms of Trypanosoma brucei identified protein kinases required for proliferation 
in vitro. In order to investigate which protein kinases are also essential virulence 
factors in vivo, lines were pooled, inoculated into mice and screened for loss of 
fitness after 48 hours RNAi compared to uninduced controls. The presence of 
trypanosomes in the bloodstream was assessed using RNAi target sequencing 
(RITseq) and compared to an in vitro control. This revealed 49 protein kinases 
with a significant loss of fitness in vivo in two independent experiments, and a 
strong correlation between in vitro and in vivo loss of fitness for the majority. 
However, depletion of nine protein kinases affected more pronouncedly the 
growth in vivo than in vitro. Amongst these protein kinases were several with 
putative functions related with stress responses mediated through the PI3K/TOR 
or MAPK signaling cascades including CK2A2, a promiscuous protein kinase whose 
activity can be stress-induced; two MAP3Ks, involved in cell integrity upon 
osmotic shock; VPS15, component of the PI3K complex with roles in 
autophagosome formation and vesicular trafficking; BUD32, transducer of the 
PI3K/TOR pathway involved in translational regulation; and FAZ20, a parasite-
specific pseudo-kinase localizing to the flagellum attachment zone. The other 
three have been implicated in repair of alkylation-induced cellular damage: 
SRPK1, a stress response RNA splicing regulator; AUK2, which acts during mitosis; 
and CAMKL, an AMPK with calcium-binding domains putatively involved in 
metabolic regulation. Identification of these virulence-associated protein kinases 
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provides new insights in T. brucei-host interaction and reveals novel potential 
drug targets for protein kinase inhibitors. 
This RNAi screen revealed that the evolutionary divergent NEK kinase Repressor 
of Differentiation Kinase 2 (RDK2) has severe loss of fitness both in vitro and in 
vivo.  Depletion of RDK2 had been shown previously to promote differentiation 
from bloodstream to procyclic-like forms causing the parasite’s death. Further 
investigation showed RDK2 to be an active protein kinase capable both of 
phosphorylating a substrate and to autophosphorylate. Protein kinase activity 
could be ablated by mutation of lysine 70 to methionine.  Mutation of both 
serine residues (195 and 197), identified as sites of phosphorylation by 
phosphoproteomics, to alanine or glutamic acid, preventing and mimicking 
phosphorylation respectively, had no effect on protein kinase activity, 
suggesting they do not have a direct regulatory role on protein kinase activity. 
Introducing in the RNAi line a recoded RDK2 whose transcript eluded 
interference, permitted to some extent the rescue of the induced phenotype, 
while introducing a recoded inactive mutant did not. This may suggest that the 
lack of kinase activity was responsible for the RNAi phenotype and not depletion 
of the protein alone. RDK2 RNAi-differentiated cells could be maintained in 
conditioned procyclic form media for more than a week. However, they were 
unable to proliferate. Overexpression of RDK2 blocked the differentiation 
mediated by sequential treatment with 8-pCPT-cAMP and citrate/cis-aconitate 
(CCA). RNAi experiments in combination with known differentiation cues, 
suggested that when differentiation is triggered by the CCA signalling pathway, 
RDK2 inactivation happens downstream of the phosphatase TbPTP1. 
Differentiation caused by RDK2 inactivation could be traced in flow cytometry by 
the detection of EP procyclin expression. This was exploited in a cell-based 
mechanism-directed phenotypic screen for RDK2 inhibitors. A preliminary run 
with 518 drug-like molecules that had shown protein kinase inhibition, 
trypanocidal activity and/or activation of the EP procyclin promoter, unveiled 6 
compounds triggering EP procyclin expression and parasite death in the low 
micromolar range. These compounds can be investigated further to assess 
whether RDK2 is their in vivo target. 
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Chapter 1 General introduction 
 
1.1 Trypanosoma brucei 
The obligatory parasitic protozoan Trypanosoma brucei is an early divergent 
eukaryote widely used as a model organism to study many conserved and not 
conserved cellular functions. It is taxonomically clustered in the class 
“kinetoplastida” which groups flagellated protozoa characterized by a dense 
complex of mitochondrial circular DNA called the “kinetoplast”. It is the causal 
agent of African Trypanosomiasis, a neurological disease of mammals that 
remains a major Public Health and economic problem in the areas of sub-
Saharan Africa where the blood-feeding insect vector responsible for 
transmission, the tsetse fly, lives. African Trypanosomiasis has been neglected 
for years by the drug development industry as the potential market –large 
proportions of the population living in poor rural areas without access to decent 
health care systems- was not considered safe in order to recover the investment. 
Since the 2012 London Declaration on Neglected Tropical Diseases (inspired by 
the WHO 2020 roadmap), the raising of public-private partnerships, the 
connection of health care organizations with global experts trying to understand 
the disease, and the commitment of local and international authorities, society 
is in a position to achieve elimination in the not too distant future. 
1.1.1 Kinetoplastids 
The class Kinetoplastida are highly divergent eukaryotic protozoan belonging to 
the supergroup Excavata, group Discoba, subgroup Discicristata, and phylum 
Euglenozoa (Moreira, López-García and Vickerman, 2004), Figure 1-1. It is 
further divided in Prokinetoplastina and Metakinetoplastina, two sub classes, the 
last of which contains the order Trypanosomatida that includes three of the 
parasitic uniflagellates responsible for some of the diseases that cause greater 
economic and public health burden in the most impoverished areas of the world: 
Trypansoma brucei, Trypanosoma cruzi and Leishmania species (Lukeš et al., 
2014). T. brucei and T. cruzi genomes share an average of 57% identify, while T. 
brucei and L. major share about 44% (El-Sayed, Myler, Blandin, et al., 2005). 
There is evidence that it is possible to develop therapies able to target the three 
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parasites with a single drug (Khare et al., 2016). All kinetoplastids share 
divergent aspects of cell biology in respect to other eukaryotes as mitochondrial 
RNA editing, a particular genomic organization that will be discussed below, 
mRNA trans-splicing, or compartmentalized glycolysis (Simpson, Stevens and 
Lukeš, 2006; Lukeš et al., 2014). 
 
Figure 1-1. Eukaryotic phylogenetic tree highlighting the taxonomic 
classification of kinetoplastid parasites.  
Modified from (Lukeš et al., 2014) 
 
1.2 African Trypanosomiasis 
There are two subspecies described as a cause for Human African 
Trypanosomiasis (HAT) also called “sleeping sickness” due to the characteristic 
sleep-wake cycle disorders: Trypanosoma brucei rhodesiense, that has acute 
symptoms killing the patients in weeks or months, and is endemic in East and 
South Africa; and Trypanosoma brucei gambiense, that is a more progressive 
chronic debilitating disease, and is prevalent in Central and West Africa. T. b. 
gambiense causes 95% of the reported cases (Stuart et al., 2008; Brun et al., 
2010).  
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There is only one subspecies responsible for the veterinary disease called Animal 
African Trypanosomiasis (AAT) or “Nagana”: Trypanosoma brucei brucei. In 
addition, AAT can be caused by other three trypanosome species: Trypanosoma 
vivax, Trypanosoma evansi, and Trypanosoma congolense. These animal 
pathogens rarely produce disease in humans although few cases have been 
reported (Truc et al., 1996; Joshi et al., 2005; Deborggraeve et al., 2008). They 
cause great financial losses in local economies, e.g. $1.3 billion were estimated 
in 1999 (Kristjanson et al., 1999), as they compromise food security and life-
stock farming due to increase in mortality, reduction in calving rates, draft 
power or meat and milk production (Holt et al., 2016). T. b. brucei is commonly 
used as a laboratory model to study HAT.  
1.2.1 Physiopathology 
Even when the subspecies of the parasite cause different chronicity and 
virulence, they both develop two consecutive stages. Firstly, haemolymphatic, 
which happens when the parasite lives and replicates in the circulatory 
apparatus -blood and lymph- causing intermittent but chronic fever, itching, 
headache, lymphadenopathy, and sometimes hepato-splenomegaly. Secondly, 
meningo-encephalitic stage, that is when eventually the parasite penetrates the 
Central Nervous System (CNS) causing sleep disorders, coma and death if stays 
untreated (Brun et al., 2010). It is unclear to what extent the neurological 
symptoms are caused by the parasite itself or by the immune response that it 
triggers (Kristensson et al., 2010).  
During the meningeal stage, T. brucei access to the cerebrospinal fluid at the 
circumventricular organs (together with inflammatory cells) throughout the 
fenestrated capillaries at the coroid plexus, where the blood brain barrier (BBB) 
is absent (Mhlanga, Bentivoglio and Kristensson, 1997; Kristensson et al., 2010).  
During the encephalitic stage, access to the brain parenchyma through the BBB 
has been documented in experiments with craniotomized mice. It was unclear 
whether it happened by crossing the vascular endothelium, or by invading the 
subarachnoid space, and spreading along the Virchov-Robin space (Frevert et al., 
2012). Experiments performed with non-invasive in vivo-imaging techniques, 
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however, were unable to reproduce this observation and parasites were retained 
in the cortical dura (Coles et al., 2015). 
Since the parasite expresses major surface metalloproteases (Grandgenett et 
al., 2007), oligopeptidases, or cysteine peptidases such as brucipain (Lonsdale-
Eccles and Grab, 2002) it has been proposed a proteolytic opening of the BBB, 
however there is no evidence of its disruption during transmigration of the 
parasites (Wolburg et al., 2012).  
It has been proposed also that brucipain may activate protease-sensitive G-
protein coupled endothelial receptor, triggering Ca2+-PKC signalling that would 
open tight junctions in the BBB (Grab et al., 2009). Finally, passage from the 
perivascular space to the CNS may also happen with an increase of BBB 
permeability associated with lymphocyte-derived IFN- production. This has been 
proposed to happen in areas of the parenchymal basement membrane coated 
with laminin 4 (Masocha et al., 2004), assisted by increased adhesion triggered 
by ICAM-1 and VCAM-1 expression, and secretion of endothelium activation 
factors (Grab and Kennedy, 2008) 
Infection of the neurohypophisis, subformical organ, and the vascular organ of 
the lamina terminalis, causes also deregulation of vasopressin and luteinizing 
hormone causing oedema, impotency, and infertility (Kennedy, 2013). 
Death happens by heart failure, usually after pancarditis in acute HAT mainly; or 
by opportunistic infection, malnourishment, and encephalitis, in chronic HAT 
(Schmidt, 1983). 
Animal models for all subspecies of T. brucei show good correlation with 
observations made in post-mortem human samples of the disease: they all 
suffered neuroinflammation, progressing from meningitis to cerebral vasculitis 
and final encephalitis. They show infiltrates of lymphocytes, plasma cells and 
macrophages (accompanied by the parasites); activation of astrocytes and 
microglia is frequently reported; and little demyelinization occurs towards the 
terminal stages of the disease while nervous tissue is generally spared (Rodgers, 
2010; Mogk et al., 2016). 
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1.2.2 Epidemiology 
Trypanosoma brucei is transmitted mainly by the bite of a blood-feeding vector, 
the tsetse fly: 31 species and subspecies of the genus Glossina (Jordan, 1977). 
The parasite spreads across all the regions where the insect lives (Brun et al., 
2010): mainly in rural areas of 30 sub-Saharan African countries Figure 1-2, 
although it has been reported in urban and periurban locations too (Robays et al. 
2004). Additionally, for T. b. gambiense infection -which is an anthroponotic- a 
few cases have been identified after congenital transmission (Lindner and 
Priotto, 2010), or laboratory accidents (Herwaldt, 2001), and -at least one case 
reported- sexual interaction (Rocha et al., 2004). Although it has never been 
documented, blood transfusions or organ donations would constitute a risk of 
infection too (World Health Organization, 2013). Efficiency of transmission in T. 
b. rhodesiense –which is a zoonosis and has its reservoir in domestic livestock- 
has been proven much higher: a single parasite can colonize the vector (Maudlin 
and Welburn, 1989) and a single tsetse bite can infect the mammal (Thuita et 
al., 2008). Lower efficiency in T. b. gambiense is compensated by chronicity of 
the infection in the mammalian host making the parasite available in blood for 
longer (World Health Organization, 2013). 
 
Figure 1-2. Distribution of human African trypanosomiasis caused by T. b. 
gambiense and T. b. rhodesiense.  
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Adapted from World Health Organization, Control of Neglected Tropical diseases 
site (http://www.who.int/trypanosomiasis_african/country/en/), accessed 
December 2016.  
 
The World Health Organization (WHO) considered 2020 a realistic deadline for 
elimination as a public health problem of Human African Trypanosomiasis (HAT), 
which would mean reducing the incidence to less than 1 new case per every 
10000 inhabitants (Savioli and Daumerie, 2012). In 2012, 13.1 million people 
lived still in areas where this was not true. Only by better usage of the drugs 
already available, and the coordinated work of local and international bodies, 
2015 provided the lowest record of new reports of T. b. gambiense HAT in 
history: 3000 new cases in 24 countries of west and central Africa. Together with 
T. b. rhodesiense HAT data for east and southern Africa in 2014 (117 new cases 
in 13 countries), these are symptoms that WHO 2020 goals might be achievable 
(Drugs for Neglected Diseases initiative, 2015).  
A model-based analysis of screening data predicted underestimation in 50% of 
the studies (Jo Robays et al., 2004; Checchi et al., 2012). The existence of 
animal reservoirs (El-Sayed, Myler, Bartholomeu, et al., 2005), the climate 
change leading to vector redistribution (Moore et al., 2012) and the sexual 
recombination described at least during the insect stages (Peacock, Bailey, et 
al., 2014) have produced resurgence from lower levels in the past (Delespaux 
and de Koning, 2007; Brun et al., 2011). Namely, after figures close to 
eradication in the 1960s, African independence and civil warfare led to 
interruption of control and surveillance measures implemented during the 
colonial period producing a peak of incidence (>300,000 estimated infections) in 
the 1990s (Paquet et al., 1995; Ekwanzala et al., 1996; Smith, Pepin and Stich, 
1998; Barrett, 1999; Moore and Richer, 2001; Stanghellini and Josenando, 2001; 
Van Nieuwenhove et al., 2001). T. b. gambiense tends to be epidemic (Ford, 
1969; World Health Organization, 2013) while T. b. rhodesiense is more 
endemic, with a large variety of wild and domestic animal reservoirs 
1.2.3 Diagnostics 
A major problem affecting epidemiology of African Trypanosomiasis is the lack of 
systematic screens, which is limited to specific campaigns conducted in high- 
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and moderate-transmission areas. Many patients are identified by self-reporting 
to health care centres, something that is not possible in poor remote areas. For 
T. b. gambiense, there are serological diagnostic tools as the card agglutination 
test for trypanosomiasis (CATT). Otherwise diagnostics relays on evaluation of 
clinical symptoms and visual parasite identification. Thus, analysing samples of 
blood or chancre aspirates under the microscope requires skilled medical teams. 
In order to determine the disease stage, identification of the parasite in 
cerebrospinal fluid is conducted after lumbar puncture. There are no serological 
tests currently available for T. b. rhodesiense, most of these cases are identified 
attending to signs and symptoms (Sutherland et al., 2015). Optimization of new 
rapid diagnostic tests is under way (Sternberg et al., 2014), and a series of new 
antigens that may be useful also for T. b. rhodesiense diagnostics have been 
proposed (Biéler et al., 2016). 
1.2.4 Therapies and control strategies 
The current therapies have limitations due to high toxicity and difficult 
administration patterns (Wilkinson and Kelly, 2009). For the early 
haemolymphatic stage, pentamidine (T. b. gambiense) and suramin (T. b. 
rhodesiense) are the treatments of choice. Once the parasite reaches the 
central nervous system (stage 2), for T. b. gambiense, the most satisfactory 
solution is NECT (Nifurtimox-Eflornithine Combined Therapy), less toxic than 
melarsoprol and of easier administration than eflornithine in independent 
therapy. However, for T. b. rhodesiense, melarsoprol is still the only available 
stage 2 option. Since the Drugs for Neglected Diseases Initiative (DNDi) has been 
in place, another two drugs have entered clinical trials (fexinidazole and SCYX-
7158) however, fears of development of parasite resistance make essential 
appointment of novel treatment options (Jones et al., 2015; Wyllie et al., 2015). 
A lot need still to be done. 
In T. b. gambiense infection control, mass-screening and treatment has been 
shown successful in reducing the prevalence as humans are the main reservoir 
for the parasite (Simarro et al., 2006, 2015) but the above mentioned 
underestimation rates led to persistence in many cases (Jo Robays et al., 2004; 
Checchi et al., 2012). 
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In 2000, after the 36th summit of the Organisation of African Unity (OAU), 
several African Heads of State engaged with the Pan African Tsetse and 
Trypanosomiasis Eradication Campaign (PATTEC) whose objective was the total 
eradication of tsetse flies across the continent aiming to blocking transmission 
(Kabayo, 2002). Although commitment of local governments with the initiative 
have been cyclic along time, four approaches were used mainly for this purpose: 
artificial baits (insecticide-treated traps), insecticide-treated cattle, aerial 
spraying, and the sterile insect technique (Shaw et al., 2013a), cost-
effectiveness of the different approaches have been subject of debate in the 
field (Bouyer, Seck and Sall, 2013; Shaw et al., 2013b).  
1.3 Life cycle 
T. brucei exhibits a complex life cycle that requires adaptation to many 
different environments, including different compartments within the blood-
feeding insect vector responsible for transmission between different mammalian 
hosts: the tsetse fly (Glossina sp.). Figure 1-3. 
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Figure 1-3. Trypanosoma brucei life-cycle.  
(1) Procyclic trypomastigote, (2) elongated mesocyclic trypomastigote, (3) long 
epimastigote, (4) short epimastigote, (5) attached salivary gland epimastigote, 
(6) mammalian-infective metacyclic trypomastigote, (7) Slender bloodstream 
trypomastigote, and (8) stumpy bloodstream trypomastigote. Curved arrows = 
replicating stages. * = single asymmetric division. Adapted from Gluenz et al. 
(2015). 
 
1.3.1 T. brucei in the mammalian host 
Once in the mammal, T. brucei resides extracellularly in the bloodstream, tissue 
fluids, central nervous system, adipose tissue (Trindade et al., 2016), and –as 
recently shown- in the skin (Capewell et al., 2016). It presents two main life 
cycle stages: the slender, replicative, trypomastigote; and the stumpy, cell 
cycle-arrested form. These are two ends of an irreversible differentiation 
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process, which proceeds through many intermediate stages, and happens in 
response to density-dependent signalling (Rico et al., 2013). All of them are 
coated with a densely packed single Variant Surface Glycoprotein (VSG) that 
assists the parasite in overcoming the immune response at a population level 
(Mugnier, Stebbins and Papavasiliou, 2016). 
1.3.1.1 Slender to stumpy form differentiation 
Differentiation to stumpy forms relies upon a quorum sensing mechanism in 
response to high densities reached by the parasite in the peak of parasitemia 
(Rico et al., 2013). Many laboratory-adapted strains passaged repetitively from 
in vitro culture to mice without the natural mediation of the insect vector, lost 
their ability to differentiate into stumpy forms by monitoring their own 
concentration (Turner, 1990). These cells, selected before cryopreservation 
methods became available, can grow without limit until killing the host a few 
days after the infection. Their high virulence would be counter–selective in 
natural conditions as flies would not have time to transmit parasites before they 
were able to kill the host (Mony and Matthews, 2015). 
Known signalling pathways involved in slender to stumpy form 
differentiation 
The quorum sensing molecule has not been identified yet but has been proposed 
to be soluble, of low molecular weight, and heat stable, originated by T. brucei 
as an autocrine response (Vassella et al., 1997). It has been termed Stumpy 
Induction Factor (SIF), and monomorphic parasites are not responsive to it 
(MacGregor et al., 2012). 
A 2-3 fold increase of cAMP levels has been detected in the peak of parasitemia 
which declines immediately after stumpy differentiation (Mancini and Patton, 
1981), conditioned medium with SIF also increases cAMP in cultured pleomorphic 
parasites (Vassella et al., 1997). Differentiation could only be triggered by 
hydrolysable analogues of cAMP, such as 8-(4-Chlorophenylthio)adenosine 3′,5′-
cyclic monophosphate (8-pCPT-cAMP), suggesting that its metabolites (and not 
cAMP itself) are the responsible factors for triggering differentiation. The 
process requires phosphodiesterase activity (Oberholzer et al., 2007). Unlike SIF, 
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cell permeable, hydrolysable cAMP analogues triggered stumpy differentiation 
also in monomorphic parasites: “stumpy*” (Laxman et al., 2006). This suggests 
that monomorphic T. brucei conserves some of the downstream components of 
the SIF-mediated stumpy differentiation pathway. 
A phenotypic screen detected RNA interference (RNAi) of several proteins 
causing insensitivity to 8-cPTP-cAMP, suggesting that they are involved in 
pathways regulating this signalling mechanism (Mony et al., 2013).  
Several protein kinases and phosphatases were found in this study with yeast 
orthologues having dormancy-triggering functions in response to glucose-
starvation (Mony and Matthews, 2015). Among them there was a YAK 
(Tb927.10.15020) protein kinase, a dual specificity phosphatase (DsPhos, 
Tb927.7.7960), and the PKA regulatory subunit (PKA-R, Tb927.11.4610), all 
having yeast orthologues connected in a same pathway. In yeast, YAK 
translocates to the nucleus upon glucose starvation where it phosphorylates PKA-
R, causing inactivation that leads to cell cycle arrest (Griffioen et al., 2001); and 
DsPhos regulates PKA directing transcriptional changes also linked to glucose 
starvation (Zaman et al., 2008). PKA (cAMP-dependent protein kinase) increases 
proliferation in glucose-rich media, activated by cAMP (Griffioen et al., 2000). 
As it happens in yeast, glucose starvation following the peak of parasitemia, may 
be the cause for cAMP decrease and subsequent cell cycle arrest. PKA has been 
found in the flagellar matrix of T. brucei and RNAi impairs the parasite´s 
motility (Oberholzer et al., 2011), a function regulated by PKA in other 
eukaryotes such as Dictyostelium discoideum (Simon et al., 1992). 
An AMPK2 catalytic subunit (Tb927.3.4560) was also identified as required for 
stumpy development in the RNAi screen with yeast orthologues inhibiting TOR 
(Carling et al., 2011). Interestingly, TbTOR4 downregulation triggers stumpy 
formation in T. brucei (Barquilla et al., 2012). AMPK may act, like the yeast 
orthologue, as an energy sensor that reduces catabolism when AMP levels 
increase as a consequence of glucose starvation (Mony and Matthews, 2015). In 
fact, AMPK2 has been shown to form complexes with AMPK1 (Tb927.10.5310), 
whose activation via phosphorylation in a tyrosine residue at the activation loop, 
is mediated by cAMP analogues (that also inhibit TbTOR4) and oxidative stress; 
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and that once it is active, triggers differentiation to stumpy forms (Saldivia et 
al., 2016). 
MAPK (mitogen-activated protein kinase) cascades, are a three module system of 
protein kinases that convey extracellular signals activating transcription factors 
in other eukaryotes (Garrington and Johnson, 1999). In T. brucei, knockdown of 
a MAP3K (upstream component of these cascades), Tb927.2.2720, also renders 
cells insensitive to 8-pCTP-cAMP and SIF-mediated differentiation (Mony and 
Matthews, 2015). Finally, a NEK family of kinases, indistinguishable via RNAi 
(Tb927.10.5930/5940/5950), was also found retarding stumpy differentiation 
upon knockdown. NEKs (Never in mitosis A-related kinases) are a family of 
check-point regulators in the cell cycle (Moniz et al., 2011; Fry et al., 2012). 
This family of protein kinases is relatively expanded in T. brucei (Parsons et al., 
2005), likely having parasite specific functions as regulation of progression 
throughout the life cycle. In fact other NEK, RDK2, that will be analysed in detail 
in one of the chapters of this thesis, has been identified regulating this aspect of 
the parasite biology in subsequent stages of the life cycle (Jones et al., 2014). 
Several gene expression-regulation factors have been identified in the RNAi 
screen selecting lines after 8-pCTP-cAMP treatment as, for instance, the 
transcriptional-silencing Imitation SWItch (ISWI), which is a stumpy inducer 
(Hughes et al., 2007; Stanne et al., 2011). But more relevant according to T. 
brucei biology, they found RNA binding proteins (RBPs), which are the principally 
responsible for post-transcriptional regulation in the parasite (Clayton, 2014; 
Kolev, Ullu and Tschudi, 2014). RBP7A and RBP7B (Tb927.10.12090 and 
Tb927.10.12100, respectively) were found as required for slender-to-stumpy 
differentiation mediated by 8-pCTP-cAMP in the RNAi screen, with 
overexpression causing premature stumpy formation (Mony et al., 2013). Other 
three hypothetical proteins found in this screen were identified as positive 
(Tb927.9.4080) or negative (Tb927.11.6600) transcriptional regulators in a whole 
genome overexpression analysis targeting RNA binding proteins (Erben et al., 
2014). The third, Tb927.11.2250, has not been validated yet as a stumpy inducer 
individually but it does bind RNA (Mony and Matthews, 2015). 
Another 10 hypothetical proteins were identified in the RNAi screen, that have 
orthologues in other eukaryotes involved in mitochondrial import or 
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ubiquitination (Mony et al., 2013). They may be involved in mitochondrion 
development, intrinsic to stumpy formation; or degradation of proteins that are 
no longer needed in that stage of the life cycle (Mony and Matthews, 2015). 
Transition to stumpy forms is accompanied by silencing of the VSG expression 
site (ES) (Amiguet-Vercher et al., 2004), while RNAi of VSG causes cell cycle 
arrest (Sheader et al., 2005; Smith et al., 2009). This prepares stumpy cells for 
quick coat exchange upon tsetse fly uptake, and may cause their death in the 
bloodstream upon VSG turnover (Sheader et al., 2005), possibly due to lysis 
mediated by the alternative pathway of the complement (Ferrante and Allison, 
1983). That would explain the 55 h life-span calculated in the bloodstream for 
this particular life-stage (MacGregor et al., 2012). Depletion of three expression 
site-associated genes (ESAG1, 2, and 8) has also been described causing 
expression of stumpy-specific PAD transporters (Dean et al., 2009), and 
producing cell cycle arrest (Batram et al., 2014). It happens in a reversible 
manner and orchestrated by disruptor of telomeric silencing-1B (DOT1B)-
mediated histone methylation.  
Other factors that had been linked to stumpy formation before the RNAi screen 
was performed were: zinc finger kinase (ZFK), in vitro but not in vivo (Vassella 
et al., 2001); and TbMAPK5, in vivo and in vitro although reducing the parasite 
survival in the mouse bloodstream (Domenicali Pfister et al., 2006). While ZFK 
and MAPK5 knockdown only caused stumpy differentiation in pleomorphic 
parasites, TbTOR4 RNAi caused it also in monomorphic cells. It may suggest a 
role of TbTOR4 downstream the other two, in the part of the pathway retained 
by monomorphic strains which is sensitive to 8-pCTP-cAMP but not to SIF (Mony 
and Matthews, 2015). 
1.3.1.2 Antigenic variation to evade the immune system 
Slender forms replicate actively and travel in the blood colonizing the host, 
while expressing a single glycophosphatidyl inositol (GPI)-anchored Variant 
Surface Glycoprotein (VSG) per cell, which can be switched upon expansion of 
the population to create diversity (McCulloch and Field, 2015).  
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The parasite harbours >1000 different VSG genes placed at the subtelomeric 
regions within 15-20 expression sites (ES) located in the telomeres (see below). 
Only one ES is active at a given time, expressing a single VSG. 80% of VSG genes 
are pseudogenes with only about 400 complete open reading frames (Berriman 
et al., 2005; Cross, Kim and Wickstead, 2014). Switches happen in situ, when 
one ES inactivates after a second becomes active; or by “gene conversion”, 
when a different VSG jumps into the active ES (Pays et al., 2001; Li, 2015). It is 
also possible homologous recombination leading to generation of novel variants, 
the so-called “mosaic” VSG (Mugnier, Stebbins and Papavasiliou, 2016). At a 
given time in an infection, >80 different VSG-expressing clones have been 
identified (Hall, Wang and David Barry, 2013; Mugnier, Cross and Papavasiliou, 
2015), Figure 1-4. 
 
Figure 1-4. In vivo dynamics of VSG expression.  
Based in RNA levels during the first 30 days of 4 mice infections, purifying 
parasites from blood every 3-4 days. Black line represents overall parasitemia 
levels. Coloured lines represent those VSG variants expressed that constituted 
more than 0.1% of the population. Adapted from Mugnier et al. (2015) 
 
The host builds an adaptive immune response against at least the most abundant 
variants, leading to their clearance and enabling outgrowth of cells that have 
switched to an antigenically distinct VSG. Iteration of this process -coupled to 
stumpy differentiation- leads to the characteristic waves of parasitemia 
(Matthews, McCulloch and Morrison, 2015). Antigenic variation makes it 
extremely difficult to develop an effective vaccine (Deitsch, Lukehart and 
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Stringer, 2009; MacGregor et al., 2012).  Since current therapies have limitations 
due to high toxicity and difficult administration patterns, there is a need to 
explore new routes for disease treatment and parasite eradication. 
Immunoglobulin M (IgM) is the critical antibody isotype for VSG recognition and 
clearance in acute infections developed by monomorphic parasites unable to 
undergo stumpy differentiation (Tyler et al., 2001), but IgG anti-VSG is the main 
antibody responsible for opsonisation in pleomorphic strains and in the natural 
environment (Schwede et al., 2015). Parasites expressing a given VSG are 
cleared within a week (Magez et al., 2008), once the antibody titre overwhelms 
the endocytosis and degradation pathways (Engstler et al., 2007). Protruding 12-
15 nm from the surface, VSG shields most of invariable surface proteins (such as 
hexose transporters). However, IgG has been proven to access other surface 
antigens, some able to reach above the top of the VSG barrier, as the invariant 
surface glycoproteins (ISG) or ESAG4 transmembrane proteins (Hsia, Beals and 
Boothroyd, 1996; Schwede et al., 2015). Antibodies against the invariable 
proteins are not sufficient to produce immunity (Ziegelbauer and Overath, 1993; 
Sullivan et al., 2013). 
Slender forms undergo VSG switching at a higher rate, stumpy are more efficient 
at antibody clearance by internalization and recycling of opsonized VSGs through 
the flagellar pocket located in their posterior end. They have been shown to be 
dragged there by means of hydrodynamic flow (Engstler et al., 2007). Upon 
stumpy form differentiation, the haptoglobin-haemoglobin receptor (HpHgR) is 
downregulated, contributing to the immune defence of quiescent forms. HpHgR 
is the internalization route for the serum-borne trypanosome lytic factor (TLF1) 
(Vanhollebeke et al., 2008), and protection against it is mediated by SRA, a VSG 
expression site (ES) component (Van Xong et al., 1998). Depletion of HpHgR may 
compensate ES downregulation in stumpy forms. 
1.3.2 T. brucei in the tsetse fly 
T. brucei progression throughout the tsetse fly is the more challenging section of 
the life cycle, as less than 20% of the flies develop a mature infection under 
optimised laboratory conditions or in the wild (Haines, 2013). Susceptibility 
toward infection and capacity of the parasites to progress until metacyclogenesis 
Chapter 1 37 
 
in the salivary glands is variable between different species of fly and parasite 
(Macleod et al., 2007; Peacock et al., 2012). Immune response clears 95% of 
trypanosomes in the fly (Aksoy, Gibson and Lehane, 2003). Once in the tsetse 
midgut the stumpy forms develop into procyclic trypomastigotes, which 
eventually cross the peritrophic membrane and proliferate in the ectoperitrophic 
space (Gibson and Bailey, 2003). Then, they migrate to the proventriculus (Van 
Den Abbeele et al., 1999), where they differentiate into long mesocyclic 
trypomastigotes able to divide into short and long epimastigotes (Sharma et al., 
2008). Epimastigotes can re-enter the gut lumen migrating through the foregut 
with apparently only the short epimastigotes entering the salivary glands (Van 
Den Abbeele et al., 1999). There, evidence of meiosis -causing genetic 
exchange- has been reported (Peacock et al., 2011) but it is not needed for the 
final differentiation to mammalian-infective metacyclic trypomastigotes (Van 
Den Abbeele et al., 1999), Figure 1-5. Overexpression in vitro of an RNA binding 
protein, RBP6 (Tb927.3.2930), has been proven to reproduce in axenic culture 
all the fly stages of the parasite, depending on the duration and level of 
expression (Kolev et al., 2012). 
 
Figure 1-5. Schematic representation of the migration of Trypanosoma 
brucei throughout the different compartments of the tsetse fly.  
(i) Midgut lumen, (ii) peritrophic matrix, (iii) midgut epitelium, (iv) 
ectoperitrophic space, (v) proventriculus, (vi) oesophagus, and (vii) salivary 
glands. Colours representing stage-specific surface antigens: EP procyclin 
(green), GPEET procyclin (red), brucei alanine-rich protein (BARP, blue). 
Adapted from (Imhof and Roditi, 2015). 
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1.3.2.1 Stumpy to procyclic form differentiation 
Stumpy forms are cell cycle-arrested and pre-adapted for survival in the insect 
midgut upon parasite uptake. They express PAD1 and PAD2, carboxylate surface 
receptors (Dean et al., 2009), whose transport to the membrane increases at the 
lower temperatures that the parasite reaches in the tsetse fly. Under exposure 
to the environment they find in the midgut -rich in intermediates of the 
tricarboxylic acid cycle- they differentiate to procyclic forms more readily than 
slender forms. This can be mimicked in vitro by citrate/cis-aconitate incubation, 
limited protease digestion, or mild acidic treatment, (Rico et al., 2013). 
Differentiation involves a fast coat exchange of VSG for dipeptide (EP) and 
pentapeptide (GPEET) repeats-enriched procyclins, which bear a protease 
resistant C-terminal domain (Acosta-Serrano et al., 2001) and whose expression 
is regulated by mitochondrial factors (Vassella et al., 2004). In addition, stumpy 
forms present a more elaborated mitochondrion, which provides metabolic 
adaptation. In the tsetse midgut proline, instead of glucose, becomes the main 
carbon source (Vassella et al., 2000). Transcripts for mitochondrial proteins and 
procyclins are stocked up in stumpy forms (Kabani et al., 2009; Queiroz et al., 
2009), ready for translation upon exposure to the environmental cues driving 
procyclic formation in the fly. 
Non-differentiated slender forms die in a few hours while procyclic forms 
continue the life cycle. In addition, stumpy cell cycle arrest provides at least 
two selective advantages: it avoids overwhelming the mammal causing 
premature death before fly transmission; and prevents DNA replication during 
the environmental shock at the fly midgut that could induce mutations (Rico et 
al., 2013).  
A phosphatase cascade is the best-described signalling pathway regulating this 
developmental transition. A tyrosine phosphatase, TbPTP1 (Szöor et al., 2006), 
prevents stumpy forms from differentiating to procyclic until internalization of 
citrate or cis-aconitate (CCA) (Brun and Schonenberger, 1981), through the PAD 
transporters (Dean et al., 2009). This can be mimicked in vitro by exposure to 
CCA, but also to mild acidic conditions (Rolin et al., 1998), or conducting 
TbPTP1-specific inhibition with a tool compound (BZ3) (Szöor et al., 2006). In 
the absence of these triggers, a glycosomal DxDxT phosphatase, TbPIP39 (Szöor 
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et al., 2010), is dephosphorylated by TbPTP1 in a feed back loop where the 
dephosphorylated enzyme empowers activity of its phosphatase. Upon TbPTP1 
inactivation via the above-mentioned differentiation cues, TbPIP39 is 
phosphorylated and the parasite progresses to the procyclic form. This can be 
triggered also by exposure of the cell surface to limited protease digestion in a 
mechanism independent of the phosphatase cascade (Szöőr et al., 2013). 
Exposure to both CCA and protease treatment at once, seems to have a 
synergistic effect (Sbicego et al., 1999), so both triggers may have a combined 
effect in vivo. 
A kinome-focused RNAi screen of the parasite in vitro (Jones et al., 2014) that 
identified several protein kinases fundamental for cell cycle regulation, 
detected also two -RDK1 and RDK2- whose depletion triggered spontaneous 
differentiation from bloodstream to procyclic-like forms. As bloodstream form 
“repressors”, they cannot be responsible for TbPIP39 phosphorylation because 
they have the opposite effect, but their role will be discussed in detail in the 
fourth chapter of this thesis. 
6 hours upon initiating differentiation with CCA, VSG is released from the 
surface by GPI hydrolysis mediated by GPI-PLC and TbMSP-B (Gruszynski et al., 
2006). Then, immediately after a peak of intracellular cAMP, takes place the 
first cell division followed by ESAG4 loss, a transmembrane adenylate cyclase 
(Rolin et al., 1993). Translation activates again 1-6 hours upon CCA exposure 
(Capewell et al., 2013), DNA synthesis starts only after 8-10 hours, and 
procyclins express in the surface from 2 hours post induction (Matthews and 
Gull, 1994). There is another peak of adenylate cyclase activation immediately 
before cells start proliferating, between 8-19 hours (Rolin et al., 1993). 
Upon differentiation, EP and GPEET procyclins, that are resistant to GPI-PLC 
hydrolysis (Field, Menon and Cross, 1991), are co-expressed in what are called 
“early procyclic forms” but after 7-9 days, GPEET is downregulated coinciding 
with colonisation of the ectoperitrophic space (“late procyclic forms”). In vitro 
GPEET can be maintained by addition of glycerol, or removed quickly by 
hypoxia. GPEET is regulated post-transcriptionally by a sequence in the 
3´untranslated region (Vassella et al., 2000). 
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It has recently been observed that when early procyclics (GPEET+) are 
inoculated into agarose plates, to mimic the semi-solid nature of the surfaces 
they find in the tsetse fly, they are capable of developing social motility (SoMo). 
Isolated colonies grew until a threshold of about 1.6x106 parasites and then 
created radial projections (Imhof and Roditi, 2015). These finger-like protrusions 
moved in masse from the inoculation site and, if streams protruding from 
different colonies came close, they shifted their direction to avoid contact, 
suggesting a repellent substance might be emitted from different streams. As it 
happens with stumpy form formation or procyclic forms grown in liquid culture, 
a density sensing mechanism must be in place holding cells together in a stream 
and also guiding them radially in finger-like shapes. It is the developmental state 
(early or late procyclic) and not the presence of the GPEET marker what causes 
SoMo (Imhof et al., 2014). Several proteins are differentially expressed in early 
and late stages although none has been yet linked to the phenomenon. It has 
been proposed that this behaviour might have implications toward colonization 
of the ectoperitrophic space that happens around 3 days post infection (Gibson 
and Bailey, 2003). Less than 1% of the parasites can make it (Oberle et al., 2010; 
Imhof and Roditi, 2015). Independent procyclic forms have been shown to fuse 
their flagellar membrane and exchange proteins in a form of cell-to-cell 
communication (Imhof et al., 2016).  
1.3.2.2 Procyclic trypomastigote-mesocyclic trypomastigote-epimastigote 
The way T. brucei access the ectoperitrophic space is not well understood, but 
analysis of the peritrophic matrix structure suggests the need of proteases and 
lipases in order to cross the inner membrane (Evans and Ellis, 1983; Rose et al., 
2014). There is evidence of parasites crossing, -flagellum first,  through holes in 
the membrane suggesting its damage (Ellis and Evans, 1977; Evans and Ellis, 
1983). It is hypothesized that peritrophic membrane thickness and composition 
affects refractoriness or susceptibility of the fly toward infection (Dyer et al., 
2013). Flies are less susceptible in the first 48h upon emergence but, after this, 
the possibilities of getting infected are higher in “teneral” (non-blood-fed) flies 
than in those that have taken previous uninfected bloodmeals (Kubi et al., 2006; 
Walshe, Lehane and Haines, 2011).  
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Ectoperitrophic procyclic forms elongate as they move forward toward the 
proventriculus until reaching a length-threshold of about 35 m and then stop 
proliferating (Van Den Abbeele et al., 1999; Sharma et al., 2008). Cell cycle is 
arrested in G2 until parasites break into the proventriculus where they elongate 
further until 40-60 m becoming mesocyclic trypomastigotes (Vickerman, 1985; 
Sharma et al., 2008). Then, asymmetric division happens that generates the long 
and short epimastigotes (1/3 in size), of which only the short is believed to 
survive, re-enter the gut lumen, migrate through the foregut, and colonize the 
salivary glands (Van Den Abbeele et al., 1999; Sharma et al., 2008). None of the 
epimastigotes are able to proliferate in the proventriculus (Sharma et al., 2009). 
The time that takes T. brucei to invade the salivary glands since they enter the 
fly after a blood meal can oscillate between 6 and 30 days depending on the 
species (Van Den Abbeele et al., 1999; Aksoy, Gibson and Lehane, 2003). 
1.3.2.3 Epimastigote-metacyclic trypomastigote 
Upon colonization of the salivary glands, 4 morphologies of T. brucei have been 
defined: attached epimastigotes, pre-metacyclics, nascent metacyclics, and 
mature free metacyclics (Steiger, 1973; Vickerman, 1985). The lack of an 
efficient in vitro culture technique has limited our capacity to study these 
stages but evidence of procyclin transcripts without procyclin expression has 
been reported (Acosta-Serrano et al., 2001; Urwyler et al., 2005), and a 
particular surface antigen, isoform of the bloodstream stage alanine-rich protein 
(BARP), has been defined as stage-specific marker (Urwyler et al., 2007). It is in 
that location where the parasite undergoes genetic exchange throughout 
meiosis, with kinetoplastid DNA (linked to the mitochondrion) inherited 
biparentally, suggesting that genetic exchange involves fusion of cell bodies 
(Peacock, Ferris, et al., 2014). 
Short epimastigotes are able to replicate in the salivary glands upon attachment 
to the host microvilli by intricate ramified flagellar protrusions, which branch 
between indentations and form hemidesmosome-like attachment plaques, 
forming an undulating membrane (Vickerman, 1969). Flagellar outgrowths 
retract while parasites develop into uncoated trypomastigotes (pre-metacyclic 
forms) that remain attached through the plaques and are capable of replication. 
The so called “nascent metacyclic” forms stop replicating, and express a surface 
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VSG coat accompanied by changes in the glycosome and mitochondrion while 
remaining attached. In the final step, the non-replicative mature metacyclic 
forms, expressing VSG and preadapted for conditions encountered in the 
mammalian bloodstream, detach from the salivary gland surface (Tetley and 
Vickerman, 1985) and are inoculated into a mammalian host during a tsetse fly 
blood meal. 
1.4 Other fundamental aspects of T. brucei cell biology 
1.4.1 Cell structure 
T. brucei is a single-cell protozoan and constitutes an excellent biology model 
because it is equipped with mostly single-copy organelles, including the flagellar 
pocket, the flagellum, the Golgi apparatus, the mitochondrion, the kinetoplast, 
and the nucleus (Matthews, 2005), Figure 1-6. 
 
Figure 1-6. Cell structure of Trypanosoma brucei.  
Adapted from (Matthews, 2005). 
 
Along the T. brucei life cycle the parasite experiences extensive modifications in 
the metabolic, transcriptomic and proteomic profiles. From the morphological 
perspective, two main stages have been described that subdivide in slightly 
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different sub-stages: trypomastigotes (bloodstream, procyclic, mesocyclic and 
metacyclic) and epimastigote (long and short). The most obvious difference 
between these two forms is the location of the kinetoplast: posterior respect to 
the nucleous in trypomastigotes, and anterior in epimastigotes. All the sub-
stages within each of these two types are slightly different but their general 
cellular structure is conserved (Wheeler, Gluenz and Gull, 2013). 
They all share an elongated shape with a highly polarized microtubular structure 
that has its “plus” ends facing towards the posterior end, except for a particular 
microtubule quartet, which has the opposite orientation (Sunter and Gull, 2016).  
The flagellum controls body length and is important for motility, signalling and 
cell division (Field and Carrington, 2009; Langousis and Hill, 2014). The 
canonical 9+2 axoneme structure with parafragellar rod of the flagellum starts in 
the basal body, which is connected to the kinetoplast via the tripartite 
attachment complex through the mitochondrial membrane. It exits the cell 
through the flagellar pocket, located in the posterior end of the cells (in 
trypomastigotes), or between the nucleus and the apical end (in epimastigotes) 
(Wheeler, Gluenz and Gull, 2013). The flagellar pocket, attached to the 
flagellum throughout a collar structure, is the only place where endo- and 
exocytosis takes place in the parasite (Overath and Engstler, 2004; Perdomo, 
Bonhivers and Robinson, 2016). The flagellum is connected to the whole cell 
body following a defined helical path by a complex cytoskeletal structure, the 
flagellar attachment zone (FAZ). Filaments in the FAZ are linked to the 
antiparallel microtubule quartet of the cell microtubular corset, leaving free the 
distal tip of the flagellum (Sunter and Gull, 2016). 
1.4.2 Cell cycle  
Cell-cycle of trypomastigotes in T. brucei is similar to that of other eukaryotes 
but with peculiarities due to the presence of single-copy organelles and the 
class-specific kinetoplast (Matthews, 2005; Vaughan and Gull, 2008). Organelles 
are duplicated by a template-based mechanism where a new cellular component 
is generated close to the old one (Vaughan and Gull, 2008). Regulatory 
molecular mechanisms are divergent too (Hammarton, Monnerat and Mottram, 
2007; Li, 2012), for instance the checkpoint that prevents cytokinesis until 
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mitosis is completed is missing in bloodstream forms (Ploubidou et al., 1999; 
Hammarton et al., 2003), Figure 1-7.  
In the G1 phase, the basal body duplicates and the new flagellum starts being 
synthetized (Woodward and Gull, 1990; Wheeler, Gluenz and Gull, 2013). 
Immediately after, the parasite duplicates the Golgi apparatus (Ho et al., 2006). 
 
Figure 1-7. Comparative sequence of cell cycle events in procyclic and 
bloodstream trypomastigotes.  
Adapted from (Gluenz et al., 2015). 
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G1 cells have 1 nucleus and 1 kinetoplast (1N1K) but their relative position is 
different in bloodstream forms (BSF), where the kinetoplast sits at the terminal 
end of the cells; and in procyclic forms (PCF), where the kinetoplast is midway 
between the cell end and the nucleus. PCF are larger and wider than BSF, with 
the flagellum tip protruding at the apical end being shorter than BSF (Wheeler, 
Gluenz and Gull, 2013). 
Kinetoplastid (kDNA) and nuclear DNA (nDNA) enter S-phase in an asynchronous 
but coordinated manner (Woodward and Gull, 1990). Initiation factors are 
different for kDNA, which replicates first and faster (Liu et al., 2005; Jensen and 
Englund, 2012); and for nDNA (Tiengwe, Marques and McCulloch, 2014). When 
the nucleus enters S phase, the kinetoplast starts G2; and when the nucleus 
enters G2, basal bodies separate causing kinetoplast segregation (Liu et al., 
2005; Jensen and Englund, 2012). Golgi complex also segregates at this point 
(Hall et al., 2006). 
Before nuclear division, where chromosomes align and segregate by assembly of 
an evolutionary divergent kinetochore (Akiyoshi and Gull, 2014), cells have one 
nucleus and two kinetoplasts (1N2K) (Woodward and Gull, 1990). After 
chromosome segregation, upon mitosis, 2N2K cells are generated (Ogbadoyi et 
al., 2000) but the relative position of nuclei and kinetoplasts vary from 
bloodstream and procyclic trypomastigotes: 1K1N1K1N in procyclic cells and 
1K1K1N1N in bloodstream forms (Wheeler, Gluenz and Gull, 2013). 
This accurate DNA replication pattern makes it easy to explore the time-wise 
implications of factors regulating the cell cycle with chemical or genetic tools 
(see below), as the K/N distribution phenotype precisely informs about the cell-
cycle stage: 1N1K cells are in nuclear G1; cells with 1N2K are in nuclear G2; and 
cells with 2N2K have undergone mitosis but have not completed cytokinesis yet 
(Woodward and Gull, 1990; Siegel, Hekstra and Cross, 2008). 
Whilst in G1, the new flagellum grows along the cell bringing with its base the 
new flagellar pocket and the new kinetoplast. In PCF cells, the tip of the new 
flagellum attaches to the old and slides towards the apical end up to a short 
distance from the top limit (Langousis and Hill, 2014). The two flagella only 
separate with cytoplasm/cell membrane invagination during cytokinesis (“furrow 
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ingression”). In BSF, the growing new flagellum is not connected to the old and 
protrudes free outside the cell, just before reaching the apical end (Hughes et 
al., 2013), just before cytokinesis (Wheeler, Gluenz and Gull, 2013). 
Cytokinesis starts immediately after mitosis. Unidirectional furrow ingression 
happens along the longitudinal axis backwards (Hammarton et al. 2007). The 
moment where the last cytoplasmic bridge breaks is known as abscission (Farr 
and Gull, 2012; Li, 2012; Wheeler, Gluenz and Gull, 2013).  
1.4.3 Genome organization and gene expression 
The haploid genome of T. b. brucei has 35 megabases (Mb) split between kDNA 
and nDNA although it can vary up to a 25% between different isolates (El-Sayed 
et al., 2000; Berriman et al., 2005).  
1.4.3.1 Nuclear genome 
The nuclear genome is organized in 11 megabase-size chromosomes (0.9-5.7 Mb), 
2-4 intermediate size (300-900 kb), and about 150 minichromosomes (50-100 kb) 
(El-Sayed et al., 2000; Berriman et al., 2005), Figure 1-8. All of them have 
telomeres containing the same repeats (TTAGGG) observed in mammals 
(Dreesen, Li and Cross, 2006), which contain the bloodstream expression sites 
(ES) encoding VSG and expression site associated genes (ESAGs). Uniquely, these 
genes are transcribed by RNA polymerase I (Daniels, Gull and Wickstead, 2010; 
Ersfeld, 2011; Glover, Alsford and Horn, 2013; Morrison, McCulloch and Hall, 
2014). T. brucei is the only known organism where RNA Pol I transcribes protein-
coding genes (ESAG, VSG and procyclins) and not only rRNA genes (Günzl et al., 
2003; Haenni et al., 2006, 2009). 
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Figure 1-8. Schematic representation of nuclear genome organisation in the 
three types of chromosome.  
Subtelomeres encode more than 2000 variants of VSG genes and pseudogenes, 
repetitive sequences found there are supposed to regulate monoallelic 
expression control and VSG swithching. Subtelomeres at the megabase 
chromosomes are hemizygous with the core region beingdiploid. There is only 
one active bloodstream expression site (BES) per genome. Adapted from (Glover 
et al. 2013). 
 
Both, intermediate chromosomes and minichromosomes, encode VSG genes or 
pseudogenes that can recombine to generate novel “mosaic” VSGs, expanding 
the parasite´s repertoire (Glover, Alsford and Horn, 2013; Morrison, McCulloch 
and Hall, 2014). In total, more than 20% of the nuclear genome is devoted to 
generate antigenic variation (Berriman et al., 2005). 
The minichromosomes consist of a 20-80 Kbp-long palindromic core (made of 177 
bp repeats), flanked by short subtelomeric regions containing non-repetitive 
DNA, and the telomeres (Wickstead, Ersfeld and Gull, 2004). 
The megabase chromosomes were predicted originally to encode 9068 genes 
(Berriman et al., 2005) but, after transcriptomic analysis, the figure expanded 
to 11425 (Siegel et al., 2010). Their core regions contain ~7,500 housekeeping 
genes transcribed by RNA polymerase II (RNA Pol II), while the large hemizygous 
subtelomeres encode ~1,500 VSG genes and pseudogenes (Marcello and Barry, 
2007; Cross, Kim and Wickstead, 2014). The centromeres have been mapped only 
for chromosomes 1 to 8 (Obado et al., 2007). They colocalize with protein 
components of the divergent T. brucei kinetochore (Akiyoshi and Gull, 2014). A 
500 Mb segmental duplication during evolution between chromosome 4 and 8 
produced 75 genes uniquely duplicated in T. b. brucei (Jackson, 2007b).  
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House keeping genes are organized in polycistronic transcription units (PTU) 
that, unlike operons, directionally align head-to-tail genes that do not necessary 
belong to the same biological pathways (Daniels, Gull and Wickstead, 2010; 
Ersfeld, 2011; Jackson, 2014). Neighbouring PTUs are encoded in different DNA 
strands that can be convergent, divergent or head-to-tail in terms of their 
coding sense. The meeting point is known as strand switch region (SSR). 
Transcription, mediated by RNA pol II, is initiated from divergent SSRs (Daniels, 
Gull and Wickstead, 2010; Ersfeld, 2011). Transcriptional control is believed to 
be limited to codon adaptation (Horn, 2008) and gene duplication (Jackson, 
2007b). Gene expression is mainly controlled at a post-transcriptional level. 
Several epigenetic modifications have been related with transcription initiation 
at head-to-tail or divergent SSR, i.e. histone H4 acetylated at lysine 10, histone 
H3 trimethylated at lysine 4 (Wright, Siegel and Cross, 2010) and histone H2 
variants H2AZ and H2BZ (Siegel et al., 2009). Termination is poorly understood 
though (Ersfeld, 2011), transcription is believed to stop at convergent SSR, which 
are rich in certain histone variants (H3V and H4V) and a chromatin modification 
of thymine, known as base J (Siegel et al., 2009; Reynolds et al., 2016). The 
tandem base J-H3V can be found both at the end of polycistronic units 
(transcribed by RNA pol II), and at subtelomeric regions silencing VSG variants 
(Reynolds et al., 2016).  
1.4.3.2 Mitocondrial genome (kinetoplast) 
The mitochondrial genome (kinetoplast) consists of a complex, concatenated 
network of DNA including minicircles and maxicircles (Liu et al., 2005). The 
maxicircles encode mitochondrial genes that, after transcription, require 
modification by RNA editing. The guide RNAs required for this process are 
encoded in the minicircles. RNA editing was first described in trypanosomes but 
is now known to occur in other organisms (Simpson et al., 2004).  
Evolutionary close dyskinetoplastic trypanosmes are T. evansi and T. 
equiperdum, for instance. The loss of the mitochondrial genome has been 
induced in vitro for T. brucei (Schnaufer, Domingo and Stuart, 2002; Dean et al., 
2013).  
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1.4.3.3 Post-transcriptional regulation 
Polycistronic transcription units produced by RNA pol II are trans-spliced by 
addition of a 39 nucleotides-long spliced leader (SL) at the 5´end of each 
monocistronic mRNA (Michaeli, 2011); and polyadenylation, which is still not 
well understood (Clayton and Michaeli, 2011). The SL is the only sequence for 
which a RNA pol II promoter has been found in T. brucei (Das et al., 2005; 
Schimanski, Nguyen and Gu, 2005). Together with translational regulation, 
processes determining the fate of the spliced transcripts are the main 
mechanisms controlling expression levels: mature RNA degradation in the 
nucleus, export to the cytoplasm, and degradation in the cytosol (Clayton, 
2014). RNA decay or translation depends on a diverse network of RNA binding 
proteins that attach to the 3´ or 5´untranslated regions contributing to promote 
or prevent recruitment of the RNA degradation machinery, therefore disrupting 
translation (Clayton, 2014). Upon stress conditions, such as transmission to a 
new host, mature RNAs can be sequestered from the translation and degradation 
machinery in “stress granules” (Clayton, 2014). 
1.5 Protein kinases 
Protein kinases are the best-studied set of signalling proteins in the eukaryotic 
cell. They catalyse the transfer of the -phosphate of a purine nucleotide 
triphosphate (ATP or GTP) to the hydroxyl group of a substrate, establishing a 
monoester bond. Such modification alters the conformation of the substrate 
peptide affecting its activation and interaction networks. 
Protein kinases play fundamental roles as central regulators in many 
intracellular biological functions including metabolism, transcription, cell cycle 
progression, cytoskeletal rearrangement, cell movement, apoptosis, and 
differentiation. But in complex organisms they regulate also intercellular 
communication during development, physiological responses, homeostasis, or in 
the functioning of the nervous and immune systems (Manning et al. 2002). Their 
dysregulation contributes to the aetiology of many medical conditions of which 
many forms of cancer are prominent representatives. They are the largest family 
of druggable targets in the proteome (Hopkins and Groom, 2002).  
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1.5.1 Classification 
Protein kinases group into two main subdivisions: protein-serine/threonine 
kinases and protein-tyrosine kinases. In addition, the less abundant dual 
specificity kinases can phosphorylate both. A first in-depth analysis and 
classification was reviewed in the pre-genomic era (Hanks and Hunter, 1995) 
that was updated later with the publication of the kinome complement of the 
human genome (Manning et al. 2002).  
The human kinome (Figure 1-9) is classified in 478 eukaryotic (ePKs) and 40 
atypical protein kinases (aPKs). ePKs are divided in 9 broad groups comprising 
184 families, 51 conserved also in flies, worms and yeast (Manning et al. 2002). 
There are some exclusive families and others asymmetrically expanded between 
different organisms, e.g. humans have 14 Eph receptor tyrosine kinases (RTKs) 
while Drosophila melanogaster only has one. 25 subfamilies have one single 
member in each of the 4 mentioned organisms, suggesting unduplicated 
functions. 10% are “pseudokinases” missing some of the key residues required 
for catalytic activity but conserving all the other features of the catalytic 
domain that will be described in the next section (Kroiher, Miller and Steele, 
2001; Morrison, 2001; Zervas and Brown, 2002). Some of them might still 
function by non-canonical mechanisms but they mainly modulate other catalytic 
domains or have other implications in protein-protein interaction. In addition, 83 
different alternative domains have been identified in human protein kinases 
(SH2, GTPase, lipid signalling, Ca2+ signalling…). Some of them regulate protein 
kinase activity, some link them to other signalling modules, and others assist 
protein localization. Finally, pseudogenes encoding disrupted protein kinase 
genes are also found in the genome, probably due to viral retrotransposition of 
processed transcripts.   
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Figure 1-9. The human protein kinome. 
Left hand panel: table with major groups of ePKs and aPKs, indicating the 
number of families that they contain. Right hand panel: phylogenetic 
dendrogram of 491 ePK human domains. Major groups are highlighted in colours. 
Modified from Manning et al. (2002). 
 
1.5.2 The protein kinase catalytic domain: structure and functions 
The protein kinase catalytic domain plays three fundamental roles: binding and 
orientation of the substrate peptide; binding and orientation of the ATP (or GTP) 
as a complex with a cation (Mg2+ or Mn2+); and transfer of the -phosphate from 
the ATP (or GTP) to the acceptor hydroxyl group of a serine, threonine or 
tyrosine residue. There is no need for binding first substrate or ATP, but there is 
a thermodynamic preference for the nucleotide (Cook et al., 1982; Grant and 
Adams, 1996). The phosphorylated residue in the substrate peptide, 
“phosphosite” (P-site), needs to be framed by a consensus recognition sequence 
with affinity for the catalytic site (Chan, Hurst and Graves, 1982; Pearson and 
Kemp, 1991). 
The protein kinase catalytic domain structure (250-300 amino acids) is common 
to the entire eukaryotic tree including animals, plants, fungi and protozoa 
(Taylor and Radzio-Andzelm, 1994). It has 12 subdomains characterised by 
patterns of conserved residues nearly invariant throughout the protein kinase 
superfamily, these subdomains are never interrupted by large amino acid 
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insertions and fall into topologically similar core structures. The variable non-
conserved insertions build up non-catalytically relevant features of the protein 
surface. The non-catalytic domain can modulate activity interacting with the 
protein kinase core, or binding other proteins that enhance or repress the 
catalytic function (Pawson and Gish, 1992; Newton, 1997; Sicheri and Kuriyan, 
1997; Brushia and Walsh, 1999). Other factors affecting activation are fatty acid 
acylation (Blenis and Resh, 1993; Johnson and Cornell, 1999), isoprenylation 
(Inglese and Premont, 1996; Pitcher, Freedman and Lefkowitz, 1998), second 
messengers (Rasmussen, 1989; Liscovitch and Cantley, 1994; Lucas et al., 2000), 
subcellular localization (Pawson and Scott, 1997; Garrington and Johnson, 1999; 
Scott and Pawson, 2000), and phosphorylation (Shenolikar, 1988; Hunter, 1995). 
The first crystal structure of a catalytic protein kinase domain available was a 
mouse PKA with a substrate (Ben-David et al., 1991; Rossomando et al., 1992), 
soon obtained also with the complexes ATP-Mn2+ and ATP-Mg2+ (Pearson and 
Kemp, 1991). As new structures of other protein kinases were published it was 
confirmed that the topology of the catalytic domain was well conserved in 
eukaryotes. It is an overall two-lobe structure with a small NH2-terminal lobe 
comprising subdomains I-IV, and a large COOH-terminal lobe including domains 
VIa –XI (Figure 1-10A and C). The hinge region is constituted by subdomain V, 
which protrudes towards both lobes creating the catalytic cleft. The NH2-
terminal lobe folds predominantly in antiparallel -sheet secondary structure 
and its main function is anchoring and orientation of the ATP (or GTP). The 
COOH-terminal lobe is mainly -helix configuration and is responsible for the 
phosphotransfer initiation. While the ATP nests deep into the pocket, the 
substrate remains in the periphery (Adams, 2001).  
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Figure 1-10. Protein kinase catalytic domain.  
A. Ribbon diagram of PKA co-crystallized with ATP and a peptide inhibitor. NH2-
terminal lobe (mainly -sheet) and COOH-terminal lobe (predominantly -helix) 
are highlighted. Arrows point to the activation loop and its P-site, pThr-197, 
required for protein kinase activation. B. Key residue interactions in the active 
site of PKA. Mg1 and Mg2 represent the activating and inhibitory divalent metal 
ions, Mg2+, respectively (schematic representation based on A). Dotted lines 
indicate close contacts under 2.6 Å but are not drawn to scale. The hydroxyl of 
the substrate is shown based on a binary complex of PKA with a substrate 
peptide. C. ePK catalytic domain indicating the 12 conserved subdomains 
(Roman numerals). Positions of amino-acid residues and motifs highly conserved 
throughout the ePK superfamily are indicated above, using single-letter amino-
acid code with x as any amino acid. A and B, adapted from Adams 2001. C, 
adapted from Hanks 2003. 
 
The structure-activity relationship of the different conserved motives has been 
reviewed in the literature (Hanks and Hunter, 1995; Adams, 2001). Using as 
reference residues in PKA, subdomain I constitutes a clamp anchoring the non-
transferable phosphates on the ATP through H-bonds with Ser53, Phe54 and 
Gly55. Leu49 and Val47 form a hydrophobic space to fit the adenine ring. There 
is a consensus sequence throughout most of protein kinases at this domain: 
Gly50-x-Gly-x-x-Gly-x-Val. 
The main feature at subdomain II is Lys72, a residue essential for maximal 
activity whose substitution is commonly used to produce inactive mutants 
(Hixson and Krebs, 1979; Hathaway, Zoller and Traugh, 1981; Buhrow et al., 
1983; Weinmaster, Zoller and Pawson, 1986). It does not affect ATP binding but 
NH2-lobe	
COOH-lobe	
A	 B	
C	
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is critical for correct orientation of the nucleotide. Lys72 forms a salt bridge 
with the invariable Glu91, which helps orientation and anchoring of ATP in the 
large -helix of subdomain III, Figure 1-10B. 
Subdomain IV and VIa are apparently not involved in catalysis and do not have 
any invariable residues. Subdomain V articulates the hinge region with half -
helix and half -sheet. The consensus Glu121, Val123, and Glu127, in the joint, 
anchor ATP forming H-bonds with adenine and the ribose ring. Met120, Tyr122 
and Val123, also help forming a hydrophobic pocket. Glu127 forms in addition an 
ion pair with an arginine in the peptide recognition sequence. 
Subdomain VIb contains the “catalytic loop”, the consensus His164-Arg-Asp-Leu-
Lys-x-x-Asn. Asp166 may accept the proton from the substrate hydroxyl group, 
while Lys168 (sometimes an Arg) neutralize the negative charge of the 
phosphate during the transference. Asp166 also stabilize the loop establishing a 
H-bond with Asn171, which chelates the Mg2+ that bridges - and -phosphates, 
Figure 1-10B. Glu170 forms a H-bond with the ribose and an ion pair with an Arg 
in the peptide recognition consensus. 
Subdomain VII has the consensus Asp184-Phe-Gly. Asp184 is essential as the 
kinase is not functional when replaced (Gibbs and Zoller, 1991). It forms an H-
bond with Gly186 and chelates Mg2+ between - and -phosphates, assisting ATP 
orientation, Figure 1-10B. 
Containing many peptide binding residues and a hydrophobic pocket made of 
Leu198, Cys199, Pro202 and Leu205, subdomain VIII has the characteristic 
consensus Ala206-Pro207-Glu208 (APE). Frequently this domain contains residues 
that require phosphorylation before the protein kinase becomes active (Chan, 
Hurst and Graves, 1982; Luo, Zhou and Lodish, 1995; Songyang et al., 1995). 
Subdomain IX, contains the conserved Asp220 that forms H-bonds with Arg165 
and Tyr164 in the “catalytic loop” contributing to its stability and to substrate 
recognition. Subdomain X is the less conserved, with all CMGC kinases presenting 
large insertions. Finally, subdomain XI has the invariable His-x-Aromatic-
Hydrophobic-10x-Arg280. This last residue forming an ion pair with Glu208 in the 
APE motive of subdomain VIII. 
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1.5.3 Protein kinases as drug targets 
Protein kinases are a promising source for druggable targets with more than 100 
inhibitors already in clinical trials (Naula, Parsons and Mottram, 2005; Barouch-
bentov and Sauer, 2012) and successful drugs in the market, such as Imatinib® 
for chronic myelogenous leukemia (Deininger and Druker, 2003). It was 
estimated that in the 2000s over 30% of drug discovery programmes focused in 
kinase inhibitors (Pinna, 2003). Protein kinases represent the largest subset of 
druggable targets in the human proteome (22%) (Hopkins and Groom, 2002). 
Given the high conservation of the protein kinase domain, one of the main 
challenges is achievement of kinase selectivity (Karaman et al., 2008). Imatinib® 
was originally targeted against PGDFR but effectiveness has been later 
associated to BCR-ABL and cKIT inhibition (Lorusso and Eder, 2008). While 
inhibition of a single kinase may not be effective, targeting at once a number of 
them can have positive synergistic effects. If the objective is finding an efficient 
drug, finding selectivity with respect to the host is a more critical aspect than 
finding selectivity for a particular kinase. That is why target-based assays with 
the purified protein are losing priority compared to cell-based phenotypic 
screens. Intra-organism protein kinase-specificity can be crucial only if the 
objective is identification of a tool compound and it may require 
functionalization that increase molecular weight, risking its drug-like attributes 
(Gill et al., 2007). 
The prototypical kinase inhibitors are aromatic heterocycles with H-bond 
donor/acceptor motifs. The most effective ones fit easily into the protein kinase 
lipophilic pocket, so optimal physicochemical properties for inhibition challenge 
solubility and absorption properties. In order to circumvent this problem, 
chemical functionalization of the molecules with planarity-breaking and 
hydrophilic motives has been undertaken (Merritt et al., 2014). 
The increasing availability of structural data describing the kinase-substrate 
geometry, including orientation and key contacts for activity, is informing 
medicinal chemistry to develop more specific kinase inhibitors based on the 
structure-activity relationship (SAR) (Merritt et al., 2014). 
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Two types of protein kinase inhibitors interact directly with the catalytic site in 
the active conformation. Type I (called DFG-in, due to position of the conserved 
triad at subdomain VII) compete directly with ATP for binding. Type II (DFG-out) 
bind in the surroundings of the ATP pocket but do not compete with the 
nucleotide for binding. Allosteric inhibitors (type III or type IV, depending on 
their distance to the catalytic cleft) change enzyme conformation preventing 
activation or blocking activity. As a general rule, non-competitive inhibitors 
show higher potencies because ATP concentrations are very high in the cells (1-
10 mM), (Liu and Gray, 2006; Knight and Shokat, 2007) 
1.5.4 Protein kinases in Trypanosoma brucei 
Bioinformatics analyses based on multilevel Hidden Markov Model sequence 
alignment of the catalytic domain followed by manual curation showed 2% of the 
Trypanosome brucei proteome to have putative protein kinase activity (Parsons 
et al., 2005; Nett et al., 2009). Although other organisms, such as Toxoplasma 
gondii, possess a larger number of predicted protein kinases (356 protein 
kinases), the proportion they represent of the total proteome is comparatively 
smaller (1.5%). In absolute numbers, the T. brucei protein kinome is ~1.5 times 
larger than that of Saccharomyces cerevisiae or Schizosaccharomyces pombe 
(Miranda-Saavedra et al., 2007), ~2 times the size of the one of the malaria 
parasite (Ward et al., 2004), or ~1.7 times the protein kinase complement of the 
intracellular parasite E. cuniculi (Miranda-Saavedra et al., 2007). This means 
that T. brucei exhibits a relative expansion on the protein kinome when 
compared with many other single celled eukaryotes. 
T. brucei encodes 170 eukaryotic protein kinases (ePKs), 13 atypical protein 
kinases, and 12 pseudo-kinases predicted to be non-functional as they miss some 
of the canonical residues required for activity (Parsons et al., 2005; Nett et al., 
2009; Urbaniak et al., 2012; Jones et al., 2014).  
It is remarkable the lack in the parasite of receptor guanylate cyclases (RPC), 
which bear a protein kinase-like domain and are considered an evolutionary 
innovation of late metazoans; receptor and non-receptor tyrosine kinases; and 
tyrosine kinase-like kinases, when compared to other eukaryotes. Tyrosine 
phosphorylation has been reported though (Nett et al., 2009). Phosphotyrosine 
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residues have been identified in several CMGC protein kinases and, at least, 
some of them are very likely due to conserved phosphorylation events conducted 
by dual specificity kinases such as Wee1, DYRKs, or GSK3. Wee1 mediates a 
tyrosine phosphorylation event in human CDK1 which is conserved in 
trypanosomes (Krupa, Preethi and Srinivasan, 2004; Nett et al., 2009); the last 
two protein kinase types require autophosphorylation at a tyrosine to become 
active threonine/serine kinases and these phosphotyrosines have been identified 
by proteomics (Kentrup et al., 1996; Cole, Frame and Cohen, 2004; Lochhead et 
al., 2005). 
T. brucei has relatively expanded the CMGC, STE and NEK families of kinases, 
which contain several highly divergent proteins that are very likely to play 
parasite-specific functions (Parsons et al., 2005; Nett et al., 2009). 
Reversible phosphorylation is one of the main signalling mechanisms in the 
eukaryotic organisms and has been linked to regulation of most cellular 
processes (Cohen, 2000). Relevance of this signalling applies also to T. brucei, 
where 491 distinct phosphorylated proteins have been found in the cytosolic 
fraction of the parasite’s bloodstream form. 75% of these were modified at 
serine residues, 21.5% at threonine, and 3.5% at tyrosine residues (Nett et al., 
2009). It is interesting that this distribution (75/21.5/3.5) is closer to 
prokaryotic organisms (70/20/10) than to human HeLa cells (86/12/2), for 
instance (Usacheva et al., 2003; Macek et al., 2007; Nett et al., 2009). 
Protein kinase involvement in intricate phosphorylation-dephosphorylation 
networks is also conserved in T. brucei as 44 protein kinases were found to be 
phosphorylated, 50% in more than one site (Nett et al., 2009). Domains for 
phosphopeptide recognition are abundant in the T. brucei proteome, e.g. 14-3-3 
proteins that bind to specific phosphoserine and phosphothreonine motifs (Inoue 
et al., 2005). Among the protein kinases, there is a CAMK with a forkhead-
associated domain (FHA), which binds phosphothreonine (Parsons et al., 2005); 
and there is a polo-like kinase (TbPLK) with a phosphoserine/threonine-binding 
polo box domain (Kumar and Wang, 2006; Hammarton et al., 2007). 
Remarkably, phosphotyrosine-binding domains present in other eukaryotes such 
as Src homology 2 (SH2) or phosphotyrosine-binding (PTB), are missing in T. 
Chapter 1 58 
 
brucei consistent with the lack of tyrosine kinases or tyrosine-like kinases (Nett 
et al., 2009). 
One of the best described phosphorylation cascades are MAPKs, conveying mainly 
extracellular signals and activating transcription factors (Widmann et al., 1999). 
The canonical three-step module includes STEs (STE7s, STE11s and STE20s), one 
of the proportionally expanded groups of protein kinases in trypanosomes 
compared to other eukaryotes. Many of these protein kinases are phosphorylated 
in T. brucei (Nett et al., 2009), but the unconventional transcription regulation 
in the parasite may suggest non-canonical functioning. In fact, MAPK cascades 
are missing in other protozoan parasites, such as those from the phylum 
Apicomplexa -as Plasmodium or Toxoplasma- or E. cunicula (Miranda-Saavedra et 
al., 2007). 
As protein kinases are central regulators of many cellular functions and have 
been proven good drug targets in humans, there are many studies assessing 
essentiality of these molecules in T. brucei with the prospect of targeting them 
in drug discovery programmes.  
1.5.5 Approaches undertaken for functional analysis of protein 
kinases in kinetoplastids 
Different approaches have been undertaken to determine the role of protein 
kinases in T. brucei and fellow kinetoplastid parasites, in an individualized 
manner or in high throughput campaigns. They are based in genetic 
manipulation, chemical inhibition or both. 
1.5.5.1 Genetic approaches 
At a DNA level, gene deletion of the two alleles encoding a particular protein 
(null mutant) has been extensively used to analyse the effects it produces in the 
cellular phenotype. For instance, MKK1, a MAPK, was determined not to be 
essential for bloodstream form fitness in culture by this method, however the 
null mutant was unable to colonise successfully the salivary glands in the tsetse 
fly indicating MKK1 relevance for progression of the life cycle (Morand et al., 
2012). A protein is considered potentially essential when the null mutant (double 
knockout) is impossible to generate, this happened analysing CK1 isoform 2 
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where the second allele was impossible to remove (Urbaniak, 2009). Yet, it 
raises concerns that the reason for such impossibility may be technical. This has 
been solved through development of conditional null mutants where deletion of 
the second allele is possible by inducible expression of the gene from an 
exogenous locus (Milne, Güther and Ferguson, 2001). Once the two endogenous 
alleles are removed, withdrawal of the induction factor generates the null 
mutant (Merritt and Stuart, 2013; Damerow et al., 2016).  
Another approach -that will be discussed extensively in the introduction to 
chapter 3 is RNA of interference (RNAi). Small, double stranded RNA molecules 
with homology to a gene of interest, can be expressed that bind the gene´s 
transcripts targeting them for degradation mediated by the RNAi machinery and 
preventing protein production (Ullu, Tschudi and Chakraborty, 2004). The system 
has been developed for inducible transcription of the RNAi probe (Alsford et al., 
2005) and, coupled to next generation sequencing (RNAi target sequencing), has 
been exploited for parallel phenotyping of complete genomes (Alsford et al., 
2011). Since its implementation in T. brucei, this system has been extensively 
applied for individualized gene studies and for high throughput screens (Glover 
et al., 2014; Jones et al., 2014).  
Since T. brucei protein kinases are druggable (Urbaniak et al., 2012), specific 
inhibition can be potentially achieved when a tool compound is available. 
Targeting a particular kinase with a compound can provide almost immediate 
inhibition (Knight and Shokat, 2007). To my knowledge not a single tool 
compound specific against a particular T. brucei protein kinase has been 
identified yet.   
Combining chemical and genetic approaches, analogue-sensitive strategies have 
been developed where the conserved large gatekeeper residue at the ATP 
binding pocket of a selected kinase has been mutated to glycine or alanine 
(Knight and Shokat, 2007). This genetic modification permits ATP analogues 
bulky at the N6 position to fit in the pocket and cause specific inhibition of the 
mutant protein. It has been used in T. brucei against TbPLK (Lozano-Núñez et 
al., 2013).  
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1.5.6 Protein kinases found with roles characterised throughout 
the above described approaches 
Pointing in this direction, several studies involving RNAi or null mutant 
phenotyping have been conducted reporting many protein kinases to be essential 
for survival of the parasite or whose depletion caused a loss of fitness in the 
culture dish. 
1.5.6.1 Essential protein kinases detected in screening campaigns 
CRK12 and ERK8 were identified essential for T. brucei bloodstream forms with a 
luciferase-based RNAi screen targeting 30 protein kinases (Mackey et al., 2011), 
CRK12 was also detected in a conditional null mutant screen with 20 ePKs 
belonging to the “STE” and “Other” families. GSK3-short and CLK1 were 
reported in an RNAi screening of the 21 T. brucei “CDXG”-motif-bearing kinases 
(binding platform for hypothemicin, a trypanocidal compound) (Nishino et al., 
2013), although GSK3-short had been reported a potential drug target through 
RNAi and compound screen targeting the human homolog before (Ojo et al., 
2008). More recently, all the 180 predicted protein kinases of T. brucei were 
systematically screened for cell viability in Alamar blue® using inducible RNAi 
identifying 41 protein kinases required for normal fitness in vitro (Jones et al., 
2014). A previous whole-genome screen based in RNAi target sequencing (RITseq) 
assessing cell growth detected depletion of 42 protein kinases detrimental for 
normal growth of the bloodstream forms in cultured conditions (16 overlapping 
with the kinome-wide Alamar blue screen) (Alsford et al., 2011). 
1.5.6.2 Protein kinases with roles in the parasite´s life cycle 
Several protein kinases have been identified as critical for progression along the 
life cycle of the parasite. For instance, ZFK (Vassella et al., 2001), MAPK5 
(Domenicali Pfister et al., 2006) and TbTOR4 (Barquilla et al., 2012) have been 
identified as negative regulators of the slender-to-stumpy differentiation in T. 
brucei bloodstream forms while a genome-wide RNAi screen under stumpy-
inducing conditions discovered positive regulators (whose depletion blocked this 
developmental transition): MEK kinase (Tb927.2.2720), NEK kinases 
Tb927.10.5930/40/50 (undistinguishable in this approach) and Dyrk/Yak kinase 
(Tb927.10.15020) (Mony et al., 2013). A systematic RNAi screen of the protein 
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kinome of T. brucei unveiled involvement of 2 protein kinases (RDK1 and RDK2) 
in repression of bloodstream to insect-infective procyclic form differentiation 
(Jones et al., 2014) while different studies proved NRK (Tb927.4.5390/8.6930) -a 
protein kinase enriched in stumpy forms- to be a requirement for procyclic 
differentiation (Alsford et al., 2011; Domingo-Sananes et al., 2015). The best 
described pathway implicated in this transition is a phosphatase cascade (Szöor 
et al., 2006, 2010), inferring requirement of uncharacterized protein kinases 
antagonizing this regulation. A whole-genome RNAi parallel phenotyping 
experiment based in RNAi target sequencing, identified 16 protein kinases whose 
depletion did not cause a loss of fitness in bloodstream parasites but were 
required for normal fitness upon procyclic differentiation (Alsford et al., 2011). 
Within the insect vector, two other protein kinases, MKK1 (Morand et al., 2012) 
and AK3 (Ooi et al., 2015), have been reported necessary for progression of the 
life cycle. 
1.5.6.3 Cell cycle regulation 
Another interesting feature of T. brucei biology also regulated by many protein 
kinases is a complex cell division cycle that requires accurate segregation of 
many single copy organelles and has different progression checkpoints compared 
to the mammalian host (Ploubidou et al., 1999; Hammarton et al., 2003; 
Hammarton, 2007). Divergence of T. brucei cell cycle regulation could provide a 
unique source of potential drug targets where many protein kinases play 
essential roles (Jones et al., 2014). An evolutionary divergent kinetochore 
(highly conserved protein complex in most of Eukaryotes that is required for 
chromosome segregation) has been described for T. brucei identifying four 
protein kinases associated with the structure (KKT2, KKT3, KKT10 and KKT19) 
(Akiyoshi and Gull, 2014). RNAi of KKT3 and KKT10 caused loss of fitness in vitro 
(Alsford et al., 2011; Jones et al., 2014) 
Based in homology with other eukaryotes, 12 T. brucei cyclin-dependent kinases 
orthologues, key cell cycle regulators in other eukaryotes, were identified. They 
were called in T. brucei CDC2-Related kinases (CRKs) (Mottram and Smith, 1995; 
Hammarton et al., 2003).  
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Early experiments performing RNAi-mediated depletion showed CRK1 and CRK3 
to be involved in G1/S and G2/M transition respectively (Tu and Wang, 2004); 
AUK1 and TLK1 to be required for mitosis (Li and Wang, 2006; Li, Gourguechon 
and Wang, 2007; Jetton et al., 2009); and PLK1, PK50 and PK53 regulating 
cytokinesis (Hammarton et al., 2007; Ma et al., 2010). More recently, a 
systematic RNAi screen of the T. brucei protein kinome identified 20 other 
protein kinases required for normal progression along different stages of the cell 
division cycle (Jones et al., 2014).  
1.5.7 Kinase targets identified by small molecules 
1.5.7.1 Covalent kinase inhibitors 
21 T. brucei kinases contain a cysteine close to the DXG catalytic domain 
responsible of phosphate orientation in subdomain VII, “CDXG” kinases. 
Hypothemycin (Nishino et al., 2013) is a trypanocidal antifungal compound, 
which establishes a covalent bond with that particular cysteine. Mass 
spectrometry identified in cell lysates 12  CDXG kinases that bind to 
hypothemycin, 2 of them were essential for the parasite survival upon RNAi. One 
of them, CLK1, was a new discovery. 
1.5.7.2 Drug-mediated elution from an ATP-sepharose matrix 
T. brucei cell lysates were passed through a column charged with an ATP-
sepharose matrix so protein kinases were retained on them. After washing the 
columns, kinases were eluted by addition of 5 compounds developed against 
EGFR/VEGFR in humans. They competed with ATP for the active site of certain 
protein kinases that could be successfully eluted. 5 protein kinases (TbLBPK1-4 
and TbCBPK1) were found in eluates obtained with the 3 inhibitors of human 
EGFR and/or VEGFR with trypanocidal activity: lapatinib, canertinib and AEE788 
(Katiyar et al., 2013). 
1.5.7.3 Drug-mediated elution from a kinase inhibitor affinity matrix: 
“kinobeads”  
A system developed by Cellzome (Bantscheff et al., 2007), was applied to 
trypanosomes. A matrix composed by beads covered by immobilized pan-kinase 
inhibitors was exposed to T. brucei bloodstream form lysates in the presence or 
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absence of the screened kinase inhibitors: staurosporine, BMS-387032 and 3 hits 
each coming from target-based screens conducted against PK50, PK53 and GSK3-
short (Urbaniak et al., 2012). Detachment and quantification of protein kinases 
retained by the beads permitted comparisons of results obtained in the presence 
or absence of the inhibitors. Those protein kinases with specific affinity for the 
inhibitor tested would be competitively eluted from the kinobeads. Beyond 
identification, this technique permitted titration of the compound´s inhibitory 
activity and the experiment unveiled that protein kinases of Trypanosoma brucei 
are druggable. 
1.5.8 Medicinal chemistry applied to T. brucei protein kinases 
An ideal kinase inhibitor used in HAT treatment should have oral bioavailability 
and parasite penetrance. If expected to be efficient in stage 2 (meningo-
encephalitic), it would require the ability to cross the blood-brain barrier 
(Wager, Chandrasekaran, et al., 2010), which is linked to a limited molecular 
weight and certain restrictions considering polarity/lipophilic profiles. 
Extracellular nature of T. brucei results an advantage, as the potential 
compound does not need to penetrate the host cells in addition. 
According to the Drugs for Neglected Diseases initiative (DNDi) the HAT target 
product profile (TPP) define 2 complementary strategies. TPP1 would be a safe, 
effective and practical stage 2 compound ideally active against both stages of 
the disease; and TPP2 a simple stage 1 treatment amenable to be used in mass 
screening and treatment campaigns in endemic areas. Ideally both compounds 
should be multitarget and able to treat both gambiense and rhodesiense 
infections. TPP1 should be administered in oral treatments under one week. 
Costs should not exceed 30€/course. TPP2 should also consist in a single daily 
dose, less than 3 days of treatment. Costs should be under 10€/course (Drugs for 
Neglected Diseases initiative, 2015).  
1.5.8.1 Glycogen Synthase Kinase-3 short isoform (GSK3-short) 
GSK3-short is the T. brucei protein kinase that has focused more efforts in 
screening campaigns looking for protein kinase inhibitors. Also investigated in 
antileishmaniasis programmes, is a perfect example of “piggy back” drug 
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discovery where a validated drug target in one organism is exploited in a 
different one (Ojo et al., 2011). Two isoforms of GSK3 have been found in the T. 
brucei genome but RNAi of GSK3-short is the most deleterious (Ojo et al., 2008). 
Analysis of the molecular model showed that substantial differences with the 
mammalian orthologue in the ATP binding pocket would permit designing 
compounds capable of selective inhibition in the parasite respect to the host. In 
the same work, a set of 48 commercially available protein kinase inhibitors and a 
collection of 255 known human GSK3 inhibitors were screened against the 
recombinant protein ex vivo and the parasite in culture. In the first set, 5 
compounds were identified with acceptable efficacy both against the protein 
and in vivo. 3 showed lower EC50s in the parasite than in the protein ex vivo, 
suggesting that compounds may inhibit more than one target. In the GSK 
focused library they found better correlations between IC50s and EC50s. 
Next, 16549 Pfizer compounds were screened against both human and T. brucei 
GSK3 proteins. 362 were found with efficacy under 1 M (35 under 100 nM) and, 
among them 2 had 7-fold selectivity for the parasite protein kinase (Oduor et 
al., 2011). Regardless of selectivity, 17 of the most active were screened against 
the parasite and the human cell in culture. 6 were identified with more than 6-
fold selectivity for T. brucei. As a general rule there was a correlation between 
efficacy found in vivo and ex vivo, however a few exceptions were found due to 
problems of membrane permeability. In order to test possible multitarget 
inhibition, 13 were screened against a set of 40 human protein kinases with 1 
showing high selectivity but no penetrance in the parasite cell; 1 inhibited only 2 
protein kinases but showed no preference between human and parasite; and 1 
inhibited 4 protein kinases for which human/parasite selectivity could not be 
tested. Each of the rest inhibited more than 10 human protein kinases. 
A different screen with 4110 compounds, based in luminescence (Woodland et 
al., 2013), detected many non-specific toxins and 11 compounds with activity 
against TbGSK3-short. Only one showed good EC50 values but it did not have 
selectivity for T. brucei compared to humans. In addition, GSK3-short was among 
the protein kinases non-specifically inhibited by two of the compounds tested in 
the kinobeads assay mentioned above (Urbaniak et al., 2012). So far promising 
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leads have been appointed against this T. brucei target but they did not have a 
good selectivity-efficacy balance.  
1.5.8.2 High throughput screening campaigns including kinase inhibitors 
Several high throughput screening campaigns of compound libraries have been 
published linking trypanocidal activity with kinase inhibition (Diaz et al., 2014; 
Peña et al., 2015; Woodland et al., 2015). They will be discussed in more detail 
in the introductory section of chapter 5. 
1.5.8.3 Drug repurposing strategies 
The wealth of knowledge available for human protein kinases, and their degree 
of conservation have been conceptually exploited in research of neglected 
tropical infectious diseases. Repurposing molecules that are already in the 
pipeline of drug discovery for other medical conditions can compensate for the 
lack of investment in diseases that affect populations in the poorest areas of the 
planet. This is especially relevant for compounds tailored to treat chronic 
diseases as cancer, which focuses most of the kinase inhibitor drug discovery 
campaigns. Compounds discarded due to toxic side effects caused during long 
lasting treatments, might not be such of a problem using the short 
administration patterns required for infectious diseases. In contrast, problems 
with acute toxicity must be taken into consideration (Merritt et al., 2014).  
Aurora kinase inhibitors 
Aurora kinases are well known eukaryotic protein kinases that play critical roles 
in regulation of cell division. Their depletion disrupts formation of the mitotic 
spindle, chromosome segregation, and cytokinesis. Several inhibitors are in 
clinical trials for cancer. T. brucei has 3 aurora kinase genes, AUK1 is required 
for correct nuclear division, cytokinesis and normal growth both in vitro and in 
vivo (Li and Wang, 2006). AUK2 transcript depletion caused also loss of fitness in 
a whole-genome RNAi screen (Alsford et al., 2011). 
A couple of inhibitors of the human kinase were able to kill the parasite with 
good EC50 values but without selectivity versus human cells (Jetton et al., 2009; 
Li, Umeyama and Wang, 2009). A rational modification of them based on their 
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structure-activity relationship (SAR) led to high efficacy with >300-fold 
selectivity over human cells (Patel et al., 2014). Some of these analogues were 
also valuable against Leishmania parasites, although inactive against T. cruzi. 
SAR in the molecular model was also applied in two well-profiled molecules (one 
in clinical trials for cancer and its precursor) that had anti-trypanosome EC50s in 
the low micromolar range (Ochiana et al., 2013). One compound showed good 
selectivity over human, and a good correlation was found between predicted 
affinity in silico, and efficacy over the parasite in culture. Compounds have not 
been tested in the recombinant protein yet. 
Phosphoinositide-3 kinases and mTOR inhibitors 
PI3K and mTOR play fundamental roles in growth and metabolism in human cells. 
They have been exploited as drug targets for anticancer therapy and in for 
treatment of inflammatory disease. There are inhibitors well advanced in the 
pipeline of drug discovery able to target these two protein kinases 
independently or in a cross-reactive manner. 
PI3K orthologue in T. brucei, TbVPS34, localizes to the endosomal system and is 
required for receptor-mediated endocytosis, transport to the lysosomes, and 
exocytosis. Knockdown causes severe growth defect, which present with a block 
in cytokinesis and impaired segregation of the Golgi apparatus (Hall et al., 
2006).  Unlike many other eukaryotes, mTOR has 4 orthologues in T. brucei, 
some of them are essential for fitness and progression along the life cycle in the 
parasite in culture (Barquilla, Crespo and Navarro, 2008; Barquilla and Navarro, 
2009a, 2009b; De Jesus et al., 2010; Saldivia et al., 2013). 
A promising compound in the pipeline for drug discovery against cancer, proved 
to be effective against T. brucei, Leishmania, and T. cruzi. Phenotype resulting 
from compound treatment correlated with biological implications of RNAi against 
both targets in T. brucei. It also showed efficacy in mice infections (Diaz-
Gonzalez et al., 2011). SAR studies led to development of analogues aiming to 
increase selectivity versus human, solubility and predicted permeability to the 
CNS (Wager, Hou, et al., 2010). These conditions were achieved for two of these 
compounds although they showed lower potency than the originals (Seixas et al., 
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2014). These compounds were shown in a phosphoproteomics study inhibiting 
PI3K pathways. 
Tyrosine kinase inhibitors 
Tyrosine kinases are absent in the T. brucei kinome but tyrosine phosphorylation 
has been reported, possibly due to dual specificity kinases (Nett et al., 2009). 
Tyrphostin, a non-specific tyrosine kinase inhibitor, was shown to be a disruptor 
of receptor-mediated endocytosis of transferrin in T. brucei (Subramanya and 
Mensa-Wilmot, 2010). This suggested that these chemotypes could have utility in 
T. brucei drug development.  
With this rationale, three tyrosine kinase inhibitors beyond phase I of clinical 
trials for breast cancer, lapatinib, canertinib and AEE788, were studied in T. 
brucei. Although they targeted EGFR, which has no homologues in the parasite, 
the three drugs were trypanocidal. An ATP-sepharose affinity chromatography 
coupled to mass spectrometry after elution with the compounds unveiled 4 
candidate tyrosine kinase inhibitor-binding protein kinase targets (Katiyar et al., 
2013).  
8 analogues of these drugs designed through SAR were found with drug-like 
EC50s, 2 showing selectivity over human cells, with 1 bioavailable in oral dose. 
The compound induced a block in cytokinesis but physicochemical properties 
suggested low CNS penetrance (Patel et al., 2013). In a more recent study, 
lapatinib inhibit parasite growth compared to controls in vitro and in vivo. 3 
mice (out of 4) survived longer than the untreated controls with one cured from 
the infection (Behera, Thomas and Mensa-Wilmot, 2014).  
Other kinase inhibitor libraries screened against TbERK8 
It was mentioned above that TbERK8 (MAPK6) was demonstrated to be essential 
in a luciferase-based RNAi screen (Mackey et al., 2011). Interesting, the human 
orthologue is not indispensable. TbERK8 is an active kinase that phosphorylates 
the putative replication factor TbPCNA and that can be targeted with inhibitors 
of human ERK8 (Valenciano, Knudsen and Mackey, 2016). A library of 274 kinase 
inhibitors FDA approved or advanced in the pipeline of drug discovery was 
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screened identifying 10 novel hits that are potent against the parasite in culture. 
4 inhibited recombinant TbERK8, and one did it specifically (Valenciano et al., 
2016). 
1.6 Aims of this thesis 
My intention in this PhD was to attempt a methodical approximation to the 
preclinical stages of the drug discovery process in a tropical neglected disease. I 
designed the experimental plan so I covered the subjects of drug target 
identification, drug target characterization, and mechanism-directed active 
compound screening making the most out of the resources available at my 
institution: the Welcome Centre for Molecular Parasitology.  
As such, the objective of this thesis was to identify protein kinases of biological 
relevance in T. brucei with potential value as drug targets for chemotherapy. In 
chapter 3, I will show how I exploited RNAi target sequencing technology in 
order to understand which are required for establishment of the mammalian 
infection. Among these protein kinases, depletion of several caused a loss of 
fitness in the parasite at the mammalian bloodstream that did not occur in the 
in vitro culture. Most of these protein kinases had orthologues in other 
organisms playing roles in resistance to environmental shocks and different 
stress factors. I will show proof of requirement of some of these kinases to 
withstand serum-mediated lysis and osmotic shock treatment.  
In chapter 4, I will describe in more detail RDK2: a protein kinase found essential 
for parasite fitness both in vitro and in vivo. At the culturing conditions of 
bloodstream forms, RDK2-targeting RNAi mutants acquire characteristics of the 
insect-infective procyclic forms, 24 h prior to cell death. Interestingly, the 
procyclic-like phenotype could be maintained alive for more than one week in 
conditioned procyclic form culturing media. However parasite density did not 
increase suggesting a cell cycle arrest. Recombinant RDK2 was produced and 
proven to be an active protein kinase capable of phosphorylating a substrate and 
of autophosphorylation. Ectopic expression of RNAi-refractory mutants of RDK2 
in cell lines depleted of the wildtype did not permit to establish with clarity 
whether the phenotype was due to kinase inhibition or to other consequences 
derived of RDK2 absence. 
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In chapter 5, I present the results of a collaborative project with GSK and the 
Swiss TPH where I screen against the complete parasite 518 compounds for 
activity matching the phenotypic outcome of RDK2 depletion. I identify 6 
compounds producing signs of differentiation followed by parasite death. In 
chapter 6, I discuss the gaps of knowledge I have covered and the new questions 
and research perspectives that arise from this work.  
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Chapter 2 Materials and methods 
 
2.1 Ethics statement  
Animal procedures followed the guidelines and were approved by The Home 
Office of the UK government. The procedures here presented were covered by 
the project license PPL60/4442 entitled ‘‘Molecular Genetics of Trypanosomes 
and Leishmania’’. The University of Glasgow ethics committee also approved all 
protocols. 
2.2 General Bioinformatics 
2.2.1 Sequence retrieval 
DNA and protein sequences from the different genes analysed in this thesis were 
extracted from TriTrypDB.org, version 29 (12 Oct 2016) while this thesis is being 
written. This includes not only T. brucei brucei genes but also T. cruzi and L. 
major orthologues analysed in the RITseq chapter. Protein sequences from other 
organisms used in BLASTp for function predictions were taken from NCBI 
database (http://www.ncbi.nlm.nih.gov/). 
2.2.2 General sequence manipulation 
Sequence manipulation was conducted in CLC genomics workbench 7 (Qiagen), 
including design of primers, cloning strategies, in silico translation, hairpin 
folding and protein size predictions. Reverse translation was applied to the RDK2 
protein sequence in order to generate an RNAi refractory version of the gene, 
using T. brucei 927 codon bias to prioritise the less frequent codons. The gene 
product was assessed manually to make sure that no regions longer than 20 
nucleotides were left with identity to wild-type genes. Then they were used in 
an RNAit search (Redmond, Vadivelu and Field, 2003) to ensure that there was 
no homology to wild-type RDK2 and thus would not be downregulated by the 
RDK2 RNAi target sequence. Identification of different domains predicted for 
RDK2 was made by alignment to three hidden markov model (HMM) databases: 
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SMART (Letunic, Doerks and Bork, 2015), PFAM (Finn et al., 2014) and 
Superfamily (Gough et al., 2001). 
2.3 Molecular biology 
2.3.1 DNA preparation 
2.3.1.1 Genomic DNA 
Genomic DNA was purified with QIAamp DNA minikit (Qiagen) or DNAeasy Blood 
and Tissue (Qiagen). Concentration and purity was measured in Nanodrop 1000 
(Thermo Scientific) in a general basis.  The source of T. brucei brucei strain for 
general cloning proposes was Lister 427 wild type. DNA was isolated from all 
other cell lines used in this thesis at some point. For RNAi target sequencing 
(RITseq), Nanodrop accuracy was not considered sufficient and fluorescence-
based methods to measure double stranded DNA concentration were used: 
Qubit™ fluorometric quantitation (Thermo Scientific) for the first replicate of 
the in vivo RITseq, and Quant-iT™ PicoGreen® dsDNA Assay Kit (Thermo 
Scientific) for the second replicate in vivo and the three in vitro experiments. 
DNA preparation was conducted both by hand or using robotics (Qiacube, 
Qiagen). 
2.3.1.2 Plasmid DNA 
Plasmids were purified from overnight liquid bacterial cultures in LB medium 
with selection drugs using QIAprep Miniprep kit (Quiagen). Concentration and 
purity was measured with Nanodrop 1000 (Thermo Scientific). If required, 
successful cloning was assessed via test digestion, PCR or sequencing. 
Table 2-1. List of plasmids used in this thesis outside the pTL library. 
Mottram 
Lab Code 
Insert Function Destination Selection 
pGL2084 Gateway-modified pRPaiSL  
(Jones et al., 2014) 
Tet-inducible RNAi RRNA Hyg Ampicillin 
pGL2220 pRPax6mycx (Alsford and Horn, 2008) Tet-inducible 
Overexpression 
RRNA Hyg Ampicillin 
pGL2323 Rdk2-6myc (pGL2220-modified) Tet-inducible 
Overexpression 
RRNA Hyg Ampicillin 
pGL2324 6myc-Rdk2 (pGL2220-modified) Tet-inducible 
Overexpression 
RRNA Hyg Ampicillin 
pRM481 (Proudfoot and McCulloch, 2005) Constitutive expression Tubulin Ampicillin 
pGL2271 Rdk2REC-6xHA (pRM481-modified) Constitutive expression Tubulin Ampicillin 
pGL2297 Rdk2REC/K70M-6HA (pGL2271-modified) Constitutive expression Tubulin Ampicillin 
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pGL2471 Rdk2REC/A50C-6HA (pGL2271-modified) Constitutive expression Tubulin Ampicillin 
pGL2587 6HA-Rdk2REC (pGL2271-modified) Constitutive expression Tubulin Ampicillin 
pGL2099 Trx-Rdk2 (pET32 Xa/LIC-modified) Recombinant expression E. coli Ampicillin 
pGL2215 Trx-Rdk2K70M (pGL2099-modified) Recombinant expression E. coli Ampicillin 
pGL2654 Trx-Rdk2S195A (pGL2099-modified) Recombinant expression E. coli Ampicillin 
pGL2655 Trx-Rdk2S195E (pGL2099-modified) Recombinant expression E. coli Ampicillin 
pGL2656 Trx-Rdk2S195A/S197A (pGL2654-modif.) Recombinant expression E. coli Ampicillin 
pGL2657 Trx-Rdk2S195A/S197E (pGL2654-modif.) Recombinant expression E. coli Ampicillin 
pGL2658 Trx-Rdk2S195E/S197E (pGL2655-modif.) Recombinant expression E. coli Ampicillin 
pGL2659 Trx-Rdk2S195E/S197A (pGL2655-modif.) Recombinant expression E. coli Ampicillin 
 
2.3.2 DNA synthesis 
DNA synthesis of complete genes, such as recoded RDK2 (Figure 4-8), was 
conducted at Dundee Cell products. Routine synthesis of oligonucleotides was 
produced by Eurofins genomics.  
2.3.3 Polymerase chain reaction (PCR) 
Most of PCR reactions conducted for this thesis required the high fidelity 
polymerases Phusion HF polymerase and Q5 HF polymerase (New England Biolabs 
(NEB). Reactions were conducted in 25 or 50 l following manufacturer’s 
instructions. Annealing temperatures were calculated based on the melting 
temperature of the diverse primers based on results from NEB Tm calculator. 
When necessary, gradient PCRs were set up to select the optimal annealing 
conditions.  
2.3.3.1 RITseq PCR 
In order to enrich the DNA prepared from samples coming from any of the RITseq 
experiments in the RNAi target, a PCR was optimized using OL4161 and 
derivative barcoded primers. The PCR program was: 3 mins at 98oC; followed by 
28 cycles comprising: 10 seconds at 98oC, 10 seconds at 61oC (64oC if barcoded 
primers), and 30 seconds at 72oC; with a final extension step at 72oC for 10 mins. 
Table 2-2. List of primers used for optimization of the RITseq PCR 
Mottram Lab code Binding  site Sequence 
OL4161 AttL1 Fw1 TAATGCCAACTTTGTACAAA 
OL4162 AttL1 Fw2 TTGTACAAAAAAGCAGGC 
OL4163 Stuffer Rv1 CTCAACCCTATCTCATCG 
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OL4164 AttL2 Rv3a ACCTGTTCGTTGCAACAA 
OL4165 AttL2 Rv3b CGTTGCAACAAATTGATA 
OL4212 AttL2 Rv4 TAATGCCAACTTTGTACAAG 
Binding sites depicted in Figure 3-4. 
Table 2-3. List of primers used for the barcoded RITseq experiment 
Primers highlighted in blue showed homogeneous amplification and were used in 
the screen, Figure 3-5. 
2.3.4 PCR clean up 
When required, PCR products were purified using QIAquick PCR Purification Kit 
(Qiagen). This technique was applied for purification of digested/linearized PCR 
constructs or plasmids when it was required to create sticky ends in a PCR 
product amplified with restriction sites or it was not necessary to isolate a 
particular DNA fragment. 
Mottram Lab code RITseq barcode Sequence 
OL4440b RIT-1-F ATCACGTAATGCCAACTTTGTACAAA 
OL4442 RIT-2-F CGATGTTAATGCCAACTTTGTACAAA 
OL4444 RIT-3-F TTAGGCTAATGCCAACTTTGTACAAA 
OL4446 RIT-4-F TGACCATAATGCCAACTTTGTACAAA 
OL4448 RIT-5-F ACAGTGTAATGCCAACTTTGTACAAA 
OL4450 RIT-6-F GCCAATTAATGCCAACTTTGTACAAA 
OL4452 RIT-7-F CAGATCTAATGCCAACTTTGTACAAA 
OL4454 RIT-8-F ACTTGATAATGCCAACTTTGTACAAA 
OL4456 RIT-9-F GATCAGTAATGCCAACTTTGTACAAA 
OL4458 RIT-10-F TAGCTTTAATGCCAACTTTGTACAAA 
OL4460 RIT-11-F GGCTACTAATGCCAACTTTGTACAAA 
OL4462 RIT-12-F CTTGTATAATGCCAACTTTGTACAAA 
OL4464 RIT-13-F AGTCAATAATGCCAACTTTGTACAAA 
OL4466 RIT-14-F AGTTCCTAATGCCAACTTTGTACAAA 
OL4468 RIT-15-F ATGTCATAATGCCAACTTTGTACAAA 
OL4470 RIT-16-F CCGTCCTAATGCCAACTTTGTACAAA 
OL4472 RIT-17-F GTCCGCTAATGCCAACTTTGTACAAA 
OL4474 RIT-18-F GTGAAATAATGCCAACTTTGTACAAA 
OL4476 RIT-19-F GTGGCCTAATGCCAACTTTGTACAAA 
OL4478 RIT-20-F GTTTCGTAATGCCAACTTTGTACAAA 
OL4480 RIT-21-F CGTACGTAATGCCAACTTTGTACAAA 
OL4482 RIT-22-F GAGTGGTAATGCCAACTTTGTACAAA 
OL4484 RIT-23-F ACTGATTAATGCCAACTTTGTACAAA 
OL4486 RIT-24-F ATTCCTTAATGCCAACTTTGTACAAA 
Chapter 2 74 
 
2.3.5 Agarose gel electrophoresis 
DNA was analysed in UltraPure agarose (Invitrogen) gels made in 0.5 x TBE buffer 
(20mM Tris, 20 mM boric acid, 0.5 mM EDTA, pH 7.2). They were used 1% (w/v) 
for PCR, and 0.7% (w/v) for plasmid analysis. Gels were supplemented with 
SYBR™ Safe DNA Gel Stain (Invitrogen) to allow DNA visualization in a Gel Doc™ 
XR + Gel Documentation System (Bio-Rad). Gels were run for 1 h at 100 V, using 
1 Kb plus ladder (Invitrogen) as size standards. 
2.3.6 Gel purification 
When necessary, DNA was purified from agarose by selecting bands of interests 
in a DarkReader blue light transilluminator using a scalpel blade to remove the 
gel fragment. Excised bands were processed with MinElute Gel Extraction kit 
(Qiagen) by hand or using an automated protocol in a Qiacube (Qiagen). 
2.3.7 DNA cloning 
Different approaches have been followed in this thesis for DNA cloning purposes. 
2.3.7.1 Restriction/Ligation traditional cloning 
All restriction digestions were conducted using restriction enzymes from NEB, 
following manufacturers recommendations. Linearized backbone vectors were 
purified from agarose gels with MinElute Gel Extraction kit (Qiagen), unless the 
drop out was small enough to flow through a PCR purification column. When 
inserts were amplified from a DNA source (gDNA or plasmid) using Phusion or Q5 
polymerases (NEB) including restriction sites in the primers, they were purified 
with QIAquick PCR Purification Kit (Qiagen) prior to being digested. After 
digestion a sample was analysed in agarose gel and the rest was processed in a 
second round of PCR cleanup to discard the small cleaved fragments removed to 
create the sticky ends. If the inserts were a product of digestion of another 
plasmid, they were run in an agarose gel and the right-sized band purified with 
MinElute Gel Extraction kit (Qiagen). Backbone and inserts carrying 
complementary cohesive ends were ligated using T4 ligase (Promega), incubating 
reaction for 4 h at room temperature or at 16 oC overnight. 
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Table 2-4. List of primers used for digestion/ligation cloning in this thesis. 
Mottram 
lab code 
Gene Objective Destination System Sequence 
OL4172 Rdk2 6myc (N) AvrII Fw pGL2220 Tet-ind OE GACTCCTAGGACGGAACATAAGCGTCC 
OL4173 Rdk2 6myc (N) BamHI Rv pGL2220 Tet-ind OE GACTGGATCCTCAACGAGGCACGGCAT 
OL4174 Rdk2 6myc (C) HindIII Fw pGL2220 Tet-ind OE GACTAAGCTTATGACGGAACATAAGCG 
OL4175 Rdk2 6myc (C) XbaI Rv pGL2220 Tet-ind OE GACTTCTAGAACGAGGCACGGCATTCT 
Red=landing for the restriction enzyme/Blue=restriction sites 
2.3.7.2 Gateway cloning 
The majority of plasmids included in the pTL library were produced using 
Gateway cloning (Invitrogen), a few needed to be remade in the system in order 
to include the universal AttL flanks where the RITseq PCR primers sit (Figure 
3-2). Primers to amplify the RNAi target sequence were redesigned in CLC 
Genomics Workbench including AttB gateway flanks and synthetized by Eurofins 
genomics (Table 2-5). PCR products were generated with Phusion polymerase 
(NEB) using gDNA from T. brucei brucei Lister 427 wild type strain as a template. 
Reactions were set in 50 l following manufacturers instructions. AttP-containing 
pGL2084 was the backbone vector (Jones et al., 2014). Within both AttP-flanked 
RNAit acceptor sites this plasmid contains the ccdB gene, which is toxic unless 
cloned in One Shot® ccdB Survival™ 2 T1R Competent Cells (Invitrogen) and 
maintained at 25oC. Every batch of plasmid used required assessment by test 
digestion as deletion of ccdB happened frequently as a mechanism of resistance. 
AttB-amplified PCR products were cloned into AttP-containing pG2084 using 
Gateway® BP Clonase® II Enzyme mix (Invitrogen). Resulting lines were analysed 
in Alamar blue (see below). 
Table 2-5. List of primers to make with Gateway cloning lines that were made 
with ligation.  
Mottram 
Lab code 
Gene ID Name Sequence 
TLO41 
Tb927.10.4990 
CRK3 Fw GGGGACAAGTTTGTACAAAAAAGCAGGCTaaaggctctcgagaagaggg 
TLO42 CRK3 Rv GGGGACCACTTTGTACAAGAAAGCTGGGTagcgctggtaacacctgagt 
TLO417 
Tb927.11.12410 
KKT10 Fw GGGGACAAGTTTGTACAAAAAAGCAGGCTtaactcatccaccattgcca 
TLO418 KKT10 Rv GGGGACCACTTTGTACAAGAAAGCTGGGTagatgcatatgacgtgacgc 
TLO255 
Tb927.10.14300 
STE11 Fw GGGGACAAGTTTGTACAAAAAAGCAGGCTtgcattttcaagcaaacagc 
TLO256 STE11 Rv GGGGACCACTTTGTACAAGAAAGCTGGGTgcagaccgaaccagtacatt 
TLO419 
Tb927.7.3580 
NEK 11 Fw GGGGACAAGTTTGTACAAAAAAGCAGGCTcctgaagctgggagactttg 
TLO420 NEK 11 Rv GGGGACCACTTTGTACAAGAAAGCTGGGTgttttgttattacctcgggcg 
TLO421 
Tb927.10.16160 
Orphan Fw GGGGACAAGTTTGTACAAAAAAGCAGGCTaaatggactttaccctccgc 
TLO422 Orphan Rv GGGGACCACTTTGTACAAGAAAGCTGGGTctgcctcggctaattctgac 
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TLO423 
Tb927.3.3290 
Orphan Fw GGGGACAAGTTTGTACAAAAAAGCAGGCTtgtattgcatgtgggaggaa 
TLO424 Orphan Rv GGGGACCACTTTGTACAAGAAAGCTGGGTggcacttgtataccacgcct 
TLO425 
Tb927.3.3080 
Nek 6 Fw GGGGACAAGTTTGTACAAAAAAGCAGGCTgaagaagttgcaggtcaggc 
TLO426 Nek 6 Rv GGGGACCACTTTGTACAAGAAAGCTGGGTtcatcaaggaaactcgaccc 
TLO427 
Tb927.3.3190 
Nek 7 Fw GGGGACAAGTTTGTACAAAAAAGCAGGCTgccctcggtgtcattcttta 
TLO428 Nek 7 Rv GGGGACCACTTTGTACAAGAAAGCTGGGTtatgctctcccgattcatcc 
TLO429 
Tb927.8.1670 
Nek 13 Fw  GGGGACAAGTTTGTACAAAAAAGCAGGCTcacgtgaagagaagcagcag 
TLO430 Nek 13 Rv GGGGACCACTTTGTACAAGAAAGCTGGGTaatttcgactgaaacgtccg 
TLO431 
Tb927.9.4910 
TbPDK1 Fw GGGGACAAGTTTGTACAAAAAAGCAGGCTggtccgcaggaccttatgta 
TLO432 TbPDK1 Rv GGGGACCACTTTGTACAAGAAAGCTGGGTaccacaggcccagtaatcag 
TLO433 
Tb927.6.2250 
TbRAC Fw GGGGACAAGTTTGTACAAAAAAGCAGGCTctccagagtttctgcttggg 
TLO434 TbRAC Rv GGGGACCACTTTGTACAAGAAAGCTGGGTccactacttcatcgtccggt 
TLO435 
Tb927.11.6690 
Orphan Fw GGGGACAAGTTTGTACAAAAAAGCAGGCTatctccagacccactgatgg 
TLO436 Orphan Rv GGGGACCACTTTGTACAAGAAAGCTGGGTaggcaagggcacatacaatc 
TLO437 
Tb927.3.2440 
TbPKDH Fw GGGGACAAGTTTGTACAAAAAAGCAGGCTggcgaactcatttgttggtt 
TLO438 TbPKDH Rv GGGGACCACTTTGTACAAGAAAGCTGGGTttgtttccactttgtgcagc 
Fw= Forward primer; Rv= Revers primer; red= AttLB1 site; blue= AttLB2 site 
2.3.7.3 Ligation independent cloning 
Expression vector pGL2099 (expressing Trx:RDK2) was created by ligation 
independent cloning using pET32 Xa/LIC (Novagen following manufacturer 
instructions. RDK2 was amplified with primers containing overhangs homologous 
to the vector: 15 nucleotides in the 5’ hybridization site and 17 nucleotides in 
the 3’ end (Table 2-6). 
Table 2-6. List of primers for ligation independent cloning of RDK2 in pET32 
Xa/LIC (Novagen) 
Mottram 
Lab Code 
Gene ID Function Sequence 
OL3746  
Tb927.4.5310 
RDK2 LIC/Xa pET32 Fw GGTATTGAGGGTCGCatgacggaacataagcgtcc 
OL3747 RDK2 LIC/Xa pET32 Rv AGAGGAGAGTTAGAGCtcaacgaggcacggcattct 
Upper case=vector specific/Lower case=kinase specific 
The resulting PCR product was purified and treated with T4 DNA polymerase in 
the presence of dGTP as the only nucleotide available. This permitted the 
enzyme to act with its 3’5’ exonuclease activity until finding a position where 
dGTP could be inserted creating sticky ends that would anneal with linearized 
vector. Vector and T4 polymerase-treated insert were annealed for 5 mins at 22 
oC and then, 25 mM EDTA was added to the mix for a further 5 mins at the same 
temperature. pGL2099 was transformed in NovaBlue GigaSingles™ competent 
cells (Novagen) as described below. 
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2.3.8 Site directed mutagenesis 
Recoded Rdk2 (plasmid pGL2271) was mutated to create RDK2A50C and RDK2K70M 
variants. The recombinant protein (pGL2099) was also mutated to produce 
RDK2K70M, RDK2S195A/S197A, RDK2S195A/S197E, RDK2S195E/S197A, and RDK2S195E/S197E. To 
create the double phosphosite mutations, intermediate plasmids were generated 
encoding RDK2S195A, and RDK2S195E respectively. All these mutations were induced 
with Q5® Site-Directed Mutagenesis Kit (NEB). Primers were designed using the 
NEBaseChanger™ online tool and used in a first-stage PCR of the vector that 
introduces the selected deletions/insertions included in the primers. In a second 
stage, methylated-specific DpnI treatment removed the original template as it 
was the only one methylated by the bacterial host, and the kinase-ligase tandem 
circularized the mutated plasmid by 5’ phosphorylation and ligation. Primers 
designed for this purpose can be found in Table 2-7. 
Table 2-7. List of primers designed to introduce mutations using Q5® Site-
Directed Mutagenesis Kit (NEB). 
Mottram 
Lab Code 
Target gene Mutation Sequence 
OL4061 Rdk2REC K70M Fw GGACTTATATTTGCAGCGATGGTAATGGATACGAACAAC 
OL4062 Rdk2REC K70M Rv GTTGTTCGTATCCATTACCATCGCTGCAAATATAAGTCC 
OL4921 Rdk2REC A55C Fw CTTTGGTTCTtgcTGGCGTGTAGAGG  
OL4922 Rdk2REC A55C Rv CTACCTTGCCCTAATAAC 
OL5172 Trx-Rdk2  S195E Fw ATACGAGGACgaGCTGTCAAATCC 
OL5173 Trx-Rdk2  S195E 
or 
S195A Rv 
TGACGACTGAAGCCAAAG 
OL5174 Trx-Rdk2S195E  S197E Fw GGACGAGCTGgaAAATCCTGTTG  
OL5175 Trx-Rdk2S195E  
or  
Trx-Rdk2S195A 
S197E Rv TCGTATTGACGACTGAAG 
OL5176 Trx-Rdk2S195E S197A Fw GGACGAGCTGgCAAATCCTGT 
OL5177 Trx-Rdk2S195E S197A Rv TCGTATTGACGACTGAAGC 
OL5178 Trx-Rdk2  S195A Fw ATACGAGGACgCGCTGTCAAATC 
OL5179 Trx-Rdk2S195A S197E Fw GGACGCGCTGgaAAATCCTGTTG 
OL5180 Trx-Rdk2S195A  S197A Fw GGACGCGCTGgCAAATCCTGT 
OL5181 Trx-Rdk2S195A S197A Rv TCGTATTGACGACTGAAGCCAAAG 
 
2.3.9 Transformation in bacteria 
Plasmids were amplified by transformation in E. coli, with the objective of 
expanding the plasmid and/or generating frozen stocks. As a general rule, 50 l 
of competent cells were incubated with 2 l of plasmid for 20 mins on ice. Then, 
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tubes were heat shocked for 30 seconds at 42 oC, and left for 2 mins recovering 
on ice. After this, 150 l of SOC media were added on top, cells were incubated 
for 1 h at 37 oC, and spread on the surface of pre-warmed LB agar plates 
supplemented with selective antibiotics. After overnight incubation at 37 oC, 2-3 
colonies were isolated and expanded in overnight 5-10 ml liquid LB cultures 
supplemented with selective antibiotics. 800 l of cells were used for 
cryopreservation and the rest for plasmid purification using QIAprep Miniprep kit 
(Quiagen). 
Different plasmids required different bacterial hosts for expansion. Routine 
cloning with Tet-inducible RNAi or overexpression plasmids in Table 2-1, was 
conducted in E. coli DH5 at 37oC (Invitrogen). pGL2084, that contained the 
toxic ccdB gene, were grown in E. coli One Shot® ccdB Survival™ 2 T1R competent 
cells (Invitrogen). Finally, recombinant expression vectors in Table 2-1 were 
grown in codon-enriched E. coli RosettaTM (DE3) p-lysS strain (Novagen). pGL2099 
was grown immediately after cloning in NovaBlue GigaSingles™ competent cells 
(Novagen) including in the Xa/LIC kit, see “Ligation independent cloning” 
section. 
For cryopreservation 800 l of cells from an overnight liquid LB culture of 
transformed bacteria were diluted with 800 l of LB 40% glycerol/2% peptone 
and kept at -80 oC for long-term storage. For over one week, colonies in the 
plates could also be used. 
2.3.10 DNA sequencing 
2.3.10.1 Routine sequencing 
Routine sequencing for cloning validation or sequence identification was 
conducted at Eurofins genomics after PCR amplification with a high fidelity 
polymerase (Phusion or Q5, New England Biolabs) sending premixed samples 
including the desired primer and PCR products directly at the concentration 
indicated by the service provider. For longer reads, PCR products were purified 
and subcloned in pGEM-T easy vector (Promega) and sent with sequencing 
primers to eurofins genomics. Cloning products –such as newly made vectors- 
were sent directly with sequencing primers. Both polymerases produced blunt-
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end products so A-overhangs were added with Taq (NEB) in a single cycle of 30 
mins at 72oC. Reactions were later purified and ligated in pGEM-T easy vector 
following manufacturer instructions. Alternatively, PCR products were subcloned 
with StrataClone Blunt PCR Cloning Kit (Agilent Technologies), which permits 
blunt-end ligation.   Cloned products were transformed in MAX efficiency 
Escherichia coli DH5(Invitrogen) and plated overnight. Colonies were picked 
and grown in liquid LB overnight cultures, plasmids purified the next day with 
QIAprep Miniprep kit (Quiagen), and send for sequencing with appropriate 
primers. 
2.3.10.2 RNAi target sequencing 
The first in vivo RNAi target sequencing replicate was conducted at Glasgow 
Polyomics. 200 ng of DNA per sample were fragmented, size selected (average 
read length after sequencing ~106 nucleotides) and processed according to Ion 
Torrent library prep protocols. Multiplexed sample was subjected to emulsion 
PCR and Ion Torrent sequencing. 
The second in vivo replicate and the three in vitro experiments were sequenced 
at Eurofins genomics using Illumina HiSeq, avoiding the fragmentation and size 
selection steps. Samples for this second set of experiments were enriched in the 
PCR cassette using 14 distinct bar-coded primers (Table 2-3). In this manner they 
could be pooled to provide equal mass of every sample and 400 ng of each pool 
of 14 were sent for sequencing. 
2.4 Protein manipulation 
2.4.1 Protein sample preparation 
2.4.1.1 Bacterial cultures 
0.5 ml of bacterial cultures were pelleted at 12000xg for 2 mins per condition, 
and supernatant removed. As a general rule, if analysing protein expression, one 
sample was taken for the uninduced control and two samples for the IPTG 
induced (see below). The complete uninduced sample and one of the induced 
were resuspended in 60 l of 1x protein loading buffer (250 μl 4x NuPAGE® LDS 
sample buffer [Invitrogen], 750 μl 1x PBS and 25 μl β-mercaptoethanol), 10 
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seconds of sonication were applied, and samples were denatured at 95 oC for 10 
mins. Samples could be stored at -20 oC until being used. For the other induced 
sample, it was resuspended in 45 l of PBS, subjected to 3 cycles of sonication 
(10 seconds each) in order to obtain the soluble fraction and centrifuged again 
12000xg for 10 mins. Supernatant (soluble fraction) was transferred to a 
different tube and supplemented with 15 l of 4x NuPAGE® LDS sample buffer 
(Invitrogen). Pellet (insoluble fraction) was supplemented with 60 l of 1x 
protein loading buffer. 
2.4.1.2 Trypanosome cultures 
As a general rule, between 106-2.5x106 parasites were used per sample. They 
were centrifuged at 1500 x g for 10 mins and lysed with 20 l 1x protein loading 
buffer per sample before being denatured at 95 oC. Samples could be kept at -20 
oC until needed. 
2.4.2 SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis was used to 
separate proteins according to size. NuPAGE™ Novex™ 10% Bis-Tris Protein Gels, 
1.0 mm, 12-well (Invitrogen) were generally used in a XCell SureLock™ Mini-Cell 
Electrophoresis System (Invitrogen). NuPAGE® MES SDS Running Buffer or 
NuPAGE® MOPS SDS Running Buffer (Invitrogen) were used as running buffer. 
Samples were defrosted and denatured again at 95 oC before loading 20 l per 
lane. Electrophoresis was run for 45 mins at 150 V. 
 
To visualize proteins after electrophoresis, polyacrylamide gels were rinsed in 
milliQ water and SimplyBlue™ SafeStain ready-to-use reagent (Life technologies) 
was applied for about one h followed by three 20-minute rinses with distillate 
water. To fasten the process, the reaction was warmed up for 10 seconds in the 
microwave at maximum power. 
2.4.3 Western blotting 
For western blot, proteins separated by SDS-PAGE were transferred to a 
Polyvinylidene difluoride (PVDF) Biotrace membrane (Pall) in an X-Cell II Blot 
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Module (Invitrogen). PVDF membrane was activated in methanol for 30 seconds, 
rinsed in milliQ water then equilibrated in transfer buffer [20 % (v/v) methanol, 
20 mM Tris, 15 mM glycine]. The transfer chamber was assembled and filled with 
transfer buffer with all pads and filter papers soaked previously in it. Transfer 
was performed at 30 V for 2 h with the outer chamber filled with water to 
provide a coolant. As a general rule, membrane was rinsed in 1x PBST (PBS, 0.01 
% Tween-20 [Sigma]) for 10 mins on a rocker then incubated for 1 h in blocking 
solution (1x PBST, 5 % Milk powder [Marvel]) or if required, overnight at 4 oC. 
After, the membrane was rinsed once for 10 mins in 1x PBST then it was moved 
to blocking buffer containing the required primary antisera and incubated for 1 
h. Then, membrane was washed three times for 10 mins with 1xPBST, and 
incubated for another hour with a secondary antibody against the primary 
serotype conjugated to horseradish peroxidase (HRP). Again, the membrane was 
washed three times for 10 mins with 1 x PBST then the SuperSignal West Pico 
Chemiluminescent Substrate (Thermo-Fisher) or ECL Prime Western Blotting 
Detection Reagent (Amersham) were pipetted evenly onto the membrane 
surface, which was subsequently incubated in the dark for 5 mins. The 
membrane was then exposed in a gel doc, or using medical X-ray blue film MXB 
(Carestream) in a Kiran cassette for ~one second to overnight and films were 
developed using a Kodak M-25-M X-omat processor.  
2.4.3.1 Antibody detection 
Table 2-8. List of antibodies used for western blot in this thesis. 
Antibody Serotype Clone Concentration Supplier 
VSG 221 variant Rabbit IgG N/A 1:20000 R. McCulloch 
VSG crossreactive* Rabbit IgG N/A 1:20000 D. Horn 
EF1 Mouse IgG CBP-KK1 1:25000 Millipore 
EP procyclin Mouse IgG TBRP1/247 1:500 Cedarlane 
Myc Mouse IgG 4A6 1:7000 Millipore 
HA Mouse IgG HA-7 1:1000 Sigma 
Mouse IgG Goat IgG N/A 1:5000 Novex 
Rabbit IgG Goat IgG N/A 1:5000 Novex 
*Required hypotonic lysis to maintain folding of the crossreactive determinant 
(10 mM Tris base, pH 7.5 with HCl on ice) and centrifugation 12000xg 2 mins to 
separate supernatant separating soluble and insoluble fractions. 
^The HA antibody was incubated overnight at 4 oC 
Abbreviations: VSG (Variant Surface Glycoprotein), EF1(Elongation Factor 1, 
Ig (Immunoglobulin). 
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2.4.4 Protein expression and purification 
All proteins expressed for this thesis were mutants derived from the same Trx-
RDK2 protein and were expressed under the same conditions. Codon-enriched 
Escherichia coli RosettaTM (DE3) p-lysS strain, with T7 lysozyme to supress basal 
T7 expression, was used as the bacterial host. Protein expression was induced 
with 1 mM IPTG in 1L log-phase cells (OD600=0.5) at 17oC overnight. 
Proteins were derived from pET32 Xa/LIC expression system (Novagen). They all 
express the protein of interested fused to a N-terminal thioredoxin tag for 
solubility and a 6xHis tag for purification using ion metal affinity 
chromatography (IMAC). 
After centrifugation of an overnight induced culture, 14000g for 15 mins pellets 
were lysed with B-PER (Thermo Scientific). Then they were sonicated (5 cycles 
of 10 seconds on ice), centrifuged again to collect supernatant, and filtered 
through a 0.22 m minisart (Sigma), and loaded for IMAC in a 5 ml HisTrapTM HP 
column (GE Healthcare), precharged with Ni2 SepharoseTM High Performance 
medium on an AKTA purifier (GE Healthcare). All buffers used in the AKTA 
system were previously filtered through a 0.22 m Stericup® filtration unit 
(Millipore). The column was equilibrated with 20 mM NaH2PO4, 500 mM NaCl, 5 
mM imidazole, pH 7.4. After binding the 6xHis-tag, the column was washed with 
the same buffer but containing 35 mM imidazole. Finally, elution was conducted 
with the same buffer but including 500 mM imidazole monitoring UV absorbance 
in 1 ml fractions to detect the protein content. Spaced fractions across the 
elution peak were sampled and run in a 12% SDS-PAGE and stained with 
SimplyBlue™ SafeStain ready-to-use reagent (Life technologies) to assess purity 
of Trx-RDK2 (and derivatives) in order to pool the best fractions. Imidazole was 
removed from the pooled fractions in a PD-10 desalting column. To purify the 
protein further, the sample was loaded into a pre-equilibrated anion exchange 
HiTrap Q XL column in the AKTA purifier, washed with 10 column volumes of 25 
mM Tris-HCl pH 7.9 and eluted in the same buffer with a linear gradient 0-1M 
NaCl over 10 column volumes. Fast Protein Liquid Chromatography (FLPC) was 
monitored with UV absorbance, in order to sample fractions matching the 
elution peak for SDS-PAGE and SimplyBlue™ SafeStain ready-to-use reagent (Life 
technologies). Proteins were collected in 6-8 ml of buffer and were 
concentrated with 30 KDa molecular weight cut-off Vivaspin Turbo 15 columns 
(Sartorius).  
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Protein concentration was assessed both in Nanodrop 1000 (Thermo Scientific) 
and via Bradford assay (Bradford, 1976). Nanodrop was chosen for systematic 
measurements as it was more straightforward and provided the same range of 
concentrations. 
All proteins were stored by immersion in liquid nitrogen and storage at -80oC 
with 10% glycerol. 
2.4.5 Protein kinase assay 
Purified, recombinant Trx-RDK2 and derivative proteins (active, dead mutants 
and phosphosite mutations) were adjusted to 100 g/ml in 20 l of kinase assay 
buffer (KAB) (50 mM MOPS, 20 mM MgCl2, 10 mM DTT, 10 mM EGTA), i.e. 2g of 
protein per reaction tube. 2 reactions were prepared per protein to be assayed 
with and without a substrate. 20 l of kinase assay mastermix (KAM) were added 
to 100 M ATP, 0.37 MBq [-32P]-ATP, and 10 mg/ml of -casein (Sigma-Aldrich) 
as a substrate if applicable in KAB. Final assay concentration of the protein was 
50 g/ml. Reactions were incubated at 30oC for 30 mins with shaking and 
stopped by the addition of 40 l 2x SDS-PAGE buffer and boiling for 3 mins. 20 l 
of this was separated by SDS-PAGE, the gel was dried and placed into a cassette 
with a phosphor-storage screen (Molecular Dynamics) for 8 to 72 h before 
visualising the screen in a Typhoon 9400 imager (GE Healthcare). Alternatively, 
it was exposed for 72 h at -80 oC with a medical X-ray blue film MXB 
(Carestream) in a cassette with a calcium tungstate-intensifying screen (Kiran). 
Films were developed in a Kodak X-Omat processor. 
2.4.6 Xa factor cleavage 
In order to choose the right conditions, before scaling up, Xa factor (Novagen) 
cleavage properties were assayed in a miniaturized screen testing 0, 0.1, 0.2, 
and 0.5 U/l against 10 g of Trx-RDK2. Incubation times were optimized also 
testing 2, 4, 8, and 16 h in 50 l reactions. 10 l aliquots were mixed with 10 l 
2x loading buffer, boiled for 5 mins, separated SDS-PAGE and stained with 
SimplyBlue™ SafeStain ready-to-use reagent (Life technologies). After analysing 
results, 6 h at 0.5 U/l was used at a large scale to cleave Trx-RDK2 and Trx-
RDK2K70M.  
Chapter 2 84 
 
2.5 Parasite maintenance 
Cell lines contained in the RNAi library are listed in Table S1. Other 
Trypanosoma brucei brucei clones used in this screen are listed in Table 2-9. 
Table 2-9. List of cell lines used in this thesis besides the pTL library. 
Cell line Parental + Transfected plasmid Aim 
STL768 sTL629 + pGL2271 Rdk2REC-6HA 
STL854 sTL 629 + pGL2297 Rdk2REC/K70M-6HA 
STL967 sTL629 + pGL2471 Rdk2REC/A50C-6HA  
STL968 sTL629 + pGL2271 Rdk2REC-6HA 
STL965 2T1 + pTL247 (newly made) Tet-inducible RDK2 RNAi 
STL966 2T1 + pTL247 (newly made) Tet-inducible RDK2 RNAi 
STL969 sTL629 + pGL2587 6HA-Rdk2REC 
STL970 sTL965 + pGL2587 6HA-Rdk2REC 
sTL797 2T1 + pGL2323 clone 1 Tet-inducible RDK2 overexpression (C-term 6xMyc) 
sTL798 2T1 + pGL2323 clone 2 Tet-inducible RDK2 overexpression (C-term 6xMyc) 
sTL801 2T1 + pGL2324 Tet-inducible RDK2 overexpression (N-term 6xMyc) 
sTL629 and pTL247 are the RNAi line and vector targeting RDK2 transcripts in the 
pTL library. The rest of plasmids (labelled pGLXXXX) are described in Table 2-1.  
pTL147 is the RNAi vector targeting RDK2 
 
2.5.1 Trypanosoma brucei brucei 2T1 bloodstream forms 
Monomorphic Trypanosoma brucei brucei 2T1 bloodstream forms (Alsford and 
Horn, 2008) were cultured in HMI-11 [HMI-9 (GIBCO) supplemented with 10% 
(v/v) foetal bovine serum (GIBCO), penicillin 20 U ml-1 and streptomycin 20 mg 
ml-1 (Pen/Strep solution, Sigma-Aldrich)], at pH 7.4, 37 ºC and 5% CO2 in vented 
flasks. Selective antibiotics were used as follows: 0.2 g ml-1 puromycin, 0.5 g 
ml-1 phleomycin (InvivoGen). Parasites were maintained at a concentration of 
less than 2 x 106 parasites ml-1. 
2.5.2 Tetracycline-inducible RNAi or overexpression lines  
Cell lines generated upon transfection of 2T1s with a plasmid contained in the 
“pTL” RNAi library (Jones et al., 2014), or a pGL2220-derived (pRPax6mycx) 
overexpression construct (Alsford and Horn, 2008), were cultured in HMI11 
complemented with 0.5 g ml-1 phleomycin (InvivoGen), and 2.5 g ml-1 
hygromycin B (Calbiochem). RNAi/overexpression was induced in vitro with 
tetracycline (Sigma-Aldrich) at 1 g ml-1, and RNAi in mice with doxycycline 
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hyclate (Sigma-Aldrich) added in drinking water at 0.2 g L-1 laced with 50 g L-1 of 
sucrose. Parasites were maintained at a concentration of less than 2 x 106 
parasites ml-1 at 37ºC and 5% CO2 in vented flasks. 
2.5.3 RDK2 RNAi lines complemented with a recoded mutant 
RDK2 RNAi lines transfected with a recoded mutant using a pRM481-derived 
vector (Proudfoot and McCulloch, 2005), were maintained in HMI11 
complemented with 0.5 g ml-1 phleomycin (InvivoGen), 2.5 g ml-1 hygromycin B 
(Calbiochem), and 10 μg ml-1  blasticidin (InvivoGen). Parasites were maintained 
at a concentration of less than 2x106 parasites ml-1 at 37 ºC and 5% CO2 in vented 
flasks. 
2.5.4 T. brucei brucei Lister strain 427 wild type procyclic forms 
T. brucei brucei 427 wild type procyclic forms were kept in SDM79 (GIBCO) 
supplemented with 10% (v/v) foetal bovine serum (GIBCO), penicillin 20 U ml-1, 
streptomycin 20 mg ml-1 (Pen/Strep solution, Sigma-Aldrich), at pH 7.4. Cultures 
were maintained in a range of concentrations between 5 x 105-107 parasites ml-1 
at 27 oC in non-vented flasks. 
2.6 Transfection of bloodstream trypanosomes 
Plasmids designed for T. brucei genetic modification were linearized before 
transfection to enhance homologous recombination (Lee and Van der Ploeg, 
1990). All the vectors were subjected to an AscI-mediated double cut performed 
during an overnight digestion at 37 oC. 5 g of linearized plasmid were 
precipitated by addition to the 50 l digestion of 105 l “ethanol/salt mix” (150 
mM of sodium acetate in 70% ethanol), incubation for 15 mins in dry ice, and 
centrifugation at 13000xg at room temperature. Supernatant was discarded, and 
DNA pellet washed with 100 l of 70% ethanol. After 5 mins centrifugation at 
13000xg and room temperature, supernatant was discarded, and tubes left to 
dry in a laminar flow hood. DNA was resuspended with 11 l of MilliQ water, 1 l 
used to verify linearization in an agarose gel, and 10 l used for transfection. 
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107 log-phase parasites per transfection were purified and washed with PBS using 
two rounds of centrifugation at 1500 x g for 10 mins before being resuspended in 
100 l of Amaxa Nucleofector T-cell buffer (Lonza). The 10 l of linearized 
vector were added to the cells and transferred to an electroporation cuvette 
before shocking them with programme X-001 in a Lonza Nucleofector II machine. 
Cells were then transferred to 10 ml of prewarmed HMI11 media. From this, 1.5 
ml were diluted (1:20) to 30 ml with HMI11 and plated in a 96-well plate. From 
the 1:20, 4 ml were diluted (1:5) to 20 ml making a 1:100 dilution from the 
original concentration, and in parallel, 2 ml were diluted (1:10) to 20 ml 
representing a 1:200 dilution from the original concentration. Both dilutions, 
1:100 and 1:200, were also plated in 96-well plates. All wells were stamped with 
100 l of parasite dilutions and kept for 6 h at 37 oC. After this period, 50 l with 
selection drugs at 3x the required concentration were added on top. Clones 
were recovered after one week of drug selection. 
2.7 T. brucei brucei cryopreservation 
Frozen stocks were kept when necessary by resuspension of 2.5 x 106 parasites in 
1 ml of HMI11 (for bloodstream forms), or SDM79 (for procyclic forms), 
supplemented with 10% (v/v) glycerol. Tubes were placed for one week at -80oC 
wrapped in cotton, and later moved to liquid nitrogen. 
2.8 In vitro growth analysis 
2.8.1 RNAi, overexpression lines, and derivatives 
In vitro growth curves started with parasites at 1 x 104 cells ml-1 were counted 
daily with a haemocytometer. If log phase needed to be sustained, cultures were 
diluted 1:100 after 48 h, when fit parasites reached ~106 cells ml-1. In such cases 
cumulative curves were represented by applying the inverted dilution factor 
(x100). Growth was assessed in triplicate comparing tet-induced cells (RNAi or 
overexpression) to uninduced controls using T-test. Results were considered 
significant when P<0.05. Curves were plotted with GraphPad Prism 6.0. 
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2.8.2 RDK2 RNAi phenotype growth assessment  
Cells collected 48 h after tetracycline induction in HMI11 at 37 oC were placed at 
27 oC with 105 parasites ml-1. They were tested renewing or not tetracycline and 
maintained in different conditions: the same medium, in fresh HMI11, in fresh 
SDM79 or in conditioned SDM79. All media were 10% (v/v) foetal bovine serum. 
Conditioned SDM79 was prepared by supplementation of fresh medium with the 
product of spinning 1500 x g for 10 mins a T. brucei brucei Lister 427 procyclic 
culture in stationary phase and passaging supernatant through a Minisart filter of 
0.2 m pore size. Curves were plotted with GraphPad Prism 6.0. 
2.9 Life cycle differentiation assays 
2.9.1 Slender to stumpy* form differentiation 
Slender to stumpy* differentiation was triggered by incubation for 24 h with 100 
M 8-(4-Chlorophenylthio) adenosine 3′,5′-cyclic monophosphate sodium salt 
(pCPT-cAMP), purchased from Sigma-Aldrich (Laxman et al., 2006). Compound 
was washed off after 24 h to avoid cell toxicity. Differentiation was measured by 
an increase in response to procyclic differentiation treatment (see next section), 
by detecting levels of EP procyclin expression in Flow cytometry. 
2.9.2 Bloodstream to procyclic form differentiation 
Bloodstream-to-procyclic form differentiation was triggered in different 
conditions. The standard (Overath, Czichos and Haas, 1986) was used to test 
RDK2 overexpression effect after incubation with pCPT-cAMP. It consisted in 
treating with 3 mM of each sodium citrate and cis-aconitic acid (CCA treatment), 
both purchased from Sigma-Aldrich, in differentiation trypanosome media (DTM) 
and adjusting the pH to 7.4, at 27 oC.  
Other conditions tested with RDK2 RNAi to understand the role that this protein 
kinase plays in the signalling networks controlling differentiation were: 3 mM 
CCA treatment alone or preincubated with 100 M 8-pCPT-cAMP in HMI11, tested 
both at 27 and 37 oC; and treatment with 150 M 3-(3,5-Dibromo-4-hydroxy-
benzoyl)-2-ethyl-benzofuran-6-sulfonicacid-(4-(thiazol-2-ylsulfamyl)-phenyl)-
amide (short-named “BZ3”, purchased from Calbiochem®, Merk Millipore). 
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2.10 Making the RNAi library pool 
The pooling strategy had as a first step the mixing of RNAi lines in 9 ‘Mixed 
Stabilate Trypanosome Libraries’ (MSTL 1-8), each containing 19-25 cell lines 
(detailed grouping in Table S1 and Table 3-1). Then MSTLs were mixed to make 
the final pool. This intermediate step reduced risks of overgrowth and cross 
contamination. After the first replicate of the in vivo RITseq a few lines were 
found that had lost their stem loop construct or contained the wrong one. They 
were repaired and included in MSTL9 for a new MSTL used in the second 
replicate of the in vivo experiment and the in vitro experiment (Table 3-1). This 
part of the work was conducted in collaboration with Dr. Tiago D. Serafim. 
To make the MSTL pools, independent cell lines were defrosted diluting glycerol 
to 1% with HMI-11 and no antibiotics. After 24 h recovery at 37 oC and 5% CO2 
atmosphere, cells were diluted again adding selective drugs (hygromycin and 
phleomycin). After another day, cultures were set at 2 x 105 cells ml-1 and -24 h 
after- they were counted to pool 6 x 106 cells for each line in a common flask 
that was diluted to 50 ml. Cells were allowed to acclimatize for 1 h at 37 oC and 
the mixed culture was centrifuged 1500xg for 10 mins. Parasites were 
resuspended in 24 ml of HMI-11, 10% glycerol to generate 24 cryostabilates per 
MSTL.  
For the final pool, each sub-library was defrosted, diluted 1:10 in HMI-11 without 
drug selection and cells were accurately counted in order to identify the 
‘limiting sublibrary’: the MSTL culture containing a smaller amount of cells per 
kinase line after post-thaw recovery, see Table 3-1. The ‘limiting culture’ was 
used complete. Volumes to mix in the final pool from the other MSTLs were 
calculated to enable addition of as many parasites per line as were added using 
the whole ‘limiting MSTL’. The culture was acclimatized at 37 oC 5% CO2 for 45 
mins, cells pelleted at 1200 x g for 10 mins and resuspended at 5 x 105 cells ml-1. 
After 6 h incubation 37 oC 5% CO2, cells were counted, washed and resuspended 
with PBSG to produce 200 µl inoculums of 5 x 104 cells ml-1. Injections were 
performed intraperitoneally in mice. The rest of the pool was frozen to perform 
the in vitro experiments. 
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2.11 Animals and in vivo growth analysis 
Female CD1 outbred mice (6–8 weeks old) were obtained from Charles River 
(Edinburgh, Scotland). Animals were given water and food ad libitum. Infections 
were evaluated daily by assessing parasitemia levels with a haemocytometer by 
tail vein sampling diluting blood in 0.83% (w/v) ammonium chloride to lyse red 
blood cells. Curves were plotted with GraphPad Prism 6.0. 
During the in vivo growth curves mice were euthanized with carbon dioxide and 
cervical dislocation if parasitemia exceeded 108 cells ml -1. Growth was assessed 
in triplicate comparing tet-induced mice to uninduced controls using T-test. 
Results were considered significant when P<0.05. 
2.11.1 Parasite purification from blood with DEAE cellulose 
For the in vivo RITseq, whole blood from euthanized mice after 72 h of infection 
was collected in anticoagulant CBSS/Heparin buffer (25 mM HEPES, 120 mM 
NaCl, 5.4 mM KCl, 0.55 mM CaCl, 0.5 mM MgSO4, 5.6 mM Na2HPO4, 11.1 mM D-
glucose). The blood was centrifuged first at 200xg for 10 mins to remove the 
majority of red blood cells, parasites remained be in the supernatant that was 
applied immediately to diethylaminoethyl-cellulose (DEAE) columns (Lanham and 
Godfrey, 1970). 
Whatman® anion exchange DEAE-cellulose (Schleicher & Schuell) was suspended 
in phosphate buffered saline glucose (PSG: 44 mM NaCl, 57 mM Na2HPO4, 3 mM 
KH2PO4, and 55 mM glucose at pH8) until settled. Columns were prepared in 20 
ml syringes with a thin layer of glass wool at the bottom. Then, they were 
loaded with 10 ml DEAE slurry settled overnight. Before operation, they were 
washed with 3 column volumes of PSG buffer. Then blood was applied and 
parasites eluted with 30 ml PSG buffer pH 8.0. ±2 x 107 parasites/sample were 
harvested in the eluent. Cells were collected by centrifugation and DNA isolated 
from the parasites using QIAamp DNA kit (Qiagen). 
2.12 In vivo RNAi Target sequencing sample preparation 
Experiment 1 (Ion Torrent) and Experiment 2 (Illumina MiSeq) were processed in 
a slightly different manner.  
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The library pool used in Experiment 1 was the product of mixing MSTLs 1-8 (see 
Table 3-1). A single universal cassette-specific primer (OL4161: 5’- 
TAATGCCAACTTTGTACAAA-3’) was used to PCR enrich RNAi inserts amplified 
from 10 ng of genomic DNA obtained per sample in a 50 µl reaction using Q5® 
High-Fidelity DNA polymerase (NEB, Ipswich, USA). The PCR program was: 3 mins 
at 98oC; followed by 28 cycles comprisinging: 10 seconds at 98oC, 10 seconds at 
61oC and 30 seconds at 72oC; with a final extension step at 72oC for 10 mins. PCR 
products were cleaned up with Minielute PCR purification kit (Qiagen), and sent 
for sequencing as described above.  
The library pool used at Experiment 2 was a mix of MSTLs 1-9 (see Table 3-1). 
PCR conditions were the same but annealing temperature was elevated to 64oC 
as additional 6 nucleotide-long labels were added to the single universal primers 
(list of oligonucleotides and multiplex distribution in Table 2-3). This enabled 
pooling of the samples and using a single commercial barcode before sending for 
sequencing as described above. 
2.13 In vitro RNAi Target sequencing  
The library pool used for the in vivo RITseq was defrosted, grown for 24 h and 
diluted to contain 1 x 105 cells ml-1 in 100 ml. The culture was then split into 
two 50 ml flasks (tetracycline induced and uninduced control) and grown for 120 
h bringing down the concentration to 1 x 105 cells ml-1 every day. Before 
dilution, 1 x 107 cells were sampled daily for DNA purification, PCR enrichment 
and sequencing was conducted as for in vivo replicate 2. Time 0 sample was also 
processed and the whole experiment was conducted in triplicate. 
2.14 RITseq data analysis 
2.14.1 Processing sequencing data 
This part of the work was carried out mainly by Dr. Jonathan Wilkes.  
2.14.1.1 Reads mapping 
Artificial chromosomes were generated in silico by concatenating the 183 
amplicons representing all the RNAi targets included in this study, joining the 3' 
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end of one with the 5' end of the next using a random sequence of 15 bases. The 
coordinates of each sequence were recorded. The artificial chromosome 
sequences were indexed to use in Bowtie2 (short-read alignment software) 
(Langmead and Salzberg, 2012), using default parameters. 
For in vivo Exp.1, single end reads generated from each sample were selected by 
the presence of a 9 base long tag [GCCAACTTT] present within the universal 
primers, permitting 1 mismatch (insertion, deletion or substitution). 
Approximately 20% of the reads contained the RNAi cassette.  
For in vivo Exp.2 and in vitro RITseq, single end reads were identified and 
clustered according to our home-made 6 base-long barcodes (Table 2-3) before 
being processed as in Experiment1 finding 65-70% of reads containing the RNAi 
target. The absence of a fragmentation step conferred a substantial advantage. 
Selected reads were mapped to the artificial chromosomes with Bowtie2 
(aligning in local mode). The “.sam” format files generated by Bowtie2 were 
parsed and the coordinates of the appropriate chromosome, to which the read 
mapped, were recorded. The mapped reads were assigned to the appropriate 
protein kinase sequence by reference to the index generated above. The read 
was assigned if the read sequence overlapped the 3' or 5' end of the protein 
kinase sequence - or if it laid entirely within the protein kinase sequence.  
Bowtie2 mapping was used also to compare whole-genome/kinome-wide RITseq 
coverage (Figure 3-17). Paired ends were sequenced in both experiments, 
however only the ends containing the 9mer tag in the universal flank were 
considered for the analysis. 
2.14.1.2 Statistical analysis 
In each individual sample, accumulated reads mapping to a particular protein 
kinase sequence were expressed in Reads Per Million of mapped reads (RPM), i.e. 
reads normalized by multiplying raw counts 106 times, dividing by the sum of 
total valid reads accepted for the analysis in the whole sample and rounding to 
the next integer. A bootstrap analysis with 1000 repeats pairing randomly 
induced and control normalized counts per gene ID enabled calculation of 
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median induced/control ratios and 95% intervals of confidence. Regression of 
both in vivo replicates was calculated and plotted using GraphPad prism 6.0. T 
test comparing induced and uninduced normalized reads per gene identifier in 
each of the in vivo replicates, and in each of the time points of the in vitro 
RITseq were calculated. Volcano plots were generated from them. Means and 
ranges were calculated and plotted with Graphpad too. 
2.14.2 Phylogenetic tree with T. brucei, T. cruzi and L. major 
orthologues 
Coding sequences of 49 protein kinases with a loss-of-fitness phenotype and their 
Trypanosoma cruzi and Leishmania major orthologues were extracted from the 
TritrypDB platform (Aslett et al., 2010). They were all aligned against the 
protein kinase hidden Markov model (HMM), PF00069 (obtained from PFAM (Finn 
et al., 2014), using Hmmer [HMMER 3.1 (February 2013); http://hmmer.org/] 
and trimmed to include only sequences conformant with the profile. Resulting 
clustalW file was converted to ungapped FASTA format. Conformant sequences 
were aligned using three additional and complementary programs: T-coffee 
(Notredame, Higgins and Heringa, 2000), ClustalW (Larkin et al., 2007) and 
MUSCLE (Edgar, 2004). Results obtained from all four alignment tools were 
combined with T-coffee and the output was processed to remove low quality 
(<5) and low occupancy (<60%) regions. The resulting high quality alignment was 
used in Splits Tree (Huson and Bryant, 2006) to generate the final Neighbour-
Joining phylogenetic tree (Figure 3-13). An extract from this alignment was also 
used to depict the putative lack of kinase activity of Tb927.11.9290 (Pseudo-
Orphan/FAZ20), Figure 3-18. 
Amino acid sequences from the seven protein kinases triggering a greater loss of 
fitness upon depletion in vivo than in vitro were aligned using protein-protein 
Basic Local Alignment Search Tool (BLASTp) (Altschul SF et al., 1990; Altschul et 
al., 1997) (NCBI) against Homo sapiens, Saccharomyces cerevisiae, 
Caenorhabditis elegans, Trypanosoma brucei, Trypanosoma cruzi and 
Leishmania major non-redundant protein databases Table 3-6. 
Chapter 2 93 
 
2.15 Serum tests 
200 l of log-phase parasites in HMI11 at 106 cells ml-1 were exposed to fresh rat 
serum for 3 h (10% and 50% concentration). Relative survival was measured of 
induced and uninduced clones compared to no serum controls (Figure 3-15). The 
whole experiment was performed in triplicate. Significance of results was 
assessed with T-test. 
2.16 Mild osmotic shock test 
2 x 106 log-phase cells were collected and resuspended in 500 l of a solution 55 
mM KCl/1 mM glucose to induce cell swelling during 5 mins incubation in ice. 
Then, a second 5 mins ice incubation was allowed after addition on top of 500 l 
of a 263 mM KCl/1.75 mM MgCl2 shrinking solution. Remaining cells were washed 
once and resuspended in 1 ml of HMI11 media before counting. Survival of the 
induced cells compared to uninduced controls was plotted (Figure 3-16), and 
significant results after T-tests indicated with a star. Modified from ‘swell 
dyalisis’ protocol (Voorheis and Martin, 1980). 
2.17 Alamar blue 
2.17.1 Assessing RNAi phenotypes of new-made lines in the 
pTL library 
As done for the rest of the pTL library (Jones et al., 2014), cell cultures seeded 
at 2 x 104 parasites ml-1 per cell line were divided into two pools: induced with 1 
g/ml of tetracycline (Sigma), and uninduced. Then 200 l of each were plated 
in triplicate in a 96 well plate (Corning) and incubated for 72 h. For the last 24 
h, 20 l of Alamar blue (Resazurin 0.49 mM in PBS) was added and mixed. The 
plate was then read at excitation 530 nm and emission 590 nm in an Envision Plate 
Reader (Perkin Elmer). The ratio of the values for induced wells over uninduced 
wells was calculated and used to produce a mean and a standard deviation. 
Values under 0.8 were considered a loss of fitness. 
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2.18 Flow cytometry 
2.18.1 Differentiation analysis 
All this processing was done using ice-cold buffers and centrifuges at 4oC. 3 x 106 
parasites were pelleted per analysed condition by centrifugation at 1500xg for 
10 mins, and washed with phosphate buffered saline (PBS: 137 mM NaCl, 2.7 mM 
KCl, 10 mM Na2HPO4, and 2 mM KH2PO4). Then, cells were incubated 1 h on ice 
with a primary mouse IgG targeting EP procyclin (Clone TBRP1/247, Cedarlane), 
used at 1:500. After three washes with PBS, a secondary rabbit IgG anti-mouse 
conjugated to allophycocyanin (APC) (Clone M1-14D12, Affimetrix) was used at 
1:1000 , and incubated on ice 1 h in the dark. Three more washes were 
conducted with PBS and cells were transferred to flow cytometry tubes before 
fixing with 2% paraformaldehyde (PFA) for at least 5 mins. If convenient, cells 
were kept in the fridge for several days at this stage. After 3 rounds of PBS 
washing parasites were resuspended in 200 l of PBS and passed through nylon 
filtration cloth of 200 m opening (Nitex). Samples were analysed in a 
MACSQuant® Analyzer 10 (Miltenyi Biotec) recording 100000 events. 
Trypanosomes were gated in the forward versus side scatter plot, single cells 
selected by comparison of width and height for the forward scatter signal, and 
EP procyclin positive population selected taking as a negative reference the 
uninduced controls or the parental line. Results were analysed in FlowJo v10 
(FlowJo, LLC). 
2.18.2 Cell cycle analysis 
For cell cycle analysis, DNA of cells was stained with propidium iodide (Sigma) or 
Hoechst 33342 (Thermo Scientific). Fluorescence intensity of these molecules for 
single cell events is proportional to their DNA content. The distribution of the 
whole analysed sample was estimated across the distinct cell cycle stages based 
in the histogram profile of DNA-associated fluorescence in the entire population. 
2.19 Immunofluorescence assay (IFA) 
106 parasites per sample were pelleted at 1000xg for 10 mins, washed in PBS, 
and, after resuspending in 25 l PBS, placed in one well of a 12-well slide coated 
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with poly-L lysine solution 0.1% w/v (Sigma-Aldrich) incubated for 4 mins. Each 
well used in the slide was marked in the margins with a PAP pen (Abcam) making 
a hydrophobic barrier that avoided buffers diffusing between wells. Cells were 
then fixed with 4% paraformaldehyde (PFA) and incubated for 15 mins. 
Sometimes they were left overnight at this stage in a wet chamber. After three 
washes with PBS, cells were treated with 100 mM glycine to neutralize excess of 
PFA. After three more PBS washes, if needed, permeabilisation was conducted 
with 25 µl 1x PBS/Triton X-100 (Thermo Scientific) for 10 mins. Then 25 µl of 
primary antibody were incubated for 1 h in a wet chamber, followed three more 
washes. After, 25 µl of the secondary antibody were incubated for 1 h. Finally 
after three washes, DAPI Fluoromount-G (SouthernBiotech) was added and cover 
slip sealed with nail varnish after 4 mins incubation. 
Table 2-10. List of antibodies used in immunofluorescence assay (IFA). 
Antibody Serotype Clone Concentration Supplier 
VSG 221 variant Rabbit IgG N/A 1:8000 R. McCulloch 
Myc Mouse IgG 4A6 1:7000 Millipore 
EP procyclin Mouse IgG TBRP1/247 1:500 Cedarlane 
Mouse Alexa Fluor® 488 Goat IgG N/A 1:1000 Thermo 
Rabbit Alexa Fluor® 594 Goat IgG N/A 1:1000 Thermo 
 
2.19.1 Cell cycle analysis 
IFA slides stained with 4',6-diamidino-2-phenylindole (DAPI) were imaged at a 
magnification that maximized the number of well-isolated parasites that it was 
possible to count in a single picture. Images were analysed in Fiji ImageJ 
updated with a cell counting plugin. 200 parasites were counted per condition 
classified in G0-G1 (1 nucleus, 1 kinetoplast = 1N1K), G2 (1N2K), M (2N2K) and 
other aberrant combinations. 
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Chapter 3 Protein kinase-focused RNAi screen 
defines virulence factors of T. brucei required 
for proliferation in mammals 
 
3.1 Introduction 
 
3.1.1 RNA of interference (RNAi)  
The field of ribonucleic acid (RNA) biology has become an exciting research area 
within the last twenty years as an increasing number of non-coding functions 
have been unveiled for these molecules. The functional repertoire of the ‘small 
RNA’ universe known in the early nineties -with roles in translation (tRNA and 5S 
RNA), pre-mRNA processing (by small nuclear RNAs), and protein translocation 
across the endoplasmatic reticulum (7SL RNA)- experienced a dramatic 
expansion after the discovery of 20-30 nucleotide-long small silencing RNA 
molecules (ssRNA) able to switch off gene expression: the so-called pathway of 
RNA interference (RNAi). It was characterised for the first time in plants (Napoli, 
1990; van der Krol et al., 1990), termed RNAi and assigned to double stranded 
RNA in the nematode Caenorhabditis elegans (Fire et al., 1998), and was soon 
described for many other eukaryotes, including Trypanosoma brucei (Ngô et al., 
1998). Two main types of ssRNAs were identified in protozoa: small interfering 
RNA (siRNA), binding specific mRNAs and targeting them for degradation; and 
micro RNA (miRNA), annealing mainly to the 3’ UTR of certain transcripts and 
inhibiting their translation (Atayde, Tschudi and Ullu, 2011; Kolev, Tschudi and 
Ullu, 2011).  In T. brucei miRNA have been predicted but not detected though 
(Mallick, Ghosh and Chakrabarti, 2008; Atayde, Tschudi and Ullu, 2011). In 
addition, metazoan also have a third type: PIWI-interacting small RNAs (piRNAs) 
(Siomi et al., 2011). 
The RNAi pathway in Trypanosoma brucei has been reviewed in the literature 
(Atayde, Tschudi and Ullu, 2011; Kolev, Tschudi and Ullu, 2011). It involves two 
Dicer-like proteins: TbDCL1 (cytoplasmic) and TbDCL2 (nuclear) (Shi, Tschudi 
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and Ullu, 2006; Patrick et al., 2009). Both have RNase III activity and nuclease-
cleave double stranded RNA (dsRNA) into ssRNA. TbDCL1 activity is assisted by 
cofactor TbRIF5 (Barnes et al., 2012). The resulting 20-30 nucleotide dsRNA 
fragments are protected from nucleases through methylation in their 3’ end by 
HEN1 activity (Horwich et al., 2007; Patrick et al., 2009). After separation of the 
two strands mediated by exonuclease TbRIF4 (Barnes et al., 2012), the targeted 
transcript is specifically bound by the complementary half of the ssRNA and 
loaded into another protein, AGO1 ‘slicer’. This assembly is called RNA-induced 
silencing complex (RISC) and is responsible for the ultimate mRNA cleavage that 
limits gene expression (Durand-Dubief and Bastin, 2003; Shi et al., 2004).  
The siRNA pathway has several endogenous functions: maintenance of genome 
integrity through transposon and retrotransposon silencing; post-transcriptional 
regulation; defence against viral invasion; chromosome segregation; and 
heterochromatin formation. The RNAi pathway has also been exploited as a 
reverse genetics tool, becoming a real breakthrough in the post genomic era. 
Genetic manipulation enabled the exploitation of RNAi machinery to selectively 
target genes for transcript depletion. If their role was unknown, observation of 
the resulting phenotypes permitted examination of their putative functions. If a 
gene’s role had been already identified, RNAi could help understanding of how 
its absence or lack of activity affected other factors in the cell (Atayde, Tschudi 
and Ullu, 2011; Kolev, Tschudi and Ullu, 2011).  
Unlike other Eukaryotes, T. brucei lacks RNA-dependent RNA polymerase (RdRp), 
meaning it is unable to expand or preserve exogenous dsRNA after replication. 
Thus, the effect after transfection of dsRNA is only transient (Siomi and Siomi, 
2009; Kolev, Tschudi and Ullu, 2011). Full exploitation of RNAi was therefore not 
possible until development of a system for inducible expression of dsRNA. This 
involved integration of a DNA template in a silent genomic locus, from which the 
desired dsRNA could be inducibly expressed under control of a strong promoter 
controlled by a tetracycline operator (Orth et al., 2000; Shi et al., 2000). Since 
then, two different dsRNA expression strategies have been used: the ‘stem-
loop’, and the use of ‘opposed promoters’. In the first system, the DNA sequence 
integrates in ‘sense’ and is followed by the complementary sequence in 
‘antisense’ separated by a linker region. This allows formation of a double 
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stranded hairpin upon transcription by self-annealing of the RNA transcript. In 
the second approach, the desired RNAi target integrates in the genome flanked 
by opposed promoters. After transcription, complementary strands will result 
that anneal, producing the expected dsRNA. Both strategies were compared, 
showing stem-loop to have a better efficiency for mRNA depletion (Durand-
Dubief, Kohl and Bastin, 2003). For the Tet-operator to be effective, cell lines 
need to be modified to express the tetracycline repressor from Escherichia coli, 
which blocks transcription of the gene located downstream of the promoter until 
displaced by tetracycline (Wirtz and Clayton, 1995). 
Many variants of these systems, combining different genomic loci and promoters, 
have been applied to T. brucei research. The most commonly used has been the 
EP/GPEET procyclin promoter; however, this is down-regulated in mammal-
infective forms. In bloodstream forms one of the most widely used promoters is 
T7, which requires parasites to be modified to express the T7 RNA polymerase 
(Wirtz et al., 1999). High levels of expression of this polymerase are toxic for 
trypanosomes. Therefore, weak promoters must be used in order to achieve 
balanced levels between efficacy and toxicity. RRNA promoters have been 
proposed instead as a robust endogenous alternative that can be used in T. 
brucei regardless the life stage and permitting performance of differentiation 
studies (Alsford et al., 2005). 
Among the silent loci most successfully used to target inducible expression 
cassettes are the rRNA spacers. However, the T. brucei genome contains nine 
rRNA loci, each providing different transcription levels. After targeting a GFP 
reporter with the hygromicin resistance cassette (HYG), the best expressing 
locus was selected. Then, GFP was replaced with a puromycin resistance gene 
(PAC), while leaving HYG with only its 3´end as a non-functional tag. Such a 
strategy enabled accurate targeting of any RNAi construct to the tagged RRNA 
locus by engineering it to contain the missing 5´end of HYG. After successful 
homologous recombination, RNAi clones recover hygromycin resistance, while 
normally losing PAC (Alsford et al., 2005). 
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3.1.2 RNAi screens in Trypanosoma brucei 
Since RNAi technology became available for T. brucei research, several high 
throughput functional and phenotypic screens have been undertaken using a 
variety of RNAi libraries. A software was released providing an algorithm to 
rapidly select and design RNAi targets, called ‘RNAit’ (Redmond, Vadivelu and 
Field, 2003). RNAit identifies the best possible primer pair (e.g. temperature of 
melting, self-annealing, GC content) to amplify a gene region of the desired 
RNAi target size, and aligns the predicted amplicon against the parasite´s 
genome in BLASTn (Altschul et al., 1997) in order to certify specificity and avoid 
off-target effects of RNAi.  
A key tactical development was the first attempt of simultaneous (or parallel) 
phenotyping with a library produced by introduction of sonicated, random 
genomic fragments as RNAi targets. It was performed in insect-infective 
procyclic forms to obtain a 5-fold genomic coverage. Unfortunately, that could 
not be achieved at the time in mammal-infective bloodstream forms due to a 
limited efficiency of transfection. The library was used to identify genes 
reducing expression of the main surface glycoprotein, EP-procyclin, by detecting 
a loss of affinity for concanavalin A (Morris et al., 2002). Final identification of 
RNAi that successfully reduced EP-procyclin expression required clonal isolation 
of the selected parasites and RNAi target amplification and sequencing. This 
approach has been applied successfully in procyclic forms for identification of 
drug transporters (Schumann Burkard, Jutzi and Roditi, 2011) and mRNA 
regulators (Schumann Burkard et al. 2013).  
The first systematic screen in bloodstream forms targeted the 197 genes 
encoded in Chromosome 1, analyzing in independently developed cell lines a 
range of phenotypic characteristics, including loss of fitness (Subramaniam et 
al., 2006). The approach developed by Morris et al. (2002) was also adapted to 
bloodstream forms in order to identify components of cAMP signalling pathways 
(Gould et al. 2013). But two major breakthroughs then emerged: increased 
affordability of Next Generation Sequencing (NGS), and development of the Sce* 
T. brucei cell line that allows hyper-efficient transfection in mammal infective 
bloodstream parasites (Glover and Horn, 2009). The Sce* T. brucei line expresses 
a site-specific meganuclease, I-SceI, able to induce double stranded DNA breaks 
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in a locus tagged with a targeting sequence. Attraction of the homologous 
recombination machinery to repair the double-stranded break increased 
efficiency of recombination of exogenous constructs directed to the same 
location (Glover and Horn, 2009). The library of sonicated genomic fragments 
used previously in procyclic forms (Morris et al., 2002) could now be transfected 
into bloodstream forms with a predicted 11x coverage; NGS increased the 
throughput of RNAi target identification in parasites resisting any given selective 
pressure; and the technique could be used for quantitative analysis by 
comparison of normalized reads in the RNAi induced samples with those in the 
non-induced controls. The overall approach was termed ‘RNAi target sequencing’ 
(RITseq) and became the most popular strategy for high throughput dissection of 
trypanosome gene function (Alsford et al., 2011, 2012). 
The main limitation of the RITseq approach was the need for huge numbers of 
parasites to ensure whole genome coverage. For mice infections, we need to 
reduce the inoculum to the minimum in order to avoid overwhelming the host, 
causing early mouse death (Turner, Aslam and Dye, 1995). Moreover, if the 
library is made in a monomorphic cell line, which is unable to produce cell 
cycle-arrested stumpy forms in response to the still uncharacterized stumpy 
induction factor (Vassella et al., 1997). 
3.1.3 A kinome wide in vitro screen: the pTL library  
An RNAi screen of the complete protein kinome of T. brucei was recently 
published in bloodstream form cells, looking for potential parasite-specific drug 
targets, regulators of the cell cycle, and protein kinases involved in life stage 
maintenance (Jones et al., 2014). 183 individual cell lines were generated, in 
duplicate, (‘pTL’ library) containing tet-inducible stem loop RNAi cassettes. The 
vector used, pGL2084, was a modified version of pRPaiSL (Alsford and Horn, 
2008), containing ligation-free Gateway® sites (AttP1 and AttP2), Figure 3-1. 
This allowed directional cloning of both fragments as a stem loop (sense and 
antisense) in a single reaction. The approach increased throughput, avoiding two 
rounds of restriction digestion and ligation per construct. In addition, the system 
avoided problems of incompatibility when restriction sites needed for cloning in 
pRPaiSL were present in the RNAi target.  
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Figure 3-1. Gateway® based cloning strategy used to make the pTL library. 
A. AscI-linearized section of the backbone vector pRPaiSL as it is targeted for 
homologous recombination to the best expressing RRNA locus, tagged in 2T1 
cells with the terminal section of the hygromycin resistance gene (Alsford et al., 
2005). Includes aldolase (Ald) and procyclin (Pro) intergenic regions; RRNA 
(PRRNA) and EP procyclin (PEP) promoters; Tet operator for induction with 
tetracycline in 2T1 recipient cells (expressing Tet repressor); a lacz468 stuffer 
region to produce the hairpin; and multicloning site to assist directional ligation 
of the RNAi inserts. B. Gateway®-modified version of (A), including ccdB toxic 
gene and AttP flanks. Below, schematic representation of the BP reaction for 
directional cloning. Sequences containing the RNAi target amplified with primers 
including AttB flanks. Modified from Alsford et al. 2005. 
Gateway® cloning is based on the site-specific recombination system of phage 
lambda (Katzen, 2007). After synthesis or amplification of the RNAi target with 
primers flanked by AttB1 and AttB2 sites, BP clonase mediates recombination. 
pGL2084 contains a ccdB gene, which is toxic for standard E. coli strains, 
between each pair of AttP1 and AttP2 sites. Successful recombination replaces it 
with the RNAi target and enables positive selection. 
In the published kinome RNAi study cell survival was analysed in culture with 
Alamar Blue®, comparing uninduced controls with induced knockdowns after 72h 
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of RNAi induction. 45 protein kinases were identified showing a loss of fitness in 
vitro, which was classified as “slow growth”, “cell cycle arrest” or “death” 
phenotypes. As protein kinases of T. brucei have been shown to be druggable 
(Urbaniak et al., 2012), they can be considered potential drug targets. 21 of 
these protein kinases had never been reported to cause a loss of fitness before. 
24 cell lines in the library displayed some kind of cell cycle defect and two 
acquired procyclic-like phenotypes following RNAi induction (e.g. kinetoplast 
repositioning and EP procyclin expression).  
3.2 Research aims 
Many biological roles for protein kinases have been revealed in T. brucei, but 
they have been observed mainly in the artificial conditions of in vitro culture. In 
this chapter I address a key question of relevance both for biology and drug 
discovery: which protein kinases are required for survival of the parasite in the 
environmental conditions encountered in the mammalian bloodstream? Potential 
drug targets identified by RNAi studies in vitro require studies in mice to 
validate the targets. Multiplexing in vitro studies to genome-wide level has been 
implemented but not yet applied in vivo. Improving this would reduce the 
number of animals required to perform these studies. The adaptation of RITseq 
to simultaneously analyse the 177 cell lines contained in the pTL library, 
potentially using a single mouse, would provide new insights in T. brucei-host 
interaction and reveal novel potential drug targets for protein kinase inhibitors.  
3.3 Results 
3.3.1 Kinome-wide in vitro and in vivo RNAi screening; the 
approach 
In order to increase our capacity for screening the kinome RNAi library, we made 
a pool of the 177 cell lines contained in the ‘pTL’ library (see Table S1), which 
target 183 protein kinases because 6 are double knockdowns (Jones et al., 
2014). This pool allowed parallel phenotyping of the whole population in a single 
culture (in vitro) and in a single mouse (in vivo) through RITseq (Figure 3-2).  
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Figure 3-2. In vitro and in vivo phenotyping of a T. brucei kinome RNAi 
library.  Schematic representation of the experimental workflow.  
A. A pre-inoculation pooled kinome RNAi library was diluted to contain 1 x 105 
cell ml-1 in 100 ml and grown in culture for 24 h in triplicate. The culture was 
then split into two flasks, one was induced with tetracycline (Tet+) and the 
other remained uninduced (Tet-). 1 x 107 cells were sampled every 24 h over 5 
days for DNA purification and cultures diluted daily to contain 1x105 cells ml-1.  
B. 5 x 104 T. brucei bloodstream form parasites of the pooled kinome RNAi 
library were injected intraperitoneal into 12 CD1 mice and, 24 h post 
inoculation, RNAi was induced with doxycycline in 6 animals (Tet+) and 6 were 
left uninduced (Tet-). 48 h and 72 h post RNAi induction, parasites were purified 
from blood and genomic DNA prepared.  C. PCR enrichment in the RNAi target 
was carried out with a single primer binding at the universal Gateway® AttL sites 
flanking the 500-600 bp protein kinase-specific inserts. The gel example shows 
RNAi target distribution in 4 different samples: Tet- (1), Tet + (2), a single line 
control (3), and the input library pool (4). The experiment was performed twice 
and PCR-enriched samples from each biological replicate were sequenced with 
different platforms. 
At the required time points, parasites were isolated from in vitro cultures or 
mice blood, using DEAE cellulose (Lanham and Godfrey, 1970). Then, genomic 
DNA was purified from all samples (including input library), and polymerase 
chain reaction (PCR) was used to enrich the RNAi target. This PCR was conducted 
with a single primer that hybridized to the universal regions of the RNAi 
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cassette, located at both flanks of the protein kinase-specific sequence (Figure 
3-2).  
Cytocidal or cytostatic phenotypes were identified by a quantitative reduction in 
reads mapping to a particular RNAi target in the induced samples relative to 
their representation in the uninduced controls. For both the in vitro and the in 
vivo experiments, reads were filtered to include only those that contained a 9-
nucleotide tag encoded in the universal PCR primers and were then mapped 
against the concatenated sequences of the 177 protein kinase RNAi targets.  
For the in vitro experiment, three biological replicates were conducted, 
collecting samples daily during 120 h (5 days). Cells were diluted after sampling 
to maintain the exponential phase of growth, and tetracycline was renewed as it 
has stability for 4 days at 37 oC according to manufacturer instructions. 
For the in vivo experiment, two biological replicates were performed. Each 
replicate included 6 control mice, and 6 where RNAi was induced with 
doxycycline, which is more bioavailable and stable than tetracycline in vivo 
(Agwuh and MacGowan, 2006). Working with monomorphic parasites has the 
inconvenience of cells being unable to monitor and control their own density and 
thus rapidly causing death of the host. Ethical commitments oblige us to kill 
mice when parasitemia reaches 108 cells ml-1. With this in mind, infections were 
initiated with 5 x 104 parasites. This provided >250 parasites per kinase line, 
assuming we were able to keep homogeneous representation in the final pool; 
and 3 days growth before reaching the parasitemia limit. One mouse has roughly 
1.4 ml blood, with parasites growing faster and reaching higher concentrations 
than in culture. The choice of 6 replicates helped us reach statistically 
significant numbers and prevented eventual fails during establishment of the 
infection, as happened for one of the uninduced mice within the first replicate 
(see Table S2). Infections were allowed to establish for 24 h before adding 
doxycycline in the drinking water. RNAi inductions were then carried out for 48 h 
before killing mice and recovering parasites from the blood. 
Chapter 3 105 
 
3.3.2 Pooling strategy 
It was critical to, as much as possible, ensure equal representation of every cell 
line in the final parasite protein kinase library pool. In order to do so, a pooling 
strategy was adopted by dividing the library into 9 sub-groups, named “Mixed 
Stabilate Trypanosome Library” (MSTL1-9). Each MSTL contained between 18-27 
RNAi lines in order to ease handling and avoid overgrowing of cells. Cultures 
were always maintained below 2x106 cells x ml-1. For each cell line, the clone 
producing a stronger loss of fitness in the Alamar blue screen (Jones et al., 2014) 
was selected. Cells were defrosted, and passaged in fresh media until all lines in 
the batch presented normal fitness, assessed by shape and mobility under the 
microscope. When new cryostocks were needed, they were generated. Once 
they were in optimal conditions, cells were pooled and frozen. 24 cryovials were 
generated per sublibrary, and 2.5 x105 cells/kinase were included in each one. 
This task was undertaken in collaboration with Dr Tiago D. Serafim. 
One tube was defrosted per sublibrary in order to estimate the survival rate. The 
operation was conducted three times, with a space of several months between 
replicates. The number of parasites per kinase recovered in each case was very 
reproducible for each MSTL, Figure 3-3. However, the percentage of recovery 
per kinase line between the different libraries was variable, from 30% in MSTL4 
to over 90% in MSTL7. Since we put effort on ensuring homogeneous fitness, we 
made the assumption that cell loss upon a freezing/thawing cycle was equitable 
for all the lines included in a stabilate. It is positive that the “limiting 
sublibrary”, i.e. the one that contained the minimum amount of parasites per 
kinase line, was the same in every replicate, with the exception of the third that 
included MSTL9 and a new version of MSTL2 (MSTL2*), Figure 3-3. 
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Figure 3-3. Defrosting survival assay for sublibraries (MSTL1-9) used in the T. 
brucei protein kinome RITseq. 
3 tubes out of the 24 generated for each MSTL were defrosted with a space of 
two months between replicates. Highlighted in a red box, are number of kinase 
lines contained per MSTL. Codes for the cell lines and plasmids, together with 
alamar blue phenotypes and RNAi target sequences, can be found in Table S1. 
The third replicate was slightly different as MSTL2 was remade to contain two 
extra cell lines, and MSTL9 was added to include lines remade after they were 
not detected in the first replicate for the in vivo screen; details are provided 
below. 
The final pool was made 7 h before using the library to inoculate mice or to seed 
the in vitro experiments. This kept the cells in culture for less than 1 population 
doubling (8 h in 2T1s). After defrosting all MSTLs, glycerol was diluted and 
survivors accurately counted to identify the “limiting sublibrary”. Number of 
cells was maximized by adding to the mix the complete culture for that 
particular MSTL, and, for the rest, volumes contributing the same number of 
cells per kinase line than the “limiting sublibrary”. Details for the two pools 
used for the in vivo and in vitro RITseq experiments are provided in Table 3-1. 
MSTL2 was the limiting library in the first pool and MSTL4 in the second (as 
MSTL2 was remade). 2 cell lines were added individually to the pool in replicate 
1 in order to see if any difference was observable in our detection capacity 
compared to the premixed lines: Tb927.9.6560, which produced a loss of fitness 
in the alamar blue in vitro screen (Jones et al., 2014); and Tb927.6.2980, which 
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did not. The number of reads collected for them in the final mix after RITseq 
was in the same range as the other pooled lines, and the expected phenotypes 
after RNAi were reproduced (fit and not fit)(Tables S2 and S3). These cell lines 
were included in MSTL2* for the second replicate. In replicate 2, another 5 lines 
were added individually, as they could not be found in the first pool after 
sequencing. Details will be discussed below. 
Table 3-1. Input library composition for in vitro and in vivo RITseq 
experiments determining limiting sublibrary. 
Pool 1. In vivo Replicate 1 
Sublibrary Components 
Post-thawing 
concentration 
(cells/ml) 
Culture 
volume (ml) 
Total cells 
Cells/ 
kinase line 
  
Volume to 
mix (ml) 
MSTL1 20 2,20E+05 11,1 2,44E+06 1,22E+05   6,6 
MSTL2 18 1,26E+05 10,3 1,30E+06 7,21E+04 Limiting ALL: 10,3 
MSTL3 24 2,77E+05 10,8 2,99E+06 1,25E+05   6,3 
MSTL4 19 1,37E+05 10,5 1,44E+06 7,57E+04   10,1 
MSTL5 25 2,80E+05 11 3,08E+06 1,23E+05   6,5 
MSTL6 25 3,63E+05 10,4 3,78E+06 1,51E+05   5 
MSTL7 25 5,30E+05 10,7 5,67E+06 2,27E+05   3,4 
MSTL8 25 3,87E+05 10,7 4,14E+06 1,66E+05   4,7 
sTL206 Tb927.9.6560 6,00E+04         1,21 
sTL209 Tb927.6.2980 9,70E+04         0,749 
        Pool2. In vivo Relicate 2, and in vitro Replicates 1-3 
Sublibrary Components 
Post-thawing 
concentration 
(cells/ml) 
Culture 
volume (ml) 
Total cells 
Cells/ 
kinase line  
Volume to 
mix (ml) 
MSTL1 20 2,40E+05 9,5 2,28E+06 1,14E+05   6,3 
MSTL2* 20 3,33E+05 9,6 3,20E+06 1,60E+05   4,5 
MSTL3 24 2,80E+05 9,6 2,69E+06 1,12E+05   6,4 
MSTL4 19 1,50E+05 9,5 1,43E+06 7,50E+04 Limiting ALL: 9.5 
MSTL5 25 3,80E+05 9,5 3,61E+06 1,44E+05   4,95 
MSTL6 25 3,73E+05 9,6 3,58E+06 1,43E+05   5,03 
MSTL7 25 6,86E+05 9,5 6,52E+06 2,61E+05   2,74 
MSTL8 25 5,50E+05 9,6 5,28E+06 2,11E+05   3,41 
MSTL9 20 5,00E+05 9,7 4,85E+06 2,43E+05   3 
sTL102 Tb927.11.12310 1,08E+06         0,069 
sTL284 Tb927.3.5180 1,05E+06         0,071 
sTL598 Tb927.11.7160 7,80E+05         0,096 
sTL635 Tb927.11.5860  8,00E+05         0,093 
sTL641 Tb927.9.2240  8,83E+05         0,084 
 
The pooled culture was diluted to 50 ml and acclimatized at 37 oC 5% CO2 for 45 
min, cells were counted, pelleted at 1200 g for 10 minutes and resuspended at 
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5x105 cells ml-1. After 6 h incubation 37 oC 5% CO2, cells were counted again and 
used for the in vitro or in vivo experiments. 
3.3.3 Optimization of PCR to enrich the RNAi cassette 
Gene-specific RNAi inserts were designed using a web-based tool, RNAit 
(Redmond, Vadivelu and Field, 2003), and ranged between 450 and 650 base 
pairs. Such restricted size, in addition to the Gateway® flanks, AttL1 and AttL2, 
were exploited to design a universal PCR, which enabled homogenous 
enrichment of the RNAi targets from genomic DNA and increased efficiency of 
the sequencing reaction (Figure 3-2C). It was critical to use a high fidelity 
polymerase to ensure amplified sequences were indistinguishable from their 
templates, so we could unequivocally assign sequencing reads to the original 
templates. 
After alignment in CLC genomics workbench, AttL1 and AttL2 displayed in nearly 
identical sequences, differing in only 4 bases. Based on that, a variety of primers 
were designed, trying to achieve optimal PCR amplification (Figure 3-4A): two 
forward primers (Fw1 and Fw2) binding to AttL1; two reverse (Rv1 and Rv2) 
hybridizing in the stuffer region; and two reverse (Rv3a and Rv3b) binding to 
AttL2, Figure 3-4B.  
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Figure 3-4. PCR optimization for enrichment in the RNAi insert.  
A. (Above)Sequence alignment of the AttL sites within the universal Gateway® 
flanks. Highlighted on top, forward (Fw) and reverse (Rv) primers designed 
exploiting the single nucleotide conflicts between sequences. (Below) Schematic 
representation of the RNAi cassette (see Figure 3-1) indicating binding sites for 
all the oligonucleotides tested. B. List of all primers tested during the 
optimization process. C. Phusion® high fidelity polymerase reaction (60 oC 
annealing/30 cycles) with different combinations of primers. Depending on the 
template, lanes are labelled: G=gDNA from an RNAi line (sTL0082); P= DNA from 
its untransfected plasmid (pTL50); B=genomic DNA from parental 2T1s; W=water 
control. D. Fw1/Rv2 PCR with Phusion® high fidelity polymerase (60 oC 
annealing/30 cycles). Lanes labelled as in (C) with G*= positive control for PCR 
with gDNA from sTL0082 using primers to amplify the kinase domain of 
Tb927.9.10920. E. Fw1/Rv4 gradient PCR using pTL50 DNA and Phusion 
polymerase for 30 cycles, annealing temperature highlighted above each lane. F. 
Q5 high fidelity polymerase reaction (61oC annealing/30 cycles) using Fw1/Rv4 
and single primer Fw1. Lanes labelled as in (B) with 5xG= gDNA from 5 RNAi lines 
selected from the library. G. Fw1 (OL4161) Q5 high fidelity polymerase reaction 
(61 oC annealing/input kinase pool as a template) increasing number of PCR 
cycles.  
All combinations were tested with Phusion High Fidelity polymerase at 60 oC. As 
a DNA template we used a plasmid from the library (pTL50) and genomic DNA 
(gDNA) from the cell line generated upon pTL50 transfection into 2T1 cells 
(sTL0082), Figure 3-4C. The construct and cell line targeted ATR by RNAi, a 
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protein kinase involved in DNA repair, which has been validated previously 
somewhere else: the plasmid through restriction digestion and sequencing; and 
the cell line via antibiotic resistance, RNA/protein depletion, and decrease in 
resistance to genotoxic effects caused by methyl methanesulfonate (Stortz, PhD 
thesis, 2016). As a control for PCR, primers were also tested against gDNA from 
parental 2T1 cells, and water. We only could obtain a single defined PCR product 
that matched the predicted 628-bp with Fw1/Rv2. This size includes a small 
AttL1 portion (starting from Fw1), plus the RNAi target with the complete Attl2 
flank and the section of the stuffer before Rv2 binding site. PCR amplification 
was only possible with the plasmid template, not with gDNA.  
In order to verify that gDNA from sTL0082 was not degraded we used PCR 
conditions and primers validated to amplify the kinase domain of Tb927.9.10920 
(kindly provided by Nathaniel Jones) in parallel to the Fw1/Rv2 PCR, Figure 
3-4D. This time, more DNA was loaded in the gel in order to increase resolution. 
We observed, on the one hand, that genomic DNA was fine because a band could 
be identified at the expected size for the genomic control (882 bp), and on the 
other hand, that a secondary amplicon was produced with Fw1/Rv2. After 
sequencing the secondary band, we found it corresponded to the 488 bp-long 
product of Fw1 (OL4161) acting both as forward and reverse primer, binding to 
AttL2 with a single mismatch at the 3´end (G instead of A), Figure 3-4B.  
To solve this problem, a reverse primer targeting the site where Fw1 hybridized 
unspecifically to AttL2 was designed (Rv4). This enabled production of a single 
band, and 61 oC was selected as the annealing temperature after a gradient PCR, 
using pTL50 as a template, Figure 3-4E.  
Applying the same conditions with Fw1/Rv4 and the more efficient Q5 High 
fidelity polymerase, we were finally able to PCR amplify the RNAi target from 
sTL0082 gDNA alone and pooled with gDNA of other 5 lines included in MSTL1, 
which targeted: Tb927.2.2260 (584 bp PCR product), Tb927.8.7450 (490 bp), 
Tb927.11.850 (428 bp), and Tb927.1.1000 (437 bp). In parallel, a PCR was 
performed in the same conditions with Fw1 alone, concluding that its efficiency 
was better than using Fw1/Rv4 combined, Figure 3-4F.  
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In Figure 3-2C, which illustrates the overall approach, we displayed results of 
PCR amplification with Fw1 of four different samples: in vivo uninduced mouse 
(1), in vivo induced mouse (2), gDNA from sTL0082 (3), and input library pool 
(4). 
It was necessary to adjust the optimal number of cycles for the single primer 
PCR in order to avoid saturation levels. This can be caused by accumulation of 
double stranded DNA produced during the exponential phase, which saturates 
the polymerase. Against common thinking, saturation does not happen due to an 
exhaustion of reagents (e.g. primers, dNTPs) (Kainz, 2000). Although primers 
were designed to bind in the universal flanks, slight differences in size and GC 
content may cause some amplicons to be favoured over others. Saturation would 
overenrich the most physio-chemically privileged RNAi targets in detriment of 
the less favoured, potentially compromising the basis of the RITseq screen, even 
when this  compares induced/uninduced reads per gene ID. 28 cycles was chosen 
as this produced enough enrichment while far from saturation (Figure 3-4G) 
Addition of 6-nucleotide tags to the single primer used to perform the PCR (Fw1= 
OL4161) permitted expanding our multiplexing capacity and reducing overall 
costs of the experiment. Pooling equal masses of PCR products generated with 
distinct barcoded primers, from gDNAs purified from different experimental 
conditions or replicates, permitted creating a single sequencing sample. Reads 
could be assigned later to the original experimental condition in silico (Figure 
3-5).  
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Figure 3-5. PCR bar-coded strategy for sample enrichment of the RNAi target. 
A. Schematic representation of the strategy. 6-mer labels added to OL4161 
permits pooling equal masses of PCR products obtained from different 
experimental conditions (cond.1, 2, 3) and use of a single set of Illumina 
sequencing adapters. B. 1% agarose gel showing homogeneous amplification of 
gDNA purified from the input library with the 14 selected barcoded versions of 
OL4161. Sequences for each of the primers is depicted in the table. 
The PCR enrichment strategy required 13 plasmids and their respective cell lines 
to be remade so that they could include the universal Gateway® sites flanking 
the RNAi cassette.  The original plasmids had been made using traditional 
restriction digestion-ligation cloning and would not have been suitable for PCR 
amplification of the RNAi target sequence by OL4161. As with the rest of the 
library (Jones et al., 2014), alamar blue phenotypes after 72 h of RNAi induction 
were also analysed (Table 3-2). Among these lines a few showed a loss of fitness: 
the 2 clones made for CRK3, KKT10 and AGC1, one clone for KKT19, PDK1 and 
the orphan kinase Tb927.11.6690. 
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Table 3-2. Alamar blue (AB) ratios (Tet+/Tet-) after 72h for cell lines remade 
in the Gateway® system to enable PCR enrichment in the pooled library.  
Plasmid Gene ID PK name Cell line 
Mean  AB 
(Tet+/Tet-) 
SD 
pTL21 Tb927.10.4990 CRK3 
sTL0024 0,511 0,011 
sTL0097 0,516 0,023 
pTL23 Tb927.6.2250 AGC (RAC) 
sTL0031 0,997 0,022 
sTL0034 0,974 0,203 
pTL236 Tb927.10.16160 Orphan 
sTL590 1,049 0,040 
sTL591 0,996 0,036 
pTL237 Tb927.3.3290 Orphan 
sTL593 0,956 0,095 
sTL594* 1,031 0,031 
PTL234 TB927.11.12420 
CMGC/CLK2 
(KKT19) 
sTL538 1,023 0,058 
sTL596 0,820 0,122 
pTL128 Tb927.10.14300 STE (STE11) 
sTL616 0,984 0,045 
sTL617 0,976 0,022 
PTL233 TB927.11.12410 
CMGC/CLK 
(KKT10) 
sTL535 0,618 0,009 
sTL594 0,721 0,172 
PTL244 Tb927.3.2440 AGC1 
sTL618 0,606 0,012 
sTL619 0,801 0,019 
pTL235 Tb927.7.3580 NEK-11 
sTL708 0,945 0,002 
sTL709 1,020 0,042 
pTL238 Tb927.3.3080 NEK-6 
sTL710 1,042 0,028 
sTL711 0,985 0,014 
pTL240 Tb927.8.1670 NEK-13 
sTL712 0,979 0,016 
sTL713 0,994 0,036 
pTL241 Tb927.9.4910 
AGC 
(TbPDK1) 
sTL672 0,896 0,191 
sTL714 1,004 0,044 
pTL243 Tb927.11.6690 Orphan 
sTL715 0,502 0,014 
sTL716 1,047 0,043 
SD= standard deviation. Mean AB highlighted in red= loss of fitness phenotypes. 
PK = Protein kinase. 
 
3.3.4 RNAi target sequencing analysis 
In order to score loss of fitness in the RITseq, ratios were determined from reads 
mapped to each protein kinase gene in the induced sample relative to the 
uninduced sample (and in the uninduced sample relative to the pre-inoculation 
pool, or time 0) with a bootstrap analysis including 1000 repeats (see material 
and methods for details). This approach enabled calculation of the median and 
estimation of 95% confidence intervals for each gene (see summary of results, 
Table 3-3). Median ratios under 0.6 were considered loss of fitness phenotypes 
based on the scores for the protein kinase with an upper limit for the 95% 
confidence interval under 0.75 in both in vivo replicates. When the 0.6 
(induced/uninduced) threshold was applied to all data sets it was determined to 
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be discriminatory both in vitro and in vivo, showing a progressive increase of the 
number of targets identified with time (Figure 3-6, A and B). 
 
Figure 3-6. Ranking of in vitro and in vivo RITseq results.  
A. Bootstrap median ratios (Tet-/input and Tet+/Tet-) of triplicates for each 
time point of the in vitro RNAi screen, arranged in increasing order.  Reads were 
normalized as 106 times raw count mapped to a gene ID divided per sum of total 
reads included for the analysis in a particular sample, rounded to the next 
integer. B. Bootstrap median ratios (control/input and induced/control) of each 
in vivo experiment arranged in increasing order. 
To add an extra layer of statistical analysis, P values were calculated with T-
tests performed per gene and time point, Table S4. Volcano plots, representing 
induced/uninduced ratios versus P values, also highlighted an increase in the 
number of significant loss of fitness phenotypes with time in vitro (Figure 3-7) 
and a better separation between induced and uninduced results in vivo.  
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Figure 3-7. Volcano plots for the in vivo (A) and in vitro (B) kinome-wide 
RITseq experiments.  
Statistical significance (P values, calculated via T-test) is depicted versus 
induced/uninduced ratios. Blue lines determining thresholds of loss of fitness 
(ratios < 0.6, vertical) and of significance (P < 0.01, horizontal). 
RITseq data for all protein kinase genes are summarized in Table 3-3. Every 
protein kinase line is labelled with gene identifier, protein kinase family, and 
the MSTL library in which it was included. The table contains: in vivo results 
(median bootstrap ratios) for replicates 1 and 2 and the average between them; 
in vitro results (median bootstrap ratios) for every time point of the in vitro 
RITseq (24 h-120 h); and details of loss of fitness detected in the RNAi screens 
covering the protein kinome available in the literature (Alsford et al., 2011; 
Jones et al., 2014). Growth defect or cell cycle phenotypes, if defined by Jones 
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et al., are noted. Gene identifiers of lines that did not produce a loss of fitness 
in the alamar blue screen but were affected in vivo are highlighted in red. 
Results obtained in the whole genome RITseq developed by Alsford et al. are 
also inscribed in the table after 72 h and 144 h, with significant loss of fitness 
noted as “TRUE”. 
Details for individual lines can be found in Table S1 classified by MSTL, including 
plasmid code, RNAi target sequence, and alamar blue ratios in vitro (Jones et 
al., 2014) 
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Table 3-3. Summary of RNAi target sequencing results in vivo and in vitro 
Repl. 1 and Repl. 2 = median Tet+/Tet- for each in vivo replicate 
24h, 48h, 72h, 96h, 120h = median Tet+/Tet- for each time point at in vitro 
C= cytokinesis; M= mitosis; K= kinetoplast duplication/segregation; U= unclassified (Jones et al. 2014) 
*=Phenotypes in Jones et al. (2014) not found in Alsford et al. (2011)  
Yes = significant loss of fitness (Alsford et al. 2011) / No = no significant loss of fitness (Alsford et al. 2011) 
 
In vivo or in vitro RITseq Tet+ / Tet- <0.1 <0.3 <0.6  In vivo not in vitro  Loss of fitness (Jones et al.2014; Alsford et al. 2011)  
           
1 / 6 
Family/Name 
Sub 
library 
In vivo Tet+/Tet- (48 h) In vitro Tet+/Tet- Jones 72h Alsford 72h Alsford 144h 
Gene ID Repl 1 Repl 2 Mean 24h 48h 72h 96h 120h Growth 
Cell 
cycle 
Tet+/Tet- Signif. Tet+/Tet- Signif. 
Tb927.8.5950 STE/STE7/MKK4 MSTL3 2.796 1.994 2.395 0.668 0.401 0.759 2.571 2.807 none unknown 1.190 No 1.888 No 
Tb927.10.1910 STE/STE11 MSTL3 1.594 2.215 1.904 0.940 1.044 0.798 1.288 1.963 none unknown 1.411 No 1.288 No 
Tb927.11.11110 Other/NEK/NEK20 MSTL8 1.683 2.060 1.871 1.107 1.052 1.323 1.241 1.131 none unknown 0.808 No 0.243 Yes 
Tb927.10.12040 CMGC/MAPK/MAPK11 MSTL7 2.124 1.534 1.829 1.417 1.269 1.533 1.732 1.377 none unknown 0.696 No 0.516 Yes 
Tb927.4.3770 CAMK MSTL5 1.908 1.685 1.796 1.072 1.246 2.294 1.560 1.225 none unknown 1.144 No 1.883 No 
Tb927.7.3650 STE/STE11 MSTL3 1.895 1.669 1.782 0.442 1.324 0.868 0.848 1.080 none unknown 1.760 No 3.461 No 
Tb927.8.3770 CMGC/MAPK MSTL4 1.776 1.773 1.775 1.072 1.027 1.224 1.422 1.445 none unknown 1.058 No 1.375 No 
Tb927.11.9270 AGC/ZFK MSTL5 1.987 1.436 1.712 1.733 1.036 0.877 1.552 1.565 none unknown 1.295 No 1.523 No 
Tb927.3.4860 STE/STE7/MKK1 MSTL3 2.243 1.062 1.652 1.394 2.636 1.121 0.547 3.456 none unknown 0.723 No 0.875 No 
Tb927.8.3550 CMGC/MAPK/MAPK3 MSTL4 1.929 1.373 1.651 1.057 0.920 1.236 1.292 0.902 none unknown 1.647 No 1.910 No 
Tb927.3.1570 Orphan MSTL6 1.653 1.604 1.628 0.862 1.302 1.486 1.654 1.322 none unknown 1.436 No 1.456 No 
Tb927.10.14780 STE/STE11 MSTL3 2.052 1.196 1.624 1.301 2.203 1.690 1.219 0.670 none unknown 0.084 Yes 0.028 Yes 
Tb927.5.3320 Pseudo-Orphan MSTL6 1.679 1.561 1.620 0.995 0.890 1.287 1.582 2.215 none unknown 0.711 No 1.761 No 
Tb927.8.5500 Orphan MSTL6 1.932 1.282 1.607 0.837 1.289 1.438 1.032 1.015 none unknown 2.280 No 2.745 No 
Tb927.9.10040 Pseudo-Orphan MSTL6 1.699 1.507 1.603 1.042 0.987 1.302 0.996 0.779 none unknown 0.098 Yes 0.098 Yes 
Tb927.10.8730 aPK-ABC1 MSTL1 1.875 1.288 1.582 0.709 0.750 1.019 1.071 1.184 none unknown 0.518 No 1.186 No 
Tb927.10.11940 aPK-ABC1 MSTL1 1.313 1.837 1.575 0.842 1.306 1.434 1.306 2.269 none unknown 0.291 Yes 1.725 No 
Tb927.10.1380 Other/NEK/NEK19 MSTL8 1.745 1.401 1.573 1.239 1.334 1.134 1.490 1.554 none unknown 1.228 No 0.795 No 
Tb927.5.1650 CMGC/DYRK MSTL7 Absent 1.552 1.552 1.359 1.270 0.694 1.548 1.984 none unknown 1.308 No 2.879 No 
Tb927.11.4780 aPK-PDK MSTL1 1.664 1.411 1.537 1.059 1.194 1.117 1.838 1.609 none unknown 2.426 No 2.117 No 
Tb927.7.6680 STE/STE11 MSTL3 1.710 1.361 1.536 0.422 0.729 1.267 0.860 1.621 none unknown 0.994 No 1.465 No 
Tb927.6.2030 STE/STE11 MSTL3 2.018 1.049 1.534 1.387 1.643 1.045 0.948 1.606 none unknown 0.396 Yes 1.224 No 
Tb927.11.8150 pseudo Other/ULK MSTL8 1.124 1.932 1.528 2.304 0.976 3.410 1.490 1.771 none unknown 0.775 No 0.749 Yes 
Tb927.10.16030 CMGC/MAPK/MAPK2 MSTL4 1.441 1.612 1.527 1.240 1.696 1.215 0.603 0.915 none unknown 0.425 No 1.606 No 
Tb927.3.2690 AGC/RSK MSTL5 1.659 1.390 1.524 1.070 1.136 1.337 1.212 1.239 none unknown 1.254 No 2.106 No 
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Tb927.5.3420 aPK-ABC1 MSTL1 1.711 1.325 1.518 0.844 1.068 1.245 1.295 1.504 none unknown 0.417 No 0.523 Yes 
Tb927.10.15880 Orphan MSTL6 1.728 1.305 1.517 1.022 1.269 1.415 1.575 1.667 none unknown 1.176 No 2.440 No 
Tb927.10.5270 STE/STE7/MKK5 MSTL3 1.830 1.201 1.515 0.957 0.919 0.375 0.600 0.225 none unknown 0.969 No 1.393 No 
Tb927.11.8940 CAMK/LDK MSTL5 1.506 1.514 1.510 1.034 1.421 1.658 1.299 1.476 none unknown 0.772 No 2.635 No 
Tb927.3.1850 Orphan MSTL6 1.558 1.449 1.503 1.316 0.957 1.289 1.491 1.623 none unknown 3.515 No 5.157 No 
Tb927.7.1900 CMGC/CDK/CRK7 MSTL4 1.645 1.342 1.493 0.876 0.987 1.319 1.495 1.503 none unknown 0.047 Yes 0.000 Yes 
Tb927.10.2390 CK1/CK1 MSTL5 1.496 1.417 1.457 1.189 1.452 1.609 1.542 1.912 none unknown 0.410 Yes 1.024 No 
Tb927.5.4430 CAMK MSTL5 1.632 1.273 1.453 0.985 1.358 1.526 1.098 1.049 none unknown 1.089 No 0.278 Yes 
Tb927.4.800 aPK-PIKK/FRAP/TOR3 MSTL1 1.476 1.428 1.452 0.959 1.235 1.221 1.247 1.503 none unknown 0.910 No 1.446 No 
Tb927.9.1500 Other/NEK/NEK15 MSTL8 1.471 1.426 1.448 1.010 1.315 1.400 1.316 1.223 none unknown 1.050 No 1.428 No 
Tb927.11.7010 Other/CAMKK MSTL2 1.449 1.425 1.437 0.729 1.286 1.141 0.998 1.667 none unknown 0.373 Yes 1.479 No 
Tb927.4.2460 Pseudo-Orphan MSTL6 1.603 1.268 1.435 0.900 1.193 1.699 1.298 1.381 none unknown 0.920 No 1.116 No 
Tb927.10.460 Other/NEK/NRKC MSTL8 1.175 1.694 1.434 1.251 1.181 1.222 0.975 1.448 none unknown 0.792 No 1.173 No 
Tb927.8.870 CAMK/CAMKL MSTL5 1.371 1.482 1.426 1.147 0.918 0.922 1.325 0.851 none unknown 0.518 No 1.814 No 
Tb927.8.4260 Orphan MSTL6 1.600 1.218 1.409 1.150 1.049 1.866 1.488 1.142 none unknown 1.179 No 1.667 No 
Tb927.6.2450 AGC/putative PKB MSTL5 1.435 1.378 1.407 0.879 1.301 1.106 1.245 1.527 none unknown 0.086 Yes 0.321 Yes 
Tb927.2.2260 aPK-PIKK/ATM MSTL1 1.568 1.240 1.404 1.075 1.045 1.069 1.099 0.888 none unknown 1.014 No 1.692 No 
Tb927.9.12400 STE/STE11/KinER3 MSTL3 1.332 1.473 1.403 1.020 1.020 0.771 3.201 7.400 none unknown 0.487 Yes 1.135 No 
Tb927.11.14270 STE/STE7 MSTL3 1.512 1.292 1.402 1.216 0.959 1.018 1.900 1.582 none unknown 0.968 No 2.735 No 
Tb927.9.2350 Orphan MSTL6 1.347 1.455 1.401 1.433 1.184 1.177 1.549 1.809 none unknown 1.548 No 1.502 No 
Tb927.8.1780 STE/STE7 MSTL3 1.631 1.168 1.399 0.934 0.885 1.306 1.770 0.827 none unknown 0.535 No 0.918 No 
Tb927.8.7110 Other/NEK*/NEK12.1 MSTL8 1.352 1.432 1.392 1.244 1.156 1.334 1.528 1.542 none unknown 1.092 No 0.607 Yes 
Tb927.10.350 CMGC/DYRK/PK4 MSTL7 1.462 1.303 1.383 0.799 1.162 1.796 1.191 1.495 none unknown 0.959 No 1.683 No 
Tb927.10.9900 aPK-ABC1 MSTL1 1.483 1.279 1.381 0.958 1.263 0.931 1.420 1.376 none unknown 1.384 No 0.530 Yes 
Tb927.10.14800 CMGC/RCK/MAPK9/RCK2 MSTL7 1.530 1.205 1.368 1.139 0.970 1.018 1.482 1.439 none unknown 1.084 No 1.958 No 
Tb927.7.3190 Pseudo-Orphan MSTL6 1.361 1.365 1.363 1.141 1.211 1.396 1.719 1.377 none unknown 0.294 Yes 1.378 No 
Tb927.10.9600 CMGC/DYRK MSTL7 1.354 1.351 1.352 1.181 1.124 1.142 1.568 1.751 none unknown 0.382 Yes 1.036 No 
Tb927.8.6810 STE/STE11 MSTL3 Absent 1.350 1.350 1.199 1.110 1.442 1.469 1.626 none unknown 0.977 No 1.648 No 
Tb927.9.2140 Orphan MSTL6 1.672 1.029 1.350 1.159 0.760 1.822 1.181 1.194 none unknown 0.848 No 2.081 No 
Tb927.2.4200 CMGC/CLK MSTL7 1.241 1.456 1.349 0.883 1.190 1.385 1.657 1.854 none unknown 0.991 No 1.569 No 
Tb927.4.2500 Other/PEK/EIF2K2 MSTL2 1.435 1.253 1.344 1.650 1.050 1.156 1.468 1.574 none unknown 1.035 No 1.583 No 
Tb927.1.1530 STE MSTL3 1.416 1.272 1.344 1.294 1.133 1.734 0.865 0.486 none unknown 1.022 No 1.368 No 
Tb927.2.2120 Other/NEK/NEK22 MSTL8 1.304 1.375 1.339 1.215 1.266 1.398 1.210 1.109 none unknown 1.817 No 0.873 No 
Tb927.3.1610 CMGC/CLK MSTL7 1.537 1.140 1.338 1.040 1.182 1.659 1.463 1.173 none unknown 0.630 No 1.631 No 
Tb927.3.3190 Other/NEK/NEK7 MSTL8 1.397 1.279 1.338 1.009 1.195 1.574 1.648 2.046 none unknown 0.793 No 1.592 No 
Tb927.11.6690 Orphan MSTL8 1.491 1.181 1.336 0.848 1.329 1.168 1.802 1.421 none unknown 0.683 No 2.114 No 
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Tb927.6.1780 CMGC/MAPK/MAPK4 MSTL4 1.246 1.418 1.332 1.122 1.444 1.465 1.195 1.288 none unknown 0.848 No 0.659 No 
Tb927.3.2060 STE MSTL3 Absent 1.320 1.320 1.000 1.532 1.314 1.369 1.086 none unknown 1.141 No 2.391 No 
Tb927.10.5310 CAMK/CAMKL/TbAMPKa1 MSTL5 1.266 1.370 1.318 0.976 1.128 1.273 1.395 1.395 none unknown 0.815 No 1.104 No 
Tb927.5.3160 Orphan MSTL6 1.162 1.467 1.314 1.011 1.438 1.272 1.994 1.296 none unknown 0.789 No 1.547 No 
Tb927.11.14500 Pseudo-Orphan MSTL6 1.690 0.929 1.309 1.193 1.072 1.240 0.768 0.735 none unknown 0.222 Yes 0.712 No 
Tb927.6.3430 Other/NEK/NEK10 MSTL8 1.400 1.218 1.309 1.294 1.088 1.381 1.027 1.589 none unknown 1.048 No 1.238 No 
Tb927.10.13480/10.13490 CAMK/CAMKL MSTL5 1.388 1.223 1.306 0.833 1.110 1.302 1.097 1.541 none unknown 0.200 No 0.067 Yes 
Tb927.9.1570 CAMK/ MSTL5 Absent 1.302 1.302 0.914 1.005 1.301 1.268 1.115 none unknown 0.828 No 0.374 Yes 
Tb927.3.1630 CK1/CK1/CK1 MSTL5 Absent 1.302 1.302 1.163 1.323 1.109 1.285 1.575 none unknown 1.327 No 1.903 No 
Tb927.2.5230 pseudo CAMK MSTL8 Absent 1.287 1.287 0.836 1.273 1.132 1.514 1.764 none unknown 0.091 Yes 0.162 Yes 
Tb927.4.5390/8.6930 Other/NEK/NRKB MSTL8 1.394 1.175 1.284 0.903 1.198 0.994 1.178 1.041 none unknown 1.590 No 3.504 No 
Tb927.5.3150 Orphan/KinER5 MSTL6 1.360 1.201 1.280 1.366 0.911 0.893 1.392 1.235 none unknown 1.348 No 1.449 No 
Tb927.9.9320 CMGC/RCK-MAPK/MOK MSTL7 1.405 1.148 1.276 1.087 1.124 1.087 1.402 1.334 none unknown 0.370 Yes 2.420 No 
Tb927.6.2980 Other/PEK/TbEIFK3 MSTL2 1.392 1.161 1.276 1.001 0.921 1.167 1.311 1.392 none unknown 0.938 No 1.060 No 
Tb927.10.3340 Orphan MSTL6 Absent 1.274 1.274 1.108 1.094 1.161 1.423 1.059 none unknown 1.123 No 1.704 No 
Tb927.11.6990 Other/CAMKK MSTL2 1.159 1.385 1.272 1.283 0.893 1.190 1.434 1.240 none unknown 0.161 Yes 0.086 Yes 
Tb927.7.5220 STE/STE11/Forkhead Kinase MSTL3 Absent 1.269 1.269 1.185 1.212 1.320 1.443 1.056 none unknown 0.494 Yes 0.837 Yes 
Tb927.10.15020 CMGC/DYRK/YAK1 MSTL7 1.319 1.215 1.267 1.308 0.938 1.107 1.269 1.691 none unknown 1.368 No 1.871 No 
Tb927.7.2420 CMGC/GSK/GSK3-long MSTL4 1.366 1.161 1.263 1.033 0.983 1.347 1.252 1.536 none unknown 1.134 No 1.382 No 
Tb927.3.3080 Other/NEK/NEK6 MSTL8 1.262 1.263 1.262 0.930 1.269 1.831 1.357 1.328 none unknown 0.715 No 1.611 No 
Tb927.11.790 Orphan/ MSTL6 0.987 1.510 1.249 1.646 1.052 1.702 1.966 1.714 none unknown 2.732 No 2.846 No 
Tb927.4.840 aPK-PDK/ MSTL1 1.064 1.433 1.248 0.804 1.234 1.906 1.104 1.707 none unknown 1.053 No 0.693 No 
Tb927.3.4670 CMGC/CDK/CRK10 MSTL4 1.214 1.278 1.246 1.013 1.538 1.098 1.221 1.519 none unknown 0.244 Yes 0.000 Yes 
Tb927.11.16790 CMGC/CDKL/ECK1 MSTL7 1.131 1.340 1.236 1.100 0.931 0.622 0.338 0.219 none unknown 0.828 No 0.345 Yes 
Tb927.4.4970 aPK/ MSTL1 Absent 1.231 1.231 1.233 1.283 1.294 1.238 1.156 none unknown 1.027 No 2.147 No 
Tb927.8.4000 aPK-ABC1 MSTL1 1.130 1.325 1.228 0.740 1.001 0.914 1.441 1.191 none unknown 2.159 No 1.319 No 
Tb927.10.10870 CMGC MSTL7 1.472 0.965 1.218 0.969 1.283 0.992 1.164 0.505 none unknown 0.771 No 0.924 No 
Tb927.1.1000 aPK MSTL1 1.078 1.320 1.199 1.389 1.168 1.505 1.398 1.545 none unknown 1.085 No 0.075 Yes 
Tb927.11.15010 Other/NEK/NEK21 MSTL8 Absent 1.193 1.193 0.843 1.116 0.988 1.374 1.316 none unknown 1.589 No 2.145 No 
Tb927.4.4590 AGC MSTL5 1.227 1.149 1.188 1.051 1.005 0.952 1.409 1.714 none unknown 0.855 No 2.328 No 
Tb927.11.3140 CMGC/DYRK/DYRK2 MSTL7 1.317 1.053 1.185 1.384 0.823 0.698 0.427 0.681 none unknown 0.201 Yes 1.049 No 
Tb927.8.5390 CMGC/CDK/CRK4 MSTL4 1.126 1.243 1.185 1.089 1.053 1.282 1.694 1.302 none unknown 0.343 Yes 0.514 Yes 
Tb927.10.1940 Pseudo-CAMK/CAMKL MSTL8 1.363 0.991 1.177 1.058 1.008 1.133 1.150 0.686 none unknown 1.490 No 1.265 No 
Tb927.10.3230 CMGC/MAPK MSTL4 1.154 1.178 1.166 1.002 1.246 1.555 2.134 1.372 none unknown 1.491 No 3.566 No 
Tb927.11.7210 Other/PEK/TbEIFK1 MSTL2 1.134 1.185 1.160 0.673 0.978 1.170 1.931 1.361 none unknown 1.816 No 2.639 No 
Tb927.8.6490 Other/CAMKK MSTL2 1.078 1.234 1.156 1.162 1.154 1.214 1.195 1.482 none unknown 0.922 No 1.167 No 
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Tb927.1.3130 Orphan MSTL6 1.029 1.256 1.142 1.014 1.285 1.305 1.399 1.422 none unknown 0.951 No 3.457 No 
Tb927.10.16160 Orphan MSTL8 1.140 1.142 1.141 1.090 1.134 1.233 1.431 1.545 none unknown 0.750 No 1.766 No 
Tb927.2.2720 Orphan/FlaK MSTL6 0.961 1.315 1.138 0.858 0.949 1.147 1.031 0.595 none unknown 1.296 No 0.854 Yes 
Tb927.5.2820 Other/NEK/NEK9 MSTL8 1.178 1.081 1.130 1.196 0.816 1.115 1.287 1.225 none unknown 1.093 No 1.147 No 
Tb927.8.1670 Other/NEK*/NEK14 MSTL8 1.124 1.130 1.127 0.885 1.110 1.116 1.295 1.661 none unknown 1.134 No 3.114 No 
Tb927.10.5950/10.5940 Other/NEK MSTL8 1.096 1.141 1.118 0.878 1.246 1.178 1.258 1.182 none unknown 0.532 No 0.117 No 
Tb927.10.14420 Other/NEK/NEK16 MSTL8 1.038 1.193 1.116 0.894 1.029 0.813 0.897 0.842 none unknown 0.392 Yes 0.576 Yes 
Tb927.8.1100 STE/STE11 MSTL3 1.072 1.127 1.099 1.996 0.927 0.523 0.396 1.011 none unknown 1.197 No 1.766 No 
Tb927.6.2250 AGC/RAC MSTL8 1.174 1.023 1.099 0.958 1.019 1.375 1.259 1.590 none unknown 1.614 No 3.154 No 
Tb927.4.1700 CK1/TTBK MSTL5 1.013 1.153 1.083 1.288 1.129 0.792 1.703 0.893 none unknown 1.782 No 1.642 No 
Tb927.11.8170 CMGC/CDKL MSTL7 0.980 1.184 1.082 1.259 1.661 1.102 1.273 1.724 none unknown 0.550 No 0.624 Yes 
Tb927.3.5650 STE/kinER4 MSTL3 1.046 1.100 1.073 0.914 1.032 1.505 1.449 1.582 none unknown 0.898 No 0.923 No 
Tb927.3.4560 CAMK/CAMKL/TbAMPKa2 MSTL5 0.928 1.165 1.046 1.095 1.221 1.323 0.656 0.267 none unknown 1.235 No 1.533 No 
Tb927.7.3580 Other/NEK/NEK11 MSTL8 Absent 1.039 1.039 1.239 0.803 0.601 0.642 0.318 none unknown 0.699 No 0.765 Yes 
Tb927.9.3120 STE/STE11/KinER2 MSTL3 1.157 0.898 1.028 0.795 2.431 0.788 1.206 1.169 none unknown 1.671 No 2.614 No 
Tb927.8.1690 Other/NEK/NEK14 MSTL8 Absent 1.011 1.011 0.903 0.813 0.781 0.620 0.680 none unknown 1.134 No 3.114 No 
Tb927.10.3900 CAMK/CAMKL MSTL5 Absent 1.005 1.005 0.725 0.789 0.806 0.292 0.106 none unknown 1.659 No 0.760 No 
Tb927.9.4910 AGC/TbPDK1 MSTL7 0.880 1.076 0.978 1.287 1.553 1.935 2.066 2.111 Slow* No 1.583 No 2.645 No 
Tb927.3.3290 Orphan/ MSTL7 Absent 0.962 0.962 1.057 1.119 1.124 0.712 0.475 none unknown 2.451 No 2.435 No 
Tb927.7.3210 Pseudo-Orphan MSTL6 0.870 0.930 0.900 0.911 0.827 0.481 0.313 0.304 Slow U 0.801 No 0.398 Yes 
Tb927.6.4220 CMGC/MAPK/MAPK5 MSTL4 Absent 0.870 0.870 0.890 0.774 1.228 1.238 1.055 none unknown 0.758 No 0.333 Yes 
Tb927.6.3110 CMGC/CDK/CRK11 MSTL4 0.913 0.680 0.797 0.746 0.853 0.608 0.445 0.409 none unknown 1.153 No 2.590 No 
Tb927.7.4090 CMGC/DYRK MSTL7 0.710 0.833 0.772 1.677 1.102 1.443 0.831 1.001 none unknown 1.030 No 0.652 Yes 
Tb927.11.14070 STE/STE11/DFK/KinER1/RDK1 MSTL3 1.078 0.443 0.761 0.512 1.187 1.364 0.200 0.293 Slow No 1.555 No 1.788 No 
Tb927.4.3420 Other/WEE/WEE1 MSTL2 0.651 0.699 0.675 1.003 0.846 0.667 0.486 0.064 Slow* No 1.882 No 1.629 No 
Tb927.11.12420 CMGC/CLK/CLK2/KKT19 MSTL7 0.589 0.738 0.664 0.889 1.147 1.213 0.613 0.326 No test unknown 0.000 Yes 0.200 No 
Tb927.10.13010 AGC/PKAC3 MSTL5 0.606 0.717 0.662 1.052 1.013 0.931 0.896 0.908 none unknown 1.680 No 0.822 No 
Tb927.9.12880 STE/STE20/SLK2 MSTL3 0.371 0.911 0.641 0.856 0.262 0.086 0.050 0.023 Arrest No 0.970 No 0.811 Yes 
Tb927.11.1180 CMGC/CDK/CRK6 MSTL4 0.657 0.608 0.633 0.911 1.062 0.558 0.244 0.289 Slow* No 0.805 No 1.143 No 
Tb927.9.11100/9.11030 AGC/PKAC1 MSTL5 0.562 0.649 0.606 0.899 0.427 0.169 0.042 0.036 Slow C 0.303 No 0.045 Yes 
Tb927.2.1820 CAMK/CAMKL/CAMKL MSTL5 0.591 0.586 0.588 1.030 0.538 0.525 0.166 0.131 none unknown 0.779 No 0.145 Yes 
Tb927.6.5100 Other/PLK/PLK-like MSTL2 0.458 0.713 0.585 0.862 1.344 0.711 0.606 0.539 none unknown 0.739 No 1.108 No 
Tb927.3.3920 Other/AUR/AUK2 MSTL2 0.485 0.622 0.554 0.934 1.191 0.825 0.823 0.358 none unknown 0.105 Yes 0.000 Yes 
Tb927.10.15300 Other/CAMKK/CAMKK MSTL2 0.616 0.446 0.531 0.647 0.369 0.183 0.077 0.141 Slow No 0.668 No 0.698 Yes 
Tb927.11.9290 
Pseudo-
Orphan/ORPHAN/FAZ20 MSTL6 0.478 0.577 0.527 1.012 1.097 0.687 1.081 0.504 none unknown 0.738 No 0.649 Yes 
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Tb927.3.5400 aPK/RIO1 MSTL1 0.405 0.507 0.456 1.371 0.522 0.229 0.087 0.044 Arrest* No 1.299 No 2.017 No 
Tb927.7.2750 CAMK/CAMK3 MSTL5 0.532 0.375 0.453 1.484 0.621 0.201 0.179 0.088 Slow No 0.489 No 0.256 Yes 
Tb927.1.1930 aPK-PIKK/FRAP/TOR4 MSTL1 Absent 0.450 0.450 0.956 0.612 0.491 0.294 0.204 Slow G1/S 0.274 Yes 0.301 Yes 
Tb927.11.850 aPK/Bud32 MSTL1 0.395 0.498 0.447 1.138 0.690 0.259 0.069 0.025 none unknown 2.099 No 1.386 No 
Tb927.10.8420 aPK-PIKK/FRAP/TOR1 MSTL1 0.380 0.472 0.426 0.954 0.359 0.104 0.062 0.041 Slow U 0.677 No 0.480 No 
Tb927.10.1070 CMGC/CDK/CRK1 MSTL4 0.348 0.469 0.409 0.921 0.469 0.240 0.061 0.093 Slow G1/S 0.113 Yes 0.007 Yes 
Tb927.9.6560 pseudo Other/NAK/OTHER/NAK MSTL8 0.331 0.483 0.407 1.186 0.202 0.056 0.040 0.056 Arrest No 0.024 Yes 0.000 Yes 
Tb927.11.9190 Other/VPS15/VPS15 MSTL2 0.472 0.319 0.396 1.488 1.199 0.561 0.143 0.097 none unknown 1.583 No 0.831 No 
Tb927.7.960 CMGC/SRPK/SRPK1 MSTL7 0.387 0.357 0.372 0.837 0.997 0.671 0.588 0.472 none unknown 1.021 No 1.539 No 
Tb927.6.2840 aPK/RIO2 MSTL1 0.278 0.371 0.325 0.767 0.294 0.128 0.031 0.021 Arrest No 0.340 Yes 0.146 Yes 
Tb927.10.10350 STE/STE11/STE11/Bck1p MSTL3 0.270 0.367 0.318 0.863 1.075 1.167 0.871 0.954 none unknown 1.915 No 1.907 No 
Tb927.11.10520 Orphan/KKT2 MSTL6 Absent 0.243 0.243 0.991 0.310 0.107 0.155 0.043 none unknown 0.122 Yes 0.231 Yes 
Tb927.7.5770 AGC/NDR/PK53 MSTL5 0.131 0.344 0.237 0.884 0.893 0.417 0.294 0.085 Slow K/C 0.536 No 2.000 No 
Tb927.10.2040 STE/STE11/CDC15-like MSTL3 0.092 0.316 0.204 0.445 0.366 0.218 0.171 0.037 Death* No 0.805 No 1.210 No 
Tb927.7.3880 CMGC/DYRK/DYRK1 MSTL7 0.140 0.239 0.190 0.759 0.776 0.345 0.128 0.062 none unknown 0.353 No 0.052 Yes 
Tb927.10.14770 CAMK/CAMK1 (AKB1) MSTL5 Absent 0.174 0.174 0.821 1.203 0.612 0.175 0.067 none unknown 0.524 No 1.320 No 
Tb927.2.2430 Other/CK2/CK2A2 MSTL2 0.063 0.277 0.170 0.602 1.074 0.525 0.253 0.046 none unknown 1.280 No 1.873 No 
Tb927.11.14680 aPK-PIKK/ATR MSTL1 0.156 0.181 0.169 1.101 0.708 0.173 0.058 0.063 Arrest* M 0.742 No 0.983 No 
Tb927.7.6220 CAMK/CAMK2 MSTL5 0.114 0.188 0.151 1.003 1.445 0.847 0.112 0.031 Arrest* C 1.314 No 1.243 No 
Tb927.10.7780 CMGC/MAPK/KFR1 MSTL4 0.121 0.168 0.145 1.009 0.881 0.493 0.083 0.053 Slow* No 1.000 No 0.821 No 
Tb927.2.4510 CMGC/CDK/CRK9 MSTL4 0.131 0.156 0.144 0.709 0.216 0.040 0.024 0.028 Death K 0.205 Yes 0.285 Yes 
Tb927.11.2040 STE/STE11/STE11a MSTL3 0.102 0.171 0.136 0.902 0.043 0.021 0.020 0.053 Arrest* No 0.826 No 1.404 No 
Tb927.11.4470 Other/ULK/ULK MSTL2 0.078 0.153 0.115 1.079 1.046 0.504 0.286 0.043 Arrest K/C 0.179 Yes 0.415 Yes 
Tb927.10.14300 STE/STE11/STE11/MRK1 MSTL7 Absent 0.112 0.112 0.986 1.148 0.734 0.299 0.288 none unknown 0.639 No 0.346 Yes 
Tb927.6.4970 CMGC/SRPK/SRPK2 MSTL7 0.050 0.145 0.098 1.129 0.350 0.169 0.111 0.053 Arrest* No 0.702 No 0.680 Yes 
Tb927.7.7360 CMGC/CDK/CRK2 MSTL4 0.082 0.111 0.097 0.696 0.349 0.122 0.071 0.013 Slow* No 1.673 No 2.052 No 
Tb927.4.5310 Other/NEK/NEK12.2 /RDK2 MSTL8 0.071 0.120 0.096 0.956 0.309 0.071 0.030 0.019 Death K/C 0.028 Yes 0.094 Yes 
Tb927.10.13780 CMGC/GSK/GSK3-short MSTL4 0.037 0.080 0.058 0.611 0.418 0.077 0.025 0.023 Arrest M/C 0.054 Yes 0.000 Yes 
Tb927.8.5730 STE/STE20/SLK1 MSTL3 0.044 0.072 0.058 0.689 0.172 0.033 0.018 0.049 Arrest* No 0.946 No 0.559 No 
Tb927.3.690 CMGC/RCK/RCK1/TbMAK MSTL7 0.028 0.081 0.055 0.874 0.636 0.138 0.023 0.023 Death C 0.307 Yes 0.380 Yes 
Tb927.4.420 aPK-PIKK/FRAP/TOR2 MSTL1 Absent 0.052 0.052 1.228 1.017 0.376 0.063 0.030 Death No 1.164 No 0.730 Yes 
Tb927.10.4940 AGC/NDR/PK50 MSTL5 0.023 0.032 0.027 0.746 0.064 0.024 0.016 0.024 Arrest C 1.714 No 0.752 No 
Tb927.9.14430 Other/CK2/CK2A1 MSTL2 0.026 0.026 0.026 1.571 0.602 0.256 0.029 0.034 Arrest K 0.650 No 0.280 Yes 
Tb927.9.1670 Other/AUR/AUK3 MSTL2 0.020 0.030 0.025 1.481 0.723 0.158 0.049 0.033 Slow M/C 0.814 No 0.283 Yes 
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6 / 6 
Family/Name 
Sub 
library 
In vivo Tet+/Tet- (48 h) In vitro Tet+/Tet- Jones 72h Alsford 72h Alsford 144h 
Gene ID Repl 1 Repl 2 Mean 24h 48h 72h 96h 120h Growth 
Cell 
cycle 
Tet+/Tet- Signif. Tet+/Tet- Signif. 
Tb927.9.10920 Orphan/PK6/KKT3 MSTL6 0.024 0.020 0.022 1.268 0.567 0.045 0.021 0.024 Arrest No 0.301 Yes 0.209 Yes 
Tb927.10.4990 CMGC/CDK/CRK3 MSTL7 0.011 0.030 0.021 0.276 0.048 0.027 0.016 0.026 Death M 0.000 Yes 0.000 Yes 
Tb927.7.6310 Other/PLK/PLK1 MSTL2 Absent 0.020 0.020 0.636 0.045 0.018 0.030 0.019 none unknown 0.000 Yes 0.030 Yes 
Tb927.3.2440 AGC/AGC1 MSTL8 0.007 0.029 0.018 0.966 0.851 0.472 0.145 0.051 Death C 0.450 No 0.203 Yes 
Tb927.11.5340 CMGC/CMGC1 MSTL7 0.002 0.025 0.013 0.719 0.389 0.071 0.017 0.019 Slow* M 1.128 No 2.507 No 
Tb927.4.5180/8.7220 Other/TLK*/TLK1&2 MSTL2 0.001 0.020 0.010 1.103 0.283 0.032 0.016 0.028 Death M/C 0.214 Yes 0.615 No 
Tb927.10.5140 CMGC/MAPK/MAPK6 (ERK8) MSTL4 0.006 0.013 0.010 1.165 0.157 0.011 0.025 0.027 Death C 0.036 Yes 0.023 Yes 
Tb927.5.790/5.800 CK1/CK1*/CK1.1/CK1.2 MSTL5 0.000 0.012 0.006 0.662 0.278 0.026 0.008 0.022 Death K/C 0.102 Yes 0.022 Yes 
Tb927.11.12410 CMGC/CLK/CLK1/KKT10 MSTL7 0.000 0.011 0.006 1.239 0.567 0.062 0.024 0.034 Death M/C 0.000 Yes 0.000 Yes 
Tb927.11.8220 Other/AUR/AUK1 MSTL2 0.000 0.010 0.005 0.732 0.172 0.030 0.022 0.016 Death M 0.222 Yes 0.029 Yes 
                 
            Arranged in increasing in vivo loss of fitness (decreasing mean Tet+/Tet- between replicates 1 and 2). 
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3.3.5 In vitro results and correlation with the literature 
The in vitro RITseq screen comprised three replicates at 5 different time points, 
corresponding to 5 consecutive days upon RNAi induction (Figure 3-2). Examining 
library behaviour within such a timeframe permits comparisons with other 
screens available in the literature (Jones et al. 2014, at 72h; Alsford et al. 2011, 
at 73 and 144h), thereby assessing reliability of our approach and providing a 
more detailed scrutiny of the loss of fitness progression with time. As this RITseq 
was conducted in parallel to the in vivo screen (that will be described below), 
following the same sample processing and data analysis treatment, it also 
provides a more meaningful dataset to analyse divergence between in vitro and 
in vivo behaviour than the previously published studies (which either did not rely 
on a single, defined RNAi target for each protein kinase gene, or analysed 
growth by alamar blue and not relative abundance of the protein kinase RNAi 
cells in the population). The results of read mapping (summary and raw data in 
Table 3-3 and Table S3 respectively) show an increase with time of both the 
number of protein kinases that displayed loss of fitness (as defined by 
induced/uninduced ratios <0.6, Figure 3-6A), and the extent of loss of individual 
protein kinases from the population (Table 3-3).  
We showed in Figure 3-7 that, compared to the in vivo data set, in vitro ratios 
with a P value supporting a significant result are less abundant, see Table S4. 
However, when normalised reads were plotted (uninduced versus induced) for 
the RNAi lines showing a loss of fitness at each of the time points analysed in 
vitro, intrinsic reproducibility was still acceptable, Figure 3-8A-E. Little read-
count variability could be observed per gene and condition (Tet+ or Tet-) across 
different mice. The percentage of the kinome whose depletion caused a growth 
defect increased with time: at 24 h just 5 kinases showed a phenotype, 3.4% of 
the kinome; after 48 h this number increased to 16.4%, then 26.5% at 72h, 32.8% 
at 96h and 36.7% after 120h of RNAi induction. Amongst these protein kinases 
that show loss of fitness, those that may be interesting are highlighted later, in 
comparison with the in vivo results, but results are summarized in Table 3-3. 
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Figure 3-8. Reproducibility of the in vitro RITseq screen.  
A-E. Breakdown of results for loss of fitness RNAi lines defined by Tet+/Tet- <0.6 
within each of the individual in vitro biological replicates. Depicted average and 
range of normalized counts for the 3 cultures analyzed per condition (induced or 
uninduced) at every time point and per RNAi target. F. Venn diagram showing 
the overlap between the number of loss-of-fitness protein kinase depletions 
identified with the kinome-wide in vitro RITseq screen after 72 h of RNAi 
induction and the two in vitro studies available in the literature (Alsford et al., 
2011; Jones et al., 2014) at the same time point. 
Comparing the in vitro screen with available data in the literature, 38 out of the 
47 lines found at the 72 h time point that showed loss of fitness had also been 
identified in the 72 h in vitro Alamar blue screen performed by Jones et al. 
(2014) with the same library (Figure 3-8F). Overlap with the genome-wide RITseq 
by Alsford et al. (2011) was less pronounced, with only 18 of the protein kinases 
identified in this study being detected by Alsford, who additionally found 
another 23. Overlap between the kinome-wide and whole-genome screens is 
more evident for protein kinase depletions causing the most deleterious growth 
phenotypes. For instance, protein kinases located at the bottom of Table 3-3, 
such as AUK1, KKT10, CK1.2 or ERK8, were also identified by Alsford et al. (2011) 
after three and six days of induction. Each of these has been validated as 
essential kinases in the literature (Merritt et al., 2014) and, in the kinome-wide 
RITseq produced the strongest in vivo loss of fitness (Tet+/Tet- < 0.001). For 
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each, in vitro loss was observable from 48 h onwards and they were defined by 
Jones et al. (2014) as “death” phenotypes with the same library.  
In order to test further whether clones growing as a pool in culture acted the 
same as individually in culture, 14 of the lines used in the pool were grown 
independently to make triplicate growth curves. Ratios of induced and 
uninduced parasite counts were calculated and compared to RITseq 
induced/uninduced ratios per protein kinase gene in every independent time 
point (24 h, 48 h, 72 h and 96 h). Paired (2-tailed) t tests were performed 
comparing ratios of the growth curve and the RITseq triplicates. Results are 
plotted in Figure 3-9, showing good correspondence between the two datasets, 
with only a few exceptions from 72 h (KKT2, DYRK and Bud32) where 
differenceswere found to be significant. 
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Figure 3-9. Individual cell line versus library pool, comparative of loss of 
fitness.  
Depiction of Tet+/Tet- ratios obtained per time point for 14 different protein 
kinase lines, using growth curves counting cells in a neubauer hemocytometer 
(independent lines) and after RITseq analysis (pool). * p < 0.05 and ** p < 0.01 
using T test comparing individual and pooled results. 
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3.3.6 In vivo results and correlation with the literature  
The in vivo experiment (comprising 12 mice, 6 uninduced and 6 induced) was 
repeated to provide two biological replicates. 72 h post infection (48 h post RNAi 
induction), parasites were recovered with DEAE cellulose (Lanham and Godfrey, 
1970) and gDNA was purified from them.  
A few differences are significant between the experimental procedures in the 
two replicates, which were sequenced in different platforms. PCR enrichment 
carried out in Replicate 1 was conducted with non-barcoded OL4161 primer. PCR 
products from each sample were processed separately, being sheared, size-
selected (~106 nucleotides) and labelled with Ion Torrent adapters according to 
manufacturer’s instructions. After emulsion PCR and DNA sequencing, in silico 
processing permitted filtration of reads selecting those containing a 9-nucleotide 
tag (GCCAACTTT). This was indicative of PCR amplification with OL4161, which 
certified its origin in the RNAi cassette. 20% of the reads were finally usable. 
Induced/control ratios acquired values 1 fold lower than these of Replicate 2 
(below). In addition, infection of one of the mice was unsuccessful, and so we 
only used 5 uninduced controls. 
In the second replicate we optimized the approach. 14 different 6-nucleotide-
long barcodes were attached to the OL4161 primer, Figure 3-5. A distinct 
barcoded primer was used to enrich the RNAi target in T. brucei gDNA coming 
from different mouse infections, Table S5. As discussed before, this approach 
enabled pooling 14 PCR products, and tagging them with a single pair of Illumina 
adapters. Reads could be assigned to the original samples later, during the data 
analysis process. We reasoned, given the RNAi amplicon size, it was not 
necessary to fragment the sample. This enabled, after in silico filtration, an 
enhanced recovery of 65-70% useful reads per experimental condition. All the 12 
mice were successfully infected this time. An extra library, MSTL9, was added to 
the pool used in Replicate 2, introducing cell lines that were missed or contained 
the wrong construct after analysis of Replicate 1.  
A total of 157 RNAi cell lines were detected in the first in vivo experiment, 
including a number of cell lines that were generated using the traditional 
restriction/ligation system and were remade to include the Gateway® sites 
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required for the PCR (Table 3-2). However, 24 further cell lines were found to be 
missing, Figure 3-10A. A schematic representation of the troubleshooting 
strategy undertaken with all these lines is depicted in Figure 3-10B. When an 
RNAi target sequence was missing, the individual line was defrosted, gDNA 
purified and OL4161 PCR conducted to see whether they contained an insert. If 
the insert was present, we sequenced it. If the insert was absent, we defrosted 
the second clone available (transfected with the same construct) and repeated 
the strategy. If the insert in ether clone was not as expected, we sequenced the 
original plasmid. If the plasmid was the right one, we transfected again. If the 
plasmid was mislabelled, we generated the plasmid from scratch. Three of the 
missing lines were in the batch remade from the older ligation system (Table 
3-2). Once the missing protein kinase RNAi cells were developed (Table 3-4) and 
added to the second experiment as an additional sub-library, MSTL9, we were 
able to detect 177 protein kinases. Five protein kinases missing in Replicate 1 
contained the right insert, and so they were added again to the pool for the 
second experiment: Tb927.11.12310 (CRK12), Tb927.3.5180 (aPK/A6), 
Tb927.11.7160 (CRK8), Tb927.11.5860 (Orphan) and Tb927.9.2240 (Pseudo-
Orphan). After RITseq, they were still in low abundance, making assignment of 
reads inaccurate and were therefore excluded from the analysis; see Table 3-1 
and raw data (Tables S2-S3). Analysing the in vivo data based on the 0.6 
induced/uninduced threshold, 53 protein kinase genes were identified that 
showed a relative depletion of reads in the induced samples, indicating a loss of 
fitness 48 h after RNAi induction in one or both of the experiments. Forty genes 
showed such loss of fitness in both of the biological replicates (Table 3-3), with 6 
seen only in Replicate 1 and eight only in Replicate 2 (6 of which were absent in 
the first experiment). 
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Figure 3-10. Defective RNAi targets in the pTL library.  
A. 1% Agrose gel showing RNAi enriching PCR (OL4161), using the water and 
positive controls (sTL0082, ATR) for a number of protein kinases undetectable in 
the in vivo RITseq Replicate 1. B. Schematic representation of the trouble 
shooting strategy used to solve this problem before the second library pool. 
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Table 3-4. List of RNAi targets that were not detected in the first in vivo 
experiment, and troubleshooting strategy. 
RNAi target Cell line PTL Family/Name Sublibrary Insert Action MSTL9 
Tb927.8.1690 sTL0006 4 Other/NEK14 MSTL8 No insert Remade/retransfected STL769 
Tb927.11.15010 sTL699 10 Other/NEK21 MSTL8 Wrong insert Remade/retransfected STL762 
Tb927.10.3340 sTL0084 13 Orphan MSTL6 No insert 2nd clone used sTL0089 
Tb927.10.1460 sTL0071 38 Orphan MSTL6 No insert Missing Missing 
Tb927.11.10520 sTL0069 39 Orphan MSTL6 Wrong insert Remade/retransfected STL783 
Tb927.5.1650 sTL122 88 CMGC/DYRK MSTL7 No insert Remade/retransfected STL772 
Tb927.6.4220 sTL144 99 CMGC/MAPK5 MSTL4 No insert 2nd clone used sTL145 
Tb927.7.5220 sTL177 118 STE11/Forkhead MSTL3 No insert Remade/retransfected STL774 
Tb927.8.6810 sTL195 124 STE/STE11 MSTL3 No insert Remade/retransfected STL776 
Tb927.10.14300 sTL616 128 STE/STE11 MSTL7 No insert Remade/retransfected STL785 
Tb927.4.4970 sTL374 140 aPK MSTL1 No insert 2nd clone used sTL375 
Tb927.8.7450 sTL263 141 aPK MSTL1 No insert Missing Missing 
Tb927.4.420 sTL300 148 aPK-PIKK/TOR2 MSTL1 No insert 2nd clone used sTL301 
Tb927.7.6310 sTL213 165 Other/PLK MSTL2 Wrong insert Remade/retransfected STL777 
Tb927.3.1630 sTL271 173 CK1/CK1 MSTL5 Wrong insert Remade/retransfected STL767 
Tb927.2.5230 sTL225 176 pseudo CAMK MSTL8 Wrong insert Remade/retransfected STL780 
Tb927.10.14770 sTL329 179 CAMK/AKB1 MSTL5 No insert Plasmid retransfected STL793 
Tb927.9.1570 sTL227 181 CAMK MSTL5 No insert 2nd clone used sTL228 
Tb927.10.3900 sTL328 187 CAMK/CAMKL MSTL5 No insert Plasmid retransfected STL791 
Tb927.3.2060 sTL351 203 STE MSTL3 Wrong insert Remade/retransfected STL787 
Tb927.7.3580 sTL708 235 Other/NEK11 MSTL8 No insert 2nd clone used sTL709 
Tb927.3.3290 sTL593 237 Orphan MSTL7 No insert 2nd clone used sTL594* 
pTL= plasmid code 
 
3.3.7 Reproducibility of the in vivo data 
Linear regression across the two in vivo experiments showed good reproducibility 
for the complete dataset (R2=0.77; p<0.0001, Figure 3-11A). Indeed, 
reproducibility was substantially better if only the 49 RNAi targets with an 
average induced/uninduced ratio <0.6 between the 2 biological replicates were 
compared (R2=0.82; p<0.0001, Figure 3-11A and B). Regression values for cell 
lines with fitness ratios over the 0.6 threshold decreased to R2=0.22. The 
intrinsic reproducibility across mice for both control and induced groups per 
gene identifier was also excellent within the two biological replicates (see 
means and ranges displayed in Figure 3-11C).   
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Figure 3-11. Intrinsic reproducibility of the in vivo RITseq and correlation 
between in vivo and in vitro experiments.  
A. Bootstrap medians of ratios calculated between induced and uninduced in 
vivo samples plotted per RNAi target assessing regression of both biological 
replicates. Highlighted in red are those with a loss of fitness in the two 
experiments, in black those with a loss of fitness in one only, and in blue those 
without a loss of fitness. B. As panel A but focusing on the RNAi cell lines giving 
a loss of fitness (ratio <0.6) in at least one of the 2 biological replicates. Includes 
depicted correlation with the in vitro screen previously published by Jones et al. 
(2014) with the same library (slow growth, cell cycle arrest or death) 
highlighting protein kinases whose depletion produced loss of fitness only in 
vivo. C. Breakdown of results for loss of fitness RNAi lines within each of the 
individual in vivo biological replicates. Depicted average and range of 
normalized counts for the 6 mice analyzed per condition (Tet+ or Tet-) and per 
RNAi target. 
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Thirty-five out of 42 RNAi lines displaying loss fitness in the in vitro alamar blue 
screen (Jones et al., 2014) also had a loss of fitness in vivo, with the most 
pronounced ‘death’ or ‘cell cycle arrest’ phenotypes in vitro also having the 
most significant loss of fitness in vivo (Figure 3-11B and Figure 3-12). Among the 
seven RNAi lines displaying loss of fitness in vitro but not in vivo (this study), six 
were classified as “slow growth” and they only had significant growth 
retardation after 72 h of RNAi induction, which would not have been apparent in 
the 48 h timescale of the in vivo screen. In the whole genome in vitro RNAi 
screen described previously (Alsford et al., 2011), loss of bloodstream T. brucei 
fitness was assessed in culture after 3 and 6 days of RNAi induction.  Only 19 
(46%) of the loss of fitness-associated protein kinase genes observed in the 
Alsford study were also seen in the 48 h in vivo RITseq screen (Figure 3-12B). 
 
Figure 3-12. Comparison of in vitro and in vivo kinome-wide screens. 
A. In vitro growth curves for four independent RNAi cell lines with (from left to 
right) no growth defect, slow growth phenotype, growth arrest and cell death. 
Median ratios of induced/uninduced (Tet+/Tet-) for the in vivo RITseq are 
shown. B. Venn diagram showing the number of protein kinases with a loss of 
fitness in the present in vivo RITseq and two published in vitro RNAi studies 
(Alsford et al., 2011; Jones et al., 2014). C. Overlap between the number of cell 
lines with a loss-of-fitness phenotype detected in vivo after 48 h of induction 
and those detected with the in vitro RITseq over 120 h of RNAi. 
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In order to validate the observed correlation between the published in vitro loss-
of-fitness phenotypes and those observed in vivo, growth analysis of 4 cell lines 
showing no growth defect, slow growth, arrest and death, as defined in Jones et 
al. (2014), was performed (Figure 3-12A). A good correlation was observed 
between the in vitro growth of individual lines and the median ratios of 
induced/control for the in vivo RITseq, in concordance with the analysis 
performed with the in vitro RITseq data to assess correlation between pooled 
and independent cell lines (Figure 3-9). 
3.3.8 Comparison of the kinome wide RITseq in vivo and in vitro 
Comparing the protein kinases that showed loss of fitness in vitro and in vivo in 
the kinome-wide RITseq revealed pronounced overlap, though it was clear that 
there was a delay in the manifestation of loss of fitness in vitro when compared 
with the in vivo infection (Figure 3-12C). Data for all genes can be observed in 
detail in Table 3-3. A total of 49 protein kinases caused a fitness defect in vivo 
after 48h of RNAi. However, in vitro, the numbers required longer to rise. After 
24 h RNAi, 5 protein kinases had a reduced count in the induced compared with 
the uninduced in vitro. Three of them, all STE11 kinases, recovered later and 
the reduced counts may therefore be a product of stochastic fluctuation. 
Interestingly, one of these three is RDK1, reportedly triggering differentiation to 
procyclic forms after 72 h of RNAi induction (Jones et al., 2014); this protein 
kinase showed a phenotype later, with an increasing loss of fitness from 96 h. 
The other two protein kinases, Tb927.10.2040 (STE11/CDC15-like) and CRK3, 
maintained an in vitro loss of fitness for the complete 120 h time frame. After 
48 h RNAi, 29 cell lines had an in vitro loss of fitness phenotype, 26 of which 
were also found in vivo, providing a 59% overlap between experiments. At the 72 
h time point, 47 cell lines had an in vitro loss of fitness phenotype, 41 of which 
had been already observed in vivo after 48 h of induction (83% overlap). After 96 
h RNAi, we found 58 cell lines with a loss of fitness, 45 of which had already a 
phenotype in vivo at 48 h (91% overlap). By 120 h there was 97% overlap 
between RNAi lines showing loss of fitness in vitro and in vivo (Figure 3-12C). 
Only STE11/Bck1p showed a phenotype in vivo after 48 h that neither could be 
observed in vitro (in the whole 120 h experiment), nor was reported in the 
literature before. 
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The 49 genes with a mean < 0.6 of the median induced/uninduced ratios in vivo 
obtained in each of the two independent experiments were followed up in the 
next analyses (Table 3-5 and Figure 3-13). 
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Table 3-5. Meta-analysis of the 49 protein kinases with a loss of fitness in vivo.  
 
Gene ID Group/Family Name 
Loss of ftiness reported in the literature 
Including Jones (2014) & Alsford (2011) 
Value for the HAT box 
Peña (2015) 
Gene ID of L. major 
orthologues 
Gene ID of T. cruzi 
orthologues 
AGC 
Tb927.3.2440 AGC1 Yes - LmjF.25.2340 0 
Tb927.7.5770 PK53 Yes - LmjF.06.1180 0 
Tb927.10.4940 PK50 Yes - 0 TcCLB.510291.40 
aPK 
Tb927.3.5400 RIO1 Yes - LmjF.29.0240 TcCLB.510141.4 
Tb927.11.850 Bud32 Novel - LmjF.25.0870 TcCLB.506925.260 
Tb927.6.2840 RIO2 Yes - LmjF.30.1360 TcCLB.511753.70 
Tb927.11.14680 ATR Yes - LmjF.32.1460 TcCLB.506223.120 
Tb927.1.1930 TOR4 Yes - LmjF.20.1120 
TcCLB.508997.20,  
TcCLB.511435.49,  
TcCLB.506475.14,  
TcCLB.509989.10 
Tb927.10.8420 TOR1 Yes 
Human orthologue 
targeted 
LmjF.34.4530,  
LmjF.36.6320 
TcCLB.508549.30,  
TcCLB.508551.10 
Tb927.4.420 TOR2 Yes - 
LmjF.34.4530,  
LmjF.36.6320 
TcCLB.508549.30,  
TcCLB.508551.10 
CAMK 
Tb927.7.2750 CAMK3 Yes - LmjF.22.0810 TcCLB.510525.10 
Tb927.10.14770 AKB1 Yes - LmjF.19.0140 TcCLB.506211.220 
Tb927.7.6220 CAMK2 Yes 
Human orthologue 
targeted 
LmjF.17.0060 TcCLB.506513.50 
Tb927.2.1820 CAMKL Novel 
Divergent from human 
orthologue 
LmjF.33.1710 TcCLB.510257.130 
CK1 Tb927.5.790/5.800 CK1.1/CK1.2 Yes 
Human orthologue 
targeted 
LmjF.35.1010 
TcCLB.504929.10,  
TcCLB.504929.15,  
TcCLB.504929.15,  
TcCLB.508541.230,  
TcCLB.508541.240 
CMGC 
Tb927.11.5340 CMGC1 Yes - LmjF.24.0670 TcCLB.504125.90 
Tb927.10.1070 CRK1 Yes 
Human orthologue 
targeted 
LmjF.21.1080,  
LmjF.36.0550,  
LmjF.18.1080,  
TcCLB.504181.40,  
TcCLB.506677.20,  
TcCLB.509805.10 
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Gene ID Group/Family Name 
Loss of ftiness reported in the literature 
Including Jones (2014) & Alsford (2011) 
Value for the HAT box 
Peña (2015) 
Gene ID of L. major 
orthologues 
Gene ID of T. cruzi 
orthologues 
GMGC 
    
LmjF.35.3960,  
LmjF.35.4010 
 
Tb927.2.4510 CRK9 Yes 
Divergent from human 
orthologue 
LmjF.27.1940 TcCLB.509099.150 
Tb927.7.7360 CRK2 Yes - LmjF.05.0550 TcCLB.510609.70 
Tb927.10.4990 CRK3 Yes 
Human orthologue 
targeted 
LmjF.21.1080,  
LmjF.36.0550,  
LmjF.18.1080,  
LmjF.35.3960,  
LmjF.35.4010 
TcCLB.504181.40,  
cCLB.506677.20,  
TcCLB.509805.10 
Tb927.11.12410 CLK1/KKT10 Yes - 
LmjF.09.0400.  
LmjF.09.0410 
TcCLB.511127.320,  
TcCLB.511127.330 
Tb927.7.3880 DYRK1 Novel 
Divergent from human 
orthologue 
LmjF.14.1070,  
LmjF.21.1650 
TcCLB.506869.60 
Tb927.10.13780 GSK3-short Yes 
Human orthologue 
targeted 
LmjF.18.0270 0 
Tb927.10.7780 KFR1 Yes - LmjF.36.6470 TcCLB.504167.30 
Tb927.10.5140 MAPK6 (ERK8) Yes 
Human orthologue 
targeted 
LmjF.36.0720 TcCLB.510295.50 
Tb927.3.690 RCK1 Yes - 
LmjF.19.0180,  
LmjF.27.0100 
TcCLB.506211.180,  
TcCLB.509231.20 
Tb927.7.960 SRPK1 Novel - LmjF.26.0980 
TcCLB.477079.10,  
TcCLB.508215.3 
Tb927.6.4970 SRPK2 Yes - LmjF.30.3580 0 
ORPHAN 
Tb927.11.10520 KKT2 Yes Parasite-specific LmjF.36.5350 TcCLB.510285.70 
Tb927.9.10920 PK6/KKT3 Yes Parasite-specific LmjF.35.4050 0 
OTHER 
Tb927.3.3920 AUK2 Yes - LmjF.29.1330 TcCLB.503685.10 
Tb927.9.1670 AUK3 Yes Divergent LmjF.26.2440 
TcCLB.506715.10,  
TcCLB.510349.80 
Tb927.11.8220 AUK1 Yes 
Human orthologue 
targeted 
LmjF.28.0520 0 
Tb927.10.15300 CAMKK Yes - LmjF.19.0590 TcCLB.506505.40 
Tb927.2.2430 CK2A2 Novel - LmjF.02.0360 TcCLB.503513.10 
Tb927.9.14430 CK2A1 Yes 
Human orthologue 
targeted 
LmjF.35.1730 TcCLB.510761.60 
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In red, not identified in vitro with the same library by Jones et al (2014). 
 
Gene ID Group/Family Name 
Loss of ftiness reported in the literature 
Including Jones (2014) & Alsford (2011) 
Value for the HAT box 
Peña (2015) 
Gene ID of L. major 
orthologues 
Gene ID of T. cruzi 
orthologues 
OTHER 
Tb927.4.5310 NEK12.2 /RDK2 [16,17] 
Divergent from human 
orthologue 
LmjF.31.2960 0 
Tb927.6.5100 PLK-like Novel - 0 TcCLB.506945.350 
Tb927.7.6310 PLK1 [Yes 
Human orthologue 
targeted 
LmjF.17.0790 TcCLB.506513.160 
Tb927.4.5180/8.7220 TLK1&2 Yes - LmjF.31.2860 TcCLB.510597.9 
Tb927.11.4470 ULK Yes 
Human orthologue 
targeted 
LmjF.13.0440 TcCLB.504089.54 
Tb927.11.9190 VPS15 Novel - LmjF.28.1760 0 
PSEUDO 
Tb927.9.6560 OTHER/NAK Yes - LmjF.15.0770 TcCLB.504883.10 
Tb927.11.9290 ORPHAN/FAZ20 Novel Parsite-specific LmjF.28.1650 0 
STE 
Tb927.10.2040 STE11/CDC15-like Yes - LmjF.21.0270 TcCLB.508949.50 
Tb927.10.10350 STE11/Bck1p Novel 
Human orthologue 
targeted 
LmjF.05.0390 0 
Tb927.11.2040 STE11a Yes - LmjF.27.1370 0 
Tb927.10.14300 STE11/MRK1 Novel - LmjF.32.0120 TcCLB.506525.140 
Tb927.8.5730 SLK1 Yes 
Human orthologue 
targeted 
LmjF.16.0300 TcCLB.506743.160 
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3.3.9 Classification of protein kinases required for optimal growth 
in vivo after 48 h of induction 
The 49 protein kinases whose depletion caused an in vivo loss of fitness are 
distributed across all the major protein kinase families. There are 40 ePKs, 7 
aPKs and 2 putative pseudo-kinases. Two ePKs and one of the pseudo-kinases are 
considered “orphan” (without clear identity with known orthologues in 
Saccharomyces cerevisiae, Caenorhabditis elegans, Drosophila melanogaster or 
Homo sapiens) and are likely to be kinetoplastid-specific. All of the 49 protein 
kinases have orthologues in either Leishmania major or Trypanosoma cruzi or 
both, and 13 are closely related to human orthologues targeted by a compound 
in the HAT box with potential to be modified for specificity (Peña et al., 2015), 
Figure 3-13, Table 3-5. Among these 13 we found, for example, AUK1, which 
showed the most intense in vivo phenotype in our in vivo screen (Table 3-3); this 
protein kinase is involved in cell cycle progression and is encoded by a single 
copy gene in kinetoplastids (Brown et al., 2004) with active inhibitors found both 
in T. brucei and L. major (Patel et al., 2014). We also see CK1.2, CRK1, CRK3, 
GSK3-short, ERK8 or PLK, all of which have been already proven interesting drug 
targets in T. brucei (Merritt et al., 2014). Finally there is Bck1p, which is one of 
the novel reports in this thesis, with a loss of fitness in vivo, which materializes 
more quickly and more intensely than in vitro, Table 3-3. 
After extracting their sequences from TritrypDB, and alignment in three 
different platforms (see material and methods), protein kinase domains were 
used to build a neighbour-joining phylogenetic tree, which demonstrates 
variable levels of sequence identity between orthologues present in different 
kinetoplastid parasites. Thirty-five of the protein kinases that were identified in 
the Alamar blue kinome-wide RNAi screen have been discussed previously (Jones 
et al., 2014), and so details will not be provided here. Three of these genes 
were identified in the whole-genome RITseq (Alsford et al., 2011): PLK1 and 
KKT2, which have been shown to be essential in other studies (Hammarton et 
al., 2007; Akiyoshi and Gull, 2014), and AUK2, which only showed a loss of 
fitness in vitro after 120 h of induction (Table 3-3). 
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Figure 3-13. Neighbour-Joining phylogenetic tree of T. brucei protein kinases 
showing RNAi dependent loss-of-function in vivo with their T. cruzi and L. 
major orthologues.  
Red bars represent aPKs and blue bars ePKs. Protein kinase lines causing a 
phenotype in vivo not reported before in vitro (Alsford et al., 2011; Jones et al., 
2014) after RNAi induction are inscribed within a red box; those with a human 
orthologue targeted by a compound in the HAT box (Peña et al., 2015) are 
labelled an asterisk; L. major and T. cruzi orthologues are labelled with a green 
circle and a red square, respectively. Grey scale describes intensity of the loss of 
fitness according to the mean Tet+/Tet- ratio. 
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3.3.10 Protein kinases essential in vivo but not in vitro 
In addition to AUK2, we identified 11 other cell lines where depletion of the 
protein kinase led to a loss of fitness in vivo, but not in either the kinome- 
(Jones et al., 2014) or the genome- wide (Alsford et al., 2011) in vitro RNAi 
studies (Table 3-5 and Figure 3-13). In order to validate the observation in vitro, 
independent growth curves were performed in culture for each of the individual 
RNAi cell lines used in the inoculum pool. Where a growth defect was not 
detected after 48 h of RNAi induction in vitro, parasitemia was assessed in mice 
after infection with the selected clone for 96 h (Figure 3-14). Tb927.10.14770 
(AKB1) was not examined as has been shown to be an active kinase involved in 
regulation of cytokinesis and cell division in bloodstream and procyclic forms 
upon knock down from 48 h onwards (Inoue et al., 2015). The reason why it was 
not detected by Jones et al. is that the original cell line used in Replicate 1 did 
not contain an insert (Table 3-4). Another protein kinase gene, Tb927.7.3880 
(DYRK), had a clear and unexpected growth defect after 48 h of RNAi induction 
in vitro (Figure 3-14A), and so this gene was not considered further. For the 
other protein kinase genes, where no growth defect was detected after 48 h of 
RNAi induction in vitro, parasitemia was assessed for 72-96 h in mice, with or 
without induction of RNAi, after inoculation of each individual selected cell line 
(Figure 3-14B).  
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Figure 3-14.  Validation of RITseq in vivo-mainly loss of fitness phenotypes.  
For each RNAi cell line, cumulative in vitro growth curves are shown on the left 
hand side; and in vivo parasitemia on the right hand side. Growth curves were 
built in triplicate. In vitro cultures started at 104 cells x ml-1. Mice were culled if 
parasitemia reached 108 cells x ml-1. A. Tb927.7.3880 (DYRK). B. 9 other cell 
lines with a loss of fitness phenotype in vivo that is more pronounced than the 
one observed in vitro. * p < 0.05 and ** p < 0.01 using T-test. 
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BLAST alignment with protein sequences in other eukaryotes allowed a tentative 
proposal of the putative function of each protein kinase based on gene ontology 
(Table 3-6). Tb927.11.9290 (Pseudo-unique), Tb927.2.1820 (CAMKL), 
Tb927.11.850 (aPK/Bud32) and Tb927.11.9190 (Other/VPS15) displayed some 
evidence for growth retardation after RNAi in vitro (Figure 3-14B) but, in each 
case, the extent of growth impairment or death was more severe in vivo and 
arose more quickly. For each of the remaining six cell lines there was no 
evidence of RNAi-induced growth retardation in vitro. For two of the genes, 
Tb927.3.3920 (AUK2) and Tb927.10.10350 (STE11/Bck1p), RNAi caused growth 
retardation in vivo from 48 h, indicating a loss of fitness. For three other genes, 
Tb927.2.2430 (Other/CK2A2), Tb927.7.960 (CMGC/SRPK1) and Tb927.10.14300 
(STE11/MRK1), the loss of fitness after in vivo RNAi was even more severe, since 
a decrease in parasitemia or clearance was seen before 96 h (Figure 3-14B). 
Taken as a whole, these growth curves validate the kinome-wide RITseq both in 
vivo and in vitro for nine of eleven predicted protein kinases (Table 3-3). 
Table 3-6. Predicted function of in vivo only protein kinases based on gene 
ontology with other eukaryotes.  
pBLAST Organism Identity E value Protein Putative function 
Tb
9
2
7
.2
.2
4
3
0
 (
C
K
2
A
2
) 
T. brucei 100% 0 casein kinase II,  chain (CK2A2)  ·  Proven kinase activity. 
·  Mainly nucleolar but ubiquitous (Jensen 
et al., 2007), controlled by distribution and 
abundance (Pinna, 2003): stress-induced 
mobilization (Gerber et al., 2000; Davis et 
al., 2002). 
·  Gene expression/protein synthesis: 
survival, differentiation and proliferation 
(>300  substrates) (Meggio and Pinna, 
2003).  
·  Downregulation causes autophagy 
through PI3K/AKT/TOR pathway (Olsen, 
Svenstrup and Guerra, 2012; Hales, Taub 
and Matherly, 2014; Sanchez-Casalongue et 
al., 2015).  
·  Intersects with mitogen and stress-
activated protein kinases (Shi et al., 2009; 
Jacks and Koch, 2010). 
L. major 60% 4x10-148 putative casein kinase II,  chain 
T. cruzi 73% 0 casein kinase II,  chain 
S. cerevisiae 48% 4x10-95 Cka2p 
C. elegans 48% 1x10-87 Casein kinase II subunit  
Human 51% 10-109 Chain A, Crystal Structure Of Ck2 
Tb
9
2
7
.1
0.
1
4
3
00
 
(S
TE
11
/M
R
K
1
) 
T. brucei 100% 0 
MEKK-related kinase 1, putative 
(MRK1)  
·  Member of the HOG pathway (Zhi et al., 
2013) 
·  Response to stress signalling, mainly 
hyperosmotic shock (through actin 
recovery pathway (Zhi et al., 2013) 
·  Essential for promastigote survival, in 
Leishmania (Agron, Reed and Engel, 2005)  
L. major 37% 6x10-174 
MEKK-related kinase 1, putative 
(MRK1) 
cruzi 50% 0 
MEKK-related kinase 1, putative 
(MRK1) 
S. cerevisiae 36% 1x10-43 Ssk2p 
C. elegans 34% 7x10-37 Germinal Center Kinase family 
Human 36% 1x10-46 MAPKKK19 isoform 3 
Tb
9
2
7
.1
0.
1
0
3
50
 
(S
TE
11
/B
ck
1
p
) 
T. brucei 100% 0 protein kinase, putative ·  Contains 8 amino terminal “MORN motif” 
sequences: subcellular localization, 
membrane fusion, fission and mobility in 
other organisms (Lee, Han and Hur, 2010). 
·  Cell integrity via MAPK pathway in 
response to growth factors and stress 
(hyperosmotic, oxidative and sheer fluid 
L. major 60% 0 protein kinase, putative 
T. cruzi 73% 0 protein kinase, putative 
S. cerevisiae 41% 8x10-55 Bck1p 
C.elegans 39% 2x10-44 hypothetical protein F59A6.1 
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Human 45% 4x10-65 MEK kinase 3  
shocks) (Widmann et al., 1999) 
·  Direct activation of the stress-activated 
protein kinase (SAPK) and extracellular 
signal-regulated protein kinase (ERK) 
pathways (Ellinger-Ziegelbauer et al., 1997) 
Tb
9
2
7
.1
1.
8
5
0
 
(a
P
K
/B
u
d
3
2
) 
T. brucei 100% 0 protein kinase, putative ·  KEOPS/EKC complex: translational 
regulation throughout tRNA modification 
(Srinivasan et al., 2011; Rojas-Benítez, Ibar 
and Glavic, 2013). 
·  Transducer for TOR activation that, in 
turn, has also been related with autophagy 
and endocytosis under stress conditions 
(Ibar et al., 2013; Rojas-Benítez, Ibar and 
Glavic, 2013). 
L. major 48% 1x10-70 protein kinase, putative 
T. cruzi 63% 2x10-103 protein kinase, putative 
S. cerevisiae 32% 4x10-24 Bud32p 
C.elegans 35% 2x10-40 
Uncharacterized protein 
CELE_F52C12.6 
Human 40% 2x10-44 TP53 regulating kinase 
Tb
9
2
7
.1
1.
9
1
9
0
 
(a
P
K
/V
P
S1
5
) 
T. brucei 100% 0 protein kinase, putative 
·  PI3K complex mamber: autophagosome 
formation/regulation of protein and 
vesicular trafficking and sorting (Abraham, 
2004; Araki et al., 2013; Liu et al., 2014; 
Anding and Baehrecke, 2015). 
L. major 33% 2x10-64 protein kinase, putative 
T. cruzi 50% 0 protein kinase, putative 
S. cerevisiae 23% 6x10-32 Vps15p 
C.elegans 33% 7x10-23 Vacuolar Protein Sorting factor  
Human 24% 6x10-38 PI3K regulatory subunit 4 
Tb
9
2
7
.7
.9
6
0
 
(C
M
G
C
/S
R
P
K
) 
T. brucei 100% 0 protein kinase, putative 
·  Nucleus/cytoplasm localization  
·  Phosphorylation of splicing factors 
containing serine/arginine-rich domains 
·  Regulation of constitutive/alternative 
splicing (Zhou et al., 2012). 
 Stress-response mechanism in eukaryotes 
(Zhong et al., 2009).
L. major 53% 8x10-173 protein kinase, putative 
T. cruzi 51% 0 protein kinase, putative 
S. cerevisiae 40% 5x10-26 Sky1p 
C.elegans 39% 6x10-24 SR Protein Kinase 
Human 41% 2x10-27 
SFRS protein kinase 1, isoform 
CRA_c 
Tb
9
2
7
.1
1.
9
2
9
0
 (
P
se
u
d
o
-
O
rp
h
an
/F
A
Z2
0
) 
T. brucei 100% 0 protein tyrosine kinase, putative 
·  Parasite-specific 
·  Localizes to the tip of the flagellum 
attachment zone in both the old and the 
new cell Generated during cytokinesis 
(Zhou, Hu and Li, 2016) 
·  None predicted kinase activity (Figure 
3-18) and (Taylor et al., 2013) 
L. major 32% 2x10-35 protein kinase, putative 
T. cruzi 34% 2x10-110 protein kinase, putative 
S. cerevisiae 26% 8x10-7 Gin4p 
C.elegans 25% 3x10-4 unc-82 
Human 25% 4x10-4 NUAK family SNF1-like kinase 2 
Tb
9
2
7
.3
.3
9
2
0
 (
A
U
K
2
) 
T. brucei  100% 0 protein kinase, putative 
· Associates to the spindle poles  
· Regulates entry in mitosis and it is often 
overexpressed in human cancers (D’Assoro, 
Haddad and Galanis, 2015) 
· DNA repair candidate (Stortz, 2016) 
L. major 49% 9x10-89  protein kinase, putative  
T. cruzi  60% 0 protein kinase, putative 
S. cerevisiae 31% 1x10-33  Kin82p  
C.elegans  34% 4x10-50  
Aurora/IPL1-related protein 
kinase 2  
Human 37% 7x10-54  
Chain A, Structure Of Aurora-2 
(AUKA)  
Tb
9
2
7
.2
.1
8
2
0
 (
C
A
M
K
L)
 T. brucei 100% 0 protein kinase, putative 
· Energy balance maintenance (Salminen A, 
Kauppinen A and Kaarniranta K, 2016) 
· Phosphorylation of metabolic enzymes 
and transcription factors 
· Epigenetic regulation 
· Calcium binding (contains EF hands) 
L. major 57% 0 protein kinase, putative 
T. cruzi 63% 0 protein kinase, putative 
S. cerevisiae  40% 8x10-57 Ampk Homolog Snf1  
C.elegans  61% 7x10-59 Ampk subunit alpha-2 
Human 38% 1x10-55 Ampk subunit alpha-2 
Results of BLASTp analysis aligning against a non-redundant protein sequence 
database. E = Expect value. 
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3.3.11 Increased susceptibility of the in vivo-impaired RNAi 
mutants to fresh serum exposure  
A companion study (Stortz, PhD thesis, 2016) showed three of the in vivo specific 
kinases to have an important role in maintaining cellular integrity, with RNAi 
induced parasites shown to be more sensitive to alkylation-induced cellular 
damage with methyl methanesulfonate: Tb927.2.1820 (CAMKL), Tb927.3.3920 
(AUK2), and Tb927.7.960 (CMGC/SRPK1). For AUK2 at least, this phenotype is 
due to a role in genome maintenance or transmission. One of the most obvious 
and distinctive elements encountered by parasites during infection in mice when 
compared with the in vitro culture conditions is exposure to mammalian serum 
factors, with the VSG coat providing protection against complement-mediated 
lysis (Matthews, McCulloch and Morrison, 2015). As genome fragility affecting 
subtelomeric regions can disrupt VSG expression (Glover, Alsford and Horn, 
2013), we exposed the three candidates to fresh rat serum for 3 h (10% and 50% 
concentration) and analysed relative survival of induced and uninduced cells 
when compared to controls that were not exposed to rat serum (Table 3-5). In 
addition, we tested Tb927.7.3880 (DYRK) that was found to produce a growth 
defect both in vivo and in vitro.  
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Figure 3-15. Survival assay to rat serum exposure of four in vivo-specific 
protein kinases related to DNA repair.  
Parasites at 106 cells ml-1 were exposed to fresh rat serum for 3h (10% and 50% 
concentration). Relative survival was measured by normalizing counts for 
induced (48 h RNAi) and uninduced parasites to their respective no-serum 
controls. Induced and uninduced results were compared with T test. * = p<0.05 
(n= 3). 
RNAi induced cells, targeting the three MMS damage response protein kinases, 
showed a decrease in survival as serum concentration increased relative to 
uniduced controls. In contrast, RNAi against Tb927.7.3880 (DYRK), which caused 
impaired cell growth in vitro, caused no such increased serum sensitivity. 
3.3.12 STE11 (MAP3K) kinases involved in osmotic shock 
resistance  
Two of the MAP3K protein kinases (Tb927.10.14300 and Tb927.10.10350) that 
are essential only in vivo (Figure 3-13) have sequence identity to yeast protein 
kinases that regulate osmotic stress (Table 3-6). To test whether they might be 
involved in resistance to osmotic changes encountered during circulation in the 
mammalian host, a modified ‘Swell dialysis’ assay was performed (Voorheis and 
Martin, 1980). Controlled buffering conditions were used to produce mildly 
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turgid cells and RNAi-induced cells were assessed for survival under gentle 
osmotic shock compared with uninduced controls (Figure 3-16). RNAi against 
each predicted STE11 protein kinase resulted in a statistically significant 
reduction in cell survival under these conditions. RNAi of Tb927.10.14300 
resulted in a 20% reduction in cell viability after osmotic shock at both 48 h and 
72 h after RNAi induction. RNAi of Tb927.10.10350 resulted in a more severe 
phenotype with a 50% reduction in cell viability after osmotic shock at 48 h and 
72 h after RNAi induction.  
 
Figure 3-16. Survival assay to osmotic shock of two MAP3Ks (STE11s) found in 
the in vivo specific set.  
2 x 106 cells were subjected to a modified swell dialysis protocol (Voorheis and 
Martin, 1980): cell swelling (5 min at 4 ºC in 0.5 ml 55 mM KCl/1 mM glucose) 
followed by cell shrinking adding on top 0.5 ml 263 mM KCl/1.75 mM Mg2Cl (5 
min at 4ºC). Survival of the induced cells compared to uninduced controls is 
plotted and compared with T test. *= p <0.05.  
3.3.13 Kinome focused approach compared to genome-wide 
RITseq screenings 
The rationale behind the kinome wide screen was that the RITseq approach 
applied to a reduced cohort of cell lines that had been individually developed 
and validated, instead of with a large library of thousands of clones, would 
permit sufficient coverage with the reduced inoculum size required for a mouse 
infection. 
As overlap in the growth phenotypes seen in the two RITseq approaches was less 
than a 50% of identified genes, one interesting aspect was to understand how 
different coverage and resolution was. The whole genome RITseq data (Alsford 
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et al., 2011) was downloaded from the European Nucleotide Archive and 
processed through our pipeline. Three genes were selected, one showing a loss 
of fitness in both screens (Tb927.3.690), one identified only in the whole 
genome (Tb927.8.5390), and one identified only in the kinome-wide screen 
(Tb927.11.5340). As expected, whole genome reads scattered across the whole 
genomic sequence of each protein kinase, while the kinome focused mapped 
accurately in the flanks of the homology region targeted by the RNAi. Read 
depth in the focused library was at least 100x read depth found in the whole 
genome library (Figure 3-17). 
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Figure 3-17. Comparative kinome focused/whole genome RITseqs (Alsford et 
al., 2011).  
A. Compared read count resolution for a gene that causes loss of fitness (LOF) 
both in the kinome-wide and in the genome-wide screening (Tb927.3.690); B. for 
a gene that is a LOF only in the genome-wide (Tb927.8.5390); and C. for a gene 
that is a LOF in the kinome-wide (Tb927.11.5340). Red=reads coming from an 
induced sample. Blue= reads coming from an uninduced sample. 
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3.4 Discussion 
In this study we aimed to define the cohort of protein kinases that are essential 
for T. brucei to survive in the mammalian bloodstream. We modified whole-
genome parallel phenotyping based on RITseq technology (Alsford et al., 2011) 
and applied it to a defined collection of individually designed and validated RNAi 
cell lines. This method was used to run in vitro and in vivo experiments that 
permitted the identification of 49 essential protein kinases, including 9 protein 
kinases that are uniquely required for survival in the environment of the 
mammalian circulatory system, Figure 3-14. Protein sequence alignment for 
each gene suggested these protein kinases are involved in parasite stress-
response pathways, based on orthology with other eukaryotes. Validation of 
individual cell lines identified protein kinases that play roles in protecting the 
parasite from mammalian serum factors and osmotic stresses. These findings 
expand the repertoire of essential and potentially druggable protein kinases in 
this pathogen and begin to explore the mechanisms by which the parasite 
survives the multiple stresses of life inside its host. 
3.4.1 Adaptation of RITseq technology to pre-existing RNAi 
libraries 
Viability of the pooled approach is validated by the 91% overlap found between 
the in vitro RITseq at 72 h and results for individual cell lines obtained in the 
alamar blue screen for the same library at the same time point (Jones et al., 
2014), supported by directly comparing growth of fourteen independent lines 
and the RITseq results obtained with the pooled approach at every time point. 
The same can be inferred from the in vivo experiment results, where loss of 
fitness matched observations made with the individual lines by Jones et al 
(2014), supported by analysis of 4 independent cell lines selected to represent 
the range of loss of fitness phenotypes observed. The adaptation of genome-
wide RITseq technology to smaller, defined libraries was advantageous for in 
vivo experiments for several reasons. The coefficient of determination between 
the RNAi induced/uninduced read mapping ratios obtained between the two 
experiments (R2=0.77) was good, especially when focused on those with a loss of 
fitness RNAi phenotype (R2=0.82). Intrinsic reproducibility across replicates in 
vitro and, remarkably, across different mice within the same experiment  was 
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also good, as evidenced by the reduced standard deviation of the average read 
counts. Inclusion of a single clone per RNAi target may allow an advantage in 
terms of phenotypic homogeneity compared with strategies where a pool of RNAi 
vectors are transfected into parasites. The second approach generates an 
unknown number of clones per target with different levels of depletion after 
induction, which may mask certain phenotypes. 
We show that focusing RITseq to smaller libraries enhances resolution of the loss 
of fitness readout. While whole-genome sequencing maps reads across ~7500 
genes, our approach distributes the same reads along 183 genes (177 rationally 
targeted fragments, including six double knockdowns), enabling a ~1000-fold 
increase in sequence read depth. This increase in resolution meant that we were 
able to detect 56 protein kinases that result in a loss of fitness upon depletion 
with the kinome-library in vivo or in vitro, while only 19 of these protein 
kinases, with the most severe growth defects, were identified in a whole-
genome library RITseq screen (Alsford et al., 2011) that assessed loss of fitness 
in culture after 3 and 6 days of RNAi. A similar observation has been made in a 
screen of 99 mitochondrial proteins with procyclic forms (Mbang-Benet et al., 
2015). There, 44 RNAi phenotypes (some of them supported by individualized 
studies published before) differed from whole-genome RITseq results, but both 
studies were coincident in detection of the most severe phenotypes. 
Although whole genome RITseq screens may have lower resolution, they assess in 
parallel all the protein families, thus being a valuable tool to identify pathways 
and networks whose activity is required under any selective pressure or culturing 
condition. This has been successfully applied, for instance, to identify proteins 
required for stumpy and procyclic differentiation (Alsford et al., 2011; Mony et 
al., 2013), proteins whose depletion triggers drug resistance (Baker, Alsford and 
Horn, 2011; Alsford et al., 2012), or resistance to human serum factors (Alsford 
et al., 2014).  
Both approaches are complementary: strong phenotypes caused by any gene can 
be identified using genome wide libraries, while gene families can be 
quantitatively assessed in higher resolution with the focused-library approach. 
Importantly for this study, reduced library size and associated RITseq resolution 
allowed a 72 h in vivo model of infection in mice, which would be difficult with 
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the larger parasite numbers required to cover the whole genome without using 
lots or bigger animals, as they would cause an early host death by overwhelming 
the bloodstream (Turner, Aslam and Dye, 1995). The comparison between the in 
vivo and in vitro RITseq screens presented in this chapter also highlights that 
phenotypes observed in vitro could be observed generally before and with a 
higher statistical significance (maybe due to a larger number of replicates) in 
vivo than in vitro . 
3.4.2 Nine protein kinases causing a loss of fitness in vivo 
unveiled as novel virulence factors 
Trypanosomes are highly adaptable organisms, capable of withstanding immune 
assault by the host and responding to the many changing conditions they 
experience during their life cycles: temperature, pH, osmotic imbalance, 
availability of carbon and nitrogen sources.  This study reveals that depletion of 
9 protein kinases limits T. brucei growth in the mouse bloodstream, while the 
same cells remain fully competent for growth in culture (Figure 3-14), suggesting 
they have roles as virulence factors required to overcome challenges 
encountered only in vivo. The precise functions provided by the protein kinases 
remain to be identified, but a common theme from sequence-based functional 
predictions (Table 3-6) is the management of stress. It has been shown in 
bacteria that, in addition to ‘direct’ or sensu stricto virulence factors (such as 
toxins or invasins), elements involved in stress management are also ‘indirect’ or 
'contributory’ elements required for establishment of the infection (Sleator and 
Hill, 2002). A connection between stress resistance and virulence has been found 
for many other infectious eukaryotic organisms (Hengge-Aronis et al., 1993; 
Mattick et al., 2000; Loh, Torres and Cover, 2007; Cameron et al., 2012; 
Burbank and Stenger, 2016), including Leishmania  (Zhang and Matlashewski, 
1997; McCall and Matlashewski, 2010).  
Nine independent cell lines were tested in vivo and in vitro individually, showing 
consistency with the pooled approach. Six of them showed significant loss of 
fitness at the RITseq in vitro only after 120 h, with Bud32 and MRK1 showing also 
a phenotype after 96 h RNAi. Among these novel virulence factors of T. brucei 
there is an orphan pseudo-kinase with putative parasite-specific functions and 
another eight protein kinases showing sequence similarity with protein kinases in 
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other eukaryotes, suggesting diverse functions including gene expression, 
alternative splicing, protein synthesis/translational regulation, and stress 
adaptation linked with autophagosome formation.  
A gene first included in the in vivo-only set, Tb927.10.14770 (CAMK/AKB1), was not 
reported at the in vitro alamar blue screen (Jones et al., 2014) because the clone 
used in the original library did not contain an RNAi insert. After being remade for 
the second pool (re-transfecting the plasmid, pTL179), it was used for the in 
vivo and for the in vitro RITseqs, causing a rapid and severe loss of fitness in 
vivo and in vitro only after 96 h. AKB1 has been proven to be an active kinase, 
downregulating cytokinesis and cell division in bloodstream and procyclic forms 
upon knock down in vitro from 48h (Inoue et al., 2015). The phenotype there 
also involved morphological abnormalities. Inoue et al. showed overexpression to 
cause a similar phenotype in procyclic forms, with the AKB1 kinase activity 
responsible for this (as a kinase-dead overexpressor did not produce a similar 
effect).  
3.4.2.1 An orphan pseudo-kinase with parasite specific functions 
One of the nine protein kinases differed from the rest, in that it appears to be a 
highly divergent putative pseudo-kinase (Tb927.11.9290/FAZ20), since it lacks 
several of the key residues and subdomains required to be an active protein 
kinase (Hanks and Hunter, 1995), Figure 3-18. In the small ATP-binding NH2-
terminal lobe, FAZ20 misses two of the three conserved glycines needed in 
subdomain I to anchor the non-transferable phosphates of the nucleotide. In 
addition, the large COOH terminal lobe, which binds the substrate and initiates 
the phosphotransference in most protein kinases, is truncated. FAZ20 also lacks 
the DxxxxN catalytic loop in subdomain VIB (which accepts the proton from the 
substrate´s attacking COOH group) and the DFG motif at subdomain VII 
(responsible for -phosphate orientation). Finally, it lacks the APE motif in 
subdomain XIII, which forms an ion pair with an arginine in subdomain XI, while 
subdomain XI is totally missing. 
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Figure 3-18. FAZ20 is a putative pseudo-kinase.  
Extract of the alignment performed for the phylogenetic tree displaying amino 
acid sequence alignment of Tb927.11.9290 (Pseudo-Orphan/FAZ20) with other 
protein kinases and its lack of some of the critical subdomains and motives 
conferring to ePKs their canonical kinase activity. Protein kinase model inspired 
in the one depicted at Hanks, 2003 (Hanks, 2003). 
 
Tb927.11.9290 (FAZ20) was already identified as an ‘orphan’ kinase in the 
seminal article describing the T. brucei protein kinome, suggesting an 
evolutionary divergence with protein kinases in other eukaryotes (Parsons et al., 
2005). This is supported by observations here (Table 3-6) of poor BLASTp E-
values after alignment with similar protein kinases in other reference organisms 
(apart from the closely related Leishmania and T. cruzi parasites). Such a 
structural divergence may indicate parasite-specific functions, as may be 
inferred from FAZ20 localization to the tip of the flagellum attachment zone in 
both the old and the new cells generated during cytokinesis (Zhou, Hu and Li, 
2016). Through BioID (proximity-dependent biotin identification) and 
immunolabelling, its presence has been detected close to CIF1 and CIF2. These 
two factors play a direct role in the canonical anterior end-initiated cytokinesis, 
in cooperation with PLK1 and AUK1 (both essential also in our in vivo screen). 
RNAi-mediated depletion of CIF1 or CIF2, as well as CIF2 overexpression, causes 
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atypical initiation of cytokinesis from the posterior end, indicating the need of a 
tight regulation (Zhou, Hu and Li, 2016).  
Altogether, these data may suggest that FAZ20 involvement in the process of cell 
division may become particularly crucial in the context of the in vivo infection, 
where linkage with stress resistance mechanisms, as observed for other protein 
kinases detected in the screen, may ensure correct cytokinesis under challenges 
encountered in the bloodstream that are not reproduced in vitro. FAZ20 
classification as a putative pseudo-kinase (Hanks, 2003; Taylor et al., 2013) in 
the context of the BioID and localization results (Zhou, Hu and Li, 2016) may also 
suggest scaffolding roles for this protein.  
3.4.2.2 Two MAP3Ks (STE11) involved in osmotic shock resistance 
In other eukaryotes, Mithogen Activated Protein Kinases (MAPKs) are 
transcription activators acting at the end of a three module phosphorylation 
cascade, providing a response to extracellular stimuli in order to ensure a quick 
adaptation to environmental conditions: growth factors, cytokines, irradiation, 
osmolarity or shear stress caused by the hydrodynamic flux over the cells as they 
proliferate in the bloodstream. MAP3Ks (STE11s) are the first step of these 
cascades; they interact with MAP2Ks (STE7s), which in turn act upon MAPKs that, 
in the end, are responsible for transcription factor activation (Widmann et al., 
1999).  
In T. brucei, this pathway may have non-canonical roles, as transcription 
mechanisms are divergent from other eukaryotes. RNA polymerase II initially 
produces large polycistronic transcripts that are trans-spliced to produce mature 
mRNAs, mediated by the 39–nt-long “Splice leader” (SL). The SL transcript is 
unique, being the only gene for which an RNA Pol II promoter has been found in 
T. brucei so far (Das et al., 2005; Schimanski, Nguyen and Gu, 2005). RNA 
polymerase II is believed to initiate transcription from strand switch regions, 
regulated by epigenetic mechanisms (Siegel et al., 2009). Codon content (Horn, 
2008) and gene duplication (Jackson, 2007b) are shown to have an influence in 
the final expression levels. Expression of pooled mRNA is finally controlled by 
mRNA-binding factors (Wurst et al., 2012) . 
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Tb927.10.14300 (STE11/MRK1) has sequence similarity with members of the 
yeast High Osmolarity Glycerol (HOG) pathway, which responds to osmotic 
challenge through actin recovery (Zhi et al., 2013), while the MORN motif-
containing protein Tb927.10.10350 (STE11/Bck1p) resembles human MEKK3, a 
positive regulator of the stress-activated protein kinase (SAPK) pathway 
(Ellinger-Ziegelbauer et al., 1997) putatively involved in cell integrity 
maintenance under stress conditions. The increased susceptibility to osmotic 
shock seen after RNAi induction of these two STE11 protein kinases when 
subjected to a modified ´Swell dialysis´(Voorheis and Martin, 1980) protocol 
indicates that they may provide similar roles in T. brucei.  
Two osmosensor systems are described in yeast connected to the reactive MAPK 
cascade (HOG pathway): a 2-component transduction system, which deactivates 
the cascade in low-osmolarity conditions, and an integral membrane protein that 
activates the pathway (reviewed by Widmann et al. 1999). Interestingly, the 8 
Membrane Occupation and Recognition Nexus (MORN) motifs present in 
Tb927.10.10350 (STE11/Bck1p) may suggest membrane association (Lee, Han 
and Hur, 2010), but this needs to be studied in more detail. MORN motifs are a 
highly conserved 14-amino acid sequences found in many eukaryotes. The 
number of repeats and their position varies in the different proteins. They have 
been linked to lipid interaction and subcellular localization (Ma et al. 2006), but 
functions of these motifs are still unclear in the literature. 
Immediate downstream interaction partners of STE11s (STE7s) were not 
identified in this screen, which may suggest redundancy amongst the T. brucei 
STE7 cohort, or perhaps a non-canonical mode of action for the T. brucei STE11 
protein kinases. This is likely, as transcriptional regulation in trypanosomes is 
different from other eukaryotes. Canonical MAPK signalling modules are also 
missing in other parasites, such as Encephalitozoon cuniculi, or the complete 
Apicomplexa phylum (Miranda-Saavedra et al., 2007). 
Two other MAPKs (ERK-like), often involved in transcriptional and non-
transcriptional regulation in response to external stimuli, were found to be 
essential both in vivo and in vitro: KFR1, previously reported to be regulated by 
interferon γ in order to promote proliferation in T. brucei (Hua and Wang, 1997); 
and MAPK6 (ERK8), which regulates cytokinesis (Mackey et al., 2011).  
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Interestingly, within the first 24 h of the in vitro RITseq (Table 3-3), 5 protein 
kinase lines were identified with a relative loss of fitness and 4 of them were 
STE11s. If this is the product of stochastic fluctuation, or indicates common 
functions of T. brucei STE11s, remains to be investigated.  
Three protein kinases recovered later and two, a CDC15-like protein (together 
with CRK3), maintained the loss of fitness for the whole 120 h of the screen. 
CDC15 is an essential component of the actomyosin ring of yeast, and required 
for spindle pole separation during the anaphase of cell division (Ren et al., 
2014). It has an F-BAR domain, which links membranes to the actin cytoskeleton 
and has a strong cell cycle-dependent phospho-regulation mediated by Pom1, a 
DYRK kinase (Ullal et al., 2015). Interestingly, knockdown of CRK3, the other 
protein kinase found steadily misrepresented in the induced population with 
respect to the control along the 120 h of the in vitro experiment, has been 
related to G2/M arrest (Tu and Wang, 2004), so they could be involved in the 
same pathway. 
One of the three STE11 that displayed recovery, however, was RDK1 and shows 
again a loss of fitness after 96 h that increases at 120 h. RDK1 has been reported 
to cause differentiation to procyclic forms after 72 h of RNAi (Jones et al., 
2014). Inducing anachronistic differentiation to procyclic forms in the 
bloodstream entails VSG loss and has been proposed a novel therapeutic strategy 
(Wenzler et al., 2016). This rationale underpins also the compound screening 
presented in chapter 5 of this thesis.  
3.4.2.3 Three stress-related protein kinases linked to the PI3K/TOR pathway 
Orthologues of three other in vivo-only essential protein kinases cluster together 
within the PI3K/TOR pathway: Tb927.11.9190 (VPS15), Tb927.11.850 (Bud32) 
and Tb927.7.960 (SRPK1). Tb927.11.9190 (VPS15), is required for stress-induced 
and developmentally-triggered autophagosome formation in other eukaryotes 
(Liu et al., 2014; Anding and Baehrecke, 2015) and assembles within the PI3K 
complexes (Abraham, 2004; Araki et al., 2013). VPS15 activates VPS34, a PI3K in 
yeast. Depletion of the T. brucei orthologue, TbVPS34 (which could potentially 
be mimicked by lack of activation if VPS15 is missing), impairs correct 
segregation of the Golgi apparatus during cytokinesis, receptor-mediated 
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endocytosis, transport to the lysosome, and VSG export to the membrane (Hall 
et al., 2006). Examining these pathways after VPS15 depletion would be good 
follow up work. 
The PI3K signalling pathway in yeast involves also Bud32 (orthologues called 
PRPKs in humans and Drosophila), which is part of the KEOPS/EKC complexes. 
There, it acts as a transducer for TOR activation that, in turn, has also been 
linked to autophagy and endocytosis under stress conditions (Ibar et al., 2013; 
Rojas-Benítez, Ibar and Glavic, 2013). Through this PI3K/TOR pathway, Bud32 
has been linked to translational regulation throughout tRNA modification 
(Srinivasan et al., 2011; Rojas-Benítez, Ibar and Glavic, 2013). Finally, 
Tb927.7.960 (SRPK1), regulated via PI3K/AKT pathway (in parallel to TOR), is 
responsible for activation/inhibition of splicing factors through phosphorylation 
(Zhou et al., 2012). Localization and availability is also a stress response.  
Identification of these TOR-related protein kinases is of interest, because TOR 
pathways are central for parasite-host interaction in T. brucei (Saldivia et al., 
2013). While most eukaryotes encode 2 TOR paralogues, trypanosomatids are the 
only known organisms containing four, each integrated in a different protein 
complex, of which three are required for normal fitness both in vivo and in vitro 
(here and Jones et al., 2014). TbTOR1 regulates transcription and translation. Its 
depletion leads to the induction of autophagy, thereby enhancing survival upon 
nutritional stress, which is linked to developmental progression (Barquilla and 
Navarro, 2009a). This material recycling process enables production of new 
organelles and has also been observed in T. cruzi and Leishmania (Figueiredo, 
Rosa and Soares, 2000; Besteiro et al., 2006; Alvarez et al., 2008; Duszenko et 
al., 2011). TbTOR2 is required for actin polarization, which in turn is essential 
for secretion and endocytosis (Barquilla and Navarro, 2009a, 2009b). TbTOR3 
responds to osmotic shock by control of polyphosphates and acidocalcisomes (De 
Jesus et al., 2010), and in Leishmania has implications for in vivo infection 
(Madeira da Silva and Beverley, 2010). The acidocalcisome is crucial for 
autophagy in T. brucei (Li and He, 2014). The last paralogue, TbTOR4, is 
required for T. brucei proliferation and life stage maintenance in bloodstream 
forms as its depletion triggers differentiation from replicative slender to stumpy 
cell-cycle-arrested forms (Barquilla et al., 2012). How the three in vivo-only 
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protein kinases identified here might act within the expanded TOR signaling 
network awaits further analysis. 
3.4.2.4 A pleiotropic, stress-responsive protein kinase: CK2A2 
In the set of in vivo-only protein kinases, CK2A2 deserves a special mention as it 
is the only one that has been previously studied in T. brucei (Park et al., 2002; 
Jensen et al., 2007). This protein has a proven protein kinase activity and 
localizes mainly to the nucleolus, although remains ubiquitous throughout the 
cell. With more than 300 known substrates in humans (Meggio and Pinna, 2003), 
regulation of eukaryotic CK2 is mainly controlled by distribution and abundance 
(Pinna, 2003), with stress-induced mobilization extensively reported (Gerber et 
al., 2000; Davis et al., 2002; Yamane and Kinsella, 2005). Downregulation of CK2 
has also been implicated in the control of autophagy through intersection with 
the PI3K/AKT/TOR pathway in eukaryotes (Olsen, Svenstrup and Guerra, 2012; 
Hales, Taub and Matherly, 2014; Sanchez-Casalongue et al., 2015). Interestingly, 
CK2 signalling also intersects in humans with mitogen and stress-activated 
protein kinases (Shi et al., 2009; Jacks and Koch, 2010), and has been implicated 
as a key kinase controlling transcription elongation from yeast to mammals 
(Basnet et al., 2014).  
Regulation of VSG mono-allelic expression is not well understood yet, but there 
is evidence for epigenetic control affecting transcription conducted by RNA 
polymerase I (Günzl et al., 2015). Mammalian CK2A2 has been related with 
regulation of RNA polymerase I activity in the literature before (Panova et al., 
2006; Bierhoff et al., 2008). 
There is also evidence in the literature of inducible expression of a different VSG 
causing DOT1B-mediated histone methylation that attenuates the active 
expression site (Batram et al., 2014). When this happens, which can also be 
forced by depletion of ESAG genes, the cell acquires a cell cycle-arrested and 
PAD-expressing stumpy-like phenotype. This state reverts to normal slender 
VSG221-expressing cell morphology when the secondary VSG stops being 
induced. Among its many functions, CK2A2 has been linked to epigenetic 
regulation in many eukaryotes. Such membrane coat disruption, together with 
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the associated temporary cell cycle arrest, could be an explanation for the 
exacerbated loss of fitness in vivo compared to in vitro.  
Casein kinase 2 was one of the earliest described eukaryotic protein kinases. It 
does not cluster within any of the main families of protein kinases but it is 
distantly related with the CMGC family (Burnett and Kennedy, 1954). It is 
present mainly as a tetrapeptide with 2  (catalytic) subunits and 2  
(regulatory) subunits. The yeast counterpart is constitutively active and the  
subunit only modifies its interaction with other partners. T. brucei has 2 isotypes 
for the catalytic subunit (there is 43% identity between them, a lot lower than 
between their yeast or human orthologues) (Park et al., 2002). In contrast with 
CK2A1 (aka catalytic subunit CK2), attempts carried out to characterise CK2A2 
(aka catalytic subunit CK2’) gave mixed results. Studies based on in vitro 
translation could not prove CK2’ interaction with CK2 probably due to 
misfolding, as it lacked kinase activity. However, kinase activity (with casein as 
a substrate) was proven in CK2’, which was obtained by tandem affinity 
purification. Unfortunately, low concentration precluded identification of 
interaction partners over background contaminants (Jensen et al., 2007). RNAi 
lines targeting each of the isoforms showed a slight growth defect, visible after 
120 h. Difficulties in obtaining the purified CK2A2 stymied further analysis of this 
protein, but the degree of loss of fitness unveiled here, leading to parasite 
clearance in the mouse bloodstream, suggests it can be a promising drug target. 
There is at least one compound in the GSK HAT box targeting the closely related 
human CK2A1 (Peña et al., 2015), which may be active against both TbCK2A2 
(whose effect would be evident mainly in vivo) and TbCK2A1 (in vivo and in 
vitro), therefore having an effect in vivo greater than in vitro.  
3.4.2.5 Three protein kinases engaged with mechanisms of resistance to 
DNA damage 
It is intriguing that three protein kinases (AUK2, CAMKL and SRPK1) only 
essential for in vivo growth have also been identified in a companion RNAi 
screen for factors required for T. brucei to withstand or repair damage caused 
by DNA alkylation in vitro (Stortz, 2016). In what way, if at all, the two 
phenotypes might overlap is unclear, but potentially these T. brucei protein 
kinases, associated with serum resistance (Figure 3-15), may be involved in 
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aspects of genome maintenance. Confirming such hypothesis would require 
further investigation. From the four tested in Figure 3-15, only the one causing a 
clear loss of fitness in vitro (DYRK) was unaffected for serum exposure upon 
RNAi. Overlap between death caused by serum exposure and death caused by 
RNAi would be a reason for not finding a difference between serum treated and 
non-treated controls in DYRK. However, relative growth observed in the Tet+ 
samples as serum concentration increased discarded this as a cause. Verification 
of serum resistance as a common theme in other in vivo-specific candidates from 
our screen still remains to be done. 
AUK2 resembles AUKA, which in other eukaryotes complexes with the spindle 
poles and regulates entry in mitosis. It is often overexpressed in human cancers 
(D’Assoro, Haddad and Galanis, 2015). Unlike yeast, which only has one AUK, or 
plants which have two, T. brucei (like mammals) contains three members of this 
important family of protein kinases involved in cell cycle regulation (Carmena, 
Ruchaud and Earnshaw, 2009).  
CAMKL has great identity with AMPKs in other eukaryotes but it also bears two 
calcium binding domains (EF hands). AMPKs have functions in maintaining the 
balance of energy through phosphorylation of metabolic enzymes and 
transcription factors (Salminen A, Kauppinen A and Kaarniranta K, 2016).  
SRPK1 has been discussed above, with Bud32 and VPS15, in the set of protein 
kinases putatively linked to the PI3K pathway. It had orthologues regulating gene 
expression by phosphoryating SR-motive-containing splicing factors in response 
to stress. 
Interestingly, the fourth gene we analysed for serum resistance, Tb927.7.3880 
(DYRK), has recently been co-purified with several SR-rich proteins in a pull-
down of CRK9, a protein kinase critical for RNA splicing (Badjatia et al., 2016). 
One of these SR proteins, CYC12, is an L-type cyclin that forms a complex with 
CRK9 and has a human orthologue phosphorylated by DYRK1A (Graaf et al., 
2004). This suggests that a similar pathway can be in place for T. brucei, and 
SRPK1 might be involved in the network.Tb927.7.3880 (DYRK) was in the original 
set of in vivo loss of fitness not reported in vitro by Jones et al. (2014) but upon 
validation showed a growth defect (Figure 3-14A). It is a dual specificity kinase 
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predicted to require tyrosine autophosphorylation in order to activate serine-
threonine kinase activity. This mechanism suggests that they may have also dual 
sensitivity to protein kinase inhibitors (Lochhead et al., 2005).In yeast, DYRKs 
have functions in activation of cytokinesis and growth by mediating interaction 
of their cellular machineries with actin and microtubules (Bähler and Nurse, 
2001). A role for DYRKs regulating cytokinesis has been also detected in C. 
elegans during embryogenesis (Pang et al., 2004) and in neurogenesis in more 
complex metazoans, including Drosophila (Tejedor et al., 1995) and mammals 
(Guimera et al., 1999; Fotaki et al., 2002).  
3.4.2.6 A PLK-like protein kinase without polo-box domains 
One protein kinase with an induced/uninduced median ratio under 0.6 detected 
only in vivo was missed in the original analysis because ratios in the in vivo 
Replicate 1 were not calculated with the bootstrapping approach at first. 
Tb927.6.5100 has homology with polo-like kinases in other eukaryotes, but lacks 
the characteristic polo box domains at the C-terminal end of the protein that 
allosterically inhibit the kinase domain until binding the substrate (Elia et al., 
2003). We do not have validation data for this loss of fitness phenotype, so it 
will not be discussed further. 
3.4.3 Potential of 49 protein kinases with in vivo value as drug 
targets 
T. brucei protein kinases can be targeted with chemical inhibitors in the low 
micromolar and nanomolar range of concentration (Urbaniak et al., 2012). 
Despite conservation of the protein kinase catalytic domain, protein kinase 
inhibitors can be designed for selectivity and have been proven good drug 
candidates (Cohen, 2002; Weinmann and Metternich, 2005; Cohen and 
Tcherpakov, 2010). This work identifies 49 protein kinases that are required for 
in vivo fitness. For those causing strong phenotypes, leading to parasite 
clearance (Table 3-3), it may provide evidence of their potential as drug targets, 
though a more thorough genetic validation is required, as lethal phenotypes 
observed upon protein kinase depletion via RNAi are not necessarily due only to 
protein kinase inhibition. For instance, the absence of the protein in a given 
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interaction network can cause harm by itself, something that could not be 
reproduced with a chemical inhibitor.  
One method to analyse this would be integration into the RNAi line of a recoded 
version of the targeted gene. The resulting transcript would be unharmed by the 
RNAi machinery, while producing the original protein. If this recovers the wild 
type phenotype, we would confirm that RNAi is on target. If, on the other hand, 
cells are unable to recover when the recoded gene has key mutations for 
activity, e.g. substitution of the catalytic lysine in the second subdomain (Hanks 
and Hunter, 1995), it would confirm that the same phenotype could be obtained 
with a targeted kinase inhibitor. One protein kinase in the set, RDK2, has been 
targeted with this approach and results are described in the next chapter. 
Another important consideration is the timing and severity of the outcome. Upon 
chemical inhibition, the derived phenotype can happen immediately after 
addition of the compound. RNAi requires transcription machinery to be active 
and, as transcript depletion avoids production of fresh protein, time is required 
to deplete the cell of available stocks. To examine transcript and protein levels 
with qRT-PCR and western blot in order to understand the timing is critical. 
In addition to the obvious possibility of designing protein kinase-specific screens 
targeting them individually, some protein kinases identified here open an 
opportunity to develop drug-repurposing strategies. A phylogenetic comparative 
between the T. brucei and Homo sapiens kinomes showed how 13 out of the 49 
protein kinases found to be important in vivo had close human orthologues 
targeted by at least one of the compounds in the ‘HAT box’ (Peña et al., 2015). 
Interestingly, among them is Tb927.10.10350 (STE11/Bck1p), from the in vivo 
only set. These molecules could be chemically modified to achieve T. brucei 
specificity. This has been also suggested for aurora kinases (Patel et al., 2014) 
and PI3K/TOR kinase inhibitors (Diaz-Gonzalez et al., 2011). Both pathways have 
putative components detected also in the in vivo-only set, Table 3-6.In contrast, 
the other 8 in vivo validated protein kinases are highly divergent from any 
human kinase. Three ‘orphan’ kinases in this set are very likely to play parasite-
specific functions. Selectively targeting these may be easier than other more 
conserved protein kinases.  
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3.4.3.1 Leishmania/Trypanosoma cruzi extrapolation 
Most of these 49 protein kinases have close orthologues in Trypanosoma cruzi 
and Leishmania major (see Figure 3-13/Table 3-5). Extrapolation of results 
based on gene ontology using T. brucei as a model may be a valuable 
perspective to identify potential drug targets, since to date these organisms lack 
efficient reverse genetics tools for kinome- or genome-wide studies. Examples of 
protein kinases with a loss of fitness in our study, which also play essential roles 
for survival of Leishmania include MPK1 (called KFR1 in T. brucei (Wiese, 1998), 
CK1 (Knockaert et al., 2000; Rachidi et al., 2014), CRK3 (Hassan et al., 2001; 
Walker et al., 2011) and GSK3-short (Xingi et al., 2009; Ojo et al., 2011). The 
last three are genetically validated targets and have had HTS screens where 
inhibitors have been identified. In addition, one of the MAP3Ks observed to have 
an only in vivo fitness defect, MRK1 (with a role in osmotic resistance), has a L. 
major orthologue proven essential for promastigote survival (Agron, Reed and 
Engel, 2005). All the main hits causing a loss of fitness in Table 3-3 are 
potentially worthy of further consideration in this manner. For example, the L. 
donovani orthologue of AUK1 (LdAIRK) has been tested showing implications in 
cell cycle but requires further analysis (Chhajer et al., 2016). KKT10, the 
kinetoplastid-specific kinetochore member, may be targeted with specificity, 
like CK2A1 and CK2A2,with human orthologues targeted by compounds with 
trypanocidal activity in the HATbox (Peña et al., 2015), suggesting potential for 
drug repurposing. A CK2-targetting compound may have enhanced in vivo 
efficacy, according to results shown in this chapter. Supporting its potential, a 
CK2 orthologue in L. braziliensis has been shown to be secreted, helping 
macrophage association prior to invasion (Zylbersztejn et al., 2015). Others, like 
DYRK1, CRK9, AUK3, or RDK2, which are highly divergent from any human 
orthologues according to a phylogenetic comparative made by Peña et al (2015), 
may be interesting kinetoplastid-specific targets too, Table 3-5. 
3.4.4 Potential applications of RITseq used in other pre-existing 
libraries 
With this study we prove that RITseq can be applied to any pre-existing RNAi 
library, expanding our capacity to search for genes involved in specific aspects 
of T. brucei biology for which a screen can be devised. Reduced library size may 
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be an advantage by increasing resolution and requiring less starting material in 
order to obtain significant results, as we have shown by in vivo infections. The 
barcoded primer approach reduced costs and increased our multiplexing 
capacity. Possibilities are endless, but we have already used this library to 
identify protein kinases required for kinetoplast maintenance, cell cycle 
regulation, withstanding or repairing alkylation-mediated DNA damage, and 
differentiation of bloodstream to procyclic forms.  
Technically it would be possible to use this library to find the target of a kinase 
inhibitor whose time to kill at a given concentration and EC50 is well profiled. 
We should be able to find a time frame where a synergistic effect due to overlap 
of kinase inhibition and kinase depletion can produce a reduction the IC50. The 
population, after a certain incubation time, would be enriched in the parasites 
that do not target with RNAi the liable protein kinase. 
The library could also be used for the identification of the protein kinase 
responsible for a particular phosphorylation event, if a specific antibody is 
available against the phosphorylated peptide. The library, induced and 
uninduced, would be fixed before staining with such antibody, which could be 
directly or indirectly coupled to a fluorophore. Then, cells would be processed 
through fluorescence-activated cell sorting (FACS) so the non-phosphorylated 
(and non-stained) population could be isolated. Sequencing the RNAi targets of 
the unstained population would show which kinase depletions were responsible 
for the lack of phosphorylation. The main challenge would be choosing the right 
timing in case the responsible kinase caused a strong loss of fitness. Induction 
should be sustained long enough for the protein kinase to be depleted so the 
phosphorylation defect becomes evident. However, it cannot be so long that the 
cell line of interest is cleared if the protein kinase is essential. 
This rationale can be subsequently applied to libraries of genetically modified 
parasites of many different makes (e.g. overexpression, knock out, fluorescent 
or luminescent tagging) as soon as we can use universal primers to enrich in a 
quantifiable molecular label, e.g. a barcode, an RNAi cassette or an 
overexpression cassette. For instance, an RNAi library made in a bioluminescent 
pleomorphic parasite could be used to test which proteins are needed to invade 
the central nervous system by infecting mice. We could track the progress of the 
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parasites throughout the host organism to certify invasion of the central nervous 
system with an in vivo imaging system (IVIS), before purifying DNA from the 
brain tissue or haematoencephalic fluid. Genomic DNA would be enriched in the 
cassette and sequencing reads assigned to it filtered in silico. No protein kinase 
has been reported to date as specifically required to cross the blood brain 
barrier (BBB) in the parasite, although this signalling is fundamental in the 
endothelial cells to permit this to happen. Examples of T. brucei-secreted 
factors proven to have a direct role in BBB crossing are two cathepsin-B-like 
cysteine-proteases (brucipains). In addition, others have been proposed that may 
have a role are the closely related oligopeptidase B or acid phosphatases 
expressed in the surface (Lonsdale-Eccles and Grab, 2002). Focused RNAi 
libraries targeting protein kinases or peptidases could be used in this manner. 
The screen described in this thesis is not foolproof. False negatives in RITseq 
studies are rare, but can be caused by a failure to produce dsRNA or leaky 
phenotypes giving a reduced count (due to cell line depletion) both in the 
induced and uninduced pools (Glover et al., 2014). Starting with a pool of 
validated cell lines is time-consuming but gives a strategic advantage. False 
positives can happen due to rare off-target effects. With time, loss in complexity 
in the induced sample could cause unequal expansion of different clones in the 
library, due to uneven access to energy resources. Deletion of the RNAi target 
from the genome after induction has been also detected.  
3.4.5 Final conclusion 
All together, we showed in this chapter that application of next generation 
sequencing to pre-existing libraries of RNAi lines enhances greatly our capacity 
to evaluate the impact of protein depletion on the cell phenotype when 
subjected to selective pressures of any kind that mimic relevant cellular 
processes. As a proof of concept we used the library to understand what protein 
kinases in T. brucei are indispensable for mammalian infection, something of 
interest both for drug discovery and biology. We validated in vivo the effect in 
loss of fitness that had been observed in vitro for more than 40 protein kinases. 
Interestingly, we identified at least 9 which showed a degree of essentiality in 
the context of a mouse infection that could not be reproduced in culture, 
therefore behaving as potential virulence factors. Most of these in vivo-
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indispensable protein kinases showed phylogenetic relationship with orthologues 
in other organisms that had a role in regulation of stress response pathways, 
including osmotic shock control, gene expression or autophagy mediated by the 
PI3K/TOR axis. We demonstrated the contribution of some of these in vivo-only 
kinases towards serum resistance, and tolerance to osmotic shock. 
Severity of the phenotype in more than 20 protein kinases in this screen 
highlights their potential value as drug targets. We discussed how kinase 
inhibitor chemotypes are generally enriched in the available collections of 
trypanocydal compounds. All of them had orthologue proteins in L. major and T. 
brucei, and they may be also essential in those organisms. Until proper high-
content genetic dissection tools, equivalent to RNAi, are developed in these 
parasites, extrapolation from observations made in T. brucei can be a successful 
approach.  
Given the reduced size of the library, this technique provided the advantage -
compared to whole-genome approaches- of increasing greatly our resolution in 
terms of read depth, permitting more compelling results using a smaller number 
of parasites, as required for mice inoculation. Possibilities of RITseq and similar 
genetic approaches are endless.  
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Chapter 4 Repressor of differentiation kinase 2 
 
4.1 Introduction 
When the kinome-wide RNAi library of T. brucei bloodstream forms was screened 
for regulators of differentiation, two protein kinases were found that upon 
depletion triggered spontaneous differentiation from bloodstream 
trypomastigote to procyclic-like forms. This differentiation event was 
characterised by cell elongation, kinetoplast repositioning and EP procyclin 
expression (Jones et al., 2014). These two protein kinases were named RDK1 
(Tb927.11.14070) and RDK2 (Tb927.4.5310), denoting Repressor of 
Differentiation Kinase as they seem to play a role in bloodstream stage 
maintenance. Interestingly, depletion of RDK2 by RNAi knockdown led to an 
important loss of fitness both in vitro (Jones et al., 2014) and in vivo, as 
described in the RITseq experiment reported in Chapter 3. 
4.1.1 Repressor of differentiation kinases 1 and 2 
RDK1 (STE11-like/Tb927.11.14070) is a putative MAP3K: the first of a three-
member cascade of protein kinases (MAP3K>MAP2K>MAPK) responsible for 
transcription activation in response to extracellular signals in many eukaryotes. 
RDK1 has 2-3 predicted N-terminal transmembrane domains, which appear 
functional as the protein localises to the membrane fraction of parasite lysates  
and is detected by IFA in the whole cell body, including the flagellum 
(Oberholzer et al., 2011; Jones et al., 2014). Although induction of RNAi does 
not lead to cell death, procyclic form differentiation (entailing VSG loss) would 
make the parasites susceptible to complement-mediated lysis (Ferrante and 
Allison, 1983; Wenzler et al., 2016), suggesting RDK1 inhibition may be a 
potential therapeutic strategy. After 72 h of RNAi in standard bloodstream form 
culture conditions, 20% of cells expressed EP procyclin on the surface. RNAseq 
data of parasites at this time point post-RNAi revealed that 236 genes (out of 
275 differentially transcribed if compared to non-induced controls) matched 
mRNA profiles of procyclic forms, even though only one fifth of the population 
expressed the phenotype. 
Chapter 4 168 
 
The progenitor T. brucei line used in RDK1 RNAi analysis was 2T1, which is 
derived from Lister 427 and is considered monomorphic, as long term in vitro/in 
vivo passage -carried out before the development of effective cryopreservation 
methods- rendered cells unable to produce stumpy forms in response to high 
parasite densities (Rico et al., 2013). Suspicion existed that the 20% of procyclic-
like forms obtained upon RNAi induction would match the reduced 
differentiation-competent subset of the monomorphic culture, also known as 
stumpy* forms (Alsford and Horn, 2008; Jones et al., 2014). This hypothesis is 
supported by observation of a 2-fold increase in the number of EP-procyclin-
positive cells after RDK1 depletion in cells co-treated with 8-pCPT-cAMP. As with 
other cell-permeable hydrolysable analogues of cAMP, 8-pCPT-cAMP induces 
differentiation to stumpy* forms in monomorphic cultures (mimicking the high 
density-mediated effect observed in pleomorphic forms) (Reuner et al., 1997; 
Laxman et al., 2006). 8-pCPT-cAMP also increased transcription of PAD1, a 
stumpy stage specific marker (Dean et al., 2009), 2-fold in 2T1 T. brucei. In 
addition, differentiation triggered by RNAi of RDK1 was enhanced, generating 
60% EP positive cells, by treating the induced culture with a TbPTP1 inhibitor 
(BZ3); this additive effect has been proposed to be a response to two parallel 
pathways affecting two different subsets of cells (Jones et al., 2014). 
RDK2 (NEK12.2/Tb927.4.5310) belongs to the NEK family of protein kinases, 
which is expanded in T. brucei with respect to humans (Parsons et al., 2005). 
The expanded NEK family may have parasite-specific functions, with RDK2 
providing a clear example since it seems to regulate life-stage maintenance. In 
addition to triggering differentiation, knock down of RDK2 causes cell cycle 
arrest, which is associated with a block in cytokinesis (after 48h of RNAi 
induction), followed by cell death (after 72h) (Jones et al., 2014). 
RDK2 (NEK12.2) has 87% sequence identity with NEK12.1 (Tb927.8.7110), Figure 
4-1. The two genes may be the evolutionary product of a duplication event that 
has been reported for the 3’ regions of chromosomes 4 and 8 (Jackson, 2007a). 
Unlike the majority of protein kinases, NEK12.1 has a smaller gate-keeper 
residue in the ATP binding pocket (alanine instead of methionine), making the 
pocket putatively larger. This variation may allow substrate identification, by 
labelling the -phosphate of large ATP analogues and determining the substrates 
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by tag detection, or protein kinase inhibition, with bulky analogues that would 
compete with ATP for the binding pocket of NEK12.1 only (Bishop et al., 2000; 
Elphick et al., 2007). The original cell line showing differentiation to procyclic-
like forms prior to cell death upon RNAi induction targeted an identical section 
of both genes (RDK2 and NEK12.1), causing a double knockdown, so specific RNAi 
constructs were designed by joining small divergent fragments longer than 20 
nucleotides (Jones et al., 2014). Only the RDK2-specific RNAi line showed cell 
elongation, kinetoplast repositioning and EP procyclin expression phenotypes 
characteristic of the dual RNAi line. Transcription analysis (quantitative RT-PCR) 
revealed that NEK12.1 was independently downregulated with its specific RNAi 
while the original construct affected both genes. It has been suggested (Jones et 
al., 2014) that reduced expression of NEK12.1 mRNA may be a natural event that 
occurs during BSF-PCF differentiation (Jensen et al., 2009; Kolev et al., 2010). 
 
Figure 4-1. Nucleotide sequence identity of RDK2 and NEK12.1, and 
predicted protein structure.  
A. Alignment between RDK2 and NEK12.1 performed in CLC genomics 
workbench. Sequence identity between the two is displayed, highlighting 
divergent regions. B. Schematic representation (to scale) of RDK2 functional 
features, according to an alignment with three different hidden markov model 
databases: SMART (Letunic, Doerks and Bork, 2015), PFAM (Finn et al., 2014) and 
Superfamily (Gough et al., 2001). 
RNAi lines targeting RDK2 (Jones et al., 2014), showed a reduction in transcript 
abundance after 24 h of RNAi induction to 20% of the uninduced line levels. In 
that study, an alamar blue fluorescence induced/uninduced ratio of 0.676 was 
recorded after 72 h of induction, indicating a loss of fitness (Jones et al., 2014). 
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RDK2 essentiality was detected in Alsford et al’s whole genome screen at days 3 
and 6 and there, its presence was not required for procyclic form survival or for 
differentiation (Alsford et al., 2011). In the kinome-wide RITseq presented in 
this thesis (chapter 3), RDK2 depletion caused a strong loss of fitness both in 
vivo and in vitro, from 48 h onwards as indicated by median ratios between 
induced and uninduced normalized reads under the 0.6 established threshold. 
The intensity and significance of the observed loss of fitness during the in vitro 
RITseq increased with time (Table 3-3. Summary of RNAi target sequencing 
results in vivo and in vitro). 
RDK2 RNAi induction in the presence of 8-pCPT-cAMP, cold shock or BZ3 did not 
cause differentiation of more cells than the induced RNAi line alone. However, 
the proportion of cells differentiated by RDK2 knockdown was equivalent to the 
proportion obtained by RDK1 depletion empowered by these treatments. This 
suggests that RDK2 blocks differentiation of bloodstream to procyclic forms at 
least upstream of RDK1.  
The RDK2 gene putatively encodes a polypeptide of 440 amino acids (Figure 
4-1B), with the protein having a predicted molecular weight of 50.2 KDa. 
Alignment against three different hidden Markov model databases –SMART 
(Letunic, Doerks and Bork, 2015), PFAM (Finn et al., 2014) and Superfamily 
(Gough et al., 2001)- reveals an N-terminal serine-threonine protein kinase 
domain (41-299) and a C-terminal PH-like domain (348-437). Two phosphoserines 
(S195/S197) have been reported in a phosphoproteomics screen of the 
bloodstream form cytosolic fraction (Nett et al., 2009). The key lysine 
responsible for -phosphate orientation, whose mutation generally ablates kinase 
activity, is residue Lys 70  (Figure 4-1).  
4.2 Research aims 
With the objective of characterizing further a potential drug target among the 
essential protein kinases identified in the RITseq screen presented in Chapter 3, 
RDK2 was selected, since the RNAi phenotype encompassed both cell death and 
differentiation, suggesting an interesting biological role in the parasite. This 
chapter provides a mechanistic characterization of RDK2 and investigates in 
more detail the role it plays in differentiation. 
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4.3 Results 
4.3.1 RDK2 RNAi phenotype description 
For all analyses we used the RDK2-targeting RNAi line used in the RITseq screen 
described in chapter 3, sTL629 (Table S1). It was created by transfection of 2T1 
bloodstream forms (Alsford et al., 2005) with AscI-linearized pTL247, a plasmid 
derived from pGL2084 (Jones et al., 2014), as shown in Figure 3-1. The RNAi 
insert was synthetized by combining divergent fragments of RDK2, longer than 20 
nucleotides, which were not found in NEK12.1. An in silico simulation with CLC 
Genomics Workbench, suggested that the hairpin produced upon RDK2 stem loop 
transcription is highly favoured energetically (G = -1391.8 kcal/mol) (Figure 
4-2A). RNAi knockdown of RDK2 RNA was validated by qRT-PCR from cells taken 
24 h after RNAi induction. A growth curve showed growth arrest after 48 h, and 
cell death from 72 h onwards (Figure 4-2B). Analysis by flow cytometry and IFA 
permitted identification of the procyclic-like phenotype described by Jones et al 
(2014): from 36 h cells showed differentiation, as defined by elongation of the 
cell body, kinetoplast repositioning and EP procyclin expression, confirmed in 
the surface by indirect IFA without membrane permeabilization (Figure 4-2C-D). 
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Figure 4-2. RNAi phenotype of RDK2 RNAi.  
A. Highly favoured double stranded RNA hairpin predicted for the RDK2-targeting 
stem loop RNAi construct (pTL246) upon transcription. Secondary structure 
calculated with CLC Genomics Workbench. B. Triplicate growth curve starting at 
104 parasites x ml-1 of sTL629 (RDK2-targeting RNAi line) comparing RNAi induced 
(Tet+) cells to uninduced controls (Tet-). The controls were diluted (1:100) after 
48h to maintain exponential growth, and the dilution factor (100x) was applied 
to the graph, generating a cumulative analysis. Embedded qRT-PCR profile of 
sTL629 24 h post induction, taken from Jones et al. (2014). C. 
Immunofluorescent images of uninduced (Tet-) sTL629 bloodstream forms 
compared to RNAi induced cells after 48 h of growth (Tet+). On the left hand 
panel, differential interference contrast microscopy (DIC); on the right hand 
panel, fluorescence microscopy after staining DNA with DAPI (blue), and 
visualising EP procyclin using indirect immunofluorescence (green) without cell 
permeabilization. Arrows indicate kDNA D. Flow cytometry profiles of EP 
procyclin expression for uninduced (Tet-) sTL629 bloodstream forms compared to 
RNAi induced cells after 36 h of growth (Tet+). 
 
The percentage of cells with EP procyclin expression detected at every time 
point by IFA were 10% larger than the percentages detected in flow cytometry: 
for instance, at 36 h, 50% were positive in flow cytometry, compared with 60% in 
IFA; at 72 h, 70% were positive in flow cytometry and almost 80% EP procyclin 
positive in IFA, indicating that IFA was more sensitive for detection. 
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Cell cycle analysis of the RNAi phenotype was in agreement with data published 
by Jones et al (2014), Figure 4-3A-B. Enrichment in mitotic cells containing two 
nuclei and two kinetoplasts (2N2K) was indicative of a block or delay in 
cytokinesis between 36 h and 48 h after RNAi. At these time points there was a 
reduction of 1N1K and 1N2K cells compared to uninduced cells (or time 0), and 
an increase in “other” (abnormal) cell types. At 72 h there was an accumulation 
of 1N1K parasites, consistent with a slightly reduced proportion of abnormal 
cells and a drastic reduction in 2N2K cells relative to the 48 h time point. 
The block/delay in cytokinesis between 36-48 h was coincident with the first 
manifestation of growth arrest and differentiation, when 60-70% of cells became 
EP procyclin positive, Figure 4-3A-B. After 72 h of RNAi induction, ~88% of cells 
were EP procyclin positive and population numbers reduced as enrichment in 
1N1K parasites was seen, Figure 4-3A-B.  
A more detailed analysis of the phenotype, separating EP positive and EP 
negative populations, found no substantial difference in cell cycle distribution at 
48h, but a slight increase in the 2N2K subset of the undifferentiated population 
after 72 h (although calculated from a very reduced sample size, n=38), Figure 
4-3C-D.  
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Figure 4-3. Cell cycle analysis after RDK2 RNAi.  
A. Bar diagram depicting percentage of cells with increasing time after RNAi 
induction containing: one nucleus and one kinetoplast (1N1K); one nucleus and 
two kinetoplasts (1N2K); two nuclei and two kinetoplasts (2N2K); and other 
aberrant combinations (other). 200 cells were counted per time-point using 
microscopy where DNA was stained with DAPI. B. Microscopic images of cells at 
48 h (left) and 72 h (right) post RNAi induction. DNA was labelled with DAPI 
(blue) and EP procyclin with a specific antibody in indirect immunofluorescence 
(green). Flourescent images are merged with DIC to distinguish the parasite 
shape. C. Discrete cell cycle analysis for EP positive and EP negative cells using 
slides imaged in B. D. After 48h of induction, flow cytometry histograms 
assigning events to fluorescence intensity of: DNA (left), using propidium iodide 
(PI); EP procyclin expression (middle), using a specific antibody in indirect 
immunofluorescence; and DNA (PI) for individualized cell cycle analysis of EP 
positive (right above) and EP negative populations (right below). 
Optimal growth of procyclic forms in culture occurs between 105 and 5 x 107 
cells x ml-1. In order to explore further the growth phenotype of cells induced to 
differentiate by RDK2 RNAi, different culturing conditions were tested by 
collection of parasites 48 h post-induction and concentration adjustment to start 
a new culture at 1-5 x 105 cells ml-1. To ascertain whether the differentiation 
effect upon RNAi was reversible, different conditions were tested (Figure 4-4A–
D). 
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Figure 4-4. Growth properties after RDK2 RNAi.  
A. Growth curve of cells recovered 48 h after induction of RNAi with tetracycline 
(Tet+) and placed at 27 oC in the same medium or in fresh HMI11, with and 
without (Tet-) renewing tetracycline. B. Growth curve of cells recovered 48 h 
after induction of RNAi with tetracycline and placed at 27oC in fresh SDM79, with 
and without addition of tetracycline. C. Same as (B) but placing the cells in 
conditioned SDM79 medium and testing parasites that were never RNAi induced 
(with and without addition of tetracycline). D. Cells after 48 h of induction 
placed at 27 oC in conditioned SDM79 using flasks instead of plates, with and 
without addition of tetracycline. E. Microscopic images of live cells recovered 48 
h post-induction and kept in SDM79 conditioned at 27oC with tetracycline for 96 
h; videos are provided in attached DVD (Movie_S1 and Movie_S2). 
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If placed at 27 oC in HMI-11, cell numbers were maintained for about 48 h 
(Figure 4-4A). Later, cell numbers decreased until cell death was evident by 72 
h. Death was quicker if the cells were kept in the same medium than if moved to 
fresh. Within fresh medium, those cells under sustained tetracycline induction 
resisted cell death comparatively better than those where the drug was 
removed. If placed at 27 oC but changed to fresh SDM79, the standard medium 
used to culture procyclic form parasites, cells died slowly over a period of 6 
days. In these conditions, no substantial difference was found between 
maintaining cells in tetracycline or removing it from the medium (Figure 4-4B). 
It is well known that procyclic forms are dependent on density-related 
environmental signals for optimal growth, which in some strains has been 
circumvented by removal of free radicals (Archer, 2009). When cells were 
collected after 48 h of RNAi induction and placed in conditioned SDM79 medium 
(by addition of 15% SDM79 filter sterilized from a dense procyclic culture, see 
M&Ms), they managed to survive for at least one week, with numbers tending to 
decrease slowly (Figure 4-4C). Where tetracycline induction was sustained, cells 
did comparatively better. If non-induced bloodstream forms were exposed to 
these conditions, cell cultures were dead in 24 h. 
Interestingly, all the above experiments were conducted in 6-well plates, where 
cells appeared to be attached to the bottom (Figure 4-4E). When cells were 
grown in SDM79 conditioned medium using vertical flasks, cells were not 
detectable after 48 h (Figure 4-4D). 
4.3.2 Expression of recombinant RDK2 and assessment of 
protein kinase activity 
In order to examine whether RDK2 has protein kinase activity, recombinant 
expression was conducted in E. coli. Inspired by successful experiments with the 
structurally similar NEK12.1 (Jones, 2012), the pET-32 Xa/LIC expression system 
(Novagen) was selected. This system permits a strong IPTG-inducible expression 
under control of the T7 promoter, with the protein of interest fused to an N-
terminal thioredoxin tag (Trx), which increases solubility (LaVallie et al., 1993) 
(Figure 4-5A). In addition, the fusion protein contains a six-histidine tag for 
purification via immobilized metal affinity chromatography (IMAC). A construct 
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(named pGL2099) was generated by insertion of the RDK2 coding sequence 
through ligation-independent cloning. The resulting fusion protein, Trx-RDK2, 
increased RDK2 size by 17.2 KDa to give a total predicted size of 67.4 KDa 
(Figure 4-5A). In addition, site directed mutagenesis was conducted in pGL2099 
by modification of codon 70 to produce a methionine instead of the catalytic 
lysine, which has been shown to be critical for the phosphate transference in 
protein kinases (Kamps and Sefton, 1986). The resulting Trx-RDK2K70M expressing 
construct was denoted pGL2215 (Figure 4-5A). 
 
Figure 4-5. Recombinant RDK2 expression and kinase assay.  
A. Schematic representation of recombinant Trx-RDK2 (pGL2099) and Trx-
RDK2K70M (pGL2215) as expressed in pET-32 Xa/LIC (Novagen) under control of 
the T7 promoter. N-terminal thioredoxin (Trx), His and S tags are added for 
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solubility and purification proposes. Cleavage sites of thrombin and factor Xa are 
highlighted. B. Protein kinase assay performed with [32P]-ATP radiolabel in the 
active protein (Trx-RDK2) and the protein kinase ‘dead’ mutant (Trx-RDK2K70M), 
both carried out in the presence (S) and absence (nS) of the generic substrate -
casein. Left panel represents the Coomassie blue stained gel and right panel 
represents a storage phosphor screen imaged in a Typhoon 9400, 72 h of 
exposure to the gel. C. Same as B, but protein kinase activity assay carried out 
after cleaving the tag with factor Xa. D. Coomassie blue stained gel of Trx-RDK2 
exposed to different units (U) x l-1 of factor Xa at four different incubation 
times to optimize cleavage of the tag. 
 
Kinase activity was assayed using radioactive [-32P]-ATP and the generic 
substrate, -casein, which had previously been used for NEK12.1 (Jones, 2012). 
The Trx-RDK2 protein was capable of phosphorylating -casein, whilst the Trx-
RDK2K70M was not (Figure 4-5B). Interestingly, Trx-RDK2 also carried out 
autophosphorylation and this effect was greater in the absence of an exogenous 
substrate (Figure 4-5B, arrowed). In order to see if the protein maintained its 
activity after the Trx tag was cleaved, trying to understand if the tag was the 
target of autophosphorylation, different incubation times and concentrations of 
Xa factor were tested, Figure 4-5D. The best conditions, 6 h incubation at 0.5 
U/l, were scaled up and applied to both Trx-RDK2 and Trx-RDK2K70M that, after 
cleavage, were subjected to the kinase assay. The autophosphorylation signal 
was still observable, although not as intense if the substrate was present, Figure 
4-5C. 
To attempt to purify RDK2, codon-enriched Escherichia coli RosettaTM (DE3) p-
lysS strain, with T7 lysozyme to supress basal T7 expression, was used as the 
bacterial host. Protein expression was induced with 1 mM IPTG in log-phase cells 
(OD600=0.5) during an overnight incubation at 17 oC (see M&M). Protein was 
purified from bacterial lysates with two rounds of fast protein liquid 
chromatography (FPLC). This permitted simultaneous fractionation of the elution 
and monitoring of protein content with UV absorbance, Figure 4-6.  
In the first FPLC purification, a Ni2 Sepharose column was used to retain the 
6xHis-tagged protein. After profuse washing with 35 mM imidazole buffer, 
elution was conducted by increasing imidazole to 500 mM. As this salt has more 
affinity for Nickel than the His tag, the Trx-RDK2 could be successfully released 
from the matrix, Figure 4-6A. After removing residual imidazole from the eluate 
in a desalting column, a second FPLC round was conducted with an anion 
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exchange column, Figure 4-6. Every step of purification was assessed by SDS-
PAGE and Coomassie blue staining, Figure 4-6. The purest fractions after ion 
exchange were pooled and concentrated to conduct a kinase assay. Trx-RDK2, 
and all the mutant versions used in this chapter, could be frozen at -80 oC with 
10% glycerol maintaining their capacity for phosphorylation. 
 
Figure 4-6. Trx-RDK2 purification.  
A. Immobilised metal-ion affinity chromatography using a Ni2 Sepharose column 
in an ÄKTA purifier. Left panel, UV absorbance during binding of the His-tagged 
protein with 5 mM imidazole (0-65 ml), washing with 35 mM imidazole (65-115 
ml) and elution with 500 mM imidazole (115-150 ml). 1 ml fractions were 
collected across the wash and elution peaks. Right panel, Coomassie staining of 
a 12% SDS-PAGE, loading the whole bacterial lysate before (L) and after filtration 
(F); a fraction sample from the washing peak (W); a series of fractions across the 
elution peak (F2,5,6 and 11, and G3 and 5). Fractions F4-G6 (7ml) were pooled 
and processed through a desalting column. B. Ion exchange chromatography 
using a Q sepharose column in an ÄKTA purifier. Left panel, desalted samples 
were passed through the column and washed with 10 volumes ion exchange 
buffer without NaCL (70 ml) and a gradient 0-1 M of NaCl was applied across 
other 10 column volumes for elution of the protein. Fractions were collected 
from all the process. Right panel, Coomassie staining of a 12% SDS-PAGE loading 
the desalted sample from the metal chromatography (MC); and fractions 
collected across the elution peak (1-G5, 8, and 11; f1-H3, 7 and 11; and 2-A3, 
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and 2-A8). Fractions 1-H6 to 1-H12 were pooled, kept in 10% glycerol, and used 
for subsequent kinase assays. m= protein standards. 
A study has reported the phosphoproteome of cytosolic fractions from T. brucei 
bloodstream form cells (Nett et al., 2009). There, peptides were identified 
indicating phosphorylation of two serine residues (S195 and S197) in the middle 
of the RDK2 protein kinase domain (Figure 4-7A). In order to ascertain whether 
these residues are required for kinase activity, site-directed mutageneses were 
performed to allow RDK2 recombinant protein to be expressed with mutations 
that would mimic the phosphorylated and dephosphorylated states in all the four 
possible combinations (Trx-RDK2S195E/S197E, Trx-RDK2S195E/S197A, Trx-RDK2S195A/S197E, 
and Trx-RDK2S195A/S197A). Alanine (A) prevents phosphorylation, while glutamic 
acid (E) simulates the phosphorylated state by introduction of a bulky group 
including a negative charge (Dissmeyer and Schnittger, 2011). For purification of 
these mutants we used exactly the same procedure used for Trx-RDK2 
(purification data not shown). In the absence of the phosphoserines, only Trx-
RDK2S195A/S197E was unable to phosphorylate -casein and, whilst 
autophoshorylation was still detectable in all mutants (indicative of other 
residues not reported by Nett et al. being phosphorylated), it appeared reduced 
in Trx-RDK2S195A/S197E (Figure 4-7B). Although results for this mutant were 
encouraging at first, smell of soap and excess of foam during the cell-lysis step 
were indicative of detergent contamination in the flask used to centrifuge the 
bacterial culture. If that were true, soap-triggered denaturalization of the 
protein could justify a loss of the kinase activity instead of a change of 
conformation caused by the S195A/S197E mutation. Although a faint 
autophosphorylation was detectable, it would be necessary to repeat the 
experiment before claiming a mutation-based loss of the kinase activity.I 
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Figure 4-7. RDK2 S195/S197 phosphosite mutations.  
A. Schematic representation of recombinant Trx-RDK2 highlighting 
phosphoserines found in a phosphoproteomic analysis of the cytosolic fraction in 
bloodstream trypanosomes (Nett et al., 2009). B. Mutants to mimic permanent 
phosphosphorylation (S to E) or permanent dephosphorylation (S to A) in the four 
possible combinations were expressed and subjected to a kinase assay. Left 
panel represents the Coomassie blue stained gel and right panel represents the 
x-ray film after 72 h of exposure to the radiolabel ([-32P]-ATP). Kinase assay 
conducted with the active protein (Trx-RDK2) and the four phosphosite mutants 
both in the presence (S) and absence (nS) of the generic substrate -casein. 
4.3.3 Molecular validation of the RNAi phenotype 
Aiming for molecular validation of the RDK2 RNAi knockdown phenotype, the 
protein was next re-expressed in the induced RNAi line as an RNAi-resistant 
variant. To achieve this, the RDK2 gene was recoded in silico by reverse 
translation to DNA of RDK2’s complete amino acid sequence in CLC genomics 
Workbench, giving priority to T. brucei infrequent codons. The resulting gene 
was manually curated in order to certify that no section longer than 25 
nucleotides remained identical to the original CDS of RDK2 while still producing 
the right protein (Figure 4-8A). This recoded version of RDK2 (rdk2REC) was 
cloned into plasmid pRM481 (Proudfoot and McCulloch, 2005), which targets 
inserts to the tubulin array of genes located in chromosome 1 via homologous 
recombination. After AscI linearization and transfection into the RNAi line 
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(sTL629), the new construct would produce stable constitutive expression, 
conferring blasticidin resistance to permit selection of successful transfectants. 
Transcripts from rdk2REC should not be recognised by the RNAi machinery, 
avoiding cleavage via RISC and therefore producing RDK2 protein, whilst 
endogenous RDK2 transcripts would be degraded. In order to detect expression 
by western blot, pRM481 was modified to enable fusion of RDK2 with a C- or N-
terminal 6xHA tag. Modified pRM481 expressing rdk2REC-6xHA (C-Terminal 
tagged) was renamed pGL2271, whilst the 6xHA-rdk2REC version (N-Terminal) was 
called pGL2587. Vector maps are depicted in Figure 4-8B. 
 
Figure 4-8. RNAi refractory recoded RDK2 complementation strategy.  
A. RDK2 protein sequence (RDK2) aligned to the DNA sequence annotated for 
Trypanosoma brucei brucei TREU927 in TrytripDB (RDK2) and the recoded DNA 
sequence (rdk2REC) created by reverse translation with infrequent T. brucei 
codons in CLC Genomics Workbench. B. Schematic representation of modified 
versions of the AscI linearized tubulin-targeting pRM481 by introduction of 
rdk2REC with N-terminal (pGL2587) or C-terminal (pGL2271) 6xHA tag. The 
construct includes a blasticidin resistance cassette as a selectable marker and an 
actin intergenic region for trans-splicing and polyadenylation between the 
blasticidin and RDK2 ORFs. 
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A blasticidin resistant clone (renamed sTL768) was selected after transfection of 
sTL629 with pGL2271 where protein of the expected size (57.2 KDa, with the 
6xHA tag) was detectable in western blot with anti-HA antiserum, indicative of 
successful recombination. Growth curves and EP procyclin expression (measured 
by flow cytometry) showed the recoded RDK2 could complement for loss of the 
endogenous gene, since cell growth was equivalent with or without RNAi and 
differentiation was undetectable after RNAi (Figure 4-9A).  
 
Figure 4-9. Complementation assays with RNAi refractory rdk2REC and 
rdk2REC/K70M after RNAi induction.  
A. Anti-HA western blot comparing the untagged RNAi line (sTL629) with rdk2REC-
expressing (sTL768) and rdk2REC/K70M –expressing (sTL854) RNAi cells. B. 
Cumulative growth curve (left) and flow cytometry histograms (right) for EP 
procyclin expression in the rdk2REC-expressing clone (sTL768). C. Same as (B) but 
for the rdk2REC/K70M –expressing clone (sTL854). 
In line with experiments performed with the recombinant protein (Figure 4-5) a 
kinase dead version, rdk2REC/K70M-6xHA, was produced by site directed 
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mutagenesis in the recoded plasmid (construct named pGL2297). After 
transfection and confirmation of protein expression, it was observed that 
rdk2REC/K70M-6xHA expression was unable to complement for loss of the wild type 
RDK upon RNAi, since differentiation to procyclic–like forms and a growth defect 
were detected, Figure 4-9B). These data indicate that RDK2 kinase activity, and 
not additional functions, are lost when the protein is missing after RNAi.  
RDK2 is a NEK kinase, a family whose structural properties have been exploited 
in Plasmodium falciparum to achieve specific inhibition using a tool compound 
(NCL-00016066) upon substitution of the alanine residue corresponding to codon 
55 in RDK2 for a cysteine (RDKREC/A55C) (Mitcheson et al., 2016). Aiming to obtain 
chemical validation of the phenotype, such protein modification was conducted 
in pGL2271 by site directed mutagenesis, generating the construct pGL2472. 
However, 6xHA-expressing clones obtained after pGL2474 transfection were 
unable to rescue the RNAi phenotype as before (Figure 4-10A). Unfortunately, 
when pGL2271 or pGL2587 were re-transfected in sTL629 (or newly generated 
RDK2-targeting RNAi clones) as a control, the perfect recovery observed 
previously was found not to be reproducible (Figure 4-10B-C). Clones obtained 
with both N-terminal and C-terminal fusion versions of recoded RDK2 were only 
partially able to rescue the wild type phenotype, both in terms of EP procyclin 
expression and growth. 
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Figure 4-10. Complementation assays with clones recovered after sTL629 
transfection with RNAi refractory rdk2REC/A55C and rdk2REC.  
A. Growth curve of a rdk2REC/A55C-expressing clone, induced (Tet+) and uninduced 
(Tet-) compared to backbone RNAi phenotype (sTL629 induced and uninduced). 
B. Growth curve of a rdk2REC-expressing clone 2, which was C-terminal tagged 
(top), and rdk2REC-expressing clone which was N-terminal tagged (bottom). 
Induced (Tet+) and uninduced (Tet-), compared to backbone RNAi phenotype 
(sTL629 induced and uninduced). C. Anti-HA western blot showing expression of 
the rdk2REC-expressing clones showed in (B) compared to backbone sTL629 (left 
bottom) and flow cytometry histogram profiles of EP procyclin expression for the 
same lines showing uninduced controls (Tet-, left panels) versus induced (Tet+, 
right panels). 
Although promising, the original complementation results (Figure 4-9) were not 
compelling as perfect recovery observed with clone 1 was not reproducible and 
later attempts to achieve this always rendered cell lines capable of partial 
recovery of both phenotypes (growth and differentiation), Figure 4-10. The 
pronounced difference in the extent of complementation of RDK2 RNAi by 
recoded, wild type RKD2 in Figure 4-9 and Figure 4-10 is perplexing and remains 
unexplained. 
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4.3.4 RDK2 overexpression blocks in vitro-triggered 
differentiation 
In order to test further the hypothesis that RDK2 acts as a repressor of 
bloodstream to procyclic developmental progression, the protein was 
overexpressed in cells and then subjected to standard differentiation conditions.  
To inducibly overexpress the protein, the complete RDK2 gene sequence was 
cloned into pRPax6mycx (Alsford and Horn, 2008), vector known as pGL2220 in the 
Mottram laboratory. Using the same backbone structure as the pRPaiSL RNAi 
plasmid described in the RITseq chapter (Figure 3-1), pGL2220 targets a gene of 
interest to a specific RRNA locus selected for efficient transcription. Successful 
recombination renders cells resistant to hygromycin and generally sensitive to 
puromycin. 2T1 cells express TetR, which binds the Tet operator blocking 
transcription until addition of tetracycline (Alsford et al., 2005). 
The RDK2 coding sequence was PCR-amplified from genomic DNA (obtained from 
T. brucei brucei Lister strain 427 wild type cells) and cloned into pGL2220. By 
addition of suitable restriction sites to the primers, RDK2 was fused to a 6xmyc 
tag, enabling expression to be tracked. Constructs were made using C-terminal 
(RDK2-6xmyc, pGL2323) and N-terminal (6xmyc-RDK2, pGL2324) tagging, Figure 
4-11A.  
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Figure 4-11. RDK2 inducible overexpression.  
A. Schematic representation of pRPax6mycx (pGL2220) and cloning strategy to 
generate C-terminal (pGL2323, without RDK2 stop codon) and N-terminal 
(pGL2324, with RDK2 stop codon) tagged constructs. * = stop codon. B. Western 
blot determining expression of RDK2-6Myc and 6Myc-RDK2 in clones obtained 
upon transfection in 2T1 bloodstream cells, and growth curves comparing 
progenitor 2T1s with induced (Tet+) and uninduced (Tet-) overexpression. C. 
Microscopic images of the RDK2-6Myc over-expresser phenotype after 24 h of 
induction, showing from left to right: shape (DIC); DNA stained with DAPI (blue); 
and RDK2 with anti-myc indirect immunofluorescence (green). This work has 
been undertaken in collaboration with Helena de la Torre. 
Plasmids were linearized with AscI and transfected into 2T1 cells. Hygromycin 
resistant cells recovered were tested for expression and growth under induced 
and uninduced conditions compared with progenitor 2T1 cells. Western blotting 
with an antibody that recognises the 6-myc tag showed expression of the fusion 
protein after 24 h of induction, but not in the uninduced lines, Figure 4-11B. 
Using the same antibody, IFA showed distribution of the protein across the whole 
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cell body after 24 h of induction. Parasites looked morphologically normal under 
the microscope, Figure 4-11C. Growth curves showed a slower growth in the 
induced cells compared to the uninduced, which grew at the same rate as the 
parental line, Figure 4-11B. This work was produced in collaboration with Helena 
de la Torre. 
In order to understand how RDK2 overexpression affected life stage 
maintenance, differentiation assays were carried out in vitro. It has been 
already mentioned that stumpy* formation can be induced in monomorphic 
trypanosomes, such as 2T1, by treatment with hydrolysable and cell permeable 
cAMP analogues (Laxman et al., 2006). Differentiation from bloodstream to 
procyclic forms, which is more efficient starting from stumpy* parasites, can be 
triggered in vitro by treatment with 3 mM citrate/cis-aconitate (CCA) in 
differentiation trypanosome media (DTM) at 27 oC (Overath, Czichos and Haas, 
1986). 
EP procyclin expression after differentiation treatment was assessed in flow 
cytometry for Tet-induced RDK2 overexpressers compared to uninduced, 
monitoring basal levels of EP procyclin expression in comparison with non-
treated controls for both conditions (Tet+ and Tet-). The assay consisted in 
addition of 100 M 8-pCPT-cAMP for 24 h at 37oC in HMI11, washing the 
compound out, suspending the cells in DTM with 3 mM CCA, and incubating for 
24 h at 27oC, before analysing results, Figure 4-12A.  
Cells untreated for differentiation (Tet+ and Tet-) showed a background of 0.33% 
and 0.53% EP procyclin positive populations. After treatment for differentiation, 
the positive population was ~5% for 6Myc-RDK2 over-expressers (Tet+), and >60% 
for the uninduced line (Figure 4-12). 
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Figure 4-12. Bloodstream to procyclic form differentiation assay with RDK2 
over-expresser.  
A. Treatment regimen to induce differentiation. B. Flow cytometry histograms 
for EP procyclin expression comparing RDK2 over-expressers, Tet+ and Tet- 
treated or not for differentiation. 
All together these data suggest that RDK2 overexpression efficiently blocks CCA-
mediated bloodstream to procyclic form differentiation. 
4.3.5 Exploring further RDK2 involvement in known differentiation 
pathways 
In order to learn more about the role RDK2 plays in repressing differentiation, 
and how it fits within the known molecular networks described in the general 
introduction, five different conditions were tested after 48 h of RNAi induction 
compared to uninduced cells, Figure 4-13A. The percentage of EP procyclin 
expression, measured in flow cytometry, was used as a marker for 
differentiation. All experiments were conducted in HMI11 media, with the 
distinct differentiation treatments entirely conducted at 37 oC or transferring 
the cells for the last 24 h to 27 oC.  
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Figure 4-13. RDK2 interaction with the citrate/cis-aconitate pathway of 
differentation in vitro.  
A. Schematic representation of the treatment regimen. RNAi was induced for 
48h, or uninduced and grown for an equivalent time (ctrl), and cells analysed in 
flow cytometry to detect EP procyclin expression under 5 different conditions: 
(1) untreated; (2) 3 mM CCA during the last 24 h of RNAi induction; (3) 100 M 8-
pCPT-cAMP for the first 24 h of RNAi induction, washed and incubated for a 
further 24 h with tetracycline (RNAi induced only); (4) 100 M 8-pCPT-cAMP for 
the first 24 h of RNAi induction, washed and incubated for a further 24 h with 3 
mM CCA and tetracycline (RNAi induced only); and (5) 150 M of BZ3 for the last 
24 h of RNAi induction. Last 24 h for all conditions were incubated at 27 oC or 37 
oC except BZ3 (5), which was only tested at 37 oC. B. Bar diagram depicting the 
percentage of cells displaying EP procyclin expression in uninduced (blue) and 
RNAi induced (red) cells for each temperature condition. BZ3 (5) data is split in 
two columns as only one temperature was analysed. 
First, the percentage EP expression was assessed in untreated cells (1). At 37 oC, 
70% of RNAi induced were EP positive and 0% of uninduced, validating data 
shown previously in this chapter. Placing cells at 27 oC for the last 24 h, only 
~45% of RNAi induced cells were positive. 
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Then cells were treated with 100 M 8-pCPT-cAMP (2), washed, suspended in 
fresh HMI11, and incubated for further 24 h. When analysed, RNAi produced 
~60% positive procyclin population at 37 oC and ~45% at 27 oC. Uninduced cells 
were still 0% positive. 
Next, cells were incubated for the last 24 h with 3 mM CCA (3). At 37 oC, <40% of 
RNAi cells were EP positive and uninduced cells differentiated to ~5%. 
Interestingly, both values increased at 27oC: >60% differentiated in the RNAi 
induced, and ~25% in the uninduced.  
The two previous treatments were combined for condition (4). 100 M 8-pCPT-
cAMP was incubated for the first 24 h, washed away, and 3 mM CCA added with 
fresh medium for the last day. At 37 oC more than 80% of cells were procyclin 
positive in the RNAi-induced, and almost 60% in the uninduced. Interestingly, at 
27 oC, both induced and uninduced lines showed ~90% of cells expressing EP 
procyclin. 
The last condition, treatment with 150 M of TbPTP1 inhibitor BZ3 (5), was 
conducted only at 37 oC. RNAi induced cells differentiated to produce ~20% of 
the population being procyclin positive, while uninduced produced ~45%. 
4.4 Discussion 
4.4.1 RDK2 is an active kinase 
This work demonstrates that RDK2 is an active protein kinase, since recombinant 
protein is able to phosphorylate a generic substrate and is capable of 
autophosphorylation. Furthermore, the protein kinase activity was ablated by 
mutation to methionine of the catalytic lysine in subdomain II (Kamps and 
Sefton, 1986). Two RDK2 phosphosites (S195 and S197) reported in a 
phosphoproteome screen (Nett et al., 2009) were also mutated. Trx-
RDK2S195A/S197E mutant showed only a very faint autophosphorylation signal and no 
capability of -casein phosphorylation. While the kinase assay was performed at 
the same time and with the same materials as the other serine-modified 
versions, for this mutant, the elution peak in the chromatographic purification 
was substantially different. This may have been due to soap contamination 
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during the protein extraction, as the flasks used for centrifugation of this 
particular bacterial culture were insufficiently rinsed and produced abundant 
foam that smelled of soap. This could be enough to cause, for example, 
inadequate folding. It would be necessary to repeat the protein purification in 
order to test this possibility. However if the lack of activity is real, it may be 
due to the specific orientation of these residues respect to the active site. It 
would be good to model the protein in order to visualize their orientation. It is 
intriguing why being so close to each other, S195A/S197E is so relevant whilst 
the other combinations are not. According to the alignment we performed for 
the phylogenetic tree (extract in Figure S1), these two phosphoserines are in the 
N-terminal flank of subdomain VIII that, as we indicated in the general 
introduction, often contains residues that require phosphorylation before the PK 
becomes active (Chan, Hurst and Graves, 1982; Luo, Zhou and Lodish, 1995; 
Songyang et al., 1995). RDK2 is a NEK kinase and other members of this family, 
as human NEK9, also require autophosphorylation in the activation loop in order 
to be activated (Meirelles et al., 2014) 
Autophosphorylation may be targeted to residues that were not detected in the 
phosphoproteomics screen published by Nett et al. (2009) because when the 
therein-reported serines 195 and 197 were mutated to alanine or glutamic acid, 
the signal was still apparent. However, the tag was not cleaved in those mutants 
and we cannot discard the tag itself being at least a secondary target of 
phosphorylation. On the one hand, the autophosphorylation was fainter in 
cleaved Trx-RDK2, but on the other, the band corresponding to the tag did not 
look phosphorylated. As lack of phosphorylation in the cleaved tag may be 
product of inadequate conformation when detached from the protein, cleaving 
the tag in the mutants to see whether we still see autophosphorylation would be 
a good approach.  
In addition to their impact on kinase activity directly, RDK2 phosphosites may 
have other functional implications, such as interaction with other proteins 
(Cohen, 2000). Indeed, 50% of T. brucei PKs were found to be phosphorylated in 
more than one site (Nett et al., 2009). Examples of protein kinases in T. brucei 
affected by phosphorylation in other proteins are TbPLK1, which contains a 
phosphoserine/threonine-binding POLO box (Hammarton et al., 2007), or CAMK,  
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which contains a phosphothreonine-binding forkhead associated domain (Parsons 
et al., 2005). Nonetheless, autophosphorylation is required for activation in 
some cases, such as DYRK kinasess (Lochhead et al., 2005). In most eukaryotes, 
MAPK cascades are a chain of phosphorylation events that mainly activate 
transcription factors (Widmann et al., 1999). In differentiation pathways of the 
T. brucei, for instance, TbPIP39 phosphatase is activated by tyrosine 
phosphorylation and deactivated by dephosphorylation (Szöor et al., 2010). 
4.4.2 Pleckstrin homology domain 
In terms of localization, function and structure, this study is missing a thorough 
exploration of the exact role that the C-terminal Pleckstrin Homology (PH)-like 
domain of RDK2 plays, Figure 4-1B. It would be interesting to see whether its 
presence is required for the kinase activity, by expression of a truncated 
recombinant protein containing just the PK domain; and if complementation 
with such a mutant in the RNAi induced line affects in vivo function, e.g. by 
mislocalization or deficient interaction with other partners. Truncation of PH 
domains has been successfully used in other eukaryotes to understand their 
activation mechanism (Han et al., 1998) 
PH domains are 100-120 amino acids in length and are generally folded in a -
sandwich core structure (Lemmon, Ferguson and Abrams, 2002). Crystallography 
studies suggest that PH domains could block substrate access to the active site 
of protein kinases in certain structural contexts (Soisson et al., 1998; 
Worthylake, Rossman and Sondek, 2000). In other organisms, such as  
mammalian neutrophils (Servant et al., 2016) and Dictyostelium (Jin et al., 
2000; Funamoto et al., 2001), PH domains have also been linked with protein 
polarization and chemotaxis mediated by PI3K activity through specific binding 
to phosphoinositides, acting as substrates or products. There is also evidence of 
PH carrier proteins, such as pleckstrin, where activity is regulated by 
phospholipid-dependent protein kinase C (PKC)-mediated phosphorylation in 
three adjacent sites to the PH domain (Ma and Abrams, 1999). Whether such 
phosphorylation sites may be present in RDK2, in addition the two reported 
serines (195 and 197) in the PK domain, is unknown. However, the 
phosphoproteomic screen (Nett et al., 2009) only examimed the cytosolic 
fraction of T. brucei bloodstream forms and, in order to provide unambiguous 
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validation, only considered peptides showing at least three fragment ions. Some 
low abundant peptides or phosphorylation events elsewhere in the cell may 
therefore have escaped analysis.  
Around 10% of described PH domains have high affinity and specificity for 
phosphoinositides, with small KD values that make them behave as membrane 
targeting sequences (Paterson et al., 1995; Lemmon, Ferguson and Abrams, 
2002). Others, of lower affinity, act more in protein-protein interaction, such as 
binding the  subunits of G proteins (Touhara et al., 1994; Pitcher et al., 1995), 
actin (Yao et al., 1999), RACK1 (Rodriguez et al., 1999) or PKC (Yao et al., 
1997).  
Given the role of RDK2 in the pathways regulating T. brucei differentiation, it is 
possible the kinase influences membrane and cytoskeletal remodelling through 
the PH domain. For example, expression of procyclins on the surface (EP and 
GPEET) (Vassella et al., 2000), and VSG removal (Ferguson et al., 1988; 
Grandgenett et al., 2007) may affect RDK2 activity and localization. The 
glycosylphosphatidylinositol (GPI) anchors that attach the different surface 
glycoproteins to the membrane (Schwede et al., 2015) are an example of a 
structure that may interact with RDK2 via the PH domain. This deserves to be 
investigated further. 
4.4.3  Molecular validation of the RDK2 RNAi phenotype 
Molecular validation of the phenotype observed upon RDK2 RNAi was conducted 
with an RNAi-refractory recoded version of the gene able to complement the 
endogenous protein after RNAi-mediated loss. A first clone (sTL768) was capable 
of nearly 100% recovery of the wild type phenotype, with clear expression of the 
HA-tagged recoded protein, indicative of the RNAi not producing off-target 
effects. When the same construct was introduced with a mutation in the 
catalytic lysine, the phenotype could not be rescued. This finding would validate 
RDK2 as a potential drug target for kinase inhibitors, since the lack of activity, 
and not depletion of the protein itself, appears responsible for the phenotype. 
Differentiation to procyclic forms, preceding cell death, EP procyclin expression 
could be exploited as a reporter of RDK2 inhibition in a phenotypic screen of 
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trypanocydal compounds. This approach was attempted in the following chapter 
of this thesis. 
Unfortunately, the above evidence for complementation is compromised by the 
observation that other clones, which also showed protein expression in western 
blot, were only partially able to rescue the wildtype phenotype.  
One possible explanation is the approach used to achieve RDK2 depletion 
independently from NEK12.1. RDK2-specific fragments longer than 20 
nucleotides (divergent from NEK12.1) were artificially assembled. Cleavage via 
Dicer (Patrick et al., 2009) of the resulting double-stranded RNA may produce 
unwanted small silencing RNA fragments encompassing the artificial junctions 
and binding undesired transcripts for degradation. However, RNAi having off 
target effects is difficult to envisage since the phenotype observed with the 
potentially conflictive RDK2-specific construct was identical to that observed 
with the construct that targeted also NEK12.1 (Jones et al., 2014). Another 
possible explanation for this complementation failure would be a need of tightly 
controlled levels of expression for the protein kinase to act correctly. Indeed, 
inducible overexpression of RDK2 caused a noticeable growth defect. Finally, the 
infrequent codons used to recode the gene (Figure 4-8A) may bind less abundant 
tRNAs, leading to suboptimal expression levels. This has been proposed to be 
part of the unconventional gene expression regulation in T. brucei (Horn, 2008). 
Supporting this idea, a large number of parasites -107 parasites/lane- were 
required to obtain the western blot signals in Figure 4-9A and Figure 4-10C. 
Profiling RNA levels for RDK2REC by qRT-PCR could shed light on this. 
An alternative validation system for RDK2 function would be deletion of the 
gene. If loss of fitness driving to cell death is still a consequence of RDK2 
depletion, a knockout line would be impossible to make, but a conditional null 
mutant is a possibility. A successful approach for this is replacing 1 gene allele 
with a selectable marker and introducing a Tet-inducible copy of the gene in the 
RRNA locus (Damerow et al., 2016). The second endogenous allele is then 
removed while complementing the gene expression from the RRNA copy. Finally, 
a null mutant is induced by removing tetracycline. For RDK2, we would need to 
explore the untranslated regions to see if it is possible to remove specifically 
RDK2, since homology with NEK12.1 may be a challenge. 
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Alternatively, it might be worth implementing the CRISPR/CAS9 genome editing 
technology, which has been probably the last revolution in the molecular biology 
field. Since this system has been developed and applied successfully in 
Trypanosoma cruzi (Lander et al., 2015), Leishmania major (Sollelis et al., 2015) 
and Leishmania donovani (Zhang and Matlashewski, 2015), an inducible version 
could also by attempted in Trypanosoma brucei. The approach would have great 
potential as it would be used in the same manner than RNAi is used today, with 
potential for whole genome screening. It has been recently done in Toxoplasma 
gondii (Sidik et al., 2016). Using a 2T1 background, the sgRNA sequence could be 
introduced in the RRNA locus under control of the Tet-operator and the Cas9 
expressed from the tubuline array. We would need to deal with the problem of 
modulating Cas9 to avoid off target cleavage and toxicity. In other organisms 
they solved that problem developing inducible systems (Dow et al., 2015).  
Finding a specific inhibitor of RDK2 to attempt chemical validation of the 
phenotype would provide an alternative approach. RNAi refractory rdk2REC/A55C 
was designed with the objective of specific RDK2 inhibition with compound NCL-
00016066 (Mitcheson et al., 2016) in the RNAi line depleted of endogenous RDK2. 
However, the inability to reproduce the initial complementation with the 
recoded gene forced a stop in this analysis. Nonetheless, Chapter 5 describes a 
screening campaign devoted to find an RDK2 inhibitor; further details are 
provided there. 
4.4.4 RDK2 expression levels 
The main limitation of RNAi is that it degrades transcripts and it is not clear if 
all aspects of the proteome are equivalent to the transcriptome. Kinetoplastids 
encode genes in polycistronic units that, after transcription, are spliced and 
polyadenylated into mRNAs that can be stored in pools awaiting translation 
until, for example, signalling triggered by environmental cues initiates a 
developmental adaptation (Cassola, De Gaudenzi and Frasch, 2007). This system, 
where RNA stability plays a fundamental role, enables a fast life cycle 
progression when survival of the parasite requires it. Endogenous tagging of 
RDK2 would be a useful strategy to understand better the RNAi effect on the 
cellular pools of the protein: how long before the transcript absence becomes 
severely depleted can the stocks of protein that were available prior to RNAi 
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last? Expression of EP procyclin can be detected by 36 h, but Jones et al 
reported, for the cell line targeting RDK2 used here, successful transcript 
depletion from 24 h onwards (Jones et al., 2014). 
Detailed profiling of T. brucei protein expression upon bloodstream to procyclic 
differentiation triggered by CCA has been recently described (Dejung et al., 
2016). In that work, slender and stumpy bloodstream forms are compared to 
established procyclic forms and six different time points along the 
differentiation programme (2 h, 4 h, 6 h, 12 h, 24 h and 48 h). RDK2 was highly 
expressed in bloodstream forms, with a significant increase upon stumpy 
differentiation that was sustained during the first 24 h post CCA treatment. In 
the 48 h time point, expression drastically decreased, being completely absent 
in established procyclic forms. A peak in transcript abundance found in slender 
forms preceded the peak of protein expression observed in stumpy forms. This 
‘transcriptomic anticipation’ pattern was repeated later, as a decrease in RNA 
levels was detectable between 18 h and 24 h within the programme of 
differentiation (Kabani et al., 2009; Queiroz et al., 2009), whilst not being 
evident at a protein level until 48 h. It is interesting how this matches the 36-
48h time frame required for the RNAi phenotype to arise (Figure 4-2B-D) and 
supports the idea of RDK2 transcription arrest, inferred from the transcriptomic 
datasets (Kabani et al., 2009; Queiroz et al., 2009), being a consequence of CCA 
treatment.  
A possible hypothesis to take these data into account is that major remodelling 
following life cycle progression affects RDK2’s interaction network and also the 
signalling regulating its expression levels. Here the PH domain could play an 
interesting role; for instance, it may dynamically target RDK2 to the membrane 
surroundings, which is object of some of the major remodelling events, or it may 
mediate interactions with other, unknown proteins. In this regard, it is 
interesting that another fundamental protein involved in membrane remodelling 
following CCA treatment, GPI-PLC, has a similar expression profile to RDK2 in 
the quantitative proteomics screen (Dejung et al., 2016).  
Overexpression experiments showed RDK2 to be localised throughout the BSF 
cell, although proper deconvolution of the fluorescent signal would be necessary 
to determine if it is located in the membrane environment. Also, the 
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overexpression may cause abnormal localization and it would be better to 
conduct such analysis tagging the original locus or raising an antibody against 
RDK2 in order to observe natural levels of expression. 
4.4.5 RDK2 depletion and known pathways of bloodstream-to-
procyclic differentiation. 
If we assume that the RNAi effect is exclusively a consequence of RDK2 
depletion, as the first complementation experiment seemed to suggest, it is still 
not easy to disentangle the exact role this protein kinase plays in the 
differentiation cascades. From the three pathways that have been described to 
trigger bloodstream-to-procyclic form differentiation in vitro (CCA treatment, 
mild acidic conditions and mild protease digestion), the first two have been 
proven to act through a phosphatase cascade involving TbPTP1 and TbPIP39 
(Szöőr et al., 2013). The same effect can be reproduced by inhibition of TbPTP1 
with a tool compound, BZ3 (Szöor et al., 2006). In the data shown in Figure 
4-13B, after CCA treatment at 37 oC, there were only ~5% of differentiation-
competent stumpy* cells but this effect increased to ~60% if pre-treated with 8-
pCPT-cAMP. These are the same changes observed for uninduced cells in the 
RDK2 over-expresser line, and for the parental 2T1 strain. These observations 
suggest that the uninduced mutants are good controls. Tetracycline-inducible 
constructs based on the pRPa vector (Alsford and Horn, 2008), used here for 
RNAi and overexpression, can only act on the ~95% of cells that are slender 
replicative forms, because in differentiation-competent stumpy* forms the 
transcription machinery required for production of the double stranded RNA or 
mRNA is quiescent (Brecht and Parsons, 1998; Capewell et al., 2013). 
Interestingly, in cells overexpressing RDK2, if stumpy* formation was induced by 
incubation with cAMP analogue for 24 h, washed, and incubated with CCA at 27 
oC for further 24 h, only ~5% were procyclin positive (see Figure 4-11). Assuming 
that only stumpy* cells are able to progress in the life cycle upon CCA 
treatment, we can hypothesize that RDK2 overexpression blocks stumpy* 
formation. This interpretation contradicts the elevated expression of RDK2 
observed in stumpy forms (Dejung et al., 2016). However, this dichotomy could 
be explained if the increase in expression of RDK2 were a consequence, and not 
Chapter 4 199 
 
a cause, of stumpy formation. Further experiments to evaluate stumpy markers, 
such as PAD transporter staining, are needed to test this hypothesis. 
Figure 4-13B shows that RDK2 depletion alone at 37 oC  triggers procyclic form 
differentiation to similar levels (~60%) obtained by CCA treatment in stumpy* 
cells enriched with 8-pCPT-cAMP. However, the reason why CCA treatment 
decreased the extent of differentiation obtained with RDK2 RNAi remains 
intriguing. The extra EP procyclin expression found if RNAi induced and CCA 
treated cells are incubated at 27 oC (~25%) matches the extra expression 
observed at 27 oC when the “residual” stumpy* population in the uninduced 
culture was treated with CCA. One explanation may be that formation of 
procyclic form cells in these conditions represents the additive effect of 
differentiation of slender or intermediate forms by RNAi and differentiation 
produced by CCA only in the residual stumpy* population. Slender and stumpy 
states are two ends of a developmental progression, which has many 
intermediate stations (Mony and Matthews, 2015). Under the proposed model 
(Figure 4-14), it may be that some of the transcriptionally active (RNAi 
susceptible) intermediate cells are already receptive to CCA by expression of 
PAD transporters (Dean et al., 2009), and that the concomitant effect with RDK2 
depletion is counter-productive. PAD expression should be analysed to test this. 
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Figure 4-14. Model of RDK2 RNAi-mediated differentiation interconnection 
with CCA-TbPTP1 pathway.  
A. Stumpy* cells are transcriptionally silent and insensitive to RNAi action, while 
expressing PAD transporters able to convey CCA signalling. Slender replicative 
forms are sensitive to RNAi but do not have PAD transporters to convey the CCA 
signal. BZ3 inhibits TbPTP1, which is a downstream effect of CCA, regardless the 
presence of PAD transporters. B. (1) Proposed CCA differentiation pathway 
involving RDK2 inactivation as a downstream effect, which produces viable 
procyclic forms. (2) Effect of RDK2 RNAi depletion when TbPTP1 is active, 
producing non-viable procyclic forms. (3) Effect of concomitant RDK2 RNAi-
depletion and BZ3-mediated inactivation, which produced a reduced procyclic 
positive population of untested viability. Such effect could be triggered by CCA 
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in a fraction of the population expressing PAD transporters while maintaining 
active transcription (intermediate forms). 
As mentioned above, under natural CCA-mediated action, RDK2 abundance 
remains high for the first 24 h on the differentiation programme; after 48 h it is 
reduced to levels found in slender forms and it is absent in established procyclic 
forms (Dejung et al., 2016). RDK2 presence may be a requirement for the CCA-
mediated mechanism during the first 48 h of treatment, while RDK2 depletion in 
standard bloodstream conditions may trigger the mechanism through a different 
pathway that renders imperfect procyclic cells unable to survive for long, Figure 
4-14B. Perhaps, CCA action changes the normal interactome of RDK2 in 
bloodstream forms, which may be required in the RNAi-triggered mechanism in 
order to produce a differentiation effect. Analysing RDK2 interaction partners 
through BioID (Roux et al., 2012) or immunoprecipitation linked to mass 
spectrometry in slender and stumpy bloodstream forms would be very 
informative.  
TbPTP1 inhibition with BZ3 at 37 oC, as shown Figure 4-13B, reinforces the above 
interpretation, since this treatment, which mimics a downstream effect of CCA 
treatment (Szöor et al., 2006), reduces the extent of RNAi-mediated 
differentiation (~20%) to similar levels of CCA alone. In contrast, the percentage 
of uninduced cells differentiated with BZ3 -which does not require PAD 
transporters to penetrate the cell- was similar to what it is achievable after 
consecutive treatment with 8-pCPT-cAMP and CCA. Altogether, these data 
suggest that the conflict between RDK2 RNAi-mediated differentiation and the 
CCA pathway happens downstream of TbPTP1. 
To sum up, the additive effect with RNAi observed after 8-pCPT-cAMP+CCA 
treatment can be explained by CCA-differentiation of the extended stumpy* 
population produced via 8-pCPT-cAMP. Due to transcription silencing, RNAi 
would have no penetrance in that population. The rest of differentiated cells 
would be a product of a conflict between the RNAi depletion and PTP1 inhibition 
mechanisms. On the other hand, under BZ3 treatment, we only see 
differentiation for the reduced population, as a result of the conflict between 
RDK2 RNAi and TbPTP1 inhibition. If RDK2 is not present, TbPTP1 inhibition is not 
that effective in triggering differentiation and, if TbPTP1 is not active, RDK2 
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RNAi is not capable of differentiating cells. The interactions within this intricate 
network would change between slender and stumpy stages. 
The reason why 8-pCPT-cAMP/CCA treatment permits an additive effect with 
RNAi, but BZ3 does not, would be that CCA requires PAD to penetrate stumpy* 
cells (where RNAi is uneffective), while BZ3 acts without needing stumpy* 
formation and therefore can interfere with changes following RDK2 RNAi. CCA 
would still be able to interfere with RNAi in intermediate cells, which are 
expressing PAD receptors but are transcriptionally active.  
The transport of PAD receptors to the parasite surface increases at 27 oC (Dean 
et al., 2009), which may explain why our 8-pCPT-cAMP-treated uninduced cells 
are more responsive to CCA at this temperature, Figure 4-13. We have no data of 
combined 8-pCPT-cAMP and BZ3 treatment to see whether it expands the 
procyclin positive population in uninduced cells, as occurs with CCA. If the only 
cellular rearrangement important for differentiation in stumpy* cells is targeting 
PAD transporters to the membrane, it would not increase the extent of 
differentiation triggered by BZ3. 
Although TbPTP1 inhibition (artificially produced via BZ3 treatment) mediates 
differentiation caused by mild acidic treatment, we have not tested directly the 
effect of RDK2 depletion under lower pH conditions. On the other hand, 
divergent differentiation pathways activated by mild protease digestion (Szöőr 
et al., 2013) might be of particular interest as, although RDK2 inactivation and 
depletion seems to be a consequence of TbPTP1 inactivation, early depletion 
must cause differentiation through a slightly different route. Protease 
treatment, to which procyclic forms are resistant (Acosta-Serrano et al., 2001), 
has been described to cause differentiation faster and in a more synchronous 
manner than CCA. Interestingly, this effect happens mainly in stumpy forms, as 
this treatment rapidly kills slender forms (Sbicego et al., 1999). A hypothesis 
that needs to be tested is that proteases may cause membrane remodelling that 
is able to trigger a similar effect to the one caused by RDK2 depletion, 
considering possible implications discussed for the PH domain. We know, for 
instance, that a metalloprotease (TbMSB-B) is responsible for VSG coat 
detachment (Grandgenett et al., 2007), a fundamental step in the process of 
bloodstream-to-procyclic differentiation. In addition, CCA and mild protease co-
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treatment produces a synergistic effect in differentiation (Sbicego et al., 1999), 
similar to the one observed here after combination of 8-pCPT-cAMP/CCA 
successive treatment with RDK2 RNAi. 
4.4.6 RDK2 depletion and the T. brucei cell cycle 
Differentiation to procyclic forms triggered by CCA requires cell cycle-arrested 
stumpy forms (Rico et al., 2013). To have an effect, RDK2 RNAi may require G1 
cells too. After 72 h of induction the procyclin-positive population seems 
enriched in 1N1K and aberrant cells, while the negative population looks 
enriched in 2N2K cells (see Figure 4-3C). However, the number of 
undifferentiated cells currently examined (n=38) limits the reliability of this 
counting. Indeed, contradicting this datum, DNA staining in immunofluorescence 
microscopy (n=200) or flow cytometry after 48 h RNAi showed the same cell 
cycle distribution in differentiated and undifferentiated cells (see Figure 4-3C 
and D). 
Enrichment in 2N2K cells and accumulation of an aberrant population indicated a 
block in cytokinesis between 36-48 h, coinciding with the first symptoms of 
growth arrest, see Figure 4-3A. Both cohorts of cells decreased at the 72 h time 
point, when cell death had clearly occurred, suggesting aberrant cells are those 
that die first. Surviving EP positive populations were enriched in 1N1K cells, but 
a remnant of aberrant cells were still present, as cell death continued for 
another 24h, Figure 4-3C. 
Synchronizing the cell cycle, such as with hydroxyurea (Mutomba and Wang, 
1996), would help in understanding how the different aspects of the RNAi 
phenotype come together in the context of the cell cycle, including change of 
shape, kinetoplast repositioning, EP procyclin expression, cytokinesis arrest and 
aberrant combinations of nuclear and kinetoplast DNA. In addition, 
characterising in more detail the aberrant population could also be informative. 
In the model we are proposing (Figure 4-14), when CCA induces procyclic 
formation from stumpy* forms, it also triggers a progressive loss of RDK2, as 
observed by quantitative proteomics (Dejung et al., 2016). As can be inferred 
from the effect that RNAi has in differentiation, RDK2 depletion would cause EP 
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procyclin expression, kinetoplast repositioning and cell elongation. If RDK2 is 
RNAi-depleted without rearrangement of its interaction network triggered by 
CCA treatment (and not as a cause of it), an aberrant differentiation would 
happen that would rapidly render the cells inviable. 
4.4.7 RDK2 RNAi phenotype 
RDK2 transcript depletion has been reported from 24 h post RNAi induction. The 
differentiation phenotype was evident from 36 h, with cell elongation, 
kinetoplast repositioning and EP procycling expression. Growth arrest happens 
between 36 h and 48 h and is associated with an eventual block in cytokinesis, 
which develops into aberrant cells that most likely end up dying. After 72 h of 
induction, cell numbers dropped 10 fold. 
Consistent with what has been reported in the literature at a transcriptomic and 
at a proteomic level (Kabani et al., 2009; Queiroz et al., 2009; Dejung et al., 
2016), RDK2 is no longer needed after differentiation is triggered. 
Differentiation is, most likely, irreversible. No substantial difference was 
observed between cultures whether tetracycline was maintained or removed 
(see Figure 4-4). The different attempts made to grow RNAi-differentiated cells 
as real insect-infective parasites failed to acquire standard densities of procyclic 
form cultures (~107 parasites ml-1). The cells that resulted from these 
experiments died slowly over the course of a week in fresh SDM79, but 
maintained population numbers for at least one week if cultured in conditioned 
media. Nonetheless, in these conditions the cells were still unable to grow. The 
reasons why conditioned media maintains procyclic forms generated by RDK2-
depletion alive and not the fresh media requires further investigation. The same 
media killed uninduced bloodstream forms in less than 24 h.  
The plastic-adhesion phenotype in conditioned medium is also an interesting 
feature. The fact that it was only observed in plates might be explained if 
instead of death, cells were attached to the bottom of the standing up flasks, 
precluding their quantification. This phenotype was long ago reported for 
epimastigotes, which require attachment for division to the tsetse salivary 
glands; it has also been observed in vitro for T. vivax, T. cruzi and T. congolense 
(Vickerman, 1969; Figueiredo, Rosa and Soares, 2000; Sakurai, Sugimoto and 
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Inoue, 2008). As it happens with proventricular forms although they do not 
attach until reaching the salivary glands, RNAi RDK2 cells could be maintained 
alive but they were not dividing. T. brucei epimastigotes, however have been 
always challenging to culture (Wallbanks, Molyneux and Dirie, 1989).  
It would be interesting to test stage-specific markers of tsetse fly-infective 
forms in immunofluorescence for better characterisation. Early procyclics, the 
first stage upon differentiation from bloodstream trypomastigotes, express 
GPEET procyclin (Vassella et al., 2000). This early stage shows social motility in 
vitro and is present in the midgut before colonization of the ectoperitrophic 
space (Imhof et al., 2014). Other interesting marker would be BARP, a stage-
specific surface antigen of salivary gland forms, that would tell if the plastic 
adhesion phenotype is closer to them than to early procyclics. Finally, levels of 
expression of RBP6 (Tb927.3.2930), might be worth checking as overexpression 
of this RNA binding protein permited developing in vitro all stages of the 
parasite´s life cycle in the tsetse fly (Kolev et al., 2012). 
Full understanding of the RDK2 RNAi differentiation phenotype might necessitate 
using pleomorphic parasites. These are able to produce real stumpy forms in the 
context of an in vivo infection, which renders cells less virulent for the host 
(Turner, Aslam and Dye, 1995). Some of the natural mechanisms in the process 
of differentiation may be modified in monomorphs beyond their incapacity to 
monitor their own population progressing to stumpy in response to high 
densities. 
4.4.8 Final conclusion 
This chapter has proven RDK2 to be an active protein kinase, where one 
particular double mutation of the reported phosphoserines (RDK2S195A/S197E) 
interfered its capacity for phosphorylation. Mixed results attempting 
complementation of RNAi failed to provide molecular validation of the 
phenotype. A conditional null mutant or a specific chemical inhibitor could 
dispel doubts over the cause-effect relationship between RDK2 depletion and the 
observed phenotype. 
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The RNAi effect has branded RDK2 as a key regulator in the intricate signalling 
networks controlling life cycle progression of Trypanosoma brucei bloodstream 
form cells. RDK’s presence in the slender trypomastigote form seems to function 
as a molecular break for acquisition of many features of the insect-infective 
stage of the life cycle. When released, resulting parasites look like procyclic 
forms but are unable to survive and divide in their standard culturing conditions. 
It is interesting how, despite still not getting dense, these cells survive for over 
a week in conditioned SDM79. In this environment, they acquire a plastic 
adhesive phenotype, which is more characteristic of later stages in the insect 
infection.  
Overexpression of RDK2 blocks the most exploited method of differentiation for 
monomorphic parasites in vitro. Our results may suggest RDK2 has the capacity 
to inhibit 8-pCPT-cAMP’s ability to produce stumpy* forms. However, we need to 
use stumpy-specific markers such as PAD to confirm this. Our battery of flow 
cytometry experimental conditions give indications that RDK2 inactivation and 
depletion may be a downstream effect of the CCA-TbPPT1 inhibition axis, and 
that its inhibition alone leads to a frustrated differentiation.  
A lot more research is left to be done in order to explore RDK2’s role in the cell. 
Localizing the protein along the differentiation programme, and finding its 
interaction partners, are critical next steps. Understanding the metabolic 
implications of the RDK2 phenotype, would be also very interesting. Until a more 
convincing validation is achieved of the impact that RDK2 kinase activity has on 
the phenotype we cannot prove that a kinase inhibitor would have value as a 
drug target. This is the object of a more thorough discussion in the next chapter. 
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Chapter 5 Mechanism-based phenotypic screen 
for RDK2 inhibitors  
 
5.1 Introduction 
5.1.1 Rationale 
As described in the previous chapter and by Jones et al. (2014), RDK2 has a 
proven protein kinase activity and is essential for survival of Trypanosoma brucei 
bloodstream form in vitro and in vivo. Uniquely, RNAi knockdown of RDK2 also 
results in spontaneous differentiation to the insect-infective procyclic form 36 h 
prior to cell death. We reasoned that this unique phenotype should be amenable 
to a mechanism based phenotypic screen using protein kinase inhibitor libraries, 
where inhibition of RDK2 would be detected via the expression of EP procyclin, a 
marker for differentiation. In the previous chapter an antibody targeting this 
surface antigen was used extensively in immunofluorescence assay and flow 
cytometry. These approaches could be adapted to a screening set up using high 
content cell imaging, measuring fluorescence in a plate reader, or using plate-
based flow cytometry. Protein kinase inhibitors causing both cell death and 
differentiation would be perfect candidates to test against the recombinant 
protein to confirm on target mechanism of action. An RDK2 inhibitor would be 
both a useful research tool (permitting pathway dissection) and a potential 
starting point for drug development. 
5.1.2 Anachronistic differentiation to procyclic form as a 
therapeutic strategy  
Natural and synchronous differentiation to procyclic forms happens more readily 
starting from cell cycle arrested stumpy forms (Rico et al., 2013). They are the 
key stage for transmission to the tsetse fly, while slender replicative forms are 
the relevant form of the parasite during establishment of the mammalian 
infection. Slender forms are still able to differentiate when subjected to CCA, 
mild acidic conditions or protease digestion treatments but they do so 
asynchronously and in a lower proportion than stumpy forms (Rico et al., 2013). 
The parental line used to create our RNAi mutants (2T1) is monomorphic as it 
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lost its ability to differentiate into the stumpy form. Since they are closer to the 
life cycle stage that is critical for the infection, it makes differentiation and 
death triggered by RDK2 depletion more relevant for therapeutics. Cell death 
caused by RDK2 inactivation would be enhanced by the loss of VSG, concomitant 
with EP procyclin expression, resulting in parasite clearance mediated by the 
innate and adaptive immune responses (Schwede et al., 2015). 
Interestingly, the concept of triggering anachronistic differentiation to procyclic 
form in the bloodstream as a chemotherapeutic strategy has been proposed 
before at the Swiss Tropical and Public Health Institute (Swiss TPH) (Wenzler et 
al., 2016). Another monomorphic transgenic T. brucei line (GUSone), introducing 
-glucuronidase (GUS) as a reporter under control of the EP procyclin promoter, 
was screened against a collection of compounds. These compounds were 
selected for their structural similarity with citrate and cis-aconitate (CCA), their 
capacity to act as iron chelators (mimicking CCA function), or their known value 
as MAPK inhibitors. MAPK5 has been shown to be involved in slender-to-stumpy 
differentiation (Domenicali Pfister et al., 2006), so the authors reasoned that 
other MAPK might be involved in further progression of the life cycle. That 
screen was conducted in parallel to an alamar blue cell viability assay. As a 
result, 28 compounds were found with activity in the nanomolar range and all of 
them were capable of killing the parasites in vitro. The possibility of EP 
promoter activation being a stress response upon exposure to trypanocidal drugs 
was discarded as only ~9% of the lethal compounds produced GUS activation. 
Still unpublished, the same screening pipeline has been applied to the 1.8 
million compound collection of GlaxoSmithKline (GSK) selecting 302 compounds 
able to induce GUS expression in the lower micromolar range (Tanja Wenzler 
personal communication). 
5.1.3 High throughput screening campaigns targeting protein 
kinases of Trypanosoma brucei 
PKs of T. brucei have been shown to be druggable (Urbaniak et al., 2012). Being 
a PK, the prospect of identifying an RDK2 inhibitor with drug-like properties is 
promising. ATP analogues unable to transfer the phosphate have been exploited 
to compete with endogenous ATP for the active site causing PK inhibition (type I 
inhibitors), although allosteric inhibitors (type II-IV) -which do not directly block 
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ATP binding- can work with higher potencies as type I must compete with the 
relatively high intracellular concentrations of ATP (1-10 mM) (Gribble et al., 
2000). The PK domain is often accompanied by other structural features, which 
permit the design of molecules to achieve specific targeting of the active site in 
a particular PK. Conservation of the kinase domain through evolution has not 
hampered identification of inhibitors able to act with specificity, although it is 
more crucial to find parasite versus host specificity than intra-parasite 
specificity (Merritt et al., 2014). 
Knowledge and historic data available about chemical structures active against 
homologue PKs in other organisms (mainly humans) have encouraged design of 
drug repurposing strategies (Pollastri and Campbell, 2011). The proof of concept 
in T. brucei was a study testing 8 compounds in pre-clinical or clinical stages 
targeting mammalian phosphoinositide-3-kinase (PI3K) or target of rapamycin 
(TOR) for inhibition (Diaz-Gonzalez et al., 2011), two enzymes related to 
cellular growth and proliferation. There, a compound (NVP-BEZ235) had sub-
nanomolar potency against the parasite both in vitro and in vivo. However, the 
exact mode of action in the parasite has not been identified yet. The same 
approach, where compounds with known activity against human targets are 
tested and optimized for efficacy/specificity based in SAR studies has been 
applied to Aurora kinase inhibitors (Jetton et al., 2009; Li, Umeyama and Wang, 
2009; Ochiana et al., 2013), and protein-tyrosine kinase inhibitors (Katiyar et 
al., 2013; Patel et al., 2013; Behera, Thomas and Mensa-Wilmot, 2014). 
Later a larger screening campaign tested 2979 compounds with structural 
analogy, >70% Tanimoto similarity (Bajusz, Rácz and Héberger, 2015), to the 
mentioned PI3K/TOR inhibitors; the protein kinase inhibitor set (367 compounds) 
published by GSK (Dranchak et al., 2013); and another 39098 compounds in their 
collection (Diaz et al., 2014). There, 242 compounds inhibited cell growth and 
137 resulted in lethality for the parasite with 100-fold selectivity when 
compared to human HepG2 cells. All of them had potencies in the sub-
micromolar range of concentration. 
In addition, another recent publication showed how the entire 1.8 million GSK 
compound collection was screened for cidal activity against Leishmania 
donovani, Trypanosoma cruzi and Trypanosoma brucei (Peña et al., 2015). For 
Chapter 5 210 
 
each of the parasites a primary screen was conducted followed by a 
confirmatory replicate with the anti-kinetoplastid hits, an orthogonal assay for 
validation, an in silico filtration process based on drug-like physicochemical 
properties, a dose-response titration to select those with sub-micromolar 
potency, and an acute cytotoxicity test against human cells. After this 
campaign, an anti-T. brucei collection of compounds was selected, the “HAT 
box”, containing 192 lead-like chemicals with trypanocidal activity in the 
nanomolar range and drug-like physicochemical properties (including potential 
central nervous system penetration). It is encouraging that >90 compounds 
contained there, had a history of sub-micromolar potency as protein kinase 
inhibitors in the records of the company.   
The Dundee focused kinase inhibitor collection (3885 compounds), has been also 
used in a phenotypic screen against T. b. rhodesiense identifying 121 compounds 
causing >50% inhibition at 5 M. These hits were screened against T. b. brucei 
finding three compounds that shared a chemical scaffold and had submicromolar 
potency and selectivity against human cells. Optimization of these compounds to 
achieve enhanced metabolic and physicochemical properties led to two 
promising series of compounds: 1H-imidazo[4,5-b]pyrazin-2(3H)-ones, with 
cytostatic properties; and 1H-pyrazolo[3,4-b]pyridines, with cytocidal properties 
(Woodland et al., 2015). 
5.2 Research aims 
The aim of the experiments presented in this chapter was to identify inhibitors 
of RDK2, able to provide a chemical validation for the RNAi phenotype: 
differentiation to procyclic-like forms followed by cell death at 37oC in HMI11. A 
specific RDK2 inhibitor would have value as a tool to dissect RDK2 signalling 
without the limitations of RNAi in transcriptionally arrested cells. This would 
enable work with pleomorphic parasites, able to produce stumpy forms. Such a 
compound would be also a lead-like chemical with potential for drug discovery. 
A major output for the project would be the identification of a molecular target 
for one or more hits within the screening campaigns described in the 
introduction. 
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5.3 Results 
5.3.1 Compound selection 
We reasoned that some RDK2 inhibitors were likely to be found among the sets 
of compounds described in the introduction to this chapter. They were either 
potential kinase inhibitors, or agents causing T. brucei death/differentiation. 
Interestingly many of them would have already been selected for their cidal 
activity in the lower micromolar and nanomolar range, parasite specificity 
against human cells, and filtered for their drug-like physicochemical properties. 
We initiated collaboration with researchers at Swiss TPH and GSK in order to test 
their compounds using our assay. After signing a material transfer agreement, 
we obtained 518 compounds including 188 members of the HAT box, where many 
had a history of protein kinase inhibition (Peña et al., 2015); 45 kinase inhibitor 
chemotypes (Diaz et al., 2014); and 283 GUS inducing compounds (still 
unpublished), selected in the same screen format as described in the 
introduction above (Wenzler et al., 2016). 20 l of each compound were shipped 
in two 384-well storage plates at 1 mM concentration in DMSO. 
5.3.2 High content cell-based screen optimization 
We have already shown in the previous chapter that EP procyclin expression is a 
surface marker of procyclic differentiation that can be traced with a specific 
antibody conjugated directly or indirectly to a fluorophore (Richardson et al., 
1988). As RDK2 RNAi phenotype involved bloodstream-to-procyclic form 
differentiation before killing the cells, we reasoned that such antibody could be 
exploited as a reporter in a primary screen for compounds inhibiting RDK2. If 
able to reproduce the RNAi phenotype, such compound would trigger EP 
procyclin expression before causing cell death.  
5.3.2.1 Fluorescence detection on a plate reader 
At first, we considered to analyze the EP-linked fluorescence signal in a high 
content cell-based screen using a plate reader. Trypanosoma brucei bloodstream 
forms reach the stationary phase of growth around 106 parasites x ml-1. It cannot 
reach concentrations over 4 x 106 cells x ml-1 and concentration increases 10 
times every 24 h when they are in the logarithmic phase of growth, Figure 4-2. 
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The use of a 384-well format, where the maximum volume capacity is 40 l, was 
discarded as the reduced amount of cells required to seed a 48 h-long incubation 
in such platform (400 cells/well, at 104 cells/ml) could risk uneven distribution 
of cells across the plate. 96-well plates would provide a more robust distribution 
and was an acceptable setting as we were to screen only 518 compounds. 
The protocol we used in the previous chapter for flow cytometry and IFA 
entailed the use of two antibodies (a mouse IgG anti-EP procyclin, and an 
antimouse IgG1 allophycocyanin-conjugated), and a fixation step with 
paraformaldehyde (PFA). We adapted the protocol to use with an automated 
liquid handler (Beckman BioMek FXp©), available at the Scottish Bioscreening 
Facility. After testing different makes of plates, with diverse well shapes and 
types of plastic, we chose 96 well V-bottom sterile Cellstar® (Grainer Bio-one, 
Cat. Num: 651180). V-shaped bottom enabled a better recovery of cells after 
centrifugations in the staining protocol than round or flat bottoms. They 
concentrated the parasite pellet and reduced the volume left in the plate 
(“dead volume”) after supernatant removal. Growth curves performed in these 
plates with 2T1 parasites confirmed that parasite cell density increased at the 
same rate as they did in flasks or larger plates, Figure 5-2C. After staining, cells 
were transferred to black 96-well plates with flat bottom before measuring in a 
plate reader. 
A test run was conducted using RDK2 RNAi line (sTL629), tet-induced and 
uninduced, plating the cells 48 h before fluorescence analysis (6 replicates), 
Figure 5-1A. Unfortunately, overlapping of differentiation and death phenotypes 
quenched the fluorescence signal. As the number of cells in the Tet-induced 
wells had decreased in comparison with the uninduced (see RDK2 RNAi 
phenotype in the previous chapter, Figure 4-2), the EP procyclin-associated 
fluorescence signal could not be distinguished from the background (Figure 
5-1A). To confirm this, the same experiment was performed, incubating the cells 
in separate flasks for 48 h, counting them, and plating equal numbers before 
proceeding with antibody staining and measurement in the plate reader, Figure 
5-1B. As expected, a significant increase in fluorescence associated to EP 
procyclin expression could be detected in the Tet-induced wells. 
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Figure 5-1. Differentiation phenotype caused by RDK2 RNAi as observed in a 
plate reader using an anti EP procyclin antibody.  
Cell death quenched fluorescence intensity in RNAi-differentiated cells. A. Plate 
reader results of endpoint intensity for indirect immunofluorescence (EP-
Alexa488), uninduced (Tet-, n=6), and 48 h induced (Tet+, n=6). Cells plated at 
104 parasites x ml-1 48 h before reading. B. Same as A, but plating equal number 
of Tet+ and Tet- cells just before reading. Comparisons made with paired T tests 
(* = P<0.05, and ns= P>0.05). 
 
5.3.2.2 Fluorescence detection on a flow cytometer 
In the previous chapter, we used flow cytometry to assess differentiation via 
detection of fluorescence associated to the anti EP-procyclin antibody. In flow 
cytometry, fluorescence intensity is assessed at a single-cell level and for a fixed 
number of recorded events. We reasoned that this would circumvent limitations 
described for the plate reader when differentiation and cell death phenotypes 
overlapped. If as many cells as were necessary to match the set number of 
recorded events remained alive in the wells, we could still establish meaningful 
comparisons. In addition, EP procyclin positive results would be expressed as a 
percentage of the population. It would make different wells comparable 
regardless the number of recorded events. Availability of a flow cytometer 
equipped with a 96 well plate sampler (Miltenyi Biotec MACSQuant®) at the 
Wellcome Trust Centre for Molecular Parasitology permitted the adaptation of 
the EP procyclin expression assays shown in the previous chapter to a 96-well 
plate format.  
Incubation time 
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We assumed that the phenotype caused by protein kinase inhibition would be 
detectable sooner than the phenotype caused by RNAi. A cell permeable 
compound would block RDK2 activity almost immediately, whilst RNAi-mediated 
transcript depletion would only prevent production of new protein. It would 
require depletion of available cellular stocks before producing a phenotypic 
effect. As a reference, EP procyclin is detectable 6 h after treatment in 
monomorphic cells differentiated in vitro with cis-aconitate (Bütikofer et al., 
1999). A compromise between detectable levels of EP procyclin and sufficient 
numbers of viable cells needs to be met. Since RNAi-triggered EP procyclin 
expression was traceable from 36 h onwards and cell death started after 48 h, 
the chosen incubation time was 24 h.   
Culture volume and layout 
T. brucei culture conducted in chapter 4 was carried out always in volumes 
equal or larger than 5 ml. For this screen, assay volumes were reduced to 100 l 
in order to minimize the amount of compound consumed, and maintaining 
concentration of their solvent (DMSO) under 1%. Previous tests performed in our 
lab showed that 1% DMSO caused no harm to the parasites. 100 l instead of 200 
l left also extra room for the 5% CO2 atmosphere. 
A schematic representation of the plate preparation is shown in Figure 5-2A, 
including the lay out, Figure 5-2B. 2T1 bloodstream forms were used both as the 
negative control (8 wells, incubated with 1% DMSO only) and the screening 
subject (incubated with the compounds, also at 1% DMSO). The positive control 
was RDK2 RNAi line (sTL629) induced 48 h prior to flow cytometry analysis and 
plated only for the last 24 h. 8 wells were seeded (at the same time than 2T1 
cells) at 1x106 parasites x ml-1 because they experience growth arrest between 
24-48 h of RNAi induction (chapter 4). The automated flow cytometer 
(MACSQuant®) takes samples in a column-by-column basis, moving from A-H 
within each of them and progressing through the plate from left to right,Figure 
5-2A. The bottom row of each plate (except for wells H1 and H12) was filled 
with 100 l of flow cytometry cleaning solution. This enabled washing the 
equipment circuit once every 7 samples. These arrangements left room for 70 
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compounds to be tested per plate and gave us capacity to run 2 plates per day, 
with an average sampling time of 4h per plate.  
 
Figure 5-2. Flow cytometry screen plate processing strategy.  
A. Schematic representation of the primary screen time frame including: 
induction of the positive controls 24 h prior to plate layout; compound stamping 
and plating of cells (0 h); and antibody staining and flow cytometry screen after 
24 h incubation. Sampling direction highlighted. B. Plate layout. C. Growth curve 
of the RNAi line (Tet+/Tet-) in one of the 96 well V-bottom sterile Cellstar® 
plates used in the screen. 
 
In T. brucei 2T1 (or uninduced derived lines) cell numbers grow 10 times every 
24 h in HMI11 at 37oC, also in the 96-well V-bottom plates used for this screen. 
They reached the stationary phase at around 2x106 parasites x ml-1, Figure 5-2C. 
With this in mind, we seeded our assay plates at 2x105 parasites x ml-1 24 h prior 
to flow cytometry analysis. In this way, we could maximize the number of cells 
per well at the sampling time point: 100 l at 2x106 parasites x ml-1, i.e. 2x105 
cells in total. 
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Antibody optimisation 
Antibodies are expensive consumables. Besides reducing the volume needed per 
well, optimizing the staining protocol was critical. The immuno-detection 
strategy used for flow cytometry in the previous chapter was indirect. The use of 
one fixation step, two antibody incubations and profuse washing entailed high 
risk of losing cells. The primary antibody was a mouse IgG anti-EP procyclin 
(Richardson et al., 1988), and the secondary was an anti-mouse IgG1 made in 
goat and conjugated to the fluorophore allophycocyanin (APC). APC can be 
excited at 594 and 633 nm having a fluorescence emission peak at 660 nm.  
In Figure 5-3, we show different antibody conditions (A-D) that were tested 
using: 2T1 bloodstream forms, as a negative control for EP procyclin expression; 
Lister 427 wild type procyclic forms, as a positive control for procyclic 
expression; differentiated 2T1 cells upon incubation 24 h with 100 M pCPT-
cAMP and 24 h with 3 mM citrate-cis-aconitate (CCA); RDK2 RNAi cells 
differentiated by 48h induction with 1 M tetracycline. There, we show that 
using fluorescein isothiocyanate (FITC) or equivalents such as Alexa Fluor®488 
(490 nm excitation/525 nm emission), produced a reduced signal:background 
ratio when compared to APC. This may happen due to parasite autofluorescence, 
which has been observed in the green channel of detection using 
immunofluorescence microscopy upon fixation. It is unfortunate as a primary 
anti EP procyclin antibody directly conjugated to FITC was commercially 
available and could have reduced the number of incubation and washing steps. 
The concentration of this antibody required to obtain a useful signal:background 
window was too high (1:100), Figure 5-3. 
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Figure 5-3. EP procyclin antibody optimization.  
Histograms showing number of events detected in flow cytometry (frequency) 
versus fluorescence intensity associated to EP procyclin expression. Data 
analysed with four different antibody staining conditions (A-D, annotated in the 
right hand side); and for four different type of cells: wild type 2T1 bloodstream 
forms; 2T1s differentiated to procyclic forms with pCPT-cAMP + citrate/cis-
aconitate (CCA) at 27oC; RDK2 targeting RNAi line induced for 48h; and Lister 
427 procyclic forms. 
 
We diminished the antibody volume used in both incubations, from 100 l to 50 
l per well at the staining dilution (1:500 for the primary, and 1:1000 for the 
secondary). And we reduced from 3 to 2 the number of washes after, including a 
previous large-dilution step adding 150 l of PBS over the 50 l of antibody. 
Cell fixation 
Large-scale experiments described in the previous chapter, relied on 2% 
paraformaldehyde treatment in order to fix the cells prior to flow cytometry 
analysis. A challenge encountered during protocol optimization was cell 
clumping and adhesion to the walls. These problems caused abundant loss of 
cells during transfer of the final parasite suspension into the flow cytometry 
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tubes by filtration through a Nitex mesh membrane. This step is recommended 
as cell clumps can block the microfluidics system in the flow cytometer or hinder 
identification of events associated to individual cells. The problem of plastic 
adhesion was solved first by fixing at the end, after the antibody staining, with 
cells already in the destination tubes. But still it involved cell clumping that 
would entail cell loss during the filtration process, or would risk obstructing the 
equipment. Given the small cell numbers we handled in the 96 well setup, we 
decided to miss the fixation step by keeping cells alive on ice and cold during 
the whole screening process. 
Once optimized, this system ensured that it was possible to record 6000 
parasite-associated events in flow cytometry for the 2T1 negative controls. At 
the growth rates observed in Figure 5-2C, these wells would contain ~105 cells 24 
h after seeding them at 2 x 105 parasites ml-1. This means ~90% excess, providing 
a margin to record 6000 events also in wells treated with trypanocidal 
compounds. 
5.3.3 Medium throughput screening workflow 
After completing the assay development, we reasoned that many resources 
generated in the previous chapter would be useful in a screen for RDK2 
inhibitors. In addition to the adapted flow cytometry assay -which would be the 
basis for our primary screen- other tools might be applied in subsequent 
validation steps: the RDK2 overexpressor line, the RDK2 active recombinant 
protein and the -casein phosphorylation assay. The planned workflow after the 
assay development phase is represented in Figure 5-4. 
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Figure 5-4. Schematic design and summary of the screening for RDK2 
inhibitors. 
 
The original design involved two primary 96-well plate based flow cytometry 
screens at two different concentrations (10 M and 1 M). Unfortunately, time 
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restrictions limited our schedule to a single 10 M campaign. Selected hits were 
subject of a confirmatory flow cytometry replicate but with some variations. 
Rather than a single 10 M repeat, serial dilution was applied to analyse the 
dose dependent response after incubation of compounds for 24 h and 48 h. Each 
of these assays was carried out in duplicate.  
In order to provide further validation of the EP procyclin signal, one of the 
replicates at each incubation time was analysed in an orthogonal 
immunofluorescence assay performed with a high content imaging system (GE IN 
Cell 2000®). Hoechst 33342 was added to stain DNA and facilitate focusing on the 
cells.  
Finally, EC50s were calculated upon 72 h of compound treatment using alamar 
blue assay (Räz et al., 1997). Time restriction did not allow us to pursue this but 
in the original design, EC50 values would have been calculated also for 
compounds in an RDK2-overexpressor line. If higher doses were required to 
produce the same inhibitory effect observed in 2T1 parasites, compounds would 
be tested for their capacity to inhibit recombinant RDK2 -casein kinase 
activity. 
5.3.4 Stock plate preprocessing 
Stock plates were delivered to us with 20 l of compounds at 1 mM, in a layout 
including column 6 filled with DMSO and column 18 empty. Such distribution 
required DMSO disposal and reallocation of certain compounds to ease stamping 
them in the final screening plates, Figure 5-5A.  
Chapter 5 221 
 
 
Figure 5-5. Schematic representation of the plate processing.  
Two 384 GSK plates were shipped containing 20 l of compound at 1 mM. Column 
6 contained DMSO and column 18 was empty. Plates were rearranged (A) to 
permit direct transfer by quadrants (B) to the assay 96 well plates.  
 
A 96-tip head available in our liquid handler equipment enabled transfer of a 
complete 384-well plate to four 96-well plates by quadrants. To obtain the 
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desired layout at the screening plates, columns 1, 2, 23 and 24 and rows O and 
P, needed to be empty. A schematic representation of this processing is 
displayed in Figure 5-5B. ‘Mother’ 384-well plates generated after these 
manoeuvres were labelled GSKV2_P1 and GSKV2_P2. Derived ‘daughter’ 96-well 
plates stamped for the screen were labelled GSKV2_PX_QY. In this code, ‘X’ (1 
or 2) refers for the ‘mother’ plate, and ‘Y’ (1-4) refers to the quadrant stamped. 
5.3.5 Primary screen 
Data acquisition 
We had the capacity to screen two 96-well plates per day. 24 h before flow 
cytometry, we stamped 1 l of each compound at the original 1 mM 
concentration in the ‘test’ wells of both assay plates, Figure 5-2A.  
MACSQuant® flow cytometer software was used during the data acquisition 
process to display events comparing the area of signals detected with the 
forward and side scatters. We could then gate events corresponding to the 
trypanosome population and, within such gate, select for single-cell events by 
representation of height versus width for the forward scatter signal. Displaying 
single-cell events in a histogram for APC fluorescence intensity, permitted a 
third gate to be set quantifying the EP positive population. The negative controls 
(2T1 cells) were used as a reference to establish the threshold. The instrument 
was primed to record between 6000 and 10000 events with these settings, Figure 
5-6. 
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Figure 5-6. Gating strategy used for acquisition and analysis of the cellular 
events by flow cytometry.  
Exemplified with uninduced (A) and induced (B) RDK2 RNAi line. From left to 
right: Trypanosoma brucei population was selected by area comparing forward 
and side scatter; selection of single cell events by comparison of the width and 
height of the forward scatter signal; and selection of the EP procyclin positive 
population in a histogram for fluorescence intensity of the excited fluorochrome 
APC, indirectly bound to EP procyclin. The threshold to gate the EP positive 
population was based on the negative reference, the uninduced sample. 
 
Quality control 
In every high throughput screening campaign, the assay read out is susceptible of 
variations natural to the biological system; human or instrumental errors, which 
can be systematic or occasional; and physicochemical properties of the 
compounds themselves. According to the literature, in order to assess reliability 
of the results statistic quality control approaches (Shun et al., 2011) need to be  
undertaken. All analysed parameters indicated poor quality in the first three 
plates of this screen, Table 5-1. 
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Table 5-1. Primary screen quality control. Summary of results. 
Plate ID 
Normal 
distribution 
Z´factor 
%CV      
+ ctrl 
%CV       
- crtl 
S:B 
Median test 
% EP+ 
Z-score 
> 20 
P1_Q1 Yes 0.13 33.36 27.56 15.64 3.30 0 
P1_Q2 No 0.33 14.90 50.00 9.59 4.60 0 
P1_Q3 No 0.36 21.07 38.11 141.08 0.38 4 
P1_Q4 No 0.54 14.76 53.85 101.08 0.54 1 
P2_Q1 No 0.65 11.26 26.88 111.72 1.05 4 
P2_Q2 No 0.48 17.18 22.09 128.60 1.19 7 
P2_Q3 No 0.88 3.50 39.67 96.69 1.41 0 
P2_Q4 No 0.93 2.06 59.35 144.94 0.86 0 
%CV, coefficient of variation; S:B, Signal/Background ratio; ctrl, control. 
Formulas depicted in Figure 5-7 and Figure 5-10. 
Z´-factor is the most widely accepted coefficient used to assess robustness of a 
high throughput screen (Zhang, Chung and Oldenburg, 1999), Figure 5-7. On the 
one hand, it collects the dynamic range for the signal window: the absolute 
value for the difference between the medians of the positive and negative 
controls. On the other hand, it measures a margin of variation based on the 
intrinsic fluctuation of the positive and negative signals, represented by 3 times 
their median absolute deviation (MAD). Values < 0.5 are considered poor quality 
(Shun et al., 2011). Plotted in the same graph, we present the coefficient of 
variation (%CV) of the positive and negative controls independently. %CV is a 
normalizing parameter defined as the percentage of the median of the controls 
that represents their MAD. Such normalization permits a more meaningful 
comparison between MADs calculated in different plates. %CVs < 20 are 
considered good quality values which can be said for the positive controls in 
most of our screen plates but not for the negative. 
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Figure 5-7. Primary screen quality control.  
A. Coefficient of variation (%CV) of the negative and the positive references 
plotted per plate in the 10 M screening campaign versus Z´factors. B. 
Signal/Background ratios (S:B) plotted against median of compound wells per 
plate. Formulas depicted under the graphs. MAD=Median absolute deviation; 
MAX= Positive control; MIN=Negative control; ?̃?=Median. 
 
Another key feature of a robust assay is having a good separation between the 
median signals obtained for both the positive and negative controls. 
Signal/background ratio (S:B), dividing median signal of the positive controls by 
the median signal of the negative controls, showed a narrow detection window 
in the first two plates which widens for the rest. Accordingly, median %EP 
positive population of the “test” wells (calculated per plate) followed the 
opposite trend highlighting a problem with the negative control in the first two 
plates. 
Depiction of number of events recorded (and considered for analysis) across the 
complete screening campaign showed some inter-plate variability. However, for 
most samples at least 5000 events were recorded. Those with lower recorded 
events were likely due to cell death, Figure 5-8. Heat maps for %EP positive 
population (Figure 5-9) permitted observation of a systematic pattern in some 
plates, where positive controls sampled at the end (column 12, wells E-H) 
showed a less intense fluorescence, possibly due to progressive signal 
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attenuation. Processing each plate in the flow cytometer took around 4 h. Light 
exposure along this period may be a cause for photobleaching that could explain 
a difference in intensity between positive controls in columns 1 and 12. 
 
Figure 5-8. Number of flow cytometry events collected per well in primary 
screen plates 
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Hit selection 
Data analysis was carried out in Flow Jo. We reproduced gating strategy applied 
in the acquisition process, and used the histogram of EP-linked fluorescence 
intensity (APC emission) in the negative controls as a reference to establish a 
threshold identifying the EP positive population. Percentage of parental gate 
statistics were extracted from all samples in this population. Heat maps for 
these values on plate views (Figure 5-9) and data tables were generated (Table 
S6). 
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Figure 5-9. Heat maps of %EP positive population.  
Normalized respect to the maximum signal in the plate. 
 
Several analytic methods are commonly used in high throughput screening to 
perform hit selection (Shun et al., 2011). “Z-score” is widely accepted in 
campaigns without replicates, as in our case (Zhang, 2011). It makes the 
assumption that the screen signal shows equal variability across the plate, so the 
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variability calculated for the negative controls (8 per plate) can be extrapolated 
to any other well. In the standard version, when the dataset has a normal 
distribution, it is defined as the distance of every data point from the mean, 
divided by the standard deviation of the negative control. 
However, three different normality tests performed with Graph Pad Prism 6® 
showed that, with the exception of P1_Q1, none of the plates in our screen show 
a normal distribution. This is the most common observation in high throughput 
screening and, when this happens, a more robust version of this parameter, Z*-
score, is recommended. It uses “median” instead of “mean” and “median of 
absolute deviation” (MAD) instead of “standard deviation” for the negative 
controls. MAD is the median of the absolute deviation of every data point to the 
median for the complete dataset.  
In practice, although the measured values are not normally distributed in most 
of high throughput screens, true hits behave still like outliers (Zhang, 2011). 
Based in their clear separation (Figure 5-10), we considered “hits” to follow up 
in our screen those compounds presenting a Z*-score > 20.  
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Figure 5-10. Z*score distribution of %EP positive values in the primary screen 
plates.  
Highlighted the 16 “DIF” compounds considered for further analysis. Formula 
depicted under the graphs. MAD=Median absolute deviation; MIN=Negative 
control; Xi=%EP positive of a particular well; ?̃?=Median. 
 
Under these premises, 16 compounds were considered for further analysis, Table 
S6. As they resulted from a differentiation assay they were called DIF1-DIF16. 
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The set included 5 HATbox compounds (Peña et al., 2015), 7 protein kinase 
inhibitor chemotypes (Diaz et al., 2014), and 4 GUS compounds, linked to 
procyclic form differentiation through the screening pipeline as described in 
(Wenzler et al., 2016). 
5.3.6 Validation 
After considering the quality check summary in Table 5-1, none of the 
compounds selected came from plates P1_Q1 or P1_Q2, which were regarded as 
poor quality based on their Z´factor and the narrow detection window indicated 
by their reduced S:B ratio. Four were detected in P1_Q3 that was still low 
quality according to the Z´score. However the S:B ratio was a lot larger in that 
plate and the event number distribution was comparatively more homogeneous 
Figure 5-8. We decided to include these compounds (DIF1-4) in the set for follow 
up experiments. 
Analysing the flow cytometry data 
Analysing in detail the flow cytometry data for the selected 16 “DIF” 
compounds, Figure 5-11 and Figure 5-12, most of the histograms showed a low 
shoulder protruding into the %EP positive population. The exceptions were DIF3, 
where the whole population was synchronously shifted towards the higher 
fluorescence intensities, with 19.8% of events falling within the EP positive area; 
and DIF7 where the whole peak became wider with 8.89% of events displaying 
within the EP positive gate.  
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Figure 5-11. Detailed analysis of the flow cytometry results for DIF1-8.  
A. Superimposed EP procyclin expression histograms for the negative controls in 
each plate with a compound depicted in this figure. Their median EP procyclin 
positive population, and their median absolute deviation (MAD) are inscribed in 
the plots. B. Histograms of EP procyclin expression for the DIF compounds. EP 
positive % of the population is inscribed in the upper-right corner of the plots. 
Next to it, gatting strategy leading to that population (same as Figure 5-6): 
trypanosomes (SSC-A x FSC-A), and single cells (FSC-H x FSC-W).  
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Figure 5-12. Detailed analysis of flow cytometry results for DIF9-16.  
A. Superimposed EP procyclin expression histograms for the negative controls in 
each plate with a compound depicted in this figure. Their median EP procyclin 
positive population, and their median absolute deviation (MAD) are inscribed in 
the plots. B. Histograms of EP procyclin expression for the DIF compounds. EP 
positive % of the population is inscribed in the upper-right corner of the plots. 
Next to it, gatting strategy leading to that population (same as Figure 5-6): 
trypanosomes (SSC-A x FSC-A), and single cells (FSC-H x FSC-W).  
 
In flow cytometry, the forward scatter area signal is proportional to the cell 
size, while the side scatter area signal is proportional to the granularity (i.e. 
surface complexity). Analysing the forward versus side scatter dot plot, seven 
compounds (DIF1, 4, 5, 7, 11, 15 and 16) presented two differentiated clusters 
of cellular events, Figure 5-13. One tended to expand throughout the upper left 
quadrant, indicative of smaller cells but more complex in their surface 
granularity; and the other localized more towards the bottom right, indicative of 
larger but less complex cells. Independent analysis of these populations did not 
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show a common trend but always involved enrichment of one of the two sets in 
the EP positive population. Such enrichment was particularly remarkable in DIF1, 
DIF7 and DIF15 for the shorter cells with a more granular surface. The other 
subset displayed an almost null EP procyclin expression, Figure 5-13. 
 
Figure 5-13. Seven DIF compounds that showed in the scatter plots two 
differentiated clusters of cells, in terms of size and granularity.  
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Discrete analysis of the % of EP procyclin positive cells within each of these 
populations for all of them. A = shorter and more granular events. B = larger and 
less granular events. 
 
Dose-response validation curves  
In order to confirm the primary screen results, the flow cytometry assay was 
repeated but applying nine steps of serial dilution (1:2) to the 16 selected 
compounds. It was carried out after two different incubation times (24h and 
48h), doing everything in duplicate. Plates were set up with positive and 
negative controls arranged in the same layout used for the primary screen. 
Compound dilutions were carried out across every single row. Unlike in the 
primary screen, we also used the bottom line of the plate (H2-H11) for a 
compound test allowing 8 molecules to be screened per plate. Cleaning was 
performed every 16 wells in a separate tube by stopping the system and 
resuming after washing. For the 24 h incubation we proceeded as described for 
the primary screen. For the 48 h incubation, 2T1 cells were seeded at 5 x 104 
parasites ml-1, and positive controls (RDK2 RNAi line) at 105 parasites ml-1, 
inducing with tetracycline immediately before plating. 
Plates labelled as “A” contained DIF1-5, and DIF10-12. Plates named “B” 
contained DIF13-16, and DIF6-9. Results can be found in Tables S7 and S8. 
For each time point, after antibody staining, one of the replicates was 
transferred to a black 384-well clear bottom plate, centrifuged to bring 
parasites to the bottom, and imaged in a high content microscopy system (GE IN 
Cell 2000®). Four images per well were captured, using three different channels: 
bright field (parasite shape), Hoechst 33342 (DNA staining), and APC (EP 
procyclin expression). After imaging, cells were transferred back to a 96-well V-
bottom plate for cell cytometry. 
Quality assessment was conducted as for the primary screen, Table 5-2. None of 
the plates had a normal distribution. All of them had acceptable Z´factors (> 
0.6) except for the two replicates of “B_48h”, which had Z´ scores of 0.41 and 
0.31. A comparison of the median for the whole set of tested compounds was 
not used as a quality control this time, because all compounds were expected to 
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produce a signal to some extent and neither the positive nor the negative 
reference were meant to behave the same. We also need to take into 
consideration that certain controls were removed from a few plates during the 
plate processing, due to problems with the liquid handler and the flow 
cytometer setup, see Tables S7 and S8. The detection window (S:B) was 
comparatively smaller than in the primary screen. The coefficient of variation 
remained acceptable for the positive controls, %CV<20 (Shun et al., 2011), while 
too high for the negative controls. 
Table 5-2. Quality control of the validation run. Summary of results. 
Plate ID 
Normal 
distribution 
Z´factor 
%CV      + 
ctrl 
%CV       - 
crtl 
S:B 
A_24h_1 No 0.61 10.57 34.57 20.14 
A_24h_2 No 0.65 11.09 3.08 24.27 
A_48h_1 No 0.82 4.65 29.24 26.05 
A_48h_2 No 0.77 6.68 26.63 34.84 
B_24h_1 No 0.87 2.50 51.83 29.27 
B_24h_2 No 0.84 4.56 41.59 57.92 
B_48h_1 No 0.41 6.71 50.36 5.37 
B_48h_2 No 0.31 19.01 26.09 12.23 
%CV, coefficient of variation; S:B, Signal/Background ratio; ctrl, control. 
Formulas depicted in Figure 5-7 and Figure 5-10. 
The flow cytometer was set to collect 100 l of sample per well recording a 
fixed number of events within the gate described previously (Figure 5-6). As can 
be observed in the Tables S7 and S8, and Figure 5-14, the number of events/well 
programmed to be recorded in the individual plates was different (6000, 3500 or 
2000). Due to problems during the antibody staining and the transfer between 
plates, the number of events recorded was also reduced for the positive and 
negative reference in some plates. This is not analytically relevant for the 
differentiation assay as EP positive values are normalized in percentages. 
However, many of the 16 DIF compounds caused cell death besides EP procyclin 
expression, implicating a reduction in the number of events that the system 
could possibly record within the 100 l sample.  
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Figure 5-14. Recorded events distribution in the validation flow cytometry 
run.  
In order to establish meaningful comparisons between replicates, the recorded 
events for each well were normalized against the number set to be counted per 
well in that particular run. Average of normalized counts was calculated 
between the 2 replicates analysed per condition and results plotted together 
with Z*-scores in Figure 5-15 to Figure 5-18.  
Data analysis was carried out as for the primary screen, calculating Z*-scores to 
detect significant EP-linked fluorescence standing up over the background. When 
the threshold considered for significant results in the primary screen (Z*-score > 
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20) was applied to the validation test, only compounds in plates “A” reproduced 
an EP procyclin positive signal: DIF1-5 and DIF 10-12. However, poor quality 
indicated by Z´factors observed for the “B_48h” replicates did not allow 
reliability, so they were discarded. Although always under that threshold, for 
some compounds assayed in these plates %EP positive population increased with 
compound concentration, although it is not visible at the axis scale used in the 
figures. It was the case for DIF9 (after 24 h and 48 h), DIF13 and DIF14 (both 
after 48 h incubation), Table S8. The 24 h differentiation signal observed in the 
primary screen was not reproduced for DIF6, DIF7, DIF8, DIF15 and DIF16.  
As expected, the trend was a reduction in recorded events coincident with the 
highest Z*-score at the highest compound concentrations Figure 5-15 to Figure 
5-18. However, the peak of EP procyclin was observed at concentrations lower 
than 10 M for DIF1, DIF9 and DIF10 (both after 24h and 48h incubation), and for 
DIF12 and DIF13 (after 48h incubation). This may be due to an overlap between 
cell death and differentiation. Supporting this hypothesis, curves of normalized 
recorded events and %EP positive population along the gradient of compound 
concentration mirrored each other in all cases except DIF5. 
Compounds screened in plates “A”, except DIF3, showed maximum Z*-scores 
between 2-4 times higher upon 24 h than after 48 h incubation. For compounds 
screened in “B” showing a proportional dose-response relation with the %EP 
positive population (although with Z*<20), 24 h scores are always 2 times higher 
than 48 h. 
High content microscopy analysis for the parasites treated with the 8 compounds 
showing a Z* score>20, confirmed cell loss and death phenotype in most cases. 
Positive signals were only identified in dead parasites, and could be just 
antibody aggregates. Figure 5-19 shows an extract of these images at the 
different concentrations where they were first observed. However, weakness of 
the signal even in some of the positive controls makes these results inconclusive.  
IFA analysis on individual parasites might provide more robust data. 
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Figure 5-15. Dose-response curves depicting average (n=2) Z* scores and 
average normalized recorded events for the validation run of compounds 
DIF1-4.  
Red dotted line representing the Z*score=20 threshold. Plate “A” or “B”, refers 
to the validation run where the data can be found, see Tables S7 and S8. 
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Figure 5-16. Dose-response curves depicting average (n=2) Z*scores and 
average normalized recorded events for the validation run of compounds 
DIF5-8.  
Red dotted line representing the Z*score=20 threshold. Plate “A” or “B”, refers 
to the validation run where the data can be found, see Tables S7 and S8. 
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Figure 5-17. Dose-response curves depicting average (n=2) Z*scores and 
average normalized recorded events for the validation run of compounds 
DIF9-12.  
Red dotted line representing the Z*score=20 threshold. Plate “A” or “B”, refers 
to the validation run where the data can be found, see Tables S7 and S8. 
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Figure 5-18. Dose-response curves depicting average (n=2) Z*scores and 
average normalized recorded events for the validation run of compounds 
DIF13-16.  
Red dotted line representing the Z*score=20 threshold. Plate “A” or “B”, refers 
to the validation run where the data can be found, see Tables S7 and S8. 
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Figure 5-19. In cell fluorescence microscopy images showing positive APC 
signals for the 8 compounds with a validated signal in the dose-response 
curve.  
Selection of the incubation dilutions showing positive signals after 24 h 
incubation. Green = EP procyclic-linked APC fluorescence; Blue = DNA-linked 
Hoechst 33342 fluorescence. 
 
Alamar blue cell viability assays 
To calculate EC50 values, Alamar blue cell viability assays were conducted after 
72 h of compound incubation, adding the substrate during the last 24 h of growth 
(Räz et al., 1997). Two technical replicates were carried out per compound with 
eleven steps of dilution starting at 5 M. Fluorescence results were fitted to a 
logarithmic dose-response curve conducting non-linear regression in GraphPad 
Prism 5 and EC50 values were calculated when possible. 
All compounds were trypanocydal except for DIF11 and DIF12, Figure 5-20 and 
Figure 5-21. Two other compounds did not arrest growth completely at the top 5 
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M concentration: DIF7 and DIF14. When Alamar blue results were compared to 
cell death informed by reduction in events recorded by flow cytometry (Figure 
5-15-Figure 5-18), excellent overlap was found with cell loss detected in the 
other 12 compounds after 48 h incubation. The only exceptions were the two 
found to kill everything after 72h, DIF1 and DIF5. The fixed number of events 
was almost fully countable in the 24h and 48h flow cytometry dose response-
screen. 
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Figure 5-20. Alamar blue (AB) fluorescence intensity results overlaid to Z*-
scores of %EP positive population after 24 h and 48 h incubation with 
compounds DIF1-8. 
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Figure 5-21. Alamar blue (AB) fluorescence intensity results overlaid to Z*-
scores of %EP positive population after 24 h and 48 h incubation with 
compounds DIF9-16. 
 
After all, 8 compounds were validated as expressing EP procyclin with Z*-
scores>20, although individualized immunofluorescence microscopy confirmation 
would be recommended. Two can be discarded as RDK2 inhibitors as they do not 
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kill the parasite and two kill the parasite in the 72h range even at the lower 
concentration assayed here, Table 5-3.   
Table 5-3. Summary of screening results. 
Selected 
hits 
Assay 
plate 
Collection 1ry (10 M) Val. Av. - 24h Val. Av. - 48h EC50 
(72h AB) %EP + Z*score %EP + Z*score %EP + Z*score 
DIF-1 P1_Q3 HATbox 3,23 43,19 4,88 19,25 10,60 12,14 <2.31 nM 
DIF-2 P1_Q3 HATbox 2,92 38,79 11,75 64,39 23,50 30,78 125.4 nM 
DIF-3 P1_Q3 HATbox 19,80 278,23 10,80 56,02 40,05 56,36 374.1 nM 
DIF-4 P1_Q3 HATbox 2,65 34,96 19,55 150,22 26,20 35,69 374.1 nM 
DIF-5 P1_Q4 HATbox 6,98 38,03 45,45 265,01 51,55 73,32 <2.31 nM 
DIF-6 P2_Q1 GUS 4,52 32,44 0,64 0,05 14,00 0,94 1882 nM 
DIF-7 P2_Q1 NEU 8,89 67,40 0,45 -0,91 11,96 2,18 886.8 nM 
DIF-8 P2_Q1 NEU 3,10 21,08 1,71 3,35 7,64 1,10 922.7 nM 
DIF-9 P2_Q1 GUS 4,13 29,32 1,21 2,20 23,20 8,00 1119 nM 
DIF-10 P2_Q2 GUS 8,77 87,79 17,50 111,75 15,30 19,55 406.7 nM 
DIF-11 P2_Q2 NEU 11,40 115,47 12,45 67,30 13,65 16,88 None 
DIF-12 P2_Q2 GUS 2,86 25,58 10,75 69,40 19,70 25,41 None 
DIF-13 P2_Q2 NEU 2,97 26,74 2,66 6,79 33,95 10,01 166.7 nM 
DIF-14 P2_Q2 NEU 3,28 30,00 1,88 3,37 36,85 10,74 232.5 nM 
DIF-15 P2_Q2 NEU 5,29 51,16 1,00 1,29 10,08 0,56 1056 nM 
DIF-16 P2_Q2 NEU 12,50 127,05 0,58 -0,16 11,80 0,55 384.4 nM 
In bold, best fit candidates to serve as RDK2 inhibitors. In red, Z*scores>20. Val. 
Av.= Validation average at 10 M. Compound collections: HATbox (Peña et al., 
2015); NEU (Diaz et al., 2014); and GUS, same screening pipeline as (Wenzler et 
al., 2016).  
 
5.4 Discussion 
Here we present the initial steps towards the first cell-based, mechanism-
directed phenotypic screen for drug candidates performed with Trypanosoma 
brucei to our knowledge. The aim was looking for compounds causing cell death 
preceded by EP procyclin expression, i.e. the phenotypic properties of the 
parasite upon RDK2 RNAi. The work presented in the previous chapter proved 
that such phenotype might be due, at least partiality, to inhibition of its kinase 
activity. RDK2 is a divergent NEK kinase that is important for life-stage 
maintenance, thus is essential for the parasite both in vivo and in vitro (here, 
and Jones et al. 2014). In a second phase, hits rising from this screen need to be 
tested under RDK2 overexpression conditions, in order to see whether cells 
become more resistant to the compound; and in the recombinant protein, to see 
whether they are RDK2 inhibitors ex-vivo.  
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Phenotypic screens have been proven more useful than ex-vivo target-based 
screens in drug discovery (Swinney, 2013). Compounds are identified directly 
with the physicochemical properties required to act upon the living parasite 
(solving problems such as cell uptake, or cell efflux), and the desired cytocidal 
activity. Good drugs may kill the parasite throughout interaction with more than 
one biological target, and they can be overlooked in target-based screens 
(Gilbert, 2013). In the case of infectious diseases caused by protozoans, the key 
aspect is killing the parasite with selectivity over the host cells rather than 
inhibiting a very precise target (Merritt et al., 2014). On the other hand, 
knowing the mode of action of a prospective drug helps refining its molecular 
properties in order to reduce toxicity towards the host, increasing potency 
against the infectious agent, and predicting possible resistance mechanisms. 
With this approach we attempted, at once, identification of molecules with a 
particular global effect in vivo, whose exact mechanism of action can be traced 
up to a particular target, using the resources generated in the previous chapter. 
We took advantage both of the detailed description we made of T. brucei RDK2 
phenotype, and the knowledge accumulated about the drug-like properties of 
the selected collection of compounds.  
After our 10 M flow cytometry primary screen, we identified 16 compounds out 
of 518 (3.03% hit rate) that produced an EP procyclin positive signal above the 
threshold (Z*score >20). As we incubated the compounds with bloodstream 
trypanosomes, this may be indicative of differentiation to procyclic forms. 
Among these compounds, such phenotype was reproducible for 7 molecules (8 if 
we consider DIF1, that was just under the threshold, Z*=19.25). 6 of them also 
showed trypanocidal activity with EC50s in the submicromolar range, Table 5-3. 
EP procyclin expression and cell death combined, make these compounds 
candidate RDK2 inhibitors. For the 6 compounds, the two effects are dose-
dependent after 24 and 48 h incubation, an indication of non-stochastic cause-
effect relationship, Figure 5-15-Figure 5-18. Z*score after 48 h incubation is at 
least 1 fold smaller for all of them, maybe as a consequence of parasite death. 
The only exception is DIF3, whose Z* score remains constant in the two analysed 
time points. 
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These 518 compounds were selected from phenotypic screens where they had 
proven their capacity to kill T. brucei, and their drug-like physicochemical 
properties. They are mainly divided in four blocks: trypanocidal compounds 
without records of kinase inhibition,  HATbox-A (Peña et al., 2015); trypanocidal 
compounds with a history of human kinase inhibition, HATbox-B (Peña et al., 
2015); trypanocidal kinase inhibitor chemotypes, NEU (Diaz et al., 2014); and 
compounds selected in a phenotypic screen for activators of the promoter of EP 
procyclin (GUS), not necessarily trypanocidal (Wenzler et al., 2016).  
5.4.1 Five trypanocidal compounds from the HATbox producing 
an EP procyclin-positive signal  
DIF1-5 belongs to the HATbox, a selection of compounds able to kill T. brucei 
with drug-like physicochemical properties including central nervous system 
penetration (Peña et al., 2015). They have been also assayed in human cell lines 
to prove selectivity against the parasite. 
DIF1 (MW=327.384) and DIF5 (MW=344.327) were identified as TCMDC-143364 (or 
N3447-30-41), and TCMDC-143638 (or U20127/42/3) respectively at the HATbox 
screen (Peña et al., 2015). They were the 2 most potent compounds of our 
selected hits as they killed everything after 72 h incubation. The lowest 
concentration tested in our Alamar blue assay, 2.31 nM, was enough to kill them. 
These numbers are close to the EC50s calculated in the HATbox report after 48h 
incubation: 12-60 nM, for DIF1; and 4-20 nM for DIF5. They showed a 
differentiation signal, particularly strong for DIF5 (Z*=265 after 24 h, and 
Z*=73.32 after 48 h), but it may not come from viable parasites according to the 
high content imaging data. In the primary flow cytometry screen, at 10 M, both 
showed a big cluster of events in the upper-left corner of the FSC x SSC dot plot, 
which suggests small-sized cells with high granularity, maybe representing dying 
parasites. 
DIF2 (MW=369.464) was identified as TCMDC-143357 (or N3426-35-101) in the 
HATbox screen, where it had an EC50 (after 48 h) of 125-158 nM, matching the 
125.4 nM EC50 at 72 h found in our screen. Z*scores for differentiation were of 
64.39 at 24 h, and 30.78 at 48 h.  
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DIF3 (MW=281.215), also known as TCMDC-143457 (or ST/1949505) in the 
HATbox, is the only showing a stable EP procyclin signal (Z*=56.02-56.36) not 
decreasing from 24 to 48 h incubation. The EC50 we report after 72 h incubation 
is 374.1 nM, about half the 630 nM reported at 48 h by Peña et al. (2015). In the 
primary flow cytometry screen, the peak of DIF3 events in the EP procyclin 
fluorescence intensity histogram was uniformly shifted toward the positive gate, 
being the most active hit of the screen with 20% of positive cells. 
The last, DIF4 (MW=425.322), is TCMDC-143642 (or JE98054-138P2) in the 
HATbox and shows more than one third decrease in EP procyclin positive signal 
from 24 to 48 h, and our detected EC50 after 72 h incubation (374.1 nM) is about 
half what Peña et al. (2015) reported at 48 h (794 nM-1 M). DIF4 was also 
divided in two clear clusters of different size and granularity in the FSC x SSC 
analysis at the primary screen, suggesting abundance of aberrant cells. 
Unfortunately, we have no data about which of the HATbox compounds showed 
kinase inhibition but we know that almost half of them did. They reported more 
than 90 PK inhibitors out of 188 compounds in the set. They were clustered in 
>29 chemotypes, including common hinge binding motifs such as pyrimidines, 
pyrrolopyrimidines, azaindoles, and benzimidazoles. Peña et al. (2015) did a 
phylogenetic prediction of possible T. brucei targets for the HATbox based on 
their orthology with human protein kinases against which at least one compound 
had proven activity. RDK2 was not predicted maybe because it is NEK12.2 (Jones 
et al. 2014), a quite divergent PK within a relatively expanded family in T. 
brucei respect to other eukaryotes. However, NEK2 was among the human 
kinases targeted by at least one HATbox compound. NEK2 is a mitotic regulator 
that has been explored as a drug target in anticancer therapy (Frett et al., 
2014). Several compounds have been found with potency and selectivity against 
this human PK (Whelligan et al., 2010; Henise and Taunton, 2011; Solanki et al., 
2011; Innocenti et al., 2012). If any of the 5 compounds we identified in our 
screen is a human NEK2-targeting inhibitor, we could analyse their structure-
activity relationship to optimize potency and specificity. A crystal structure of 
RDK2 (still not available) would be useful at this respect. However, other 
compounds in HAT box-A, not having typical type I PK inhibitor profiles (ATP-
competitors) may still work as allosteric inhibitors. We have already mentioned 
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in this thesis that these compounds tend to have more potency as they have no 
need to compete with physiological ATP. 
5.4.2 One GUS compound producing an EP procyclin-positive 
signal with trypanocidal activity 
DIF10 (MW= 482,949) was the only hit of our screen coming from the 283 “GUS” 
compounds, selected for their capacity to activate the EP procyclin promoter in 
a screen (Wenzler et al. in preparation) following the same procedures reported 
by Wenzler et al. (2015), but with a larger collection of compounds. In our 
screen, DIF10 had an EP procyclin signal of Z*=111.75 after 24 h incubation, that 
was reduced to Z*=19.55 after 48 h. It had an EC50 of 406.7 nM after 72h. 
Unfortunately we do not have structural or functional information about GUS 
compounds enabling useful comparisons with other hits. 
Low hit-rate for this set (1 out of 283 molecules) was unexpected, as the 
selection criteria that generated this library followed a similar rationale to that 
of our anti-RDK2 screen. We detected EP procyclin expression directly with a 
specific antibody while they did it indirectly, by introduction of -glucuronidase 
(GUS) as a reporter in the EP procyclin locus. When expressed, GUS activity over 
a substrate (4-methylumbelliferyl--D-glucuronide), could be measured by 
changes in absorbance at 405 nm that were proportional to EP procyclin 
promoter activation (Sbicego et al., 1999).  
5.4.3 Cell death limits our detection capacity 
EC50s of compounds identified in the GUS screen were not disclosed to us but we 
know that 61 compounds had their peak of activity at concentrations under 1.25 
M; while 236 had it at concentrations over 1.25 M, all measured after 43 h 
incubation (Tanja Wenzler, personal communication). DIF10 belonged to the last 
group but we cannot know how many we overlooked due to an excessive 
concentration of the compound that killed the parasites quenching the EP 
procyclin-positive signal. Wenzler et al. (2015) published a smaller library of 
compounds using the same GUS approach, and they detected a majority of cases 
where overlapping of cell death with EP locus expression activation impeded 
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detecting the differentiation-associated signal. This may be also the case at the 
10 M concentration assayed here. 
We showed in a plate reader how the increasing background noise associated 
with normal growth in the negative control population quenched the signal 
emitted by the positive population, whose growth was arrested or which 
decreased in numbers, Figure 5-1. Although single-cell analysis carried out by 
flow cytometry solved this numeric problem by estimating the proportion of the 
total parasites that produced a positive signal per well, active compounds can 
still be overlooked if the signal disappear with the dead parasites. 
One possibility is that at the 24 and 48 h time points used in the experiment, 
differentiated parasites were already dead, having lost their shape and having 
started to disintegrate. Sub-lethal concentrations of compound may not have 
induced differentiation, since the inhibitor could be less abundant than the 
natural substrate (potentially ATP). Under this hypothesis, parasite death would 
be the last step of the differentiation mechanism. This is supported by the fact 
that being dose-responsive, the EP-linked signal is always 2-4 times higher after 
24 than after 48 h incubation. At the same time point, the more compound used 
the higher the signal; but, for the same concentration, the signal fades as time 
goes by, Figure 5-20 and Figure 5-21.  
High content immunofluorescence microscopy on cells from the primary screen 
did not suggest that the signals detected in the screen come from viable 
parasites, Figure 5-19. They could be either dead parasites or debris. Slides for 
immunofluorescence microscopy need to be done after compound treatment for 
validation. 
As we said for DIF1, DIF4 and DIF5 when the flow cytometry scatter plots (SSC-A 
x FSC-A) were analysed, trypanosome events spread from the bottom left 
quadrant drawing a “comet-like” profile (Figure 5-11 and Figure 5-12). This is 
due to the elongated shape of the trypanosome cell body and the different 
possible orientations of the parasites when crossing the detector. Interestingly, 
treatment with 7 of the 16 hit compounds separated the parasites into two 
different clusters. The EP positive fraction in each of these subgroups was not 
too different for cells treated with 4 of these molecules (DIF4, DIF5, DIF11 and 
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DIF16). However for the other 3, the EP positive population was enriched in the 
subset containing the smaller sized and granular events (DIF1, DIF7, and DIF15), 
see Figure 5-13. As the high content imaging suggested, this may also support 
the idea of EP positive population being small dying parasites. As we suggested 
before, large scale IFA would provide appropriate validation for this observation. 
As discussed in chapter 4, an antibody raised against RDK2 or endogenous 
labelling of the RDK2 gene is needed to understand the protein behaviour during 
RNAi-mediated depletion. The current lack of detailed information about the 
time when RDK2 RNAi phenotype occurred in relation to the moment when RDK2 
disappeared from the parasite, made it difficult to estimate the best time frame 
to carry out the experiment. We aimed for the 24 h incubation since RDK2 RNAi 
phenotype became evident from around 36 h. The 48 h time point used for 
validation was supported by assays with GUS activity performed after 40 h 
incubation (Wenzler et al., 2016). But upon CCA treatment, for instance, cells 
express EP procyclin since 6 h post induction (Rico et al., 2013). 
An active compound should be expected to have an equal effect over all 
parasites in the well unless for some reason the compound acted only in certain 
subsets of the population. An example would be if the molecule targets proteins 
that function only in certain stages of the cell cycle or the life cycle. We 
theorized in the previous chapter that RDK2 might have different roles in 
different developmental stages, so this would most likely happen with 
prospective RDK2 inhibitors. 
Another possibility, since the flow cytometry screening was performed in live 
cells, is that parasites internalized and degraded antibodies by means of their 
flagellar pocket through hydrodynamic flow contributing to signal fading 
(Engstler et al., 2007). Interestingly, procyclic forms have 10-fold lower 
endocytosis that bloodstream forms, therefore it may be lower in differentiating 
cells (Field and Carrington, 2004). 
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5.4.4 Two non trypanocidal compounds produced an EP 
procyclin-positive signal 
A second GUS compound, DIF12 or HL209352-009A1 (MW=299.338), was found to 
produce an EP procyclin-positive signal, however it did not kill cells after 72 h at 
10 M. A Z*score=69.4 was detected after 24 h, that reduced to Z*=25.41 after 
48 h incubation. The pictures obtained in high content imaging, did not seem to 
come from viable parasites either.  
The last compound identified with a reproducible EP procyclin-positive signal, 
although unable to kill the parasite after 72h was DIF11 (MW= 293,322), the only 
representative of the NEU set (NEU-0001221 or CA200460-075A9). This collection 
is the product of the largest kinase-targeted screen ever directed against T. 
brucei (Diaz et al., 2014).  
Data mining and statistical analysis on the “NEU” results showed that compounds 
inhibiting a particular set of human kinases are more likely going to have 
inhibitory effects over T. brucei (Amata et al., 2016). This has been called 
“preferred lead repurposing” and selecting compounds with that criteria showed 
an enhanced hit rate when compared with screening of non-filtered PK inhibitor 
chemotypes (Amata et al., 2016). Although we do not know how many of the 
compounds tested in our screen were potential NEK inhibitors, among the 
“preferred” leads there were human NEK8 inhibitors that may have activity also 
against RDK2. At least the PKIS collection contained several of these. 
Seven other “NEU” compounds were identified among the top 16 hits of our 
screen (Table 5-3), however their positive signal could not be reproduced in the 
validation step. Some showed a dose-response signal under the threshold 
though, indicative of a cause-effect relationship with the compound that upon 
concentration and time-exposure adjustment may lead to positive results. 
5.4.5 Differentiation is not a stress response against a 
trypanolytic agent. 
Differentiation is a natural process in T. brucei bloodstream forms when it 
comes to escape environmental stress encountered in the tsetse midgut (Rico et 
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al., 2013). But EP positive signals observed in the screen cannot be always a 
response to stress caused by exposure to a trypanocydal drug. 
5 out of the 6 ultimate hits belong to the HATbox (Peña et al., 2015) and they 
are well profiled trypanocidals, however the presence of at least another 184 
compounds from the same set in our screen, discount parasite death as a cause 
for EP procyclin expression. Most are negative in our screen while reportedly 
killing the parasite in the nanomolar range (Diaz et al., 2014; Peña et al., 2015). 
Such killing capacity is evidenced here by the drop in numbers of the recorded 
events observed in different plates across the primary screen, Figure 5-8, and 
DIC images of high content microscopy.  
Our collaborators at the Swiss TPH have reported something similar recently. In 
the screen they published with the GUS assay (Wenzler et al., 2016), all 
molecules producing GUS activity were trypanocidal while just 9% of 
trypanocidal compounds caused GUS activation.  
5.4.6 Follow up 
The next step would be independent validation in IFA and continuing our 
screening plan (Figure 5-4), comparing EC50s of the parental cell line with the 
RDK2 overexpressor that would tell us if we are possibly on target. If EC50s were 
higher for the overexpressor, we would look for confirmation in the kinase assay 
with RDK2 recombinant protein using -casein as a substrate (see previous 
chapter). The second round of primary screen at 1 M, could show more hits. 
Other libraries that would be worth analysing in this pipeline are the Dundee 
protein kinase inhibitor collection (Woodland et al., 2015) and the complete GSK 
PKIS (Drewry, Willson and Zuercher, 2014). We had a material transfer 
agreement for the last one but time pressure did not allow us to access them. In 
addition, it may be good to test some NEK inhibitor libraries developed for 
cancer therapy (Frett et al., 2014) and try to optimize hits if successful based on 
SAR analysis.   
This preliminary screen has been useful as a starting point for developing a more 
robust pipeline. If optimized it could still produce more reliable hits. It would at 
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least validate at a protein expression level hits from the Swiss TPH screen 
(Wenzler et al., 2016). If compounds showing both phenotypes (differentiation 
and death) are confirmed in validation steps with both the RDK2 overexpressor 
and protein kinase assay with the RDK2 recombinant protein, we would have 
identified a drug target for a compound in the screened sets, which would have 
excellent prospects in terms of drug discovery. 
Such compound would also become an excellent research tool able to provide 
chemical validation of the RDK2 RNAi phenotype and help out dissecting the 
intricate signalling pathways that rule the balance between life-stage 
maintenance and cell cycle progression in Trypanosoma brucei.  
  
Chapter 6 257 
 
Chapter 6 General discussion 
 
In this thesis I applied RITseq to identify protein kinases that are essential for 
infection and survival of Trypanosoma brucei in the mammalian bloodstream. 
The value of this information is significant as protein kinases are known to be 
susceptible to small molecule inhibition and are therefore exploitable as drug 
targets. Within the 49 protein kinases whose depletion caused a loss of fitness in 
vivo, we uncovered a number involved in withstanding stress conditions related 
with adaptation to that particular environment. I validated some involved in 
osmotic shock and serum exposure resistance. Among them, putative members 
of PI3K/TOR and MAPK pathways have been highlighted, however the way they 
interact to each other and with other factors that may be also essential for in 
vitro survival needs to be investigated. Exploring further these non-canonical 
virulence factors and their contribution towards withstanding the initial 
environmental shock that involves the transference from the tsetse’s salivary 
glands to the mammalian bloodstream is an exciting perspective. 
Many of these 49 genes, including the most divergent when compared to other 
eukaryotes, have orthologues in other kinetoplastid parasites, such as T. cruzi 
and Leishmania sp. Since RNAi technology is not available for these parasites 
(Lye et al., 2010) and molecular genetic tools permitting gene deletion are so 
far more laborious and not high throughput friendly (Merritt et al., 2014), 
exploring if proteins with drug target value identified in high throughput screens 
of T. brucei have orthologues with equivalent crucial functions in these 
organisms may be a promising strategy. 
For further analysis, I focused in RDK2, a promising drug target that was 
essential both in vivo and in vitro and had very interesting biological 
implications. Inducible downregulation of RDK2 in the bloodstream form by RNAi 
caused differentiation to an aberrant procyclic form, which was unable to 
survive in culture unless placed in conditioned procyclic form media. In that 
circumstance, they survived but were unable to proliferate while acquiring a 
plastic adhesion phenotype that recalls proventricular forms within the tsetse 
fly.  
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A recently published proteomics dataset profiling CCA-mediated differentiation 
(Dejung et al., 2016) showed that RDK2 levels increase in the stumpy form, but 
are reduced dramatically upon development to the procyclic form, being absent 
in established procyclic form cultures. Monitoring EP procyclin expression as a 
marker of bloodstream-to-procyclic differentiation, I show that the RNAi effect 
on differentiation was reduced in all conditions that favour stumpy* formation 
(Rico et al., 2013), such as 8-pCPT-cAMP treatment and cold shock (may be due 
to transcriptional silencing), while these conditions ease differentiation 
mediated by CCA in uninduced cells. CCA treatment, -with limitations in the 
absence of PAD transporters (Dean et al., 2009), or a more efficient simulation 
of its downstream effects, -PTP1 inhibition with cell-permeable BZ3 (Szöor et 
al., 2010), entered in conflict with differentiation by RNAi, reducing the size of 
the EP procyclin positive population. When CCA and RNAi were applied together 
in a population pre-treated with pCPT-cAMP to induce stumpy* formation there 
was a synergistic effect though, suggesting that cells where RNAi had no effect 
were induced to differentiate by CCA, and cells where CCA had no effect were 
induced to differentiate by RNAi of RDK2. I propose that RDK2 depletion is a 
downstream effect of the CCA/PTP1 pathway, and that its premature depletion 
causes changes in the interactome that reflect interference with the CCA/PTP1 
signalling (Szöor et al., 2010), and that render imperfect procyclic forms that 
cannot survive.  
Overexpression of RDK2 blocked differentiation triggered in monomorphic 
trypomastigotes by preincubation with 8-pCPT-cAMP (inducing stumpy* forms) 
followed by CCA treatment. However, data may suggest that RDK2 
overexpression blocks 8-pCPT-cAMP-mediated stumpy differentiation mainly. 
Unfortunately, although initial findings suggested it was possible, 
complementation experiments did not permit reproducibly assigning RNAi 
phenotype to RDK2 depletion. More clear-cut gene deletion or specific chemical 
inhibition may be attempted to clarify this point. The originally successful 
complementation with a recoded active mutant (rdk2REC) compared with 
unsuccessful attempts carried out with the inactive version (rdk2REC/K70M), 
suggested that the RNAi effect may be caused by the lack of kinase activity and 
not by defect of other putative scaffolding functions which disappear when the 
protein is missing.  
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The detailed analysis of RDK2 was exploited to design a mechanism-directed 
phenotypic screen. In contrast to drug repurposing strategies, on-target 
confirmation should be easier if the predicted target is known. In this type of 
screen, we intend to attack a particular pathway or target class essential for the 
parasite that, upon mechanistic disruption, shows a characteristic-traceable 
phenotype. When confronted with target-based ex-vivo assays, phenotypic 
screens provide hits more readily. Selected molecules are active against the 
whole cells and detected based on specificity for the parasite compared to host 
cells, regardless the actual drug target in the objective organism. Effective 
drugs may have impact over more than one target at once.  
In the mechanism-directed phenotypic screen I presented in this thesis, 
compound libraries with a history of trypanocidal activity (Peña et al., 2015), 
kinase inhibition (Diaz et al., 2014; Peña et al., 2015), or activation of the EP 
procyclin promoter (Wenzler et al., 2016), were screened for chemical entities 
phenocopying the RNAi effect assigned to RDK2 inactivation: triggering EP 
procyclin expression before (or while) killing the parasite. 6 compounds were 
identified in a primary screen conducted at 10 M, a concentration intended to 
compete with cellular levels of ATP. Application of research tools developed for 
RDK2 analysis, such as the recombinant protein or the overexpression line, will 
allow an analysis of whether the 6 compounds were targeting the protein kinase. 
There were many aspects of this research that encouraged targeting RDK2 for 
drug discovery besides its depletion killing T. brucei both in vitro and in vivo. 
RDK2 is a protein kinase and therefore is potentially druggable (Urbaniak et al., 
2012). It is rather divergent and belongs to the NEK family, which is expanded in 
the parasite compared to the mammalian host. It is involved in a parasite-
specific function (life-stage maintenance), what highlights the chances of finding 
a potential drug capable of lethal parasite-specific inhibition. We proved RDK2 
to be an active protein kinase that could use -casein as a substrate, so a 
miniaturised assay could be developed to carry out a high throughput screen and 
initiate a structure-based drug discovery project. 
There is an urgent need for new drugs if we want to achieve the WHO 2020 goal 
of HAT eradication. Since the London Declaration on Neglected Tropical Diseases 
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(2012) the research community, in an unprecedented display of collaborative 
and internationalist efforts, has made good progress towards the objective. 
However, we need to be cautious. Whilst the disease was almost eliminated as a 
public health issue in the 1970s, the lack of sustained efforts and investment of 
resources ever since, relaxed surveillance and caused a dramatic re-lapse that 
has lasted until today (Franco et al., 2014). The current diagnostic and 
therapeutic tools are really obsolete: suramin (T. b. rhodesiense), and 
pentamidine (T. b. gambiense) were developed in the 1920s and 1940s (World 
Health Organization, 2013) and are still being used today (Streit and Matsumoto, 
2016). Stage 2 drugs are also very inconvenient: the current treatment for T. b. 
gambiense, NECT, requires hospitalization and frequent intravenous infusions 
(Eperon et al., 2014); while the only available treatment for T. b. rhodesiense, 
melarsoprol, kills 5% of the patients (World Health Organization, 2013). 
There is hope since 2 oral treatments (fexinidazole and SCYX-7158) entered 
clinical trials, phase II and III in 2016 (Drugs for Neglected Diseases initiative, 
2016). The existing perspective of both drugs targeting T. b. gambiense and T. 
b. rhodesiense HAT regardless of the disease stage is very promising. Key 
strategic advantages would be the possibilities of treating patients without need 
of hospitalization, and avoidance of the painful lumbar puncture that 
determines the stage of the disease. However, it is a concern that rising 
resistant parasites against the current and prospective drugs is fairly easy in the 
laboratory (Jones et al., 2015; Wyllie et al., 2015). There is a need for a more 
diverse therapeutic arsenal -with different modes of actions, internalization, or 
extrusion routes- that would prevent also cross-resistance mechanisms in 
combination therapies. 
In this thesis, I faced the drug discovery process from two complementary 
angles, which represent the opposite starting points towards identification of an 
active molecule. On the one hand, I identified potential drug targets in an RNAi 
screen, which defined protein kinases relevant for the establishment of the in 
vivo infection; and on the other, I identified compounds capable of killing the 
parasite but showing specific phenotypic features that permitted their linkage 
with a particular mode of action.  
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Coupling these two approaches may be a great perspective for drug discovery. 
First, RITseq screens of genome-wide libraries (or functionally-focused, as the 
one used here that targets protein kinases) may identify potential drug targets 
involved in essential biological processes, whose depletion elicit tractable 
phenotypes prior to causing death to the parasite.  Then, compound-screening 
campaigns may follow in order to select for drugs able to reproduce such a 
phenotype, and potentially simplifying the often-difficult target deconvolution 
phase. The more information we have about components of the targeted 
pathway, the more rationally we can choose the chemotypes integrating the 
library intended to screen. Focused libraries (e.g. kinase focussed library) have 
advantages as they are small and specific to target, but disadvantages as they 
exclude novel chemotypes that are not predicted to be inhibitors. Screening 
whole compound collections as the 1.2 million from GSK (Peña et al., 2015), also 
against the recombinant enzyme may be worth doing. 
The early evolutionary divergence of T. brucei presents many opportunities for 
this method. Genes involved in divergent specific features of T. brucei biology 
as, for instance, unconventional regulation of the cell cycle, posttranscriptional 
regulation of gene expression, VSG switching, metabolism, or progression 
throughout the life-cycle should be accessible to this type of combined screens 
(Matthews, 2005; Hammarton, 2007; Clayton, 2014). With the same flow 
cytometry approach that we used to detect EP procyclin expression, we could 
select for RNAi phenotypes or compounds triggering PAD expression, disrupting 
the VSG coat, retaining the cell cycle in a particular stage, or dysregulating 
expression of the splice leader, for instance, prior to killing the parasite. We 
could design RITseq screens coupled to fluorescence–activated cell sorting to 
select for parasites able (or unable) to express these markers, and we could look 
for potentially druggable targets within these subpopulations showing a reduced 
fitness respect to uninduced controls. A mechanism-based phenotypic screen 
would follow trying to replicate the phenotype. We would need ideally a 
detectable variable highly specific for interruption of a pathway known to be 
essential that we can measure through a biochemical reaction, an antibody, or 
by generation of the library into a cell line, where a reporter element is 
endogenously labelled. 
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Besides potential drug target identification, RITseq has helped detecting 
proteins whose depletion generates resistance to trypanocidal molecules already 
identified in phenotypic screens (Alsford et al., 2011, 2012). Such hits can be 
factors involved in mode of action, as transporters or activators whose depletion 
increases resistance of the parasite to the drug. Knowing these factors can assist 
greatly rational modelling of the drug candidate based on structure-activity 
relationship. When applied to resistant lines generated in the lab against a 
particular molecule, RITseq can theoretically identify the compound target if, 
for instance, the mechanism increasing tolerance to the compound was 
upregulation of the target itself. 
Although the importance of protein phosphorylation observed in other 
eukaryotes is well conserved in T. brucei, many protein kinases are 
phosphorylated under physiological conditions, indicating the presence of 
intricate phosphorylation networks.  Just a few mechanisms, however, have 
been described (Nett et al., 2009). The pTL library, particularly in the pooled 
format, can be a great resource to explore the myriad of processes where 
protein kinases are implicated. 
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